



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification ⁷ : C12N 15/31, C07K 14/295, C12N 1/21, 1/19, 5/10, C07K 19/00, C12N 15/62, C07K 16/02, A61K 39/118, 31/70, G01N 33/569, C12Q 1/68, A61K 48/00</p>	A2	<p>(11) International Publication Number: WO 00/34483</p> <p>(43) International Publication Date: 15 June 2000 (15.06.00)</p>												
<p>(21) International Application Number: PCT/US99/29012</p> <p>(22) International Filing Date: 8 December 1999 (08.12.99)</p> <p>(30) Priority Data:</p> <table border="0"> <tr> <td>09/208,277</td> <td>8 December 1998 (08.12.98)</td> <td>US</td> </tr> <tr> <td>09/288,594</td> <td>8 April 1999 (08.04.99)</td> <td>US</td> </tr> <tr> <td>09/410,568</td> <td>1 October 1999 (01.10.99)</td> <td>US</td> </tr> <tr> <td>09/426,571</td> <td>22 October 1999 (22.10.99)</td> <td>US</td> </tr> </table> <p>(71) Applicant (for all designated States except US): CORIXA CORPORATION [US/US]; Suite 200, 1124 Columbia Street, Seattle, WA 98104 (US).</p> <p>(72) Inventors; and</p> <p>(75) Inventors/Applicants (for US only): PROBST, Peter [DE/US]; 3282 - 21st Avenue West, #101, Seattle, WA 98199 (US). BHATIA, Ajay [IN/US]; 1120 Spring Street, #803, Seattle, WA 98104 (US). SKEIKY, Yasir, A., W. [CA/US]; 8327 - 25th Avenue N.W., Seattle, WA 98107 (US). FLING, Steven, P. [US/US]; 11414 Pinyon Avenue Northeast, Bainbridge Island, WA 98110 (US). JEN, Shyian [US/US]; 1610 - 16th Avenue, #32, Seattle, WA 98122 (US).</p>		09/208,277	8 December 1998 (08.12.98)	US	09/288,594	8 April 1999 (08.04.99)	US	09/410,568	1 October 1999 (01.10.99)	US	09/426,571	22 October 1999 (22.10.99)	US	<p>STROMBERG, Erica, Jean [US/US]; 3800 Aurora Avenue N, Apt. 206, Seattle, WA 98103 (US).</p> <p>(74) Agents: MAKI, David, J. et al.; Seed And Berry LLP, Suite 6300, 701 Fifth Avenue, Seattle, WA 98104-7092 (US).</p> <p>(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published Without international search report and to be republished upon receipt of that report.</p>
09/208,277	8 December 1998 (08.12.98)	US												
09/288,594	8 April 1999 (08.04.99)	US												
09/410,568	1 October 1999 (01.10.99)	US												
09/426,571	22 October 1999 (22.10.99)	US												
<p>(54) Title: COMPOUNDS AND METHODS FOR TREATMENT AND DIAGNOSIS OF CHLAMYDIAL INFECTION</p>														
<p>(57) Abstract</p>														
<p>Compounds and methods for the diagnosis and treatment of Chlamydial infection are disclosed. The compounds provided include polypeptides that contain at least one antigenic portion of a <i>Chlamydia</i> antigen and DNA sequences encoding such polypeptides. Pharmaceutical compositions and vaccines comprising such polypeptides or DNA sequences are also provided, together with antibodies directed against such polypeptides. Diagnostic kits containing such polypeptides or DNA sequences and a suitable detection reagent may be used for the detection of Chlamydial infection in patients and in biological samples.</p>														

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

COMPOUNDS AND METHODS FOR TREATMENT AND DIAGNOSIS OF CHLAMYDIAL INFECTION

TECHNICAL FIELD

The present invention relates generally to the detection and treatment of Chlamydial infection. In particular, the invention is related to polypeptides comprising a *Chlamydia* antigen and the use of such polypeptides for the serodiagnosis and treatment of Chlamydial infection.

BACKGROUND OF THE INVENTION

Chlamydiae are intracellular bacterial pathogens that are responsible for a wide variety of important human and animal infections. *Chlamydia trachomatis* is one of the most common causes of sexually transmitted diseases and can lead to pelvic inflammatory disease (PID), resulting in tubal obstruction and infertility. *Chlamydia trachomatis* may also play a role in male infertility. In 1990, the cost of treating PID in the US was estimated to be \$4 billion. Trachoma, due to ocular infection with *Chlamydia trachomatis*, is the leading cause of preventable blindness worldwide. *Chlamydia pneumonia* is a major cause of acute respiratory tract infections in humans and is also believed to play a role in the pathogenesis of atherosclerosis and, in particular, coronary heart disease. Individuals with a high titer of antibodies to *Chlamydia pneumonia* have been shown to be at least twice as likely to suffer from coronary heart disease as seronegative individuals. Chlamydial infections thus constitute a significant health problem both in the US and worldwide.

Chlamydial infection is often asymptomatic. For example, by the time a woman seeks medical attention for PID, irreversible damage may have already occurred resulting in infertility. There thus remains a need in the art for improved vaccines and pharmaceutical

compositions for the prevention and treatment of *Chlamydia* infections. The present invention fulfills this need and further provides other related advantages.

SUMMARY OF THE INVENTION

The present invention provides compositions and methods for the diagnosis and therapy of *Chlamydia* infection. In one aspect, the present invention provides polypeptides comprising an immunogenic portion of a *Chlamydia* antigen, or a variant of such an antigen. Certain portions and other variants are immunogenic, such that the ability of the variant to react with antigen-specific antisera is not substantially diminished. Within certain embodiments, the polypeptide comprises an amino acid sequence encoded by a polynucleotide sequence selected from the group consisting of (a) a sequence of SEQ ID NO: 1, 15, 21-25, 44-64, 66-76, 79-88, 110-119, 120, 122, 124, 126, 128, 130, 132, 134, 136, 169-174, 181-188, 263, 265 and 267-290; (b) the complements of said sequences; and (c) sequences that hybridize to a sequence of (a) or (b) under moderately stringent conditions. In specific embodiments, the polypeptides of the present invention comprise at least a portion of a *Chlamydial* protein that includes an amino acid sequence selected from the group consisting of sequences recited in SEQ ID NO: 5-14, 17-20, 26, 28, 30-32, 34, 39-43, 65, 89-109, 138-158, 167, 168, 224-262, 246, 247, 254-256, 292, and variants thereof.

The present invention further provides polynucleotides that encode a polypeptide as described above, or a portion thereof (such as a portion encoding at least 15 amino acid residues of a *Chlamydial* protein), expression vectors comprising such polynucleotides and host cells transformed or transfected with such expression vectors.

In a related aspect, polynucleotide sequences encoding the above polypeptides, recombinant expression vectors comprising one or more of these polynucleotide sequences and host cells transformed or transfected with such expression vectors are also provided.

In another aspect, the present invention provides fusion proteins comprising an inventive polypeptide, or, alternatively, an inventive polypeptide and a known *Chlamydia* antigen, as well as polynucleotides encoding such fusion proteins, in combination with a physiologically acceptable carrier or immunostimulant for use as pharmaceutical compositions and vaccines thereof.

The present invention further provides pharmaceutical compositions that comprise: (a) an antibody, both polyclonal and monoclonal, or antigen-binding fragment thereof that specifically binds to a *Chlamydia* protein; and (b) a physiologically acceptable carrier. Within other aspects, the present invention provides pharmaceutical compositions that comprise one or more *Chlamydia* polypeptides disclosed herein, or a polynucleotide molecule encoding such a polypeptide, and a physiologically acceptable carrier. The invention also provides vaccines for prophylactic and therapeutic purposes comprising one or more of the disclosed polypeptides and an immunostimulant, as defined herein, together with vaccines comprising one or more polynucleotide sequences encoding such polypeptides and an immunostimulant.

In yet another aspect, methods are provided for inducing protective immunity in a patient, comprising administering to a patient an effective amount of one or more of the above pharmaceutical compositions or vaccines.

In yet a further aspect, methods for the treatment of *Chlamydia* infection in a patient are provided, the methods comprising obtaining peripheral blood mononuclear cells (PBMC) from the patient, incubating the PBMC with a polypeptide of the present invention (or a polynucleotide that encodes such a polypeptide) to provide incubated T cells and administering the incubated T cells to the patient. The present invention additionally provides methods for the treatment of *Chlamydia* infection that comprise incubating antigen presenting cells with a polypeptide of the present invention (or a polynucleotide that encodes such a polypeptide) to provide incubated antigen presenting cells and administering the incubated antigen presenting cells to the patient. Proliferated cells may, but need not, be cloned prior to administration to the patient. In certain embodiments, the antigen presenting cells are selected from the group consisting of dendritic cells, macrophages, monocytes, B-cells, and fibroblasts. Compositions for the treatment of *Chlamydia* infection comprising T cells or antigen presenting cells that have been incubated with a polypeptide or polynucleotide of the present invention are also provided. Within related aspects, vaccines are provided that comprise: (a) an antigen presenting cell that expresses a polypeptide as described above and (b) an immunostimulant.

The present invention further provides, within other aspects, methods for

removing *Chlamydial*-infected cells from a biological sample, comprising contacting a biological sample with T cells that specifically react with a *Chlamydial* protein, wherein the step of contacting is performed under conditions and for a time sufficient to permit the removal of cells expressing the protein from the sample.

Within related aspects, methods are provided for inhibiting the development of *Chlamydial* infection in a patient, comprising administering to a patient a biological sample treated as described above. In further aspects of the subject invention, methods and diagnostic kits are provided for detecting *Chlamydia* infection in a patient. In one embodiment, the method comprises: (a) contacting a biological sample with at least one of the polypeptides or fusion proteins disclosed herein; and (b) detecting in the sample the presence of binding agents that bind to the polypeptide or fusion protein, thereby detecting *Chlamydia* infection in the biological sample. Suitable biological samples include whole blood, sputum, serum, plasma, saliva, cerebrospinal fluid and urine. In one embodiment, the diagnostic kits comprise one or more of the polypeptides or fusion proteins disclosed herein in combination with a detection reagent. In yet another embodiment, the diagnostic kits comprise either a monoclonal antibody or a polyclonal antibody that binds with a polypeptide of the present invention.

The present invention also provides methods for detecting *Chlamydia* infection comprising: (a) obtaining a biological sample from a patient; (b) contacting the sample with at least two oligonucleotide primers in a polymerase chain reaction, at least one of the oligonucleotide primers being specific for a polynucleotide sequence disclosed herein; and (c) detecting in the sample a polynucleotide sequence that amplifies in the presence of the oligonucleotide primers. In one embodiment, the oligonucleotide primer comprises at least about 10 contiguous nucleotides of a polynucleotide sequence peptide disclosed herein, or of a sequence that hybridizes thereto.

In a further aspect, the present invention provides a method for detecting *Chlamydia* infection in a patient comprising: (a) obtaining a biological sample from the patient; (b) contacting the sample with an oligonucleotide probe specific for a polynucleotide sequence disclosed herein; and (c) detecting in the sample a polynucleotide sequence that hybridizes to the oligonucleotide probe. In one embodiment, the oligonucleotide probe

comprises at least about 15 contiguous nucleotides of a polynucleotide sequence disclosed herein, or a sequence that hybridizes thereto.

These and other aspects of the present invention will become apparent upon reference to the following detailed description. All references disclosed herein are hereby incorporated by reference in their entirety as if each was incorporated individually.

SEQUENCE IDENTIFIERS

- SEQ ID NO: 1 is the determined DNA sequence for the *C. trachomatis* clone 1-B1-66.
- SEQ ID NO: 2 is the determined DNA sequence for the *C. trachomatis* clone 4-D7-28.
- SEQ ID NO: 3 is the determined DNA sequence for the *C. trachomatis* clone 3-G3-10.
- SEQ ID NO: 4 is the determined DNA sequence for the *C. trachomatis* clone 10-C10-31.
- SEQ ID NO: 5 is the predicted amino acid sequence for 1-B1-66.
- SEQ ID NO: 6 is the predicted amino acid sequence for 4-D7-28.
- SEQ ID NO: 7 is a first predicted amino acid sequence for 3-G3-10.
- SEQ ID NO: 8 is a second predicted amino acid sequence for 3-G3-10.
- SEQ ID NO: 9 is a third predicted amino acid sequence for 3-G3-10.
- SEQ ID NO: 10 is a fourth predicted amino acid sequence for 3-G3-10.
- SEQ ID NO: 11 is a fifth predicted amino acid sequence for 3-G3-10.
- SEQ ID NO: 12 is the predicted amino acid sequence for 10-C10-31.
- SEQ ID NO: 13 is the amino acid sequence of the synthetic peptide 1-B1-66/48-67.
- SEQ ID NO: 14 is the amino acid sequence of the synthetic peptide 1-B1-66/58-77.

SEQ ID NO: 15 is the determined DNA sequence for the *C. trachomatis* serovar LGV II clone 2C7-8

SEQ ID NO: 16 is the determined DNA sequence for a first putative open reading frame from *C. trachomatis* serovar D

SEQ ID NO: 17 is the predicted amino acid sequence encoded by the first putative open reading frame from *C. trachomatis* serovar D

SEQ ID NO: 18 is the amino acid sequence of the synthetic peptide CtC7.8-12

SEQ ID NO: 19 is the amino acid sequence of the synthetic peptide CtC7.8-13

SEQ ID NO: 20 is the predicted amino acid sequence encoded by a second putative open reading from *C. trachomatis* serovar D

SEQ ID NO: 21 is the determined DNA sequence for clone 4C9-18 from *C. trachomatis* LGV II

SEQ ID NO: 22 is the determined DNA sequence homologous to Lipoamide Dehydrogenase from *C. trachomatis* LGV II

SEQ ID NO: 23 is the determined DNA sequence homologous to Hypothetical protein from *C. trachomatis* LGV II

SEQ ID NO: 24 is the determined DNA sequence homologous to Ubiquinone Methyltransferase from *C. trachomatis* LGV II

SEQ ID NO: 25 is the determined DNA sequence for clone 4C9-18#2 BL21 pLysS from *C. trachomatis* LGV II

SEQ ID NO: 26 is the predicted amino acid sequence for 4C9-18#2 from *C. trachomatis* LGV II

SEQ ID NO: 27 is the determined DNA sequence for Cp-SWIB from *C. pneumonia* strain TWAR

SEQ ID NO: 28 is the predicted amino acid sequence for Cp-SWIB from *C. pneumonia* strain TWAR

SEQ ID NO: 29 is the determined DNA sequence for Cp-S13 from *C. pneumonia* strain TWAR

SEQ ID NO: 30 is the predicted amino acid sequence for Cp-S13 from *C. pneumonia* strain TWAR

SEQ ID NO: 31 is the amino acid sequence for a 10mer consensus peptide from CtC7.8-12 and CtC7.8-13

SEQ ID NO: 32 is the predicted amino acid sequence for clone 2C7-8 from *C. trachomatis* LGV II

SEQ ID NO: 33 is the determined DNA sequence of a clone from *C. trachomatis* serovar D which shows homology to clone 2C7-8

SEQ ID NO: 34 is the predicted amino acid sequence encoded by the sequence of SEQ ID NO: 33

SEQ ID NO: 35 is the DNA sequence for C.p. SWIB Nde (5' primer) from *C. pneumonia*

SEQ ID NO: 36 is the DNA sequence for C.p. SWIB EcoRI (3' primer) from *C. pneumonia*

SEQ ID NO : 37 is the DNA sequence for C.p. S13 Nde (5' primer) from *C. pneumonia*

SEQ ID NO: 38 is the DNA sequence for C.p. S13 EcoRI (3' primer) from *C. pneumonia*

SEQ ID NO: 39 is the amino acid sequence for CtSwib 52-67 peptide from *C. trachomatis* LGV II

SEQ ID NO: 40 is the amino acid sequence for CpSwib 53-68 peptide from *C. pneumonia*

SEQ ID NO: 41 is the amino acid sequence for HuSwib 288-302 peptide from Human SWI domain

SEQ ID NO: 42 is the amino acid sequence for CtSWI-T 822-837 peptide from the topoisomerase-SWIB fusion of *C. trachomatis*

SEQ ID NO: 43 is the amino acid sequence for CpSWI-T 828-842 peptide from the topoisomerase-SWIB fusion of *C. pneumonia*

SEQ ID NO: 44 is a first determined DNA sequence for the *C. trachomatis* LGV II clone 19783.3.jen.seq(1>509)CTL2#11-3', representing the 3' end.

SEQ ID NO: 45 is a second determined DNA sequence for the *C. trachomatis* LGV II clone 19783.4.jen.seq(1>481)CTL2#11-5', representing the 5' end.

SEQ ID NO: 46 is the determined DNA sequence for the C. trachomatis LGV II clone19784CTL2_12consensus.seq(1>427)CTL2#12.

SEQ ID NO: 47 is the determined DNA sequence for the C. trachomatis LGV II clone 19785.4.jen.seq(1>600)CTL2#16-5', representing the 5' end.

SEQ ID NO: 48 is a first determined DNA sequence for the C. trachomatis LGV II clone. 19786.3.jen.seq(1>600)CTL2#18-3', representing the 3' end.

SEQ ID NO: 49 is a second determined DNA sequence for the C. trachomatis LGV II clone. 19786.4.jen.seq(1>600)CTL2#18-5', representing the 5' end.

SEQ ID NO: 50 is the determined DNA sequence for the C. trachomatis LGV II clone 19788CTL2_21consensus.seq(1>406)CTL2#21.

SEQ ID NO: 51 is the determined DNA sequence for the C. trachomatis LGV II clone 19790CTL2_23consensus.seq(1>602)CTL2#23.

SEQ ID NO: 52 is the determined DNA sequence for the C. trachomatis LGV II clone 19791CTL2_24consensus.seq(1>145)CTL2#24.

SEQ ID NO: 53 is the determined DNA sequence for the C. trachomatis LGV II clone CTL2#4.

SEQ ID NO: 54 is the determined DNA sequence for the C. trachomatis LGV II clone CTL2#8b.

SEQ ID NO: 55 is the determined DNA sequence for the C. trachomatis LGV II clone15-G1-89, sharing homology to the lipoamide dehydrogenase gene CT557.

SEQ ID NO: 56 is the determined DNA sequence for the C. trachomatis LGV II clone 14-H1-4, sharing homology to the thiol specific antioxidant gene CT603.

SEQ ID NO: 57 is the determined DNA sequence for the C. trachomatis LGV II clone 12-G3-83, sharing homology to the hypothetical protein CT622.

SEQ ID NO: 58 is the determined DNA sequence for the C. trachomatis LGV II clone 12-B3-95, sharing homology to the lipoamide dehydrogenase gene CT557.

SEQ ID NO: 59 is the determined DNA sequence for the C. trachomatis LGV II clone 11-H4-28, sharing homology to the dnaK gene CT396.

SEQ ID NO: 60 is the determined DNA sequence for the *C. trachomatis* LGV II clone 11-H3-68, sharing partial homology to the PGP6-D virulence protein and L1 ribosomal gene CT318.

SEQ ID NO: 61 is the determined DNA sequence for the *C. trachomatis* LGV II clone 11-G1-34, sharing partial homology to the malate dehydrogenase gene CT376 and to the glycogen hydrolase gene CT042.

SEQ ID NO: 62 is the determined DNA sequence for the *C. trachomatis* LGV II clone 11-G10-46, sharing homology to the hypothetical protein CT610.

SEQ ID NO: 63 is the determined DNA sequence for the *C. trachomatis* LGV II clone 11-C12-91, sharing homology to the OMP2 gene CT443.

SEQ ID NO: 64 is the determined DNA sequence for the *C. trachomatis* LGV II clone 11-A3-93, sharing homology to the HAD superfamily gene CT103.

SEQ ID NO: 65 is the determined amino acid sequence for the *C. trachomatis* LGV II clone 14-H1-4, sharing homology to the thiol specific antioxidant gene CT603.

SEQ ID NO: 66 is the determined DNA sequence for the *C. trachomatis* LGV II clone CtL2#9.

SEQ ID NO: 67 is the determined DNA sequence for the *C. trachomatis* LGV II clone CtL2#7.

SEQ ID NO: 68 is the determined DNA sequence for the *C. trachomatis* LGV II clone CtL2#6.

SEQ ID NO: 69 is the determined DNA sequence for the *C. trachomatis* LGV II clone CtL2#5.

SEQ ID NO: 70 is the determined DNA sequence for the *C. trachomatis* LGV II clone CtL2#2.

SEQ ID NO: 71 is the determined DNA sequence for the *C. trachomatis* LGV II clone CtL2#1.

SEQ ID NO: 72 is a first determined DNA sequence for the *C. trachomatis* LGV II clone 23509.2CtL2#3-5', representing the 5' end.

SEQ ID NO: 73 is a second determined DNA sequence for the *C. trachomatis* LGV II clone 23509.1CtL2#3-3', representing the 3' end.

SEQ ID NO: 74 is a first determined DNA sequence for the *C. trachomatis* LGV II clone 22121.2CtL2#10-5', representing the 5' end.

SEQ ID NO: 75 is a second determined DNA sequence for the *C. trachomatis* LGV II clone 22121.1CtL2#10-3', representing the 3' end.

SEQ ID NO: 76 is the determined DNA sequence for the *C. trachomatis* LGV II clone 19787.6CtL2#19-5', representing the 5' end.

SEQ ID NO: 77 is the determined DNA sequence for the *C. pneumoniae* LGV II clone CpS13-His.

SEQ ID NO: 78 is the determined DNA sequence for the *C. pneumoniae* LGV II clone Cp_SWIB-His.

SEQ ID NO: 79 is the determined DNA sequence for the *C. trachomatis* LGV II clone 23-G7-68, sharing partial homology to the L11, L10 and L1 ribosomal protein.

SEQ ID NO: 80 is the determined DNA sequence for the *C. trachomatis* LGV II clone 22-F8-91, sharing homology to the pmpC gene.

SEQ ID NO: 81 is the determined DNA sequence for the *C. trachomatis* LGV II clone 21-E8-95, sharing homology to the CT610-CT613 genes.

SEQ ID NO: 82 is the determined DNA sequence for the *C. trachomatis* LGV II clone 19-F12-57, sharing homology to the CT858 and recA genes.

SEQ ID NO: 83 is the determined DNA sequence for the *C. trachomatis* LGV II clone 19-F12-53, sharing homology to the CT445 gene encoding glutamyl tRNA synthetase.

SEQ ID NO: 84 is the determined DNA sequence for the *C. trachomatis* LGV II clone 19-A5-54, sharing homology to the cryptic plasmid gene.

SEQ ID NO: 85 is the determined DNA sequence for the *C. trachomatis* LGV II clone 17-E11-72, sharing partial homology to the OppC_2 and pmpD genes.

SEQ ID NO: 86 is the determined DNA sequence for the *C. trachomatis* LGV II clone 17-C1-77, sharing partial homology to the CT857 and CT858 open reading frames.

SEQ ID NO: 87 is the determined DNA sequence for the *C. trachomatis* LGV II clone 15-H2-76, sharing partial homology to the pmpD and SycE genes, and to the CT089 ORF.

SEQ ID NO: 88 is the determined DNA sequence for the *C. trachomatis* LGV II clone 15-A3-26, sharing homology to the CT858 ORF.

SEQ ID NO: 89 is the determined amino acid sequence for the *C. pneumoniae* clone Cp_SWIB-His.

SEQ ID NO: 90 is the determined amino acid sequence for the *C. trachomatis* LGV II clone CtL2_LPDA_FL.

SEQ ID NO: 91 is the determined amino acid sequence for the *C. pneumoniae* clone CpS13-His.

SEQ ID NO: 92 is the determined amino acid sequence for the *C. trachomatis* LGV II clone CtL2_TSA_FL.

SEQ ID NO: 93 is the amino acid sequence for Ct-Swib 43-61 peptide from *C. trachomatis* LGV II.

SEQ ID NO: 94 is the amino acid sequence for Ct-Swib 48-67 peptide from *C. trachomatis* LGV II.

SEQ ID NO: 95 is the amino acid sequence for Ct-Swib 52-71 peptide from *C. trachomatis* LGV II.

SEQ ID NO: 96 is the amino acid sequence for Ct-Swib 58-77 peptide from *C. trachomatis* LGV II.

SEQ ID NO: 97 is the amino acid sequence for Ct-Swib 63-82 peptide from *C. trachomatis* LGV II.

SEQ ID NO: 98 is the amino acid sequence for Ct-Swib 51-66 peptide from *C. trachomatis* LGV II.

SEQ ID NO: 99 is the amino acid sequence for Cp-Swib 52-67 peptide from *C. pneumoniae*.

SEQ ID NO: 100 is the amino acid sequence for Cp-Swib 37-51 peptide from *C. pneumoniae*.

SEQ ID NO: 101 is the amino acid sequence for Cp-Swib 32-51 peptide from *C. pneumoniae*.

SEQ ID NO: 102 is the amino acid sequence for Cp-Swib 37-56 peptide from *C. pneumoniae*.

SEQ ID NO: 103 is the amino acid sequence for Ct-Swib 36-50 peptide from *C. trachomatis*.

SEQ ID NO: 104 is the amino acid sequence for Ct-S13 46-65 peptide from *C. trachomatis*.

SEQ ID NO: 105 is the amino acid sequence for Ct-S13 60-80 peptide from *C. trachomatis*.

SEQ ID NO: 106 is the amino acid sequence for Ct-S13 1-20 peptide from *C. trachomatis*.

SEQ ID NO: 107 is the amino acid sequence for Ct-S13 46-65 peptide from *C. trachomatis*.

SEQ ID NO: 108 is the amino acid sequence for Ct-S13 56-75 peptide from *C. trachomatis*.

SEQ ID NO: 109 is the amino acid sequence for Cp-S13 56-75 peptide from *C. pneumoniae*.

SEQ ID NO: 110 is the determined DNA sequence for the *C. trachomatis* LGV II clone 21-G12-60, containing partial open reading frames for hypothetical proteins CT875, CT229 and CT228.

SEQ ID NO: 111 is the determined DNA sequence for the *C. trachomatis* LGV II clone 22-B3-53, sharing homology to the CT110 ORF of GroEL.

SEQ ID NO: 112 is the determined DNA sequence for the *C. trachomatis* LGV II clone 22-A1-49, sharing partial homology to the CT660 and CT659 ORFs.

SEQ ID NO: 113 is the determined DNA sequence for the *C. trachomatis* LGV II clone 17-E2-9, sharing partial homology to the CT611 and CT 610 ORFs.

SEQ ID NO: 114 is the determined DNA sequence for the *C. trachomatis* LGV II clone 17-C10-31, sharing partial homology to the CT858 ORF.

SEQ ID NO: 115 is the determined DNA sequence for the *C. trachomatis* LGV II clone 21-C7-66, sharing homology to the dnaK-like gene.

SEQ ID NO: 116 is the determined DNA sequence for the *C. trachomatis* LGV II clone 20-G3-45, containing part of the pmpB gene CT413.

SEQ ID NO: 117 is the determined DNA sequence for the *C. trachomatis* LGV II clone 18-C5-2, sharing homology to the S1 ribosomal protein ORF.

SEQ ID NO: 118 is the determined DNA sequence for the *C. trachomatis* LGV II clone 17-C5-19, containing part of the ORFs for CT431 and CT430.

SEQ ID NO: 119 is the determined DNA sequence for the *C. trachomatis* LGV II clone 16-D4-22, contains partial sequences of ORF3 and ORF4 of the plasmid for growth within mammalian cells.

SEQ ID NO: 120 is the determined full-length DNA sequence for the *C. trachomatis* serovar LGV II Cap1 gene CT529.

SEQ ID NO: 121 is the predicted full-length amino acid sequence for the *C. trachomatis* serovar LGV II Cap1 gene CT529.

SEQ ID NO: 122 is the determined full-length DNA sequence for the *C. trachomatis* serovar E Cap1 gene CT529.

SEQ ID NO: 123 is the predicted full-length amino acid sequence for the *C. trachomatis* serovar E Cap1 gene CT529.

SEQ ID NO: 124 is the determined full-length DNA sequence for the *C. trachomatis* serovar 1A Cap1 gene CT529.

SEQ ID NO: 125 is the predicted full-length amino acid sequence for the *C. trachomatis* serovar 1A Cap1 gene CT529.

SEQ ID NO: 126 is the determined full-length DNA sequence for the *C. trachomatis* serovar G Cap1 gene CT529.

SEQ ID NO: 127 is the predicted full-length amino acid sequence for the *C. trachomatis* serovar G Cap1 gene CT529.

SEQ ID NO: 128 is the determined full-length DNA sequence for the *C. trachomatis* serovar F1 NII Cap1 gene CT529.

SEQ ID NO: 129 is the predicted full-length amino acid sequence for the *C. trachomatis* serovar F1 NII Cap1 gene CT529.

SEQ ID NO: 130 is the determined full-length DNA sequence for the *C. trachomatis* serovar L1 Cap1 gene CT529.

SEQ ID NO: 131 is the predicted full-length amino acid sequence for the C. trachomatis serovar L1 Cap1 gene CT529.

SEQ ID NO: 132 is the determined full-length DNA sequence for the C. trachomatis serovar L3 Cap1 gene CT529.

SEQ ID NO: 133 is the predicted full-length amino acid sequence for the C. trachomatis serovar L3 Cap1 gene CT529.

SEQ ID NO: 134 is the determined full-length DNA sequence for the C. trachomatis serovar Ba Cap1 gene CT529.

SEQ ID NO: 135 is the predicted full-length amino acid sequence for the C. trachomatis serovar Ba Cap1 gene CT529.

SEQ ID NO: 136 is the determined full-length DNA sequence for the C. trachomatis serovar MOPN Cap1 gene CT529.

SEQ ID NO: 137 is the predicted full-length amino acid sequence for the C. trachomatis serovar MOPN Cap1 gene CT529.

SEQ ID NO: 138 is the determined amino acid sequence for the Cap1 CT529 ORF peptide #124-139 of *C. trachomatis* serovar L2.

SEQ ID NO: 139 is the determined amino acid sequence for the Cap1 CT529 ORF peptide #132-147 of *C. trachomatis* serovar L2.

SEQ ID NO: 140 is the determined amino acid sequence for the Cap1 CT529 ORF peptide #138-155 of *C. trachomatis* serovar L2.

SEQ ID NO: 141 is the determined amino acid sequence for the Cap1 CT529 ORF peptide #146-163 of *C. trachomatis* serovar L2.

SEQ ID NO: 142 is the determined amino acid sequence for the Cap1 CT529 ORF peptide #154-171 of *C. trachomatis* serovar L2.

SEQ ID NO: 143 is the determined amino acid sequence for the Cap1 CT529 ORF peptide #162-178 of *C. trachomatis* serovar L2.

SEQ ID NO: 144 is the determined amino acid sequence for the Cap1 CT529 ORF peptide #138-147 of *C. trachomatis* serovar L2.

SEQ ID NO: 145 is the determined amino acid sequence for the Cap1 CT529 ORF peptide #139-147 of *C. trachomatis* serovar L2.

SEQ ID NO: 146 is the determined amino acid sequence for the Cap1 CT529 ORF peptide #140-147 of *C. trachomatis* serovar L2.

SEQ ID NO: 147 is the determined amino acid sequence for the Cap1 CT529 ORF peptide #138-146 of *C. trachomatis* serovar L2.

SEQ ID NO: 148 is the determined amino acid sequence for the Cap1 CT529 ORF peptide #138-145 of *C. trachomatis* serovar L2.

SEQ ID NO: 149 is the determined amino acid sequence for the Cap1 CT529 ORF peptide # F140->I of *C. trachomatis* serovar L2.

SEQ ID NO: 150 is the determined amino acid sequence for the Cap1 CT529 ORF peptide # #S139>Ga of *C. trachomatis* serovar L2.

SEQ ID NO: 151 is the determined amino acid sequence for the Cap1 CT529 ORF peptide # #S139>Gb of *C. trachomatis* serovar L2.

SEQ ID NO: 152 is the determined amino acid sequence for the peptide # 2 C7.8-6 of the 216aa ORF of *C. trachomatis* serovar L2.

SEQ ID NO: 153 is the determined amino acid sequence for the peptide # 2 C7.8-7 of the 216aa ORF of *C. trachomatis* serovar L2.

SEQ ID NO: 154 is the determined amino acid sequence for the peptide # 2 C7.8-8 of the 216aa ORF of *C. trachomatis* serovar L2.

SEQ ID NO: 155 is the determined amino acid sequence for the peptide # 2 C7.8-9 of the 216aa ORF of *C. trachomatis* serovar L2.

SEQ ID NO: 156 is the determined amino acid sequence for the peptide # 2 C7.8-10 of the 216aa ORF of *C. trachomatis* serovar L2.

SEQ ID NO: 157 is the determined amino acid sequence for the 53 amino acid residue peptide of the 216aa ORF within clone 2C7.8 of *C. trachomatis* serovar L2.

SEQ ID NO: 158 is the determined amino acid sequence for the 52 amino acid residue peptide of the CT529 ORF within clone 2C7.8 of *C. trachomatis* serovar L2.

SEQ ID NO: 159 is the determined DNA sequence for the 5' (forward) primer for cloning full-length CT529 serovar L2.

SEQ ID NO: 160 is the determined DNA sequence for the 5' (reverse) primer for cloning full-length CT529 serovar L2.

SEQ ID NO: 161 is the determined DNA sequence for the 5' (forward) primer for cloning full-length CT529 for serovars other than L2 and MOPN.

SEQ ID NO: 162 is the determined DNA sequence for the 5' (reverse) primer for cloning full-length CT529 serovars other than L2 and MOPN.

SEQ ID NO: 163 is the determined DNA sequence for the 5' (forward) primer for cloning full-length CT529 serovar MOPN.

SEQ ID NO: 164 is the determined DNA sequence for the 5' (reverse) primer for cloning full-length CT529 serovar MOPN.

SEQ ID NO: 165 is the determined DNA sequence for the 5' (forward) primer for pBIB-KS.

SEQ ID NO: 166 is the determined DNA sequence for the 5' (reverse) primer for pBIB-KS.

SEQ ID NO: 167 is the determined amino acid sequence for the 9-mer epitope peptide Cap1#139-147 from serovar L2.

SEQ ID NO: 168 is the determined amino acid sequence for the 9-mer epitope peptide Cap1#139-147 from serovar D.

SEQ ID NO: 169 is the determined full-length DNA sequence for the *C. trachomatis* pmpI gene.

SEQ ID NO: 170 is the determined full-length DNA sequence for the *C. trachomatis* pmpG gene.

SEQ ID NO: 171 is the determined full-length DNA sequence for the *C. trachomatis* pmpE gene.

SEQ ID NO: 172 is the determined full-length DNA sequence for the *C. trachomatis* pmpD gene.

SEQ ID NO: 173 is the determined full-length DNA sequence for the *C. trachomatis* pmpC gene.

SEQ ID NO: 174 is the determined full-length DNA sequence for the *C. trachomatis* pmpB gene.

SEQ ID NO: 175 is the predicted full-length amino acid sequence for the *C. trachomatis* pmpI gene.

SEQ ID NO: 176 is the predicted full-length amino acid sequence for the *C. trachomatis* pmpG gene.

SEQ ID NO: 177 is the predicted full-length amino acid sequence for the *C. trachomatis* pmpE gene.

SEQ ID NO: 178 is the predicted full-length amino acid sequence for the *C. trachomatis* pmpD gene.

SEQ ID NO: 179 is the predicted full-length amino acid sequence for the *C. trachomatis* pmpC gene.

SEQ ID NO: 180 is the predicted full-length amino acid sequence for the *C. trachomatis* pmpB gene.

SEQ ID NO: 181 is the determined DNA sequence minus the signal sequence for the *C. trachomatis* pmpI gene.

SEQ ID NO: 182 is a subsequently determined full-length DNA sequence for the *C. trachomatis* pmpG gene.

SEQ ID NO: 183 is the determined DNA sequence minus the signal sequence for the *C. trachomatis* pmpE gene.

SEQ ID NO: 184 is a first determined DNA sequence representing the carboxy terminus for the *C. trachomatis* pmpD gene.

SEQ ID NO: 185 is a second determined DNA sequence representing the amino terminus minus the signal sequence for the *C. trachomatis* pmpD gene.

SEQ ID NO: 186 is a first determined DNA sequence representing the carboxy terminus for the *C. trachomatis* pmpC gene.

SEQ ID NO: 187 is a second determined DNA sequence representing the amino terminus minus the signal sequence for the *C. trachomatis* pmpC gene.

SEQ ID NO: 188 is the determined DNA sequence representing the *C. pneumoniae* serovar MOMPS pmp gene in a fusion molecule with Ra12.

SEQ ID NO: 189 is the predicted amino acid sequence minus the signal sequence for the *C. trachomatis* pmpI gene.

SEQ ID NO: 190 is subsequently predicted amino acid sequence for the *C. trachomatis* pmpG gene.

SEQ ID NO: 191 is the predicted amino acid sequence minus the signal sequence for the *C. trachomatis* pmpE gene.

SEQ ID NO: 192 is a first predicted amino acid sequence representing the carboxy terminus for the *C. trachomatis* pmpD gene.

SEQ ID NO: 193 is a second predicted amino acid sequence representing the Amino terminus minus the signal sequence for the *C. trachomatis* pmpD gene.

SEQ ID NO: 194 is a first predicted amino acid sequence representing the Carboxy terminus for the *C. trachomatis* pmpC gene.

SEQ ID NO: 195 is a second predicted amino acid sequence representing the Amino terminus for the *C. trachomatis* pmpC gene.

SEQ ID NO: 196 is the predicted amino acid sequence representing the *C. pneumoniae* serovar MOMPS pmp gene in a fusion molecule with Ra12.

SEQ ID NO: 197 is the determined DNA sequence for the 5' oligo primer for cloning the *C. trachomatis* pmpC gene in the SKB vaccine vector.

SEQ ID NO: 198 is the determined DNA sequence for the 3' oligo primer for cloning the *C. trachomatis* pmpC gene in the SKB vaccine vector.

SEQ ID NO: 199 is the determined DNA sequence for the insertion sequence for cloning the *C. trachomatis* pmpC gene in the SKB vaccine vector.

SEQ ID NO: 200 is the determined DNA sequence for the 5' oligo primer for cloning the *C. trachomatis* pmpD gene in the SKB vaccine vector.

SEQ ID NO: 201 is the determined DNA sequence for the 3' oligo primer for cloning the *C. trachomatis* pmpD gene in the SKB vaccine vector.

SEQ ID NO: 202 is the determined DNA sequence for the insertion sequence for cloning the *C. trachomatis* pmpD gene in the SKB vaccine vector.

SEQ ID NO: 203 is the determined DNA sequence for the 5' oligo primer for cloning the *C. trachomatis* pmpE gene in the SKB vaccine vector.

SEQ ID NO: 204 is the determined DNA sequence for the 3' oligo primer for cloning the *C. trachomatis* pmpE gene in the SKB vaccine vector.

SEQ ID NO: 205 is the determined DNA sequence for the 5' oligo primer for cloning the *C. trachomatis* pmpG gene in the SKB vaccine vector.

SEQ ID NO: 206 is the determined DNA sequence for the 3' oligo primer for cloning the *C. trachomatis* pmpG gene in the SKB vaccine vector.

SEQ ID NO: 207 is the determined DNA sequence for the 5' oligo primer for cloning the amino terminus portion of the *C. trachomatis* pmpC gene in the pET17b vector.

SEQ ID NO: 208 is the determined DNA sequence for the 3' oligo primer for cloning the amino terminus portion of the *C. trachomatis* pmpC gene in the pET17b vector.

SEQ ID NO: 209 is the determined DNA sequence for the 5' oligo primer for cloning the carboxy terminus portion of the *C. trachomatis* pmpC gene in the pET17b vector.

SEQ ID NO: 210 is the determined DNA sequenc for the 3' oligo primer for cloning the carboxy terminus portion of the *C. trachomatis* pmpC gene in the pET17b vector.

SEQ ID NO: 211 is the determined DNA sequence for the 5' oligo primer for cloning the amino terminus portion of the *C. trachomatis* pmpD gene in the pET17b vector.

SEQ ID NO: 212 is the determined DNA sequence for the 3' oligo primer for cloning the amino terminus portion of the *C. trachomatis* pmpD gene in the pET17b vector.

SEQ ID NO: 213 is the determined DNA sequence for the 5' oligo primer for cloning the carboxy terminus portion of the *C. trachomatis* pmpD gene in the pET17b vector.

SEQ ID NO: 214 is the determined DNA sequence for the 3' oligo primer for cloning the carboxy terminus portion of the *C. trachomatis* pmpD gene in the pET17b vector.

SEQ ID NO: 215 is the determined DNA sequence for the 5' oligo primer for cloning the *C. trachomatis* pmpE gene in the pET17b vector.

SEQ ID NO: 216 is the determined DNA sequence for the 3' oligo primer for cloning the *C. trachomatis* pmpE gene in the pET17b vector.

SEQ ID NO: 217 is the determined DNA sequence for the insertion sequence for cloning the *C. trachomatis* pmpE gene in the pET17b vector.

SEQ ID NO: 218 is the amino acid sequence for the insertion sequence for cloning the *C. trachomatis* pmpE gene in the pET17b vector.

SEQ ID NO: 219 is the determined DNA sequence for the 5' oligo primer for cloning the *C. trachomatis* pmpG gene in the pET17b vector.

SEQ ID NO: 220 is the determined DNA sequence for the 3' oligo primer for cloning the *C. trachomatis* pmpG gene in the pET17b vector.

SEQ ID NO: 221 is the amino acid sequence for the insertion sequence for cloning the *C. trachomatis* pmpG gene in the pET17b vector.

SEQ ID NO: 222 is the determined DNA sequence for the 5' oligo primer for cloning the *C. trachomatis* pmpI gene in the pET17b vector.

SEQ ID NO: 223 is the determined DNA sequence for the 3' oligo primer for cloning the *C. trachomatis* pmpI gene in the pET17b vector.

SEQ ID NO: 224 is the determined amino acid sequence for the *C. pneumoniae* Swib peptide 1-20.

SEQ ID NO: 225 is the determined amino acid sequence for the *C. pneumoniae* Swib peptide 6-25.

SEQ ID NO: 226 is the determined amino acid sequence for the *C. pneumoniae* Swib peptide 12-31.

SEQ ID NO: 227 is the determined amino acid sequence for the *C. pneumoniae* Swib peptide 17-36.

SEQ ID NO: 228 is the determined amino acid sequence for the *C. pneumoniae* Swib peptide 22-41.

SEQ ID NO: 229 is the determined amino acid sequence for the *C. pneumoniae* Swib peptide 27-46.

SEQ ID NO: 230 is the determined amino acid sequence for the *C. pneumoniae* Swib peptide 42-61.

SEQ ID NO: 231 is the determined amino acid sequence for the *C. pneumoniae* Swib peptide 46-65.

SEQ ID NO: 232 is the determined amino acid sequence for the *C. pneumoniae* Swib peptide 51-70.

SEQ ID NO: 233 is the determined amino acid sequence for the *C. pneumoniae* Swib peptide 56-75.

SEQ ID NO: 234 is the determined amino acid sequence for the *C. pneumoniae* Swib peptide 61-80.

SEQ ID NO: 235 is the determined amino acid sequence for the *C. pneumoniae* Swib peptide 66-87.

SEQ ID NO: 236 is the determined amino acid sequence for the *C. trachomatis* OMCB peptide 103-122.

SEQ ID NO: 237 is the determined amino acid sequence for the *C. trachomatis* OMCB peptide 108-127.

SEQ ID NO: 238 is the determined amino acid sequence for the *C. trachomatis* OMCB peptide 113-132.

SEQ ID NO: 239 is the determined amino acid sequence for the *C. trachomatis* OMCB peptide 118-137.

SEQ ID NO: 240 is the determined amino acid sequence for the *C. trachomatis* OMCB peptide 123-143.

SEQ ID NO: 241 is the determined amino acid sequence for the *C. trachomatis* OMCB peptide 128-147.

SEQ ID NO: 242 is the determined amino acid sequence for the *C. trachomatis* OMCB peptide 133-152.

SEQ ID NO: 243 is the determined amino acid sequence for the *C. trachomatis* OMCB peptide 137-156.

SEQ ID NO: 244 is the determined amino acid sequence for the *C. trachomatis* OMCB peptide 142-161.

SEQ ID NO: 245 is the determined amino acid sequence for the *C. trachomatis* OMCB peptide 147-166.

SEQ ID NO: 246 is the determined amino acid sequence for the *C. trachomatis* OMCB peptide 152-171.

SEQ ID NO: 247 is the determined amino acid sequence for the *C. trachomatis* OMCB peptide 157-176.

SEQ ID NO: 248 is the determined amino acid sequence for the *C. trachomatis* OMCB peptide 162-181.

SEQ ID NO: 249 is the determined amino acid sequence for the *C. trachomatis* OMCB peptide 167-186.

SEQ ID NO: 250 is the determined amino acid sequence for the *C. trachomatis* OMCB peptide 171-190.

SEQ ID NO: 251 is the determined amino acid sequence for the *C. trachomatis* OMCB peptide 171-186.

SEQ ID NO: 252 is the determined amino acid sequence for the *C. trachomatis* OMCB peptide 175-186.

SEQ ID NO: 252 is the determined amino acid sequence for the *C. trachomatis* OMCB peptide 175-186.

SEQ ID NO: 253 is the determined amino acid sequence for the *C. pneumoniae* OMCB peptide 185-198.

SEQ ID NO: 254 is the determined amino acid sequence for the *C. trachomatis* TSA peptide 96-115.

SEQ ID NO: 255 is the determined amino acid sequence for the *C. trachomatis* TSA peptide 101-120.

SEQ ID NO: 256 is the determined amino acid sequence for the *C. trachomatis* TSA peptide 106-125.

SEQ ID NO: 257 is the determined amino acid sequence for the *C. trachomatis* TSA peptide 111-130.

SEQ ID NO: 258 is the determined amino acid sequence for the *C. trachomatis* TSA peptide 116-135.

SEQ ID NO: 259 is the determined amino acid sequence for the *C. trachomatis* TSA peptide 121-140.

SEQ ID NO: 260 is the determined amino acid sequence for the *C. trachomatis* TSA peptide 126-145.

SEQ ID NO: 261 is the determined amino acid sequence for the *C. trachomatis* TSA peptide 131-150.

SEQ ID NO: 262 is the determined amino acid sequence for the *C. trachomatis* TSA peptide 136-155.

SEQ ID NO: 263 is the determined full-length DNA sequence for the *C. trachomatis* CT529/Cap 1 gene serovar I.

SEQ ID NO: 264 is the predicted full-length amino sequence for the *C. trachomatis* CT529/Cap 1 gene serovar I.

SEQ ID NO: 265 is the determined full-length DNA sequence for the *C. trachomatis* CT529/Cap 1 gene serovar K.

SEQ ID NO: 266 is the predicted full-length amino sequence for the *C. trachomatis* CT529/Cap 1 gene serovar K.

SEQ ID NO: 267 is the determined DNA sequence for the *C. trachomatis* clone 17-G4-36 sharing homology to part of the ORF of DNA-directed RNA polymerase beta subunit- CT315 in serD.

SEQ ID NO: 268 is the determined DNA sequence for the partial sequence of the *C. trachomatis* CT016 gene in clone 2E10.

SEQ ID NO: 269 is the determined DNA sequence for the partial sequence of the *C. trachomatis* tRNA synthase gene in clone 2E10.

SEQ ID NO: 270 is the determined DNA sequence for the partial sequence for the *C. trachomatis* clpX gene in clone 2E10.

SEQ ID NO: 271 is a first determined DNA sequence for the *C. trachomatis* clone CtL2gam-30 representing the 5'end.

SEQ ID NO: 272 is a second determined DNA sequence for the *C. trachomatis* clone CtL2gam-30 representing the 3'end.

SEQ ID NO: 273 is the determined DNA sequence for the *C. trachomatis* clone CtL2gam-28.

SEQ ID NO: 274 is the determined DNA sequence for the *C. trachomatis* clone CtL2gam-27.

SEQ ID NO: 275 is the determined DNA sequence for the *C. trachomatis* clone CtL2gam-26.

SEQ ID NO: 276 is the determined DNA sequence for the *C. trachomatis* clone CtL2gam-24.

SEQ ID NO: 277 is the determined DNA sequence for the *C. trachomatis* clone CtL2gam-23.

SEQ ID NO: 278 is the determined DNA sequence for the *C. trachomatis* clone CtL2gam-21.

SEQ ID NO: 279 is the determined DNA sequence for the *C. trachomatis*

clone CtL2gam-18.

SEQ ID NO: 280 is the determined DNA sequence for the *C. trachomatis* clone CtL2gam-17.

SEQ ID NO: 281 is a first determined DNA sequence for the *C. trachomatis* clone CtL2gam-15 representing the 5' end.

SEQ ID NO: 282 is a second determined DNA sequence for the *C. trachomatis* clone CtL2gam-15 representing the 3' end.

SEQ ID NO: 283 is the determined DNA sequence for the *C. trachomatis* clone CtL2gam-13.

SEQ ID NO: 284 is the determined DNA sequence for the *C. trachomatis* clone CtL2gam-10.

SEQ ID NO: 285 is the determined DNA sequence for the *C. trachomatis* clone CtL2gam-8.

SEQ ID NO: 286 is a first determined DNA sequence for the *C. trachomatis* clone CtL2gam-6 representing the 5' end.

SEQ ID NO: 287 is a second determined DNA sequence for the *C. trachomatis* clone CtL2gam-6 representing the 3' end.

SEQ ID NO: 288 is the determined DNA sequence for the *C. trachomatis* clone CtL2gam-5.

SEQ ID NO: 289 is the determined DNA sequence for the *C. trachomatis* clone CtL2gam-2.

SEQ ID NO: 290 is the determined DNA sequence for the *C. trachomatis* clone CtL2gam-1.

SEQ ID NO: 291 is the determined full-length DNA sequence for the *C. pneumoniae* homologue of the CT529 gene.

SEQ ID NO: 292 is the predicted full-length amino acid sequence for the *C. pneumoniae* homologue of the CT529 gene.

SEQ ID NO: 293 is the determined DNA sequence for the insertion sequence for cloning the *C. trachomatis* pmpG gene in the SKB vaccine vector.

DESCRIPTION OF THE FIGURES

Fig. 1 illustrates induction of INF- γ from a *Chlamydia*-specific T cell line activated by target cells expressing clone 4C9-18#2.

Fig. 2 illustrates retroviral vectors pBIB-KS1,2,3 modified to contain a Kosak translation initiation site and stop codons.

Fig. 3 shows specific lysis in a chromium release assay of P815 cells pulsed with *Chlamydia* peptides CtC7.8-12 (SEQ ID NO: 18) and CtC7.8-13 (SEQ ID NO: 19).

Fig. 4 shows antibody isotype titers in C57Bl/6 mice immunized with *C. trachomatis* SWIB protein.

Fig. 5 shows *Chlamydia*-specific T-cell proliferative responses in splenocytes from C3H mice immunized with *C. trachomatis* SWIB protein.

Fig. 6 illustrates the 5' and 3' primer sequences designed from *C. pneumoniae* which were used to isolate the SWIB and S13 genes from *C. pneumoniae*.

Figs. 7A and 7B show induction of IFN- γ from a human anti-*chlamydia* T-cell line (TCL-8) capable of cross-reacting to *C. trachomatis* and *C. pneumonia* upon activation by monocyte-derived dendritic cells expressing chlamydial proteins.

Fig. 8 shows the identification of T cell epitopes in Chlamydial ribosomal S13 protein with T-cell line TCL 8 EB/DC.

Fig. 9 illustrates the proliferative response of CP-21 T-cells generated against *C. pneumoniae*-infected dendritic cells to recombinant *C. pneumonia*-SWIBprotein, but not *C. trachomatis* SWIB protein.

Fig. 10 shows the *C. trachomatis*-specific SWIB proliferative responses of a primary T-cell line (TCT-10 EB) from an asymptomatic donor.

Fig. 11 illustrates the identification of T-cell epitope in *C. trachomatis* SWIB with an antigen specific T-cell line (TCL-10 EB).

DETAILED DESCRIPTION OF THE INVENTION

As noted above, the present invention is generally directed to compositions and methods for the diagnosis and treatment of Chlamydial infection. In one aspect, the compositions of the subject invention include polypeptides that comprise at least one immunogenic portion of a *Chlamydia* antigen, or a variant thereof.

In specific embodiments, the subject invention discloses polypeptides comprising an immunogenic portion of a *Chlamydia* antigen, wherein the *Chlamydia* antigen comprises an amino acid sequence encoded by a polynucleotide molecule including a sequence selected from the group consisting of (a) nucleotide sequences recited in SEQ ID NO: 1, 15, 21-25, 44-64, 66-76, 79-88, 110-119, 120, 122, 124, 126, 128, 130, 132, 134, 136, 169-174, 181-188, 263, 265 and 267-290 (b) the complements of said nucleotide sequences, and (c) variants of such sequences.

As used herein, the term "polypeptide" encompasses amino acid chains of any length, including full length proteins (*i.e.*, antigens), wherein the amino acid residues are linked by covalent peptide bonds. Thus, a polypeptide comprising an immunogenic portion of one of the inventive antigens may consist entirely of the immunogenic portion, or may contain additional sequences. The additional sequences may be derived from the native *Chlamydia* antigen or may be heterologous, and such sequences may (but need not) be immunogenic.

The term "polynucleotide(s)," as used herein, means a single or double-stranded polymer of deoxyribonucleotide or ribonucleotide bases and includes DNA and corresponding RNA molecules, including HnRNA and mRNA molecules, both sense and anti-sense strands, and comprehends cDNA, genomic DNA and recombinant DNA, as well as wholly or partially synthesized polynucleotides. An HnRNA molecule contains introns and corresponds to a DNA molecule in a generally one-to-one manner. An mRNA molecule corresponds to an HnRNA and DNA molecule from which the introns have been excised. A polynucleotide may consist of an entire gene, or any portion thereof. Operable anti-sense polynucleotides may comprise a fragment of the corresponding polynucleotide, and the definition of "polynucleotide" therefore includes all such operable anti-sense fragments.

An "immunogenic portion" of an antigen is a portion that is capable of reacting with sera obtained from a *Chlamydia*-infected individual (*i.e.*, generates an absorbance reading with sera from infected individuals that is at least three standard deviations above the absorbance obtained with sera from uninfected individuals, in a representative ELISA assay described herein). Such immunogenic portions generally comprise at least about 5 amino acid residues, more preferably at least about 10, and most

preferably at least about 20 amino acid residues. Methods for preparing and identifying immunogenic portions of antigens of known sequence are well known in the art and include those summarized in Paul, *Fundamental Immunology*, 3rd ed., Raven Press, 1993, pp. 243-247 and references cited therein. Such techniques include screening polypeptides for the ability to react with antigen-specific antibodies, antisera and/or T-cell lines or clones. As used herein, antisera and antibodies are "antigen-specific" if they specifically bind to an antigen (*i.e.*, they react with the protein in an ELISA or other immunoassay, and do not react detectably with unrelated proteins). Such antisera and antibodies may be prepared as described herein, and using well known techniques. An immunogenic portion of a native *Chlamydia* protein is a portion that reacts with such antisera and/or T-cells at a level that is not substantially less than the reactivity of the full length polypeptide (*e.g.*, in an ELISA and/or T-cell reactivity assay). Such immunogenic portions may react within such assays at a level that is similar to or greater than the reactivity of the full length polypeptide. Such screens may generally be performed using methods well known to those of ordinary skill in the art, such as those described in Harlow and Lane, *Antibodies: A Laboratory Manual*, Cold Spring Harbor Laboratory, 1988. For example, a polypeptide may be immobilized on a solid support and contacted with patient sera to allow binding of antibodies within the sera to the immobilized polypeptide. Unbound sera may then be removed and bound antibodies detected using, for example, ¹²⁵I-labeled Protein A.

Examples of immunogenic portions of antigens contemplated by the present invention include, for example, the T cell stimulating epitopes provided in SEQ ID NO: 9, 10, 18, 19, 31, 39, 93-96, 98, 100-102, 106, 108, 138-140, 158, 167, 168, 246, 247 and 254-256. Polypeptides comprising at least an immunogenic portion of one or more *Chlamydia* antigens as described herein may generally be used, alone or in combination, to detect Chlamydial infection in a patient.

The compositions and methods of the present invention also encompass variants of the above polypeptides and polynucleotide molecules. Such variants include, but are not limited to, naturally occurring allelic variants of the inventive sequences. In particular, variants include other *Chlamydiae* serovars, such as serovars D, E and F, as well as the several LGV serovars which share homology to the inventive polypeptide and

polynucleotide molecules described herein. Preferably, the serovar homologues show 95-99% homology to the corresponding polypeptide sequence(s) described herein.

A polypeptide "variant," as used herein, is a polypeptide that differs from the recited polypeptide only in conservative substitutions and/or modifications, such that the antigenic properties of the polypeptide are retained. In a preferred embodiment, variant polypeptides differ from an identified sequence by substitution, deletion or addition of five amino acids or fewer. Such variants may generally be identified by modifying one of the above polypeptide sequences, and evaluating the antigenic properties of the modified polypeptide using, for example, the representative procedures described herein. In other words, the ability of a variant to react with antigen-specific antisera may be enhanced or unchanged, relative to the native protein, or may be diminished by less than 50%, and preferably less than 20%, relative to the native protein. Such variants may generally be identified by modifying one of the above polypeptide sequences and evaluating the reactivity of the modified polypeptide with antigen-specific antibodies or antisera as described herein. Preferred variants include those in which one or more portions, such as an N-terminal leader sequence or transmembrane domain, have been removed. Other preferred variants include variants in which a small portion (*e.g.*, 1-30 amino acids, preferably 5-15 amino acids) has been removed from the N- and/or C-terminal of the mature protein. Polypeptide variants preferably exhibit at least about 70%, more preferably at least about 90% and most preferably at least about 95% identity (determined as described below) to the identified polypeptides.

As used herein, a "conservative substitution" is one in which an amino acid is substituted for another amino acid that has similar properties, such that one skilled in the art of peptide chemistry would expect the secondary structure and hydrophobic nature of the polypeptide to be substantially unchanged. Amino acid substitutions may generally be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity and/or the amphipathic nature of the residues. For example, negatively charged amino acids include aspartic acid and glutamic acid; positively charged amino acids include lysine and arginine; and amino acids with uncharged polar head groups having similar hydrophilicity values include leucine, isoleucine and valine; glycine and alanine; asparagine and glutamine; and serine, threonine, phenylalanine and tyrosine. Other groups of amino acids that may represent

conservative changes include: (1) ala, pro, gly, glu, asp, gln, asn, ser, thr; (2) cys, ser, tyr, thr; (3) val, ile, leu, met, ala, phe; (4) lys, arg, his; and (5) phe, tyr, trp, his. A variant may also, or alternatively, contain nonconservative changes. In a preferred embodiment, variant polypeptides differ from a native sequence by substitution, deletion or addition of five amino acids or fewer. Variants may also (or alternatively) be modified by, for example, the deletion or addition of amino acids that have minimal influence on the immunogenicity, secondary structure and hydrophobic nature of the polypeptide. Variants may also, or alternatively, contain other modifications, including the deletion or addition of amino acids that have minimal influence on the antigenic properties, secondary structure and hydrophobic nature of the polypeptide. For example, a polypeptide may be conjugated to a signal (or leader) sequence at the N-terminal end of the protein which co-translationally or post-translationally directs transfer of the protein. The polypeptide may also be conjugated to a linker or other sequence for ease of synthesis, purification or identification of the polypeptide (e.g., poly-His), or to enhance binding of the polypeptide to a solid support. For example, a polypeptide may be conjugated to an immunoglobulin Fc region.

A polynucleotide "variant" is a sequence that differs from the recited nucleotide sequence in having one or more nucleotide deletions, substitutions or additions such that the immunogenicity of the encoded polypeptide is not diminished, relative to the native protein. The effect on the immunogenicity of the encoded polypeptide may generally be assessed as described herein. Such modifications may be readily introduced using standard mutagenesis techniques, such as oligonucleotide-directed site-specific mutagenesis as taught, for example, by Adelman et al. (*DNA*, 2:183, 1983). Nucleotide variants may be naturally occurring allelic variants as discussed below, or non-naturally occurring variants. Variant nucleotide sequences preferably exhibit at least about 70%, more preferably at least about 80% and most preferably at least about 90% identity (determined as described below) to the recited sequence.

The polypeptides provided by the present invention include variants that are encoded by polynucleotide sequences which are substantially homologous to one or more of the polynucleotide sequences specifically recited herein. "Substantial homology," as used herein, refers to polynucleotide sequences that are capable of hybridizing under moderately

stringent conditions. Suitable moderately stringent conditions include prewashing in a solution of 5X SSC, 0.5% SDS, 1.0 mM EDTA (pH 8.0); hybridizing at 50°C-65°C, 5X SSC, overnight or, in the event of cross-species homology, at 45°C with 0.5X SSC; followed by washing twice at 65°C for 20 minutes with each of 2X, 0.5X and 0.2X SSC containing 0.1% SDS. Such hybridizing polynucleotide sequences are also within the scope of this invention, as are nucleotide sequences that, due to code degeneracy, encode a polypeptide that is the same as a polypeptide of the present invention.

Two nucleotide or polypeptide sequences are said to be "identical" if the sequence of nucleotides or amino acid residues in the two sequences is the same when aligned for maximum correspondence as described below. Comparisons between two sequences are typically performed by comparing the sequences over a comparison window to identify and compare local regions of sequence similarity. A "comparison window" as used herein, refers to a segment of at least about 20 contiguous positions, usually 30 to about 75, 40 to about 50, in which a sequence may be compared to a reference sequence of the same number of contiguous positions after the two sequences are optimally aligned.

Optimal alignment of sequences for comparison may be conducted using the Megalign program in the Lasergene suite of bioinformatics software (DNASTAR, Inc., Madison, WI), using default parameters. This program embodies several alignment schemes described in the following references: Dayhoff, M.O. (1978) A model of evolutionary change in proteins – Matrices for detecting distant relationships. In Dayhoff, M.O. (ed.) *Atlas of Protein Sequence and Structure*, National Biomedical Research Foundation, Washington DC Vol. 5, Suppl. 3, pp. 345-358; Hein J. (1990) Unified Approach to Alignment and Phylogenesis pp. 626-645 *Methods in Enzymology* vol. 183, Academic Press, Inc., San Diego, CA; Higgins, D.G. and Sharp, P.M. (1989) Fast and sensitive multiple sequence alignments on a microcomputer *CABIOS* 5:151-153; Myers, E.W. and Muller W. (1988) Optimal alignments in linear space *CABIOS* 4:11-17; Robinson, E.D. (1971) *Comb. Theor* 11:105; Santou, N. Nes, M. (1987) The neighbor joining method. A new method for reconstructing phylogenetic trees *Mol. Biol. Evol.* 4:406-425; Sneath, P.H.A. and Sokal, R.R. (1973) *Numerical Taxonomy – the Principles and Practice of Numerical Taxonomy*, Freeman Press, San

Francisco, CA; Wilbur, W.J. and Lipman, D.J. (1983) Rapid similarity searches of nucleic acid and protein data banks *Proc. Natl. Acad., Sci. USA* 80:726-730.

Preferably, the "percentage of sequence identity" is determined by comparing two optimally aligned sequences over a window of comparison of at least 20 positions, wherein the portion of the polynucleotide sequence in the comparison window may comprise additions or deletions (i.e. gaps) of 20 percent or less, usually 5 to 15 percent, or 10 to 12 percent, as compared to the reference sequences (which does not comprise additions or deletions) for optimal alignment of the two sequences. The percentage is calculated by determining the number of positions at which the identical nucleic acid bases or amino acid residue occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the reference sequence (i.e. the window size) and multiplying the results by 100 to yield the percentage of sequence identity.

Also included in the scope of the present invention are alleles of the genes encoding the nucleotide sequences recited in herein. As used herein, an "allele" or "allelic sequence" is an alternative form of the gene which may result from at least one mutation in the nucleic acid sequence. Alleles may result in altered mRNAs or polypeptides whose structure or function may or may not be altered. Any given gene may have none, one, or many allelic forms. Common mutational changes which give rise to alleles are generally ascribed to natural deletions, additions, or substitutions of nucleotides. Each of these types of changes may occur alone or in combination with the others, one or more times in a given sequence. In specific embodiments, the subject invention discloses polypeptides comprising at least an immunogenic portion of a *Chlamydia* antigen (or a variant of such an antigen), that comprises one or more of the amino acid sequences encoded by (a) a polynucleotide sequence selected from the group consisting of SEQ ID NO: 1-4, 15 21-25, 44-64, 66-76 and 79-88; (b) the complements of such DNA sequences or (c) DNA sequences substantially homologous to a sequence in (a) or (b). As discussed in the Examples below, several of the *Chlamydia* antigens disclosed herein recognize a T cell line that recognizes both *Chlamydia trachomatis* and *Chlamydia pneumoniae* infected monocyte-derived dendritic cells, indicating that they may represent an immunoreactive epitope shared by *Chlamydia trachomatis* and

Chlamydia pneumoniae. The antigens may thus be employed in a vaccine for both *C. trachomatis* genital tract infections and for *C. pneumonia* infections. Further characterization of these *Chlamydia* antigens from *Chlamydia trachomatis* and *Chlamydia pneumonia* to determine the extent of cross-reactivity is provided in Example 6. Additionally, Example 4 describes cDNA fragments (SEQ ID NO: 15, 16 and 33) isolated from *C. trachomatis* which encode proteins (SEQ ID NO: 17-19 and 32) capable of stimulating a *Chlamydia*-specific murine CD8⁺ T cell line.

In general, *Chlamydia* antigens, and polynucleotide sequences encoding such antigens, may be prepared using any of a variety of procedures. For example, polynucleotide molecules encoding *Chlamydia* antigens may be isolated from a *Chlamydia* genomic or cDNA expression library by screening with a *Chlamydia*-specific T cell line as described below, and sequenced using techniques well known to those of skill in the art. Additionally, a polynucleotide may be identified, as described in more detail below, by screening a microarray of cDNAs for *Chlamydia*-associated expression (*i.e.*, expression that is at least two fold greater in *Chlamydia*-infected cells than in controls, as determined using a representative assay provided herein). Such screens may be performed using a Synteni microarray (Palo Alto, CA) according to the manufacturer's instructions (and essentially as described by Schena et al., *Proc. Natl. Acad. Sci. USA* 93:10614-10619, 1996 and Heller et al., *Proc. Natl. Acad. Sci. USA* 94:2150-2155, 1997). Alternatively, polypeptides may be amplified from cDNA prepared from cells expressing the proteins described herein.. Such polynucleotides may be amplified via polymerase chain reaction (PCR). For this approach, sequence-specific primers may be designed based on the sequences provided herein, and may be purchased or synthesized.

Antigens may be produced recombinantly, as described below, by inserting a polynucleotide sequence that encodes the antigen into an expression vector and expressing the antigen in an appropriate host. Antigens may be evaluated for a desired property, such as the ability to react with sera obtained from a *Chlamydia*-infected individual as described herein, and may be sequenced using, for example, traditional Edman chemistry. See Edman and Berg, *Eur. J. Biochem.* 80:116-132, 1967.

Polynucleotide sequences encoding antigens may also be obtained by screening an appropriate *Chlamydia* cDNA or genomic DNA library for polynucleotide sequences that hybridize to degenerate oligonucleotides derived from partial amino acid sequences of isolated antigens. Degenerate oligonucleotide sequences for use in such a screen may be designed and synthesized, and the screen may be performed, as described (for example) in Sambrook et al., *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratories, Cold Spring Harbor, NY (and references cited therein). Polymerase chain reaction (PCR) may also be employed, using the above oligonucleotides in methods well known in the art, to isolate a nucleic acid probe from a cDNA or genomic library. The library screen may then be performed using the isolated probe.

An amplified portion may be used to isolate a full length gene from a suitable library (e.g., a *Chlamydia* cDNA library) using well known techniques. Within such techniques, a library (cDNA or genomic) is screened using one or more polynucleotide probes or primers suitable for amplification. Preferably, a library is size-selected to include larger molecules. Random primed libraries may also be preferred for identifying 5' and upstream regions of genes. Genomic libraries are preferred for obtaining introns and extending 5' sequences.

For hybridization techniques, a partial sequence may be labeled (e.g., by nick-translation or end-labeling with ^{32}P) using well known techniques. A bacterial or bacteriophage library is then screened by hybridizing filters containing denatured bacterial colonies (or lawns containing phage plaques) with the labeled probe (see Sambrook et al., *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratories, Cold Spring Harbor, NY, 1989). Hybridizing colonies or plaques are selected and expanded, and the DNA is isolated for further analysis. cDNA clones may be analyzed to determine the amount of additional sequence by, for example, PCR using a primer from the partial sequence and a primer from the vector. Restriction maps and partial sequences may be generated to identify one or more overlapping clones. The complete sequence may then be determined using standard techniques, which may involve generating a series of deletion clones. The resulting overlapping sequences are then assembled into a single contiguous sequence. A full length cDNA molecule can be generated by ligating suitable fragments, using well known

techniques.

Alternatively, there are numerous amplification techniques for obtaining a full length coding sequence from a partial cDNA sequence. Within such techniques, amplification is generally performed via PCR. Any of a variety of commercially available kits may be used to perform the amplification step. Primers may be designed using techniques well known in the art (see, for example, Mullis et al., *Cold Spring Harbor Symp. Quant. Biol.* 51:263, 1987; Erlich ed., *PCR Technology*, Stockton Press, NY, 1989), and software well known in the art may also be employed. Primers are preferably 22-30 nucleotides in length, have a GC content of at least 50% and anneal to the target sequence at temperatures of about 68°C to 72°C. The amplified region may be sequenced as described above, and overlapping sequences assembled into a contiguous sequence.

One such amplification technique is inverse PCR (see Triglia et al., *Nucl. Acids Res.* 16:8186, 1988), which uses restriction enzymes to generate a fragment in the known region of the gene. The fragment is then circularized by intramolecular ligation and used as a template for PCR with divergent primers derived from the known region. Within an alternative approach, sequences adjacent to a partial sequence may be retrieved by amplification with a primer to a linker sequence and a primer specific to a known region. The amplified sequences are typically subjected to a second round of amplification with the same linker primer and a second primer specific to the known region. A variation on this procedure, which employs two primers that initiate extension in opposite directions from the known sequence, is described in WO 96/38591. Additional techniques include capture PCR (Lagerstrom et al., *PCR Methods Applic.* 1:111-19, 1991) and walking PCR (Parker et al., *Nucl. Acids. Res.* 19:3055-60, 1991). Transcription-Mediated Amplification, or TMA is another method that may be utilized for the amplification of DNA, rRNA, or mRNA, as described in Patent No. PCT/US91/03184. This autocatalytic and isothermal non-PCR based method utilizes two primers and two enzymes: RNA polymerase and reverse transcriptase. One primer contains a promoter sequence for RNA polymerase. In the first amplification, the promoter-primer hybridizes to the target rRNA at a defined site. Reverse transcriptase creates a DNA copy of the target rRNA by extension from the 3' end of the promoter-primer. The RNA in the resulting complex is degraded and a second primer binds to the DNA copy. A

new strand of DNA is synthesized from the end of the primer by reverse transcriptase creating double stranded DNA. RNA polymerase recognizes the promoter sequence in the DNA template and initiates transcription. Each of the newly synthesized RNA amplicons re-enters the TMA process and serves as a template for a new round of replication leading to the exponential expansion of the RNA amplicon. Other methods employing amplification may also be employed to obtain a full length cDNA sequence.

In certain instances, it is possible to obtain a full length cDNA sequence by analysis of sequences provided in an expressed sequence tag (EST) database, such as that available from GenBank. Searches for overlapping ESTs may generally be performed using well known programs (*e.g.*, NCBI BLAST searches), and such ESTs may be used to generate a contiguous full length sequence. Full length cDNA sequences may also be obtained by analysis of genomic fragments.

Polynucleotide variants may generally be prepared by any method known in the art, including chemical synthesis by, for example, solid phase phosphoramidite chemical synthesis. Modifications in a polynucleotide sequence may also be introduced using standard mutagenesis techniques, such as oligonucleotide-directed site-specific mutagenesis (*see* Adelman et al., *DNA* 2:183, 1983). Alternatively, RNA molecules may be generated by *in vitro* or *in vivo* transcription of DNA sequences encoding a *Chlamydial* protein, or portion thereof, provided that the DNA is incorporated into a vector with a suitable RNA polymerase promoter (such as T7 or SP6). Certain portions may be used to prepare an encoded polypeptide, as described herein. In addition, or alternatively, a portion may be administered to a patient such that the encoded polypeptide is generated *in vivo* (*e.g.*, by transfecting antigen-presenting cells, such as dendritic cells, with a cDNA construct encoding a *Chlamydial* polypeptide, and administering the transfected cells to the patient).

A portion of a sequence complementary to a coding sequence (*i.e.*, an antisense polynucleotide) may also be used as a probe or to modulate gene expression. cDNA constructs that can be transcribed into antisense RNA may also be introduced into cells of tissues to facilitate the production of antisense RNA. An antisense polynucleotide may be used, as described herein, to inhibit expression of a *Chlamydial* protein. Antisense technology can be used to control gene expression through triple-helix formation, which

compromises the ability of the double helix to open sufficiently for the binding of polymerases, transcription factors or regulatory molecules (*see* Gee et al., *In Huber and Carr, Molecular and Immunologic Approaches*, Futura Publishing Co. (Mt. Kisco, NY; 1994)). Alternatively, an antisense molecule may be designed to hybridize with a control region of a gene (*e.g.*, promoter, enhancer or transcription initiation site), and block transcription of the gene; or to block translation by inhibiting binding of a transcript to ribosomes.

A portion of a coding sequence, or of a complementary sequence, may also be designed as a probe or primer to detect gene expression. Probes may be labeled with a variety of reporter groups, such as radionuclides and enzymes, and are preferably at least 10 nucleotides in length, more preferably at least 20 nucleotides in length and still more preferably at least 30 nucleotides in length. Primers, as noted above, are preferably 22-30 nucleotides in length.

Any polynucleotide may be further modified to increase stability *in vivo*. Possible modifications include, but are not limited to, the addition of flanking sequences at the 5' and/or 3' ends; the use of phosphorothioate or 2' O-methyl rather than phosphodiesterase linkages in the backbone; and/or the inclusion of nontraditional bases such as inosine, queosine and wybutosine, as well as acetyl- methyl-, thio- and other modified forms of adenine, cytidine, guanine, thymine and uridine.

Nucleotide sequences as described herein may be joined to a variety of other nucleotide sequences using established recombinant DNA techniques. For example, a polynucleotide may be cloned into any of a variety of cloning vectors, including plasmids, phagemids, lambda phage derivatives and cosmids. Vectors of particular interest include expression vectors, replication vectors, probe generation vectors and sequencing vectors. In general, a vector will contain an origin of replication functional in at least one organism, convenient restriction endonuclease sites and one or more selectable markers. Other elements will depend upon the desired use, and will be apparent to those of ordinary skill in the art.

Synthetic polypeptides having fewer than about 100 amino acids, and generally fewer than about 50 amino acids, may be generated using techniques well known in the art. For example, such polypeptides may be synthesized using any of the commercially available solid-phase techniques, such as the Merrifield solid-phase synthesis method, where

amino acids are sequentially added to a growing amino acid chain. See Merrifield, *J. Am. Chem. Soc.* 85:2149-2146, 1963. Equipment for automated synthesis of polypeptides is commercially available from suppliers such as Perkin Elmer/Applied BioSystems Division, Foster City, CA, and may be operated according to the manufacturer's instructions.

As noted above, immunogenic portions of *Chlamydia* antigens may be prepared and identified using well known techniques, such as those summarized in Paul, *Fundamental Immunology*, 3d ed., Raven Press, 1993, pp. 243-247 and references cited therein. Such techniques include screening polypeptide portions of the native antigen for immunogenic properties. The representative ELISAs described herein may generally be employed in these screens. An immunogenic portion of a polypeptide is a portion that, within such representative assays, generates a signal in such assays that is substantially similar to that generated by the full length antigen. In other words, an immunogenic portion of a *Chlamydia* antigen generates at least about 20%, and preferably about 100%, of the signal induced by the full length antigen in a model ELISA as described herein.

Portions and other variants of *Chlamydia* antigens may be generated by synthetic or recombinant means. Variants of a native antigen may generally be prepared using standard mutagenesis techniques, such as oligonucleotide-directed site-specific mutagenesis. Sections of the polynucleotide sequence may also be removed using standard techniques to permit preparation of truncated polypeptides.

Recombinant polypeptides containing portions and/or variants of a native antigen may be readily prepared from a polynucleotide sequence encoding the polypeptide using a variety of techniques well known to those of ordinary skill in the art. For example, supernatants from suitable host/vector systems which secrete recombinant protein into culture media may be first concentrated using a commercially available filter. Following concentration, the concentrate may be applied to a suitable purification matrix such as an affinity matrix or an ion exchange resin. Finally, one or more reverse phase HPLC steps can be employed to further purify a recombinant protein.

Any of a variety of expression vectors known to those of ordinary skill in the art may be employed to express recombinant polypeptides as described herein. Expression may be achieved in any appropriate host cell that has been transformed or transfected with an

expression vector containing a polynucleotide molecule that encodes a recombinant polypeptide. Suitable host cells include prokaryotes, yeast and higher eukaryotic cells. Preferably, the host cells employed are *E. coli*, yeast or a mammalian cell line, such as COS or CHO. The DNA sequences expressed in this manner may encode naturally occurring antigens, portions of naturally occurring antigens, or other variants thereof.

In general, regardless of the method of preparation, the polypeptides disclosed herein are prepared in an isolated, substantially pure, form. Preferably, the polypeptides are at least about 80% pure, more preferably at least about 90% pure and most preferably at least about 99% pure.

Within certain specific embodiments, a polypeptide may be a fusion protein that comprises multiple polypeptides as described herein, or that comprises at least one polypeptide as described herein and an unrelated sequence, such as a known *Chlamydial* protein. A fusion partner may, for example, assist in providing T helper epitopes (an immunological fusion partner), preferably T helper epitopes recognized by humans, or may assist in expressing the protein (an expression enhancer) at higher yields than the native recombinant protein. Certain preferred fusion partners are both immunological and expression enhancing fusion partners. Other fusion partners may be selected so as to increase the solubility of the protein or to enable the protein to be targeted to desired intracellular compartments. Still further fusion partners include affinity tags, which facilitate purification of the protein. A DNA sequence encoding a fusion protein of the present invention may be constructed using known recombinant DNA techniques to assemble separate DNA sequences encoding, for example, the first and second polypeptides, into an appropriate expression vector. The 3' end of a DNA sequence encoding the first polypeptide is ligated, with or without a peptide linker, to the 5' end of a DNA sequence encoding the second polypeptide so that the reading frames of the sequences are in phase to permit mRNA translation of the two DNA sequences into a single fusion protein that retains the biological activity of both the first and the second polypeptides.

A peptide linker sequence may be employed to separate the first and the second polypeptides by a distance sufficient to ensure that each polypeptide folds into its secondary and tertiary structures. Such a peptide linker sequence is incorporated into the

fusion protein using standard techniques well known in the art. Suitable peptide linker sequences may be chosen based on the following factors: (1) their ability to adopt a flexible extended conformation; (2) their inability to adopt a secondary structure that could interact with functional epitopes on the first and second polypeptides; and (3) the lack of hydrophobic or charged residues that might react with the polypeptide functional epitopes. Preferred peptide linker sequences contain Gly, Asn and Ser residues. Other near neutral amino acids, such as Thr and Ala may also be used in the linker sequence. Amino acid sequences which may be usefully employed as linkers include those disclosed in Maratea et al., *Gene* 40:39-46, 1985; Murphy et al., *Proc. Natl. Acad. Sci. USA* 83:8258-8562, 1986; U.S. Patent No. 4,935,233 and U.S. Patent No. 4,751,180. The linker sequence may be from 1 to about 50 amino acids in length. As an alternative to the use of a peptide linker sequence (when desired), one can utilize non-essential N-terminal amino acid regions (when present) on the first and second polypeptides to separate the functional domains and prevent steric hindrance.

The ligated DNA sequences are operably linked to suitable transcriptional or translational regulatory elements. The regulatory elements responsible for expression of DNA are located only 5' to the DNA sequence encoding the first polypeptides. Similarly, stop codons required to end translation and transcription termination signals are only present 3' to the DNA sequence encoding the second polypeptide.

Fusion proteins are also provided that comprise a polypeptide of the present invention together with an unrelated immunogenic protein. Preferably the immunogenic protein is capable of eliciting a recall response. Examples of such proteins include tetanus, tuberculosis and hepatitis proteins (*see*, for example, Stoute et al. *New Engl. J. Med.*, 336:86-91, 1997).

Within preferred embodiments, an immunological fusion partner is derived from protein D, a surface protein of the gram-negative bacterium *Haemophilus influenza* B (WO 91/18926). Preferably, a protein D derivative comprises approximately the first third of the protein (*e.g.*, the first N-terminal 100-110 amino acids), and a protein D derivative may be lipidated. Within certain preferred embodiments, the first 109 residues of a Lipoprotein D fusion partner is included on the N-terminus to provide the polypeptide with additional exogenous T-cell epitopes and to increase the expression level in *E. coli* (thus functioning as

an expression enhancer). The lipid tail ensures optimal presentation of the antigen to antigen presenting cells. Other fusion partners include the non-structural protein from influenzae virus, NS1 (hemagglutinin). Typically, the N-terminal 81 amino acids are used, although different fragments that include T-helper epitopes may be used.

In another embodiment, the immunological fusion partner is the protein known as LYTA, or a portion thereof (preferably a C-terminal portion). LYTA is derived from *Streptococcus pneumoniae*, which synthesizes an N-acetyl-L-alanine amidase known as amidase LYTA (encoded by the *LytA* gene; *Gene* 43:265-292, 1986). LYTA is an autolysin that specifically degrades certain bonds in the peptidoglycan backbone. The C-terminal domain of the LYTA protein is responsible for the affinity to the choline or to some choline analogues such as DEAE. This property has been exploited for the development of *E. coli* C-LYTA expressing plasmids useful for expression of fusion proteins. Purification of hybrid proteins containing the C-LYTA fragment at the amino terminus has been described (see *Biotechnology* 10:795-798, 1992). Within a preferred embodiment, a repeat portion of LYTA may be incorporated into a fusion protein. A repeat portion is found in the C-terminal region starting at residue 178. A particularly preferred repeat portion incorporates residues 188-305. Additionally, the fusion protein Ra12 may be linked to the inventive polynucleotides to facilitate protein expression.

In another aspect, the present invention provides methods for using one or more of the above polypeptides or fusion proteins (or polynucleotides encoding such polypeptides or fusion proteins) to induce protective immunity against Chlamydial infection in a patient. As used herein, a "patient" refers to any warm-blooded animal, preferably a human. A patient may be afflicted with a disease, or may be free of detectable disease and/or infection. In other words, protective immunity may be induced to prevent or treat Chlamydial infection.

In this aspect, the polypeptide, fusion protein or polynucleotide molecule is generally present within a pharmaceutical composition or a vaccine. Pharmaceutical compositions may comprise one or more polypeptides, each of which may contain one or more of the above sequences (or variants thereof), and a physiologically acceptable carrier. Vaccines may comprise one or more of the above polypeptides and an immunostimulant,

such as an adjuvant or a liposome (into which the polypeptide is incorporated). Such pharmaceutical compositions and vaccines may also contain other *Chlamydia* antigens, either incorporated into a combination polypeptide or present within a separate polypeptide.

Alternatively, a vaccine may contain polynucleotides encoding one or more polypeptides or fusion proteins as described above, such that the polypeptide is generated *in situ*. In such vaccines, the polynucleotides may be present within any of a variety of delivery systems known to those of ordinary skill in the art, including nucleic acid expression systems, bacterial and viral expression systems. Appropriate nucleic acid expression systems contain the necessary polynucleotide sequences for expression in the patient (such as a suitable promoter and terminating signal). Bacterial delivery systems involve the administration of a bacterium (such as *Bacillus-Calmette-Guerrin*) that expresses an immunogenic portion of the polypeptide on its cell surface. In a preferred embodiment, the polynucleotides may be introduced using a viral expression system (e.g., vaccinia or other pox virus, retrovirus, or adenovirus), which may involve the use of a non-pathogenic (defective) virus. Techniques for incorporating polynucleotides into such expression systems are well known to those of ordinary skill in the art. The polynucleotides may also be administered as "naked" plasmid vectors as described, for example, in Ulmer et al., *Science* 259:1745-1749, 1993 and reviewed by Cohen, *Science* 259:1691-1692, 1993. Techniques for incorporating DNA into such vectors are well known to those of ordinary skill in the art. A retroviral vector may additionally transfer or incorporate a gene for a selectable marker (to aid in the identification or selection of transduced cells) and/or a targeting moiety, such as a gene that encodes a ligand for a receptor on a specific target cell, to render the vector target specific. Targeting may also be accomplished using an antibody, by methods known to those of ordinary skill in the art.

Other formulations for therapeutic purposes include colloidal dispersion systems, such as macromolecule complexes, nanocapsules, microspheres, beads, and lipid-based systems including oil-in-water emulsions, micelles, mixed micelles, and liposomes. A preferred colloidal system for use as a delivery vehicle *in vitro* and *in vivo* is a liposome (i.e., an artificial membrane vesicle). The uptake of naked polynucleotides may be increased by incorporating the polynucleotides into and/or onto biodegradable beads, which are efficiently transported into the cells. The preparation and use of such systems is well known in the art.

In a related aspect, a polynucleotide vaccine as described above may be administered simultaneously with or sequentially to either a polypeptide of the present invention or a known *Chlamydia* antigen. For example, administration of polynucleotides encoding a polypeptide of the present invention, either "naked" or in a delivery system as described above, may be followed by administration of an antigen in order to enhance the protective immune effect of the vaccine.

Polypeptides and polynucleotides disclosed herein may also be employed in adoptive immunotherapy for the treatment of *Chlamydial* infection. Adoptive immunotherapy may be broadly classified into either active or passive immunotherapy. In active immunotherapy, treatment relies on the *in vivo* stimulation of the endogenous host immune system with the administration of immune response-modifying agents (for example, vaccines, bacterial adjuvants, and/or cytokines).

In passive immunotherapy, treatment involves the delivery of biologic reagents with established immune reactivity (such as effector cells or antibodies) that can directly or indirectly mediate anti-*Chlamydia* effects and does not necessarily depend on an intact host immune system. Examples of effector cells include T lymphocytes (for example, CD8+ cytotoxic T-lymphocyte, CD4+ T-helper), killer cells (such as Natural Killer cells, lymphokine-activated killer cells), B cells, or antigen presenting cells (such as dendritic cells and macrophages) expressing the disclosed antigens. The polypeptides disclosed herein may also be used to generate antibodies or anti-idiotypic antibodies (as in U.S. Patent No. 4,918,164), for passive immunotherapy.

The predominant method of procuring adequate numbers of T-cells for adoptive immunotherapy is to grow immune T-cells *in vitro*. Culture conditions for expanding single antigen-specific T-cells to several billion in number with retention of antigen recognition *in vivo* are well known in the art. These *in vitro* culture conditions typically utilize intermittent stimulation with antigen, often in the presence of cytokines, such as IL-2, and non-dividing feeder cells. As noted above, the immunoreactive polypeptides described herein may be used to rapidly expand antigen-specific T cell cultures in order to generate sufficient number of cells for immunotherapy. In particular, antigen-presenting cells, such as dendritic, macrophage, monocyte, fibroblast, or B-cells, may be pulsed with

immunoreactive polypeptides, or polynucleotide sequence(s) may be introduced into antigen presenting cells, using a variety of standard techniques well known in the art. For example, antigen presenting cells may be transfected or transduced with a polynucleotide sequence, wherein said sequence contains a promoter region appropriate for increasing expression, and can be expressed as part of a recombinant virus or other expression system. Several viral vectors may be used to transduce an antigen presenting cell, including pox virus, vaccinia virus, and adenovirus; also, antigen presenting cells may be transfected with polynucleotide sequences disclosed herein by a variety of means, including gene-gun technology, lipid-mediated delivery, electroporation, osmotic shock, and particulate delivery mechanisms, resulting in efficient and acceptable expression levels as determined by one of ordinary skill in the art. For cultured T-cells to be effective in therapy, the cultured T-cells must be able to grow and distribute widely and to survive long term *in vivo*. Studies have demonstrated that cultured T-cells can be induced to grow *in vivo* and to survive long term in substantial numbers by repeated stimulation with antigen supplemented with IL-2 (see, for example, Cheever, M., *et al*, "Therapy With Cultured T Cells: Principles Revisited," *Immunological Reviews*, 157:177, 1997).

The polypeptides disclosed herein may also be employed to generate and/or isolate chlamydial-reactive T-cells, which can then be administered to the patient. In one technique, antigen-specific T-cell lines may be generated by *in vivo* immunization with short peptides corresponding to immunogenic portions of the disclosed polypeptides. The resulting antigen specific CD8+ or CD4+ T-cell clones may be isolated from the patient, expanded using standard tissue culture techniques, and returned to the patient.

Alternatively, peptides corresponding to immunogenic portions of the polypeptides may be employed to generate *Chlamydia* reactive T cell subsets by selective *in vitro* stimulation and expansion of autologous T cells to provide antigen-specific T cells which may be subsequently transferred to the patient as described, for example, by Chang *et al*, (*Crit. Rev. Oncol. Hematol.*, 22(3), 213, 1996). Cells of the immune system, such as T cells, may be isolated from the peripheral blood of a patient, using a commercially available cell separation system, such as Isolex™ System, available from Nexell Therapeutics, Inc. Irvine, CA. The separated cells are stimulated with one or more of the immunoreactive

polypeptides contained within a delivery vehicle, such as a microsphere, to provide antigen-specific T cells. The population of antigen-specific T cells is then expanded using standard techniques and the cells are administered back to the patient.

In other embodiments, T-cell and/or antibody receptors specific for the polypeptides disclosed herein can be cloned, expanded, and transferred into other vectors or effector cells for use in adoptive immunotherapy. In particular, T cells may be transfected with the appropriate genes to express the variable domains from chlamydia specific monoclonal antibodies as the extracellular recognition elements and joined to the T cell receptor signaling chains, resulting in T cell activation, specific lysis, and cytokine release. This enables the T cell to redirect its specificity in an MHC-independent manner. See for example, Eshhar, Z., *Cancer Immunol Immunother*, 45(3-4):131-6, 1997 and Hwu, P., et al, *Cancer Res*, 55(15):3369-73, 1995. Another embodiment may include the transfection of chlamydia antigen specific alpha and beta T cell receptor chains into alternate T cells, as in Cole, DJ, et al, *Cancer Res*, 55(4):748-52, 1995.

In a further embodiment, syngeneic or autologous dendritic cells may be pulsed with peptides corresponding to at least an immunogenic portion of a polypeptide disclosed herein. The resulting antigen-specific dendritic cells may either be transferred into a patient, or employed to stimulate T cells to provide antigen-specific T cells which may, in turn, be administered to a patient. The use of peptide-pulsed dendritic cells to generate antigen-specific T cells and the subsequent use of such antigen-specific T cells to eradicate disease in a murine model has been demonstrated by Cheever et al, *Immunological Reviews*, 157:177, 1997). Additionally, vectors expressing the disclosed polynucleotides may be introduced into stem cells taken from the patient and clonally propagated *in vitro* for autologous transplant back into the same patient.

Within certain aspects, polypeptides, polynucleotides, T cells and/or binding agents disclosed herein may be incorporated into pharmaceutical compositions or immunogenic compositions (*i.e.*, vaccines). Pharmaceutical compositions comprise one or more such compounds and a physiologically acceptable carrier. Vaccines may comprise one or more such compounds and an immunostimulant. An immunostimulant may be any substance that enhances or potentiates an immune response to an exogenous antigen.

Examples of immunostimulants include adjuvants, biodegradable microspheres (e.g., polylactic galactide) and liposomes (into which the compound is incorporated; see e.g., Fullerton, U.S. Patent No. 4,235,877). Vaccine preparation is generally described in, for example, M.F. Powell and M.J. Newman, eds., "Vaccine Design (the subunit and adjuvant approach)," Plenum Press (NY, 1995). Pharmaceutical compositions and vaccines within the scope of the present invention may also contain other compounds, which may be biologically active or inactive. For example, one or more immunogenic portions of other *Chlamydial* antigens may be present, either incorporated into a fusion polypeptide or as a separate compound, within the composition or vaccine.

A pharmaceutical composition or vaccine may contain DNA encoding one or more of the polypeptides as described above, such that the polypeptide is generated *in situ*. As noted above, the DNA may be present within any of a variety of delivery systems known to those of ordinary skill in the art, including nucleic acid expression systems, bacteria and viral expression systems. Numerous gene delivery techniques are well known in the art, such as those described by Rolland, *Crit. Rev. Therap. Drug Carrier Systems* 15:143-198, 1998, and references cited therein. Appropriate nucleic acid expression systems contain the necessary DNA sequences for expression in the patient (such as a suitable promoter and terminating signal). Bacterial delivery systems involve the administration of a bacterium (such as *Bacillus-Calmette-Guerrin*) that expresses an immunogenic portion of the polypeptide on its cell surface or secretes such an epitope. In a preferred embodiment, the DNA may be introduced using a viral expression system (e.g., vaccinia or other pox virus, retrovirus, or adenovirus), which may involve the use of a non-pathogenic (defective), replication competent virus. Suitable systems are disclosed, for example, in Fisher-Hoch et al., *Proc. Natl. Acad. Sci. USA* 86:317-321, 1989; Flexner et al., *Ann. N.Y. Acad. Sci.* 569:86-103, 1989; Flexner et al., *Vaccine* 8:17-21, 1990; U.S. Patent Nos. 4,603,112, 4,769,330, and 5,017,487; WO 89/01973; U.S. Patent No. 4,777,127; GB 2,200,651; EP 0,345,242; WO 91/02805; Berkner, *Biotechniques* 6:616-627, 1988; Rosenfeld et al., *Science* 252:431-434, 1991; Kolls et al., *Proc. Natl. Acad. Sci. USA* 91:215-219, 1994; Kass-Eisler et al., *Proc. Natl. Acad. Sci. USA* 90:11498-11502, 1993; Guzman et al., *Circulation* 88:2838-2848, 1993; and Guzman et al., *Cir. Res.* 73:1202-1207, 1993.

Techniques for incorporating DNA into such expression systems are well known to those of ordinary skill in the art. The DNA may also be "naked," as described, for example, in Ulmer et al., *Science* 259:1745-1749, 1993 and reviewed by Cohen, *Science* 259:1691-1692, 1993. The uptake of naked DNA may be increased by coating the DNA onto biodegradable beads, which are efficiently transported into the cells.

While any suitable carrier known to those of ordinary skill in the art may be employed in the pharmaceutical compositions of this invention, the type of carrier will vary depending on the mode of administration. Compositions of the present invention may be formulated for any appropriate manner of administration, including for example, topical, oral, nasal, intravenous, intracranial, intraperitoneal, subcutaneous or intramuscular administration. For parenteral administration, such as subcutaneous injection, the carrier preferably comprises water, saline, alcohol, a fat, a wax or a buffer. For oral administration, any of the above carriers or a solid carrier, such as mannitol, lactose, starch, magnesium stearate, sodium saccharine, talcum, cellulose, glucose, sucrose, and magnesium carbonate, may be employed. Biodegradable microspheres (e.g., polylactate polyglycolate) may also be employed as carriers for the pharmaceutical compositions of this invention. Suitable biodegradable microspheres are disclosed, for example, in U.S. Patent Nos. 4,897,268 and 5,075,109.

Such compositions may also comprise buffers (e.g., neutral buffered saline or phosphate buffered saline), carbohydrates (e.g., glucose, mannose, sucrose or dextrans), mannitol, proteins, polypeptides or amino acids such as glycine, antioxidants, chelating agents such as EDTA or glutathione, adjuvants (e.g., aluminum hydroxide) and/or preservatives. Alternatively, compositions of the present invention may be formulated as a lyophilizate. Compounds may also be encapsulated within liposomes using well known technology.

Any of a variety of immunostimulants may be employed in the vaccines of this invention. For example, an adjuvant may be included. Most adjuvants contain a substance designed to protect the antigen from rapid catabolism, such as aluminum hydroxide or mineral oil, and a stimulator of immune responses, such as lipid A, *Bordetella pertussis* or *Mycobacterium tuberculosis* derived proteins. Suitable adjuvants are commercially available

as, for example, Freund's Incomplete Adjuvant and Complete Adjuvant (Difco Laboratories, Detroit, MI); Merck Adjuvant 65 (Merck and Company, Inc., Rahway, NJ); aluminum salts such as aluminum hydroxide gel (alum) or aluminum phosphate; salts of calcium, iron or zinc; an insoluble suspension of acylated tyrosine; acylated sugars; cationically or anionically derivatized polysaccharides; polyphosphazenes; biodegradable microspheres; monophosphoryl lipid A and quil A. Cytokines, such as GM-CSF or interleukin-2, -7, or -12, may also be used as adjuvants.

Within the vaccines provided herein, under select circumstances, the adjuvant composition may be designed to induce an immune response predominantly of the Th1 type or Th2 type. High levels of Th1-type cytokines (*e.g.*, IFN- γ , TNF α , IL-2 and IL-12) tend to favor the induction of cell mediated immune responses to an administered antigen. In contrast, high levels of Th2-type cytokines (*e.g.*, IL-4, IL-5, IL-6 and IL-10) tend to favor the induction of humoral immune responses. Following application of a vaccine as provided herein, a patient will support an immune response that includes Th1- and Th2-type responses. Within a preferred embodiment, in which a response is predominantly Th1-type, the level of Th1-type cytokines will increase to a greater extent than the level of Th2-type cytokines. The levels of these cytokines may be readily assessed using standard assays. For a review of the families of cytokines, see Mosmann and Coffman, *Ann. Rev. Immunol.* 7:145-173, 1989.

Preferred adjuvants for use in eliciting a predominantly Th1-type response include, for example, a combination of monophosphoryl lipid A, preferably 3-de-O-acylated monophosphoryl lipid A (3D-MPL), together with an aluminum salt. MPL adjuvants are available from Ribi ImmunoChem Research Inc. (Hamilton, MT) (*see* US Patent Nos. 4,436,727; 4,877,611; 4,866,034 and 4,912,094). CpG-containing oligonucleotides (in which the CpG dinucleotide is unmethylated) also induce a predominantly Th1 response. Such oligonucleotides are well known and are described, for example, in WO 96/02555. Another preferred adjuvant is a saponin, preferably QS21, which may be used alone or in combination with other adjuvants. For example, an enhanced system involves the combination of a monophosphoryl lipid A and saponin derivative, such as the combination of QS21 and 3D-MPL as described in WO 94/00153, or a less reactogenic composition where the QS21 is quenched with cholesterol, as described in WO 96/33739. Other preferred formulations

comprises an oil-in-water emulsion and tocopherol. A particularly potent adjuvant formulation involving QS21, 3D-MPL and tocopherol in an oil-in-water emulsion is described in WO 95/17210. Any vaccine provided herein may be prepared using well known methods that result in a combination of antigen, immune response enhancer and a suitable carrier or excipient.

The compositions described herein may be administered as part of a sustained release formulation (*i.e.*, a formulation such as a capsule, sponge or gel (composed of polysaccharides, for example) that effects a slow release of compound following administration). Such formulations may generally be prepared using well known technology and administered by, for example, oral, rectal or subcutaneous implantation, or by implantation at the desired target site. Sustained-release formulations may contain a polypeptide, polynucleotide or antibody dispersed in a carrier matrix and/or contained within a reservoir surrounded by a rate controlling membrane. Carriers for use within such formulations are biocompatible, and may also be biodegradable; preferably the formulation provides a relatively constant level of active component release. The amount of active compound contained within a sustained release formulation depends upon the site of implantation, the rate and expected duration of release and the nature of the condition to be treated or prevented.

Any of a variety of delivery vehicles may be employed within pharmaceutical compositions and vaccines to facilitate production of an antigen-specific immune response that targets *Chlamydia*-infected cells. Delivery vehicles include antigen presenting cells (APCs), such as dendritic cells, macrophages, B cells, monocytes and other cells that may be engineered to be efficient APCs. Such cells may, but need not, be genetically modified to increase the capacity for presenting the antigen, to improve activation and/or maintenance of the T cell response, to have anti-*Chlamydia* effects *per se* and/or to be immunologically compatible with the receiver (*i.e.*, matched HLA haplotype). APCs may generally be isolated from any of a variety of biological fluids and organs, and may be autologous, allogeneic, syngeneic or xenogeneic cells.

Certain preferred embodiments of the present invention use dendritic cells or progenitors thereof as antigen-presenting cells. Dendritic cells are highly potent APCs

(Banchereau and Steinman, *Nature* 392:245-251, 1998) and have been shown to be effective as a physiological adjuvant for eliciting prophylactic or therapeutic immunity (see Timmerman and Levy, *Ann. Rev. Med.* 50:507-529, 1999). In general, dendritic cells may be identified based on their typical shape (stellate *in situ*, with marked cytoplasmic processes (dendrites) visible *in vitro*), their ability to take up, process and present antigens with high efficiency, and their ability to activate naïve T cell responses. Dendritic cells may, of course, be engineered to express specific cell-surface receptors or ligands that are not commonly found on dendritic cells *in vivo* or *ex vivo*, and such modified dendritic cells are contemplated by the present invention. As an alternative to dendritic cells, secreted vesicles antigen-loaded dendritic cells (called exosomes) may be used within a vaccine (see Zitvogel et al., *Nature Med.* 4:594-600, 1998).

Dendritic cells and progenitors may be obtained from peripheral blood, bone marrow, lymph nodes, spleen, skin, umbilical cord blood or any other suitable tissue or fluid. For example, dendritic cells may be differentiated *ex vivo* by adding a combination of cytokines such as GM-CSF, IL-4, IL-13 and/or TNF α to cultures of monocytes harvested from peripheral blood. Alternatively, CD34 positive cells harvested from peripheral blood, umbilical cord blood or bone marrow may be differentiated into dendritic cells by adding to the culture medium combinations of GM-CSF, IL-3, TNF α , CD40 ligand, LPS, flt3 ligand and/or other compound(s) that induce differentiation, maturation and proliferation of dendritic cells.

Dendritic cells are conveniently categorized as "immature" and "mature" cells, which allows a simple way to discriminate between two well characterized phenotypes. However, this nomenclature should not be construed to exclude all possible intermediate stages of differentiation. Immature dendritic cells are characterized as APC with a high capacity for antigen uptake and processing, which correlates with the high expression of Fc γ receptor and mannose receptor. The mature phenotype is typically characterized by a lower expression of these markers, but a high expression of cell surface molecules responsible for T cell activation such as class I and class II MHC, adhesion molecules (e.g., CD54 and CD11) and costimulatory molecules (e.g., CD40, CD80, CD86 and 4-1BB).

APCs may generally be transfected with a polynucleotide encoding a

Chlamydial protein (or portion or other variant thereof) such that the *Chlamydial* polypeptide, or an immunogenic portion thereof, is expressed on the cell surface. Such transfection may take place *ex vivo*, and a composition or vaccine comprising such transfected cells may then be used for therapeutic purposes, as described herein. Alternatively, a gene delivery vehicle that targets a dendritic or other antigen presenting cell may be administered to a patient, resulting in transfection that occurs *in vivo*. *In vivo* and *ex vivo* transfection of dendritic cells, for example, may generally be performed using any methods known in the art, such as those described in WO 97/24447, or the gene gun approach described by Mahvi et al., *Immunology and cell Biology* 75:456-460, 1997. Antigen loading of dendritic cells may be achieved by incubating dendritic cells or progenitor cells with the *Chlamydial* polypeptide, DNA (naked or within a plasmid vector) or RNA; or with antigen-expressing recombinant bacterium or viruses (e.g., vaccinia, fowlpox, adenovirus or lentivirus vectors). Prior to loading, the polypeptide may be covalently conjugated to an immunological partner that provides T cell help (e.g., a carrier molecule). Alternatively, a dendritic cell may be pulsed with a non-conjugated immunological partner, separately or in the presence of the polypeptide.

Routes and frequency of administration of pharmaceutical compositions and vaccines, as well as dosage, will vary from individual to individual. In general, the pharmaceutical compositions and vaccines may be administered by injection (e.g., intracutaneous, intramuscular, intravenous or subcutaneous), intranasally (e.g., by aspiration) or orally. Between 1 and 3 doses may be administered for a 1-36 week period. Preferably, 3 doses are administered, at intervals of 3-4 months, and booster vaccinations may be given periodically thereafter. Alternate protocols may be appropriate for individual patients. A suitable dose is an amount of polypeptide or DNA that, when administered as described above, is capable of raising an immune response in an immunized patient sufficient to protect the patient from *Chlamydial* infection for at least 1-2 years. In general, the amount of polypeptide present in a dose (or produced *in situ* by the DNA in a dose) ranges from about 1 pg to about 100 mg per kg of host, typically from about 10 pg to about 1 mg, and preferably from about 100 pg to about 1 µg. Suitable dose sizes will vary with the size of the patient, but will typically range from about 0.1 mL to about 5 mL.

While any suitable carrier known to those of ordinary skill in the art may be employed in the pharmaceutical compositions of this invention, the type of carrier will vary depending on the mode of administration. For parenteral administration, such as subcutaneous injection, the carrier preferably comprises water, saline, alcohol, a fat, a wax or a buffer. For oral administration, any of the above carriers or a solid carrier, such as mannitol, lactose, starch, magnesium stearate, sodium saccharine, talcum, cellulose, glucose, sucrose, and magnesium carbonate, may be employed. Biodegradable microspheres (e.g., polylactic galactide) may also be employed as carriers for the pharmaceutical compositions of this invention. Suitable biodegradable microspheres are disclosed, for example, in U.S. Patent Nos. 4,897,268 and 5,075,109.

In general, an appropriate dosage and treatment regimen provides the active compound(s) in an amount sufficient to provide therapeutic and/or prophylactic benefit. Such a response can be monitored by establishing an improved clinical outcome in treated patients as compared to non-treated patients. Increases in preexisting immune responses to a *Chlamydial* protein generally correlate with an improved clinical outcome. Such immune responses may generally be evaluated using standard proliferation, cytotoxicity or cytokine assays, which may be performed using samples obtained from a patient before and after treatment.

In another aspect, the present invention provides methods for using the polypeptides described above to diagnose *Chlamydial* infection. In this aspect, methods are provided for detecting *Chlamydial* infection in a biological sample, using one or more of the above polypeptides, either alone or in combination. For clarity, the term "polypeptide" will be used when describing specific embodiments of the inventive diagnostic methods. However, it will be clear to one of skill in the art that the fusion proteins of the present invention may also be employed in such methods.

As used herein, a "biological sample" is any antibody-containing sample obtained from a patient. Preferably, the sample is whole blood, sputum, serum, plasma, saliva, cerebrospinal fluid or urine. More preferably, the sample is a blood, serum or plasma sample obtained from a patient. The polypeptides are used in an assay, as described below, to determine the presence or absence of antibodies to the polypeptide(s) in the sample, relative

to a predetermined cut-off value. The presence of such antibodies indicates previous sensitization to *Chlamydia* antigens which may be indicative of *Chlamydia*-infection.

In embodiments in which more than one polypeptide is employed, the polypeptides used are preferably complementary (*i.e.*, one component polypeptide will tend to detect infection in samples where the infection would not be detected by another component polypeptide). Complementary polypeptides may generally be identified by using each polypeptide individually to evaluate serum samples obtained from a series of patients known to be infected with *Chlamydia*. After determining which samples test positive (as described below) with each polypeptide, combinations of two or more polypeptides may be formulated that are capable of detecting infection in most, or all, of the samples tested.

A variety of assay formats are known to those of ordinary skill in the art for using one or more polypeptides to detect antibodies in a sample. *See, e.g.*, Harlow and Lane, *Antibodies: A Laboratory Manual*, Cold Spring Harbor Laboratory, 1988, which is incorporated herein by reference. In a preferred embodiment, the assay involves the use of polypeptide immobilized on a solid support to bind to and remove the antibody from the sample. The bound antibody may then be detected using a detection reagent that contains a reporter group. Suitable detection reagents include antibodies that bind to the antibody/polypeptide complex and free polypeptide labeled with a reporter group (*e.g.*, in a semi-competitive assay). Alternatively, a competitive assay may be utilized, in which an antibody that binds to the polypeptide is labeled with a reporter group and allowed to bind to the immobilized antigen after incubation of the antigen with the sample. The extent to which components of the sample inhibit the binding of the labeled antibody to the polypeptide is indicative of the reactivity of the sample with the immobilized polypeptide.

The solid support may be any solid material known to those of ordinary skill in the art to which the antigen may be attached. For example, the solid support may be a test well in a microtiter plate, or a nitrocellulose or other suitable membrane. Alternatively, the support may be a bead or disc, such as glass, fiberglass, latex or a plastic material such as polystyrene or polyvinylchloride. The support may also be a magnetic particle or a fiber optic sensor, such as those disclosed, for example, in U.S. Patent No. 5,359,681.

The polypeptides may be bound to the solid support using a variety of techniques known to those of ordinary skill in the art. In the context of the present invention, the term "bound" refers to both noncovalent association, such as adsorption, and covalent attachment (which may be a direct linkage between the antigen and functional groups on the support or may be a linkage by way of a cross-linking agent). Binding by adsorption to a well in a microtiter plate or to a membrane is preferred. In such cases, adsorption may be achieved by contacting the polypeptide, in a suitable buffer, with the solid support for a suitable amount of time. The contact time varies with temperature, but is typically between about 1 hour and 1 day. In general, contacting a well of a plastic microtiter plate (such as polystyrene or polyvinylchloride) with an amount of polypeptide ranging from about 10 ng to about 1 μ g, and preferably about 100 ng, is sufficient to bind an adequate amount of antigen.

Covalent attachment of polypeptide to a solid support may generally be achieved by first reacting the support with a bifunctional reagent that will react with both the support and a functional group, such as a hydroxyl or amino group, on the polypeptide. For example, the polypeptide may be bound to supports having an appropriate polymer coating using benzoquinone or by condensation of an aldehyde group on the support with an amine and an active hydrogen on the polypeptide (*see, e.g.*, Pierce Immunotechnology Catalog and Handbook, 1991, at A12-A13).

In certain embodiments, the assay is an enzyme linked immunosorbent assay (ELISA). This assay may be performed by first contacting a polypeptide antigen that has been immobilized on a solid support, commonly the well of a microtiter plate, with the sample, such that antibodies to the polypeptide within the sample are allowed to bind to the immobilized polypeptide. Unbound sample is then removed from the immobilized polypeptide and a detection reagent capable of binding to the immobilized antibody-polypeptide complex is added. The amount of detection reagent that remains bound to the solid support is then determined using a method appropriate for the specific detection reagent.

More specifically, once the polypeptide is immobilized on the support as described above, the remaining protein binding sites on the support are typically blocked. Any suitable blocking agent known to those of ordinary skill in the art, such as bovine serum albumin (BSA) or Tween 20™ (Sigma Chemical Co., St. Louis, MO) may be employed. The

immobilized polypeptide is then incubated with the sample, and antibody is allowed to bind to the antigen. The sample may be diluted with a suitable diluent, such as phosphate-buffered saline (PBS) prior to incubation. In general, an appropriate contact time (*i.e.*, incubation time) is that period of time that is sufficient to detect the presence of antibody within an HGE-infected sample. Preferably, the contact time is sufficient to achieve a level of binding that is at least 95% of that achieved at equilibrium between bound and unbound antibody. Those of ordinary skill in the art will recognize that the time necessary to achieve equilibrium may be readily determined by assaying the level of binding that occurs over a period of time. At room temperature, an incubation time of about 30 minutes is generally sufficient.

Unbound sample may then be removed by washing the solid support with an appropriate buffer, such as PBS containing 0.1% Tween 20™. Detection reagent may then be added to the solid support. An appropriate detection reagent is any compound that binds to the immobilized antibody-polypeptide complex and that can be detected by any of a variety of means known to those in the art. Preferably, the detection reagent contains a binding agent (such as, for example, Protein A, Protein G, immunoglobulin, lectin or free antigen) conjugated to a reporter group. Preferred reporter groups include enzymes (such as horseradish peroxidase), substrates, cofactors, inhibitors, dyes, radionuclides, luminescent groups, fluorescent groups and biotin. The conjugation of binding agent to reporter group may be achieved using standard methods known to those of ordinary skill in the art. Common binding agents may also be purchased conjugated to a variety of reporter groups from many commercial sources (*e.g.*, Zymed Laboratories, San Francisco, CA, and Pierce, Rockford, IL).

The detection reagent is then incubated with the immobilized antibody-polypeptide complex for an amount of time sufficient to detect the bound antibody. An appropriate amount of time may generally be determined from the manufacturer's instructions or by assaying the level of binding that occurs over a period of time. Unbound detection reagent is then removed and bound detection reagent is detected using the reporter group. The method employed for detecting the reporter group depends upon the nature of the reporter group. For radioactive groups, scintillation counting or autoradiographic methods

are generally appropriate. Spectroscopic methods may be used to detect dyes, luminescent groups and fluorescent groups. Biotin may be detected using avidin, coupled to a different reporter group (commonly a radioactive or fluorescent group or an enzyme). Enzyme reporter groups may generally be detected by the addition of substrate (generally for a specific period of time), followed by spectroscopic or other analysis of the reaction products.

To determine the presence or absence of anti-*Chlamydia* antibodies in the sample, the signal detected from the reporter group that remains bound to the solid support is generally compared to a signal that corresponds to a predetermined cut-off value. In one preferred embodiment, the cut-off value is the average mean signal obtained when the immobilized antigen is incubated with samples from an uninfected patient. In general, a sample generating a signal that is three standard deviations above the predetermined cut-off value is considered positive for *Chlamydia*-infection. In an alternate preferred embodiment, the cut-off value is determined using a Receiver Operator Curve, according to the method of Sackett et al., *Clinical Epidemiology: A Basic Science for Clinical Medicine*, Little Brown and Co., 1985, pp. 106-107. Briefly, in this embodiment, the cut-off value may be determined from a plot of pairs of true positive rates (*i.e.*, sensitivity) and false positive rates (100%-specificity) that correspond to each possible cut-off value for the diagnostic test result. The cut-off value on the plot that is the closest to the upper left-hand corner (*i.e.*, the value that encloses the largest area) is the most accurate cut-off value, and a sample generating a signal that is higher than the cut-off value determined by this method may be considered positive. Alternatively, the cut-off value may be shifted to the left along the plot, to minimize the false positive rate, or to the right, to minimize the false negative rate. In general, a sample generating a signal that is higher than the cut-off value determined by this method is considered positive for Chlamydial infection.

In a related embodiment, the assay is performed in a rapid flow-through or strip test format, wherein the antigen is immobilized on a membrane, such as nitrocellulose. In the flow-through test, antibodies within the sample bind to the immobilized polypeptide as the sample passes through the membrane. A detection reagent (*e.g.*, protein A-colloidal gold) then binds to the antibody-polypeptide complex as the solution containing the detection reagent flows through the membrane. The detection of bound detection reagent may then be

performed as described above. In the strip test format, one end of the membrane to which polypeptide is bound is immersed in a solution containing the sample. The sample migrates along the membrane through a region containing detection reagent and to the area of immobilized polypeptide. Concentration of detection reagent at the polypeptide indicates the presence of anti-*Chlamydia* antibodies in the sample. Typically, the concentration of detection reagent at that site generates a pattern, such as a line, that can be read visually. The absence of such a pattern indicates a negative result. In general, the amount of polypeptide immobilized on the membrane is selected to generate a visually discernible pattern when the biological sample contains a level of antibodies that would be sufficient to generate a positive signal in an ELISA, as discussed above. Preferably, the amount of polypeptide immobilized on the membrane ranges from about 25 ng to about 1 μ g, and more preferably from about 50 ng to about 500 ng. Such tests can typically be performed with a very small amount (*e.g.*, one drop) of patient serum or blood.

Of course, numerous other assay protocols exist that are suitable for use with the polypeptides of the present invention. The above descriptions are intended to be exemplary only. One example of an alternative assay protocol which may be usefully employed in such methods is a Western blot, wherein the proteins present in a biological sample are separated on a gel, prior to exposure to a binding agent. Such techniques are well known to those of skill in the art.

The present invention further provides agents, such as antibodies and antigen-binding fragments thereof, that specifically bind to a *Chlamydial* protein. As used herein, an antibody, or antigen-binding fragment thereof, is said to "specifically bind" to a *Chlamydial* protein if it reacts at a detectable level (within, for example, an ELISA) with a *Chlamydial* protein, and does not react detectably with unrelated proteins under similar conditions. As used herein, "binding" refers to a noncovalent association between two separate molecules such that a complex is formed. The ability to bind may be evaluated by, for example, determining a binding constant for the formation of the complex. The binding constant is the value obtained when the concentration of the complex is divided by the product of the component concentrations. In general, two compounds are said to "bind," in the context of the present invention, when the binding constant for complex formation exceeds about 10^3

L/mol. The binding constant may be determined using methods well known in the art.

Binding agents may be further capable of differentiating between patients with and without a *Chlamydial* infection using the representative assays provided herein. In other words, antibodies or other binding agents that bind to a *Chlamydial* protein will generate a signal indicating the presence of a *Chlamydial* infection in at least about 20% of patients with the disease, and will generate a negative signal indicating the absence of the disease in at least about 90% of individuals without infection. To determine whether a binding agent satisfies this requirement, biological samples (e.g., blood, scra, sputum urine and/or tissue biopsies) from patients with and without *Chlamydial* infection (as determined using standard clinical tests) may be assayed as described herein for the presence of polypeptides that bind to the binding agent. It will be apparent that a statistically significant number of samples with and without the disease should be assayed. Each binding agent should satisfy the above criteria; however, those of ordinary skill in the art will recognize that binding agents may be used in combination to improve sensitivity.

Any agent that satisfies the above requirements may be a binding agent. For example, a binding agent may be a ribosome, with or without a peptide component, an RNA molecule or a polypeptide. In a preferred embodiment, a binding agent is an antibody or an antigen-binding fragment thereof. Antibodies may be prepared by any of a variety of techniques known to those of ordinary skill in the art. See, e.g., Harlow and Lane, *Antibodies: A Laboratory Manual*, Cold Spring Harbor Laboratory, 1988. In general, antibodies can be produced by cell culture techniques, including the generation of monoclonal antibodies as described herein, or via transfection of antibody genes into suitable bacterial or mammalian cell hosts, in order to allow for the production of recombinant antibodies. In one technique, an immunogen comprising the polypeptide is initially injected into any of a wide variety of mammals (e.g., mice, rats, rabbits, sheep or goats). In this step, the polypeptides of this invention may serve as the immunogen without modification. Alternatively, particularly for relatively short polypeptides, a superior immune response may be elicited if the polypeptide is joined to a carrier protein, such as bovine serum albumin or keyhole limpet hemocyanin. The immunogen is injected into the animal host, preferably according to a predetermined schedule incorporating one or more booster immunizations, and

the animals are bled periodically. Polyclonal antibodies specific for the polypeptide may then be purified from such antisera by, for example, affinity chromatography using the polypeptide coupled to a suitable solid support.

Monoclonal antibodies specific for an antigenic polypeptide of interest may be prepared, for example, using the technique of Kohler and Milstein, *Eur. J. Immunol.* 6:511-519, 1976, and improvements thereto. Briefly, these methods involve the preparation of immortal cell lines capable of producing antibodies having the desired specificity (*i.e.*, reactivity with the polypeptide of interest). Such cell lines may be produced, for example, from spleen cells obtained from an animal immunized as described above. The spleen cells are then immortalized by, for example, fusion with a myeloma cell fusion partner, preferably one that is syngeneic with the immunized animal. A variety of fusion techniques may be employed. For example, the spleen cells and myeloma cells may be combined with a nonionic detergent for a few minutes and then plated at low density on a selective medium that supports the growth of hybrid cells, but not myeloma cells. A preferred selection technique uses HAT (hypoxanthine, aminopterin, thymidine) selection. After a sufficient time, usually about 1 to 2 weeks, colonies of hybrids are observed. Single colonies are selected and their culture supernatants tested for binding activity against the polypeptide. Hybridomas having high reactivity and specificity are preferred.

Monoclonal antibodies may be isolated from the supernatants of growing hybridoma colonies. In addition, various techniques may be employed to enhance the yield, such as injection of the hybridoma cell line into the peritoneal cavity of a suitable vertebrate host, such as a mouse. Monoclonal antibodies may then be harvested from the ascites fluid or the blood. Contaminants may be removed from the antibodies by conventional techniques, such as chromatography, gel filtration, precipitation, and extraction. The polypeptides of this invention may be used in the purification process in, for example, an affinity chromatography step.

Within certain embodiments, the use of antigen-binding fragments of antibodies may be preferred. Such fragments include Fab fragments, which may be prepared using standard techniques. Briefly, immunoglobulins may be purified from rabbit serum by affinity chromatography on Protein A bead columns (Harlow and Lane, *Antibodies: A*

Laboratory Manual, Cold Spring Harbor Laboratory, 1988) and digested by papain to yield Fab and Fc fragments. The Fab and Fc fragments may be separated by affinity chromatography on protein A bead columns.

Monoclonal antibodies of the present invention may be coupled to one or more therapeutic agents. Suitable agents in this regard include radionuclides, differentiation inducers, drugs, toxins, and derivatives thereof. Preferred radionuclides include ^{90}Y , ^{123}I , ^{125}I , ^{131}I , ^{186}Re , ^{188}Re , ^{211}At , and ^{212}Bi . Preferred drugs include methotrexate, and pyrimidine and purine analogs. Preferred differentiation inducers include phorbol esters and butyric acid. Preferred toxins include ricin, abrin, diphtheria toxin, cholera toxin, gelonin, *Pseudomonas* exotoxin, Shigella toxin, and pokeweed antiviral protein.

A therapeutic agent may be coupled (*e.g.*, covalently bonded) to a suitable monoclonal antibody either directly or indirectly (*e.g.*, via a linker group). A direct reaction between an agent and an antibody is possible when each possesses a substituent capable of reacting with the other. For example, a nucleophilic group, such as an amino or sulfhydryl group, on one may be capable of reacting with a carbonyl-containing group, such as an anhydride or an acid halide, or with an alkyl group containing a good leaving group (*e.g.*, a halide) on the other.

Alternatively, it may be desirable to couple a therapeutic agent and an antibody via a linker group. A linker group can function as a spacer to distance an antibody from an agent in order to avoid interference with binding capabilities. A linker group can also serve to increase the chemical reactivity of a substituent on an agent or an antibody, and thus increase the coupling efficiency. An increase in chemical reactivity may also facilitate the use of agents, or functional groups on agents, which otherwise would not be possible.

It will be evident to those skilled in the art that a variety of bifunctional or polyfunctional reagents, both homo- and hetero-functional (such as those described in the catalog of the Pierce Chemical Co., Rockford, IL), may be employed as the linker group. Coupling may be effected, for example, through amino groups, carboxyl groups, sulfhydryl groups or oxidized carbohydrate residues. There are numerous references describing such methodology, *e.g.*, U.S. Patent No. 4,671,958, to Rodwell et al.

Where a therapeutic agent is more potent when free from the antibody portion

of the immunoconjugates of the present invention, it may be desirable to use a linker group which is cleavable during or upon internalization into a cell. A number of different cleavable linker groups have been described. The mechanisms for the intracellular release of an agent from these linker groups include cleavage by reduction of a disulfide bond (*e.g.*, U.S. Patent No. 4,489,710, to Spitler), by irradiation of a photolabile bond (*e.g.*, U.S. Patent No. 4,625,014, to Senter et al.), by hydrolysis of derivatized amino acid side chains (*e.g.*, U.S. Patent No. 4,638,045, to Kohn et al.), by serum complement-mediated hydrolysis (*e.g.*, U.S. Patent No. 4,671,958, to Rodwell et al.), and acid-catalyzed hydrolysis (*e.g.*, U.S. Patent No. 4,569,789, to Blattler et al.).

It may be desirable to couple more than one agent to an antibody. In one embodiment, multiple molecules of an agent are coupled to one antibody molecule. In another embodiment, more than one type of agent may be coupled to one antibody. Regardless of the particular embodiment, immunoconjugates with more than one agent may be prepared in a variety of ways. For example, more than one agent may be coupled directly to an antibody molecule, or linkers which provide multiple sites for attachment can be used. Alternatively, a carrier can be used.

A carrier may bear the agents in a variety of ways, including covalent bonding either directly or via a linker group. Suitable carriers include proteins such as albumins (*e.g.*, U.S. Patent No. 4,507,234, to Kato et al.), peptides and polysaccharides such as aminodextran (*e.g.*, U.S. Patent No. 4,699,784, to Shih et al.). A carrier may also bear an agent by noncovalent bonding or by encapsulation, such as within a liposome vesicle (*e.g.*, U.S. Patent Nos. 4,429,008 and 4,873,088). Carriers specific for radionuclide agents include radiohalogenated small molecules and chelating compounds. For example, U.S. Patent No. 4,735,792 discloses representative radiohalogenated small molecules and their synthesis. A radionuclide chelate may be formed from chelating compounds that include those containing nitrogen and sulfur atoms as the donor atoms for binding the metal, or metal oxide, radionuclide. For example, U.S. Patent No. 4,673,562, to Davison et al. discloses representative chelating compounds and their synthesis.

A variety of routes of administration for the antibodies and immunoconjugates may be used. Typically, administration will be intravenous, intramuscular, subcutaneous or

in site-specific regions by appropriate methods. It will be evident that the precise dose of the antibody/immunoconjugate will vary depending upon the antibody used, the antigen density, and the rate of clearance of the antibody.

Antibodies may be used in diagnostic tests to detect the presence of *Chlamydia* antigens using assays similar to those detailed above and other techniques well known to those of skill in the art, thereby providing a method for detecting Chlamydial infection in a patient.

Diagnostic reagents of the present invention may also comprise DNA sequences encoding one or more of the above polypeptides, or one or more portions thereof. For example, at least two oligonucleotide primers may be employed in a polymerase chain reaction (PCR) based assay to amplify *Chlamydia*-specific cDNA derived from a biological sample, wherein at least one of the oligonucleotide primers is specific for a DNA molecule encoding a polypeptide of the present invention. The presence of the amplified cDNA is then detected using techniques well known in the art, such as gel electrophoresis. Similarly, oligonucleotide probes specific for a DNA molecule encoding a polypeptide of the present invention may be used in a hybridization assay to detect the presence of an inventive polypeptide in a biological sample.

As used herein, the term "oligonucleotide primer/probe specific for a DNA molecule" means an oligonucleotide sequence that has at least about 80%, preferably at least about 90% and more preferably at least about 95%, identity to the DNA molecule in question. Oligonucleotide primers and/or probes which may be usefully employed in the inventive diagnostic methods preferably have at least about 10-40 nucleotides. In a preferred embodiment, the oligonucleotide primers comprise at least about 10 contiguous nucleotides of a DNA molecule encoding one of the polypeptides disclosed herein. Preferably, oligonucleotide probes for use in the inventive diagnostic methods comprise at least about 15 contiguous oligonucleotides of a DNA molecule encoding one of the polypeptides disclosed herein. Techniques for both PCR based assays and hybridization assays are well known in the art (see, for example, Mullis *et al. Ibid*; Ehrlich, *Ibid*). Primers or probes may thus be used to detect *Chlamydia*-specific sequences in biological samples. DNA probes or primers

comprising oligonucleotide sequences described above may be used alone or in combination with each other.

The following Examples are offered by way of illustration and not by way of limitation.

EXAMPLE 1

ISOLATION OF DNA SEQUENCES ENCODING *CHLAMYDIA* ANTIGENS

Chlamydia antigens of the present invention were isolated by expression cloning of a genomic DNA library of *Chlamydia trachomatis* LGV II essentially as described by Sanderson et al. (*J. Exp. Med.*, 1995, 182:1751-1757) and were shown to induce PBMC proliferation and IFN- γ in an immunoreactive T cell line.

A *Chlamydia*-specific T cell line was generated by stimulating PBMCs from a normal donor with no history of chlamydial genital tract infection with elementary bodies of *Chlamydia trachomatis* LGV II. This T cell line, referred to as TCL-8, was found to recognize both *Chlamydia trachomatis* and *Chlamydia pneumonia* infected monocyte-derived dendritic cells.

A randomly sheared genomic library of *Chlamydia trachomatis* LGV II was constructed in Lambda ZAP (Stratagene, La Jolla, CA) and the amplified library plated out in 96 well microtiter plates at a density of 30 clones/well. Bacteria were induced to express recombinant protein in the presence of 2 mM IPTG for 3 h, then pelleted and resuspended in 200 μ l of RPMI 10% FBS. 10 μ l of the induced bacterial suspension was transferred to 96 well plates containing autologous monocyte-derived dendritic cells. After a 2 h incubation, dendritic cells were washed to remove free *E. coli* and *Chlamydia*-specific T cells were added. Positive *E. coli* pools were identified by determining IFN- γ production and proliferation of the T cells in response to the pools.

Four positive pools were identified, which were broken down to yield four pure clones (referred to as 1-B1-66, 4-D7-28, 3-G3-10 and 10-C10-31), with insert sizes of 481 bp, 183 bp, 110 bp and 1400 bp, respectively. The determined DNA sequences for 1-B1-66, 4-D7-28, 3-G3-10 and 10-C10-31 are provided in SEQ ID NO: 1-4, respectively. Clone 1-B1-66 is approximately in region 536690 of the *C. trachomatis* genome (NCBI C.

trachomatis database). Within clone 1-B1-66, an open reading frame (ORF) has been identified (nucleotides 115 - 375) that encodes a previously identified 9 kDa protein (Stephens, et al. Genbank Accession No. AE001320), the sequence of which is provided in SEQ ID NO: 5). Clone 4-D7-28 is a smaller region of the same ORF (amino acids 22-82 of 1-B1-66). Clone 3-G3-10 is approximately in region 74559 of the *C. trachomatis* genome. The insert is cloned in the antisense orientation with respect to its orientation in the genome. The clone 10-C10-31 contains an open reading frame that corresponds to a previously published sequence for S13 ribosomal protein from *Chlamydia trachomatis* (Gu, L. et al. *J. Bacteriology*, 177:2594-2601, 1995). The predicted protein sequences for 4-D7-28 and 10-C10-31 are provided in SEQ ID NO: 6 and 12, respectively. Predicted protein sequences for 3-G3-10 are provided in SEQ ID NO: 7-11.

In a related series of screening studies, an additional T cell line was used to screen the genomic DNA library of *Chlamydia trachomatis* LGV II described above. A *Chlamydia*-specific T cell line (TCT-1) was derived from a patient with a chlamydial genital tract infection by stimulating patient PBMC with autologous monocyte-derived dendritic cells infected with elementary bodies of *Chlamydia trachomatis* LGV II. One clone, 4C9-18 (SEQ ID NO: 21), containing a 1256 bp insert, elicited a specific immune response, as measured by standard proliferation assays, from the *Chlamydia*-specific T cell line TCT-1. Subsequent analysis revealed this clone to contain three known sequences: lipamide dehydrogenase (Genbank Accession No. AE001326), disclosed in SEQ ID NO: 22; a hypothetical protein CT429 (Genbank Accession No. AE001316), disclosed in SEQ ID NO: 23; and part of an open reading frame of ubiquinone methyltransferase CT428 (Genbank Accession No. AE001316), disclosed in SEQ ID NO: 24.

In further studies involving clone 4C9-18 (SEQ ID NO: 21), the full-length amino acid sequence for lipamide dehydrogenase (SEQ ID NO: 22) from *C. trachomatis* (LGV II) was expressed in clone CtL2-LPDA-FL, as disclosed in SEQ ID NO: 90.

To further characterize the open reading frame containing the T cell stimulating epitope(s), a cDNA fragment containing nucleotides 1-695 of clone 4C9-18 with a cDNA sequence encoding a 6X-Histidine tag on the amino terminus was subcloned into the NdeI/EcoRI site of the pET17b vector (Novagen, Madison, WI), referred to as clone 4C9-

18#2 BL21 pLysS (SEQ ID NO: 25, with the corresponding amino acid sequence provided in SEQ ID NO: 26) and transformed into *E. coli*. Selective induction of the transformed *E. coli* with 2 mM IPTG for three hours resulted in the expression of a 26 kDa protein from clone 4C9-18#2 BL21 pLysS, as evidenced by standard Coomassie-stained SDS-PAGE. To determine the immunogenicity of the protein encoded by clone 4C9-18#2 BL21 pLysS, *E. coli* expressing the 26 kDa protein were titrated onto 1×10^4 monocyte-derived dendritic cells and incubated for two hours. The dendritic cell cultures were washed and 2.5×10^4 T cells (TCT-1) added and allowed to incubate for an additional 72 hours, at which time the level of IFN- γ in the culture supernatant was determined by ELISA. As shown in Fig. 1, the T-cell line TCT-1 was found to respond to induced cultures as measured by IFN- γ , indicating a *Chlamydia*-specific T-cell response against the lipamide dehydrogenase sequence. Similarly, the protein encoded by clone 4C9-18#2 BL21 pLysS was shown to stimulate the TCT-1 T-cell line by standard proliferation assays.

Subsequent studies to identify additional *Chlamydia trachomatis* antigens using the above-described CD4+ T-cell expression cloning technique yielded additional clones. The TCT-1 and TCL-8 *Chlamydia*-specific T-cell lines, as well as the TCP-21 T-cell line were utilized to screen the *Chlamydia trachomatis* LGVII genomic library. The TCP-21 T-cell line was derived from a patient having a humoral immune response to *Chlamydia pneumoniae*. The TCT-1 cell line identified 37 positive pools, the TCT-3 cell line identified 41 positive pools and the TCP-21 cell line identified 2 positive pools. The following clones were derived from 10 of these positive pools. Clone 11-A3-93 (SEQ ID NO: 64), identified by the TCP-21 cell line, is a 1339 bp genomic fragment sharing homology to the HAD superfamily (CT103). The second insert in the same clone shares homology with the fab I gene (CT104) present on the complementary strand. Clone 11-C12-91 (SEQ ID NO: 63), identified using the TCP-21 cell line, has a 269 bp insert that is part of the OMP2 gene (CT443) and shares homology with the 60 kDa cysteine rich outer membrane protein of *C. pneumoniae*.

Clone 11-G10-46, (SEQ ID NO: 62), identified using the TCT-3 cell line, contains a 688 bp insert that shares homology to the hypothetical protein CT610. Clone 11-G1-34, (SEQ ID NO: 61), identified using the TCT-3 cell line, has two partial open reading

frames (ORF) with an insert size of 1215 bp. One ORF shares homology to the malate dehydrogenase gene (CT376), and the other ORF shares homology to the glycogen hydrolase gene (CT042). Clone 11-H3-68, (SEQ ID NO: 60), identified using the TCT-3 cell line, has two ORFs with a total insert size of 1180 bp. One partial ORF encodes the plasmid-encoded PGP6-D virulence protein while the second ORF is a complete ORF for the L1 ribosomal gene (CT138). Clone 11-H4-28, (SEQ ID NO: 59), identified using the TCT-3 cell line, has an insert size of 552 bp and is part of the ORF for the dnaK gene (CT396). Clone 12-B3-95, (SEQ ID NO: 58), identified using the TCT-1 cell line, has an insert size of 463 bp and is a part of the ORF for the lipoamide dehydrogenase gene (CT557). Clones 15-G1-89 and 12-B3-95 are identical, (SEQ ID NO: 55 and 58, respectively), identified using the TCT-1 cell line, has an insert size of 463 bp and is part of the ORF for the lipoamide dehydrogenase gene (CT557). Clone 12-G3-83, (SEQ ID NO: 57), identified using the TCT-1 cell line, has an insert size of 1537 bp and has part of the ORF for the hypothetical protein CT622.

Clone 23-G7-68, (SEQ ID NO: 79), identified using the TCT-3 cell line, contains a 950 bp insert and contains a small part of the L11 ribosomal ORF, the entire ORF for L1 ribosomal protein and a part of the ORF for L10 ribosomal protein. Clone 22-F8-91, (SEQ ID NO: 80), identified using the TCT-1 cell line, contains a 395 bp insert that contains a part of the pmpC ORF on the complementary strand of the clone. Clone 21-E8-95, (SEQ ID NO: 81), identified using the TCT-3 cell line, contains a 2,085 bp insert which contains part of CT613 ORF, the complete ORF for CT612, the complete ORF for CT611 and part of the ORF for CT610. Clone 19-F12-57, (SEQ ID NO: 82), identified using the TCT-3 cell line, contains a 405 bp insert which contains part of the CT 858 ORF and a small part of the recA ORF. Clone 19-F12-53, (SEQ ID NO: 83), identified using the TCT-3 cell line, contains a 379 bp insert that is part of the ORF for CT455 encoding glutamyl tRNA synthetase. Clone 19-A5-54, (SEQ ID NO: 84), identified using the TCT-3 cell line, contains a 715 bp insert that is part of the ORF3 (complementary strand of the clone) of the cryptic plasmid. Clone 17-E11-72, (SEQ ID NO: 85), identified using the TCT-1 cell line, contains a 476 bp insert that is part of the ORF for Opp_2 and pmpD. The pmpD region of this clone is covered by the pmpD region of clone 15-H2-76. Clone 17-C1-77, (SEQ ID NO: 86), identified using the TCT-3 cell line, contains a 1551 bp insert that is part of the CT857 ORF, as well as part of

the CT858 ORF. Clone 15-H2-76, (SEQ ID NO: 87), identified using the TCT-1 cell line, contains a 3,031 bp insert that contains a large part of the pmpD ORF, part of the CT089 ORF, as well as part of the ORF for SycE. Clone 15-A3-26, (SEQ ID NO: 88), contains a 976 bp insert that contains part of the ORF for CT858. Clone 17-G4-36, (SEQ ID NO: 267), identified using the TCT-10 cell line, contains a 680 bp insert that is in frame with beta-gal in the plasmid and shares homology to part of the ORF for DNA-directed RNA polymerase beta subunit (CT315 in SerD).

Several of the clones described above share homology to various polymorphic membrane proteins. The genomic sequence of *Chlamydia trachomatis* contains a family of nine polymorphic membrane protein genes, referred to as pmp. These genes are designated pmpA, pmpB, pmpC, pmpD, pmpE, pmpF, pmpG, pmpH and pmpI. Proteins expressed from these genes are believed to be of biological relevance in generating a protective immune response to a *Chlamydial* infection. In particular, pmpC, pmpD, pmpE and pmpI contain predictable signal peptides, suggesting they are outer membrane proteins, and therefore, potential immunological targets.

Based on the *Chlamydia trachomatis* LGVII serovar sequence, primer pairs were designed to PCR amplify the full-length fragments of pmpC, pmpD, pmpE, pmpG, pmpH and pmpI. The resulting fragments were subcloned into the DNA vaccine vector JA4304 or JAL, which is JA4304 with a modified linker (SmithKline Beecham, London, England). Specifically, PmpC was subcloned into the JAL vector using the 5' oligo GAT AGG CGC GCC GCA ATC ATG AAA TTT ATG TCA GCT ACT GCT G and the 3' oligo CAG AAC GCG TTT AGA ATG TCA TAC GAG CAC CGC A, as provided in SEQ ID NO: 197 and 198, respectively. PCR amplification of the gene under conditions well known in the art and ligation into the 5' ASCI/3' MluI sites of the JAL vector was completed after inserting the short nucleotide sequence GCAATC (SEQ ID NO: 199) upstream of the ATG to create a Kozak-like sequence. The resulting expression vector contained the full-length pmpC gene comprising 5325 nucleotides (SEQ ID NO: 173) containing the hypothetical signal sequence, which encodes a 187 kD protein (SEQ ID NO: 179). The pmpD gene was subcloned into the JA4304 vaccine vector following PCR amplification of the gene using the following oligos: 5' oligo- TGC AAT CAT GAG TTC GCA GAA AGA TAT AAA AAG C

(SEQ ID NO: 200) and 3' oligo- CAG AGC TAG CTT AAA AGA TCA ATC GCA ATC CAG TAT TC (SEQ ID NO: 201). The gene was ligated into the a 5' blunted HindIII/3' MluI site of the JA4304 vaccine vector using standard techniques well known in the art. The CAATC (SEQ ID NO: 202) was inserted upstream of the ATG to create a Kozak-like sequence. This clone is unique in that the last threonine of the HindIII site is missing due to the blunting procedure, as is the last glycine of the Kozak-like sequence. The insert, a 4593 nucleotide fragment (SEQ ID NO: 172) is the full-length gene for pmpD containing the hypothetical signal sequence, which encodes a 161 kD protein (SEQ ID NO: 178). PmpE was subcloned into the JA4304 vector using the 5' oligo- TGC AAT CAT GAA AAA AGC GTT TTT CTT TTT C (SEQ ID NO: 203), and the 3' oligo- CAG AAC GCG TCT AGA ATC GCA GAG CAA TTT C (SEQ ID NO: 204). Following PCR amplification, the gene was ligated into the 5' blunted HindIII/3' MluI site of JA4304. To facilitate this, a short nucleotide sequence, TGCAATC (SEQ ID NO: 293), was added upstream of the initiation codon for creating a Kozak-like sequence and reconstituting the HindIII site. The insert is the full-length pmpE gene (SEQ ID NO: 171) containing the hypothetical signal sequence. The pmpE gene encodes a 105 kD protein (SEQ ID NO: 177). The pmpG gene was PCR amplified using the 5' oligo- GTG CAA TCA TGA TTC CTC AAG GAA TTT ACG (SEQ ID NO: 205), and the 3' oligo- CAG AAC GCG TTT AGA ACC GGA CTT TAC TTC C (SEQ ID NO: 206) and subcloned into the JA4304 vector. Similar cloning strategies were followed for the pmpI and pmpK genes. In addition, primer pairs were designed to PCR amplify the full-length or overlapping fragments of the pmp genes, which were then subcloned for protein expression in the pET17b vector (Novagen, Madison, WI) and transfected into E. coli BL21 pLysS for expression and subsequent purification utilizing the histidine-nickel chromatographic methodology provided by Novagen. Several of the genes encoding the recombinant proteins, as described below, lack the native signal sequence to facilitate expression of the protein. Full-length protein expression of pmpC was accomplished through expression of two overlapping fragments, representing the amino and carboxy termini. Subcloning of the pmpC-amino terminal portion, which lacks the signal sequence, (SEQ ID NO: 187, with the corresponding amino acid sequence provided in SEQ ID NO: 195) used the 5' oligo- CAG ACA TAT GCA TCA CCA TCA CCA TCA CGA

GGC GAG CTC GAT CCA AGA TC (SEQ ID NO: 207), and the 3' oligo- CAG AGG TAC CTC AGA TAG CAC TCT CTC CTA TTA AAG TAG G (SEQ ID NO: 208) into the 5' NdeI/3' KPN cloning site of the vector. The carboxy terminus portion of the gene, pmpC-carboxy terminal fragment (SEQ ID NO: 186, with the corresponding amino acid sequence provided in SEQ ID NO: 194), was subcloned into the 5' NheI/3' KPN cloning site of the expression vector using the following primers: 5' oligo- CAG AGC TAG CAT GCA TCA CCA TCA CCA TCA CGT TAA GAT TGA GAA CTT CTC TGG C (SEQ ID NO: 209), and 3' oligo- CAG AGG TAC CTT AGA ATG TCA TAC GAG CAC CGC AG (SEQ ID NO: 210). PmpD was also expressed as two overlapping proteins. The pmpD-amino terminal portion, which lacks the signal sequence, (SEQ ID NO: 185, with the corresponding amino acid sequence provided in SEQ ID NO: 193) contains the initiating codon of the pET17b and is expressed as a 80 kD protein. For protein expression and purification purposes, a six-histidine tag follows the initiation codon and is fused at the 28th amino acid (nucleotide 84) of the gene. The following primers were used, 5' oligo, CAG ACA TAT GCA TCA CCA TCA CCA TCA CGG GTT AGC (SEQ ID NO: 211), and the 3' oligo- CAG AGG TAC CTC AGC TCC TCC AGC ACA CTC TCT TC (SEQ ID NO: 212), to splice into the 5' NdeI/3' KPN cloning site of the vector. The pmpD-carboxy terminus portion (SEQ ID NO: 184) was expressed as a 92 kD protein (SEQ ID NO: 192). For expression and subsequent purification, an additional methionine, alanine and serine was included, which represent the initiation codon and the first two amino acids from the pET17b vector. A six-histidine tag downstream of the methionine, alanine and serine is fused at the 691st amino acid (nucleotide 2073) of the gene. The 5' oligo- CAG AGC TAG CCA TCA CCA TCA CCA TCA CGG TGC TAT TTC TTG CTT ACG TGG (SEQ ID NO: 213) and the 3' oligo- CAG AGG TAC TTn AAA AGA TCA ATC GCA ATC CAG TAT TCG (SEQ ID NO: 214) were used to subclone the insert into the 5' NheI/3' KPN cloning site of the expression vector. PmpE was expressed as a 106kD protein (SEQ ID NO: 183 with the corresponding amino acid sequence provided in SEQ ID NO: 191). The pmpE insert also lacks the native signal sequence. PCR amplification of the gene under conditions well known in the art was performed using the following oligo primers: 5' oligo- CAG AGG ATC CAC ATC ACC ATC ACC ATC ACG GAC TAG CTA GAG AGG TTC (SEQ ID NO: 215), and

the 3' oligo- CAG AGA ATT CCT AGA ATC GCA GAG CAA TTT C (SEQ ID NO: 216), and the amplified insert was ligated into a 5' BamHI/3' EcoRI site of JA4304. The short nucleotide sequence, as provided in SEQ ID NO: 217, was inserted upstream of the initiation codon for creating the Kozak-like sequence and reconstituting the HindIII site. The expressed protein contains the initiation codon and the downstream 21 amino acids from the pET17b expression vector, i.e., MASMTGGQQMGRDSSLVPSSDP (SEQ ID NO: 218). In addition, a six-histidine tag is included upstream of the sequence described above and is fused at the 28th amino acid (nucleotide 84) of the gene, which eliminates the hypothetical signal peptide. The sequences provided in SEQ ID NO: 183 with the corresponding amino acid sequence provided in SEQ ID NO: 191 do not include these additional sequences. The pmpG gene (SEQ ID NO: 182, with the corresponding amino acid sequence provided in SEQ ID No; 190) was PCR amplified under conditions well known in the art using the following oligo primers: 5' oligo- CAG AGG TAC CGC ATC ACC ATC ACC ATC ACA TGA TTC CTC AAG GAA TTT ACG (SEQ ID NO: 219), and the 3' oligo- CAG AGC GGC CGC TTA GAA CCG GAC TTT ACT TCC (SEQ ID NO: 220), and ligated into the 5' KPN/3' NotI cloning site of the expression vector. The expressed protein contains an additional amino acid sequence at the amino end, namely, MASMTGGQQNGRDSSLVPHHHHHH (SEQ ID NO: 221), which comprises the initiation codon and additional sequence from the pET17b expression vector. The pmpI gene (SEQ ID NO: 181, with the corresponding amino acid sequence provided in SEQ ID No; 189) was PCR amplified under conditions well known in the art using the following oligo primers: 5' oligo- CAG AGC TAG CCA TCA CCA TCA CCA TCA CCT CTT TGG CCA GGA TCC C (SEQ ID NO: 222), and the 3' oligo- CAG AAC TAG TCT AGA ACC TGT AAG TGG TCC (SEQ ID NO: 223), and ligated into the expression vector at the 5' NheI/3' SpeI cloning site. The 95 kD expressed protein contains the initiation codon plus an additional alanine and serine from the pET17b vector at the amino end of the protein. In addition, a six-histidine tag is fused at the 21st amino acid of the gene, which eliminates the hypothetical signal peptide.

Clone 14H1-4, (SEQ ID NO: 56), identified using the TCT-3 cell line, contains a complete ORF for the TSA gene, thiol specific antioxidant – CT603 (the CT603 ORF is a homolog of CPn0778 from *C. pneumoniae*). The TSA open reading frame in clone

14-H1-4 was amplified such that the expressed protein possess an additional methionine and a 6x histidine tag (amino terminal end). This amplified insert was sub-cloned into the Nde/EcoRI sites of the pET17b vector. Upon induction of this clone with IPTG, a 22.6 kDa protein was purified by Ni-NTA agarose affinity chromatography. The determined amino acid sequence for the 195 amino acid ORF of clone 14-H1-4 encoding the TSA gene is provided in SEQ ID NO: 65. Further analysis yielded a full-length clone for the TSA gene, referred to as CTL2-TSA-FL, with the full-length amino acid sequence provided in SEQ ID NO: 92.

Further studies yielded 10 additional clones identified by the TCT-1 and TCT-3 T-cell lines, as described above. The clones identified by the TCT-1 line are: 16-D4-22, 17-C5-19, 18-C5-2, 20-G3-45 and 21-C7-66; clones identified by the TCT-3 cell line are: 17-C10-31, 17-E2-9, 22-A1-49 and 22-B3-53. Clone 21-G12-60 was recognized by both the TCT-1 and TCT-3 T cell lines. Clone 16-D4-22 (SEQ ID NO: 119), identified using the TCT-1 cell line contains a 953 bp insert that contains two genes, parts of open reading frame 3 (ORF3) and ORF4 of the *C. trachomatis* plasmid for growth within mammalian cells. Clone 17-C5-19 (SEQ ID NO: 118), contains a 951 bp insert that contains part of the ORF for DT431, encoding for clpP_1 protease and part of the ORF for CT430 (diaminopimelate epimerase). Clone 18-C5-2 (SEQ ID NO: 117) is part of the ORF for S1 ribosomal protein with a 446 bp insert that was identified using the TCT-1 cell line. Clone 20-G3-45 (SEQ ID NO: 116), identified by the TCT-1 cell line, contains a 437 bp insert that is part of the pmpB gene (CT413). Clone 21-C7-66 (SEQ ID NO: 115), identified by the TCT-1 line, contains a 995bp insert that encodes part of the dnaK like protein. The insert of this clone does not overlap with the insert of the TCT-3 clone 11-H4-28 (SEQ ID NO: 59), which was shown to be part of the dnaK gene CT396. Clone 17-C10-31 (SEQ ID NO: 114), identified by the TCT-3 cell line, contains a 976 bp insert. This clone contains part of the ORF for CT858, a protease containing IRBP and DHR domains. Clone 17-E2-9 (SEQ ID NO: 113) contains part of ORFs for two genes, CT611 and CT610, that span a 1142 bp insert. Clone 22-A1-49 (SEQ ID NO: 112), identified using the TCT-3 line, also contains two genes in a 698 bp insert. Part of the ORF for CT660 (DNA gyrase{gyrA_2}) is present on the top strand where as the complete ORF for a hypothetical protein CT659 is present on the complementary

strand. Clone 22-B3-53 (SEQ ID NO: 111), identified by the TCT-1 line, has a 267 bp insert that encodes part of the ORF for GroEL (CT110). Clone 21-G12-60 (SEQ ID NO: 110), identified by both the TCT-1 and TCT-3 cell lines contains a 1461 bp insert that contains partial ORFs for hypothetical proteins CT875, CT229 and CT228.

Additional *Chlamydia* antigens were obtained by screening a genomic expression library of *Chlamydia trachomatis* (LGV II serovar) in Lambda Screen-1 vector (Novagen, Madison, WI) with sera pooled from several *Chlamydia*-infected individuals using techniques well known in the art. The following immuno-reactive clones were identified and the inserts containing *Chlamydia* genes sequenced: CTL2#1 (SEQ ID NO: 71); CTL2#2 (SEQ ID NO: 70); CTL2#3-5' (SEQ ID NO: 72, a first determined genomic sequence representing the 5' end); CTL2#3-3' (SEQ ID NO: 73, a second determined genomic sequence representing the 3' end); CTL2#4 (SEQ ID NO: 53); CTL2#5 (SEQ ID NO: 69); CTL2#6 (SEQ ID NO: 68); CTL2#7 (SEQ ID NO: 67); CTL2#8b (SEQ ID NO: 54); CTL2#9 (SEQ ID NO: 66); CTL2#10-5' (SEQ ID NO: 74, a first determined genomic sequence representing the 5' end); CTL2#10-3' (SEQ ID NO: 75, a second determined genomic sequence representing the 3' end); CTL2#11-5' (SEQ ID NO: 45, a first determined genomic sequence representing the 5' end); CTL2#11-3' (SEQ ID NO: 44, a second determined genomic sequence representing the 3' end); CTL2#12 (SEQ ID NO: 46); CTL2#16-5' (SEQ ID NO: 47); CTL2#18-5' (SEQ ID NO: 49, a first determined genomic sequence representing the 5' end); CTL2#18-3' (SEQ ID NO: 48, a second determined genomic sequence representing the 3' end); CTL2#19-5' (SEQ ID NO: 76, the determined genomic sequence representing the 5' end); CTL2#21 (SEQ ID NO: 50); CTL2#23 (SEQ ID NO: 51); and CTL2#24 (SEQ ID NO: 52).

Additional *Chlamydia trachomatis* antigens were identified by serological expression cloning. These studies used sera pooled from several *Chlamydia*-infected individuals, as described above, but, IgA, and IgM antibodies were used in addition to IgG as a secondary antibody. Clones screened by this method enhance detection of antigens recognized by an early immune response to a *Chlamydial* infection, that is a mucosal humoral immune response. The following immunoreactive clones were characterized and the inserts containing *Chlamydia* genes sequenced: CTL2gam-1 (SEQ ID NO: 290), CTL2gam-2 (SEQ

ID NO: 289), CTL2gam-5 (SEQ ID NO: 288), CTL2gam-6-3' (SEQ ID NO: 287, a second determined genomic sequence representing the 3' end), CTL2gam-6-5' (SEQ ID NO: 286, a first determined genomic sequence representing the 5' end), CTL2gam-8 (SEQ ID NO: 285), CTL2gam-10 (SEQ ID NO: 284), CTL2gam-13 (SEQ ID NO: 283), CTL2gam-15-3' (SEQ ID NO: 282, a second determined genomic sequence representing the 3' end), CTL2gam-15-5' (SEQ ID NO: 281, a first determined genomic sequence representing the 5' end), CTL2gam-17 (SEQ ID NO: 280), CTL2gam-18 (SEQ ID NO: 279), CTL2gam-21 (SEQ ID NO: 278), CTL2gam-23 (SEQ ID NO: 277), CTL2gam-24 (SEQ ID NO: 276), CTL2gam-26 (SEQ ID NO: 275), CTL2gam-27 (SEQ ID NO: 274), CTL2gam-28 (SEQ ID NO: 273), CTL2gam-30-3' (SEQ ID NO: 272, a second determined genomic sequence representing the 3' end) and CTL2gam-30-5' (SEQ ID NO: 271, a first determined genomic sequence representing the 5' end).

EXAMPLE 2

INDUCTION OF T CELL PROLIFERATION AND INTERFERON- γ PRODUCTION BY *CHLAMYDIA TRACHOMATIS* ANTIGENS

The ability of recombinant *Chlamydia trachomatis* antigens to induce T cell proliferation and interferon- γ production is determined as follows.

Proteins are induced by IPTG and purified by Ni-NTA agarose affinity chromatograph (Webb et al., *J. Immunology* 157:5034-5041, 1996). The purified polypeptides are then screened for the ability to induce T-cell proliferation in PBMC preparations. PBMCs from *C. trachomatis* patients as well as from normal donors whose T-cells are known to proliferate in response to *Chlamydia* antigens, are cultured in medium comprising RPMI 1640 supplemented with 10% pooled human serum and 50 μ g/ml gentamicin. Purified polypeptides are added in duplicate at concentrations of 0.5 to 10 μ g/mL. After six days of culture in 96-well round-bottom plates in a volume of 200 μ l, 50 μ l of medium is removed from each well for determination of IFN- γ levels, as described below. The plates are then pulsed with 1 μ Ci/well of tritiated thymidine for a further 18 hours, harvested and tritium uptake determined using a gas scintillation counter. Fractions that

result in proliferation in both replicates three fold greater than the proliferation observed in cells cultured in medium alone are considered positive.

IFN- γ is measured using an enzyme-linked immunosorbent assay (ELISA). ELISA plates are coated with a mouse monoclonal antibody directed to human IFN- γ (PharMingen, San Diego, CA) in PBS for four hours at room temperature. Wells are then blocked with PBS containing 5% (W/V) non-fat dried milk for 1 hour at room temperature. The plates are washed six times in PBS/0.2% TWEEN-20 and samples diluted 1:2 in culture medium in the ELISA plates are incubated overnight at room temperature. The plates are again washed and a polyclonal rabbit anti-human IFN- γ serum diluted 1:3000 in PBS/10% normal goat serum is added to each well. The plates are then incubated for two hours at room temperature, washed and horseradish peroxidase-coupled anti-rabbit IgG (Sigma Chemical So., St. Louis, MO) is added at a 1:2000 dilution in PBS/5% non-fat dried milk. After a further two hour incubation at room temperature, the plates are washed and TMB substrate added. The reaction is stopped after 20 min with 1 N sulfuric acid. Optical density is determined at 450 nm using 570 nm as a reference wavelength. Fractions that result in both replicates giving an OD two fold greater than the mean OD from cells cultured in medium alone, plus 3 standard deviations, are considered positive.

Using the above methodology, recombinant 1B1-66 protein (SEQ ID NO: 5) as well as two synthetic peptides corresponding to amino acid residues 48-67 (SEQ ID NO: 13; referred to as 1-B1-66/48-67) and 58-77 (SEQ ID NO: 14, referred to as 1B1-66/58-77), respectively, of SEQ ID NO: 5, were found to induce a proliferative response and IFN- γ production in a Chlamydia-specific T cell line used to screen a genomic library of *C. trachomatis* LGV II.

Further studies have identified a *C. trachomatis*-specific T-cell epitope in the ribosomal S13 protein. Employing standard epitope mapping techniques well known in the art, two T-cell epitopes in the ribosomal S13 protein (rS13) were identified with a Chlamydia-specific T-cell line from donor CL-8 (T-cell line TCL-8 EB/DC). Fig. 8 illustrates that the first peptide, rS13 1-20 (SEQ ID NO: 106), is 100% identical with the corresponding *C. pneumoniae* sequence, explaining the cross-reactivity of the T-cell line to recombinant *C. trachomatis*- and *C. pneumoniae*-rS13. The response to the second peptide

rS13 56-75 (SEQ ID NO: 108) is *C. trachomatis*-specific, indicating that the rS13 response in this healthy asymptomatic donor was elicited by exposure to *C. trachomatis* and not to *C. pneumoniae*, or any other microbial infection.

As described in Example 1, Clone 11-C12-91 (SEQ ID NO: 63), identified using the TCP-21 cell line, has a 269 bp insert that is part of the OMP2 gene (CT443) and shares homology with the 60 kDa cysteine rich outer membrane protein of *C. pneumoniae*, referred to as OMCB. To further define the reactive epitope(s), epitope mapping was performed using a series of overlapping peptides and the immunoassay previously described. Briefly, proliferative responses were determined by stimulating 2.5×10^4 TCP-21 T-cells in the presence of 1×10^4 monocyte-derived dendritic cells with either non-infectious elementary bodies derived from *C. trachomatis* and *C. pneumoniae*, or peptides derived from the protein sequence of *C. trachomatis* or *C. pneumoniae* OMCB protein (0.1 μ g/ml). The TCP-21 T-cells responded to epitopes CT-OMCB #167-186, CT-OMCB #171-190, CT-OMCB #171-186, and to a lesser extent, CT-OMCB #175-186 (SEQ ID NO: 249-252, respectively). Notably, the TCP-21 T-cell line also gave a proliferative response to the homologous *C. pneumoniae* peptide CP-OMCB #171-186 (SEQ ID NO: 253), which was equal to or greater than the response to the *C. trachomatis* peptides. The amino acid substitutions in position two (i.e., Asp for Glu) and position four (i.e., Cys for Ser) did not alter the proliferative response of the T-cells and therefore demonstrating this epitope to be a cross-reactive epitope between *C. trachomatis* and *C. pneumoniae*.

To further define the epitope described above, an additional T-cell line, TCT-3, was used in epitope mapping experiments. The immunoassays were performed as described above, except that only peptides from *C. trachomatis* were tested. The T-cells gave a proliferative response to two peptides, CT-OMCB #152-171 and CT-OMCB #157-176 (SEQ ID NO: 246 and 247, respectively), thereby defining an additional immunogenic epitope in the cysteine rich outer membrane protein of *C. trachomatis*.

Clone 14H1-4, (SEQ ID NO: 56, with the corresponding full-length amino acid sequence provided in SEQ ID NO: 92), was identified using the TCT-3 cell line in the CD4 T-cell expression cloning system previously described, and was shown to contain a complete ORF for the, thiol specific antioxidant gene (CT603), referred to as TSA. Epitope

mapping immunoassays were performed, as described above, to further define the epitope. The TCT-3 T-cells line exhibited a strong proliferative response to the overlapping peptides CT-TSA #96-115, CT-TSA #101-120 and CT-TSA #106-125 (SEQ ID NO: 254-256, respectively) demonstrating an immunoreactive epitope in the thiol specific antioxidant gene of *C. trachomatis* serovar LGVII.

EXAMPLE 3

PREPARATION OF SYNTHETIC POLYPEPTIDES

Polypeptides may be synthesized on a Millipore 9050 peptide synthesizer using Fmoc chemistry with HPTU (O-Benzotriazole-N,N,N',N'-tetramethyluronium hexafluorophosphate) activation. A Gly-Cys-Gly sequence may be attached to the amino terminus of the peptide to provide a method of conjugating or labeling of the peptide. Cleavage of the peptides from the solid support may be carried out using the following cleavage mixture: trifluoroacetic acid:ethanedithiol:thioanisole:water:phenol (40:1:2:2:3). After cleaving for 2 hours, the peptides may be precipitated in cold methyl-t-butyl-ether. The peptide pellets may then be dissolved in water containing 0.1% trifluoroacetic acid (TFA) and lyophilized prior to purification by C18 reverse phase HPLC. A gradient of 0-60% acetonitrile (containing 0.1% TFA) in water (containing 0.1% TFA) may be used to elute the peptides. Following lyophilization of the pure fractions, the peptides may be characterized using electrospray mass spectrometry and by amino acid analysis.

EXAMPLE 4

ISOLATION AND CHARACTERIZATION OF DNA SEQUENCES ENCODING
CHLAMYDIA ANTIGENS USING RETROVIRAL EXPRESSION VECTOR SYSTEMS
AND SUBSEQUENT IMMUNOLOGICAL ANALYSIS

A genomic library of *Chlamydia trachomatis* LGV II was constructed by limited digests using BamHI, BglII, BstYI and MboI restriction enzymes. The restriction digest fragments were subsequently ligated into the BamHI site of the retroviral vectors pBIB-KS1,2,3. This vector set was modified to contain a Kosak translation initiation site and stop codons in order to allow expression of proteins from short DNA genomic fragments, as shown in Fig. 2. DNA pools of 80 clones were prepared and transfected into the retroviral packaging line Phoenix-Ampho, as described in Pear, W.S., Scott, M.L. and Nolan, G.P., Generation of High Titre, Helper-free Retroviruses by Transient Transfection. Methods in Molecular Medicine: Gene Therapy Protocols, Humana Press, Totowa, NJ, pp. 41-57. The *Chlamydia* library in retroviral form was then transduced into H2-Ld expressing P815 cells, which were then used as target cells to stimulate an antigen specific T-cell line.

A *Chlamydia*-specific, murine H2^d restricted CD8⁺ T-cell line was expanded in culture by repeated rounds of stimulation with irradiated *C. trachomatis*-infected J774 cells and irradiated syngenic spleen cells, as described by Starnbach, M., in *J. Immunol.*, 153:5183, 1994. This *Chlamydia*-specific T-cell line was used to screen the above *Chlamydia* genomic library expressed by the retrovirally-transduced P815 cells. Positive DNA pools were identified by detection of IFN- γ production using Elispot analysis (SEE Lalvani et al., *J. Experimental Medicine* 186:859-865, 1997).

Two positive pools, referred to as 2C7 and 2E10, were identified by IFN- γ Elispot assays. Stable transductants of P815 cells from pool 2C7 were cloned by limiting dilution and individual clones were selected based upon their capacity to elicit IFN- γ production from the *Chlamydia*-specific CTL line. From this screening process, four positive clones were selected, referred to as 2C7-8, 2C7-9, 2C7-19 and 2C7-21. Similarly, the positive pool 2E10 was further screened, resulting in an additional positive clone, which

contains three inserts. The three inserts are fragments of the CT016, tRNA synthase and clpX genes (SEQ ID NO: 268-270, respectively).

Transgenic DNA from these four positive 2C7.8 clones were PCR amplified using pBIB-KS specific primers to selectively amplify the *Chlamydia* DNA insert. Amplified inserts were gel purified and sequenced. One immunoreactive clone, 2C7-8 (SEQ ID NO: 15, with the predicted amino acid sequence provided in SEQ ID NO: 32), is a 160 bp fragment with homology to nucleotides 597304-597145 of *Chlamydia trachomatis*, serovar D (NCBI, BLASTN search; SEQ ID NO: 33, with the predicted amino acid sequence provided in SEQ ID NO: 34). The sequence of clone 2C7-8 maps within two putative open reading frames from the region of high homology described immediately above, and in particular, one of these putative open reading frames, consisting of a 298 amino acid fragment (SEQ ID NO: 16, with the predicted amino acid sequence provided in SEQ ID NO: 17), was demonstrated to exhibit immunological activity.

Full-length cloning of the 298 amino acid fragment (referred to as CT529 and/or the Cap1 gene) from serovar L2 was obtained by PCR amplification using 5'-ttttgaagcaggtaggtgaatatg (forward) (SEQ ID NO: 159) and 5'-ttaagaaatttaaaatccctta (reverse) (SEQ ID NO: 160) primers, using purified *C. trachomatis* L2 genomic DNA as template. This PCR product was gel-purified, cloned into pCRBlunt (Invitrogen, Carlsbad, CA) for sequencing, and then subcloned into the *EcoRI* site of pBIB-KMS, a derivative of pBIB-KS for expression. The *Chlamydia pneumoniae* homologue of CT529 is provided in SEQ ID NO: 291, with the corresponding amino acid sequence provided in SEQ ID NO: 292.

Full-length DNA encoding various CT529 serovars were amplified by PCR from bacterial lysates containing 10^5 IFU, essentially as described (Denamur, E., C. Sayada, A. Souriau, J. Orfila, A. Rodolakis and J. Elion. 1991. J. Gen. Microbiol. 137: 2525). The following serovars were amplified as described: Ba (SEQ ID NO: 134, with the corresponding predicted amino acid sequence provided in SEQ ID NO: 135); E (BOUR) and E (MTW447) (SEQ ID NO: 122, with the corresponding predicted amino acid sequence provided in SEQ ID NO: 123); F (NI1) (SEQ ID NO: 128, with the corresponding predicted amino acid sequence provided in SEQ ID NO: 129); G; (SEQ ID NO: 126, with the corresponding predicted amino acid sequence provided in SEQ ID NO: 127); Ia (SEQ ID

NO: 124, with the corresponding predicted amino acid sequence provided in SEQ ID NO: 125); L1 (SEQ ID NO: 130, with the corresponding predicted amino acid sequence provided in SEQ ID NO: 131); L3 (SEQ ID NO: 132, with the corresponding predicted amino acid sequence provided in SEQ ID NO: 133); I (SEQ ID NO: 263, with the corresponding predicted amino acid sequence provided in SEQ ID NO: 264); K (SEQ ID NO: 265, with the corresponding predicted amino acid sequence provided in SEQ ID NO: 266); and MoPn (SEQ ID NO: 136, with the corresponding predicted amino acid sequence provided in SEQ ID NO: 137). PCR reactions were performed with Advantage Genomic PCR Kit (Clontech, Palo Alto, CA) using primers specific for serovar L2 DNA (external to the ORF). Primers sequences were 5'-ggataatatctctctaaatttg (forward-SEQ ID NO: 161) and 5'-agataaaaaagctgttttc' (reverse-SEQ ID NO: 162) except for MoPn which required 5'-ttttgaagcaggtaggigaatatg (forward-SEQ ID NO: 163) and 5'-tttacaataagaaaagctaagcatttgt (reverse-SEQ ID NO: 164). PCR amplified DNA was purified with QIAquick PCR purification kit (Qiagen, Valencia, CA) and cloned in pCR2.1 (Invitrogen, Carlsbad, CA) for sequencing.

Sequencing of DNA derived from PCR amplified inserts of immunoreactive clones was done on an automated sequencer (ABI 377) using both a pBIB-KS specific forward primer 5'-ccttacacagtcctctgtgac (SEQ ID NO: 165) and a reverse primer 3'-gtttccggccctcacattg (SEQ ID NO: 166). PCRBlunt cloned DNA coding for CT529 serovar L2 and pCR2.1 cloned DNA coding for CT529 serovar Ba, E (BOUR), E (MTW447), F (NI1), G, Ia, K, L1, L3 and MoPn were sequenced using T7 promoter primer and universal M13 forward and M13 reverse primers.

To determine if these two putative open reading frames (SEQ ID NO: 16 and 20) encoded a protein with an associated immunological function, overlapping peptides (17-20 amino acid lengths) spanning the lengths of the two open reading frames were synthesized, as described in Example 3. A standard chromium release assay was utilized to determine the per cent specific lysis of peptide-pulsed H2^d restricted target cells. In this assay, aliquots of P815 cells (H2^b) were labeled at 37° C for one hour with 100 µCi of ⁵¹Cr in the presence or absence of 1 µg/ml of the indicated peptides. Following this incubation, labeled P815 cells were washed to remove excess ⁵¹Cr and peptide, and subsequently plated

in duplicate in microculture plates at a concentration of 1,000 cells/well. Effector CTL (*Chlamydia*-specific CD8 T cells) were added at the indicated effector:target ratios. Following a 4 hour incubation, supernatants were harvested and measured by gamma-counter for release of ^{51}Cr into the supernatant. Two overlapping peptides from the 298 amino acid open reading frame did specifically stimulate the CTL line. The peptides represented in SEQ ID NO: 138-156 were synthesized, representing the translation of the L2 homologue of the serovar D open reading frame for CT529 (Cap1 gene) and 216 amino acid open reading frame. As shown in Fig. 3, peptides CtC7.8-12 (SEQ ID NO: 18, also referred to as Cap1#132-147, SEQ ID NO: 139) and CtC7.8-13 (SEQ ID NO: 19, also referred to as Cap1#138-155, SEQ ID NO: 140) were able to elicit 38 to 52% specific lysis, respectively, at an effector to target ratio of 10:1. Notably, the overlap between these two peptides contained a predicted H2^d (K^d and L^d) binding peptide. A 10 amino acid peptide was synthesized to correspond to this overlapping sequence (SEQ ID NO: 31) and was found to generate a strong immune response from the anti-*Chlamydia* CTL line by elispot assay. Significantly, a search of the most recent Genbank database revealed no proteins have previously been described for this gene. Therefore, the putative open reading frame encoding clone 2C7-8 (SEQ ID NO: 15) defines a gene which encompasses an antigen from *Chlamydia* capable of stimulating antigen-specific CD8+ T-cells in a MHC-I restricted manner, demonstrating this antigen could be used to develop a vaccine against *Chlamydia*.

To confirm these results and to further map the epitope, truncated peptides (SEQ ID NO: 138-156) were made and tested for recognition by the T-cells in an IFN- γ ELISPOT assay. Truncations of either Ser139 (Cap1#140-147, SEQ ID NO: 146) or Leu147 (Cap1#138-146, SEQ ID NO: 147) abrogate T-cell recognition. These results indicate that the 9-mer peptide Cap1#139-147 (SFIGGITYL, SEQ ID NO: 145) is the minimal epitope recognized by the *Chlamydia*-specific T-cells.

Sequence alignments of Cap1 (CT529) from selected serovars of *C. trachomatis* (SEQ ID NO: 121, 123, 125, 127, 129, 131, 133, 135, 137 and 139) shows one of the amino acid differences is found in position 2 of the proposed epitope. The homologous serovar D peptide is SIIGGITYL (SEQ ID NO: 168). The ability of SFIGGITYL and SIIGGITYL to target cells for recognition by the *Chlamydia* specific T-cells was compared.

Serial dilutions of each peptide were incubated with P815 cells and tested for recognition by the T-cells in a ^{51}Cr release assay, as described above. The *Chlamydia*-specific T-cells recognize the serovar L2 peptide at a minimum concentration of 1 nM and the serovar D peptide at a minimum concentration of 10 nM.

Further studies have shown that a Cap1#139-147-specific T-cell clone recognizes *C. trachomatis* infected cells. To confirm that Cap1₁₃₉₋₁₄₇ is presented on the surface of *Chlamydia* infected cells, Balb-3T3 (H-2^d) cells were infected with *C. trachomatis* serovar L2 and tested to determine whether these cells are recognized by a CD8⁺ T-cell clone specific for Cap1#139-147 epitope (SEQ ID NO: 145). The T-cell clone specific for Cap1#139-147 epitope was obtained by limiting dilution of the line 69 T-cells. The T-cell clone specifically recognized the *Chlamydia* infected cells. In these experiments, target cells were *C. trachomatis* infected (positive control) or uninfected Balb/3T3 cells, showing 45%, 36% and 30% specific lysis at 30:1, 10:1 and 3:1 effector to target ratios, respectively; or Cap1#139-147 epitope (SEQ ID NO: 145) coated, or untreated P815 cells, showing 83%, 75% and 58% specific lysis at 30:1, 10:1 and 3:1 effector to target ratios, respectively (negative controls having less than 5% lysis in all cases). This data suggests that the epitope is presented during infection.

In vivo studies show Cap1#139-147 epitope-specific T-cells are primed during murine infection with *C. trachomatis*. To determine if infection with *C. trachomatis* primes a Cap1#139-147 epitope-specific T-cell response, mice were infected i.p. with 10^8 IFU of *C. trachomatis* serovar L2. Two weeks after infection, the mice were sacrificed and spleen cells were stimulated on irradiated syngeneic spleen cells pulsed with Cap1#139-147 epitope peptide. After 5 days of stimulation, the cultures were used in a standard ^{51}Cr release assay to determine if there were Cap1#139-147 epitope-specific T-cells present in the culture. Specifically, spleen cells from a *C. trachomatis* serovar L2 immunized mouse or a control mouse injected with PBS after a 5 days culture with Cap1#139-147 peptide-coated syngeneic spleen cells and CD8⁺ T-cells able to specifically recognize Cap1#139-147 epitope gave 73%, 60% and 32% specific lysis at a30:1, 10:1 and 3:1 effector to target ratios, respectively. The control mice had a percent lysis of approximately 10% at a 30:1 effector to target ratio, and steadily declining with lowering E:T ratios. Target cells were Cap1#139-147 peptide-

coated, or untreated P815 cells. These data suggest that Cap1#139-147 peptide-specific T-cells are primed during murine infection with *C. trachomatis*.

EXAMPLE 5
GENERATION OF ANTIBODY AND T-CELL RESPONSES IN MICE IMMUNIZED
WITH *CHLAMYDIA* ANTIGENS

Immunogenicity studies were conducted to determine the antibody and CD4+ T cell responses in mice immunized with either purified SWIB or S13 proteins formulated with Montanide adjuvant, or DNA-based immunizations with pcDNA-3 expression vectors containing the DNA sequences for SWIB or S13. SWIB is also referred to as clone 1-B1-66 (SEQ ID NO: 1, with the corresponding amino acid sequence provided in SEQ ID NO: 5), and S13 ribosomal protein is also referred to as clone 10-C10-31 (SEQ ID NO: 4, with the corresponding amino acid sequence provided in SEQ ID NO: 12). In the first experiment, groups of three C57BL/6 mice were immunized twice and monitored for antibody and CD4+ T-cell responses. DNA immunizations were intradermal at the base of the tail and polypeptide immunizations were administered by subcutaneous route. Results from standard ³H-incorporation assays of spleen cells from immunized mice shows a strong proliferative response from the group immunized with purified recombinant SWIB polypeptide (SEQ ID NO: 5). Further analysis by cytokine induction assays, as previously described, demonstrated that the group immunized with SWIB polypeptide produced a measurable IFN- γ and IL-4 response. Subsequent ELISA-based assays to determine the predominant antibody isotype response in the experimental group immunized with the SWIB polypeptide were performed. Fig. 4 illustrates the SWIB-immunized group gave a humoral response that was predominantly IgG1.

In a second experiment, C3H mice were immunized three times with 10 μ g purified SWIB protein (also referred to as clone 1-B1-66, SEQ ID NO: 5) formulated in either PBS or Montanide at three week intervals and harvested two weeks after the third immunization. Antibody titers directed against the SWIB protein were determined by

standard ELISA-based techniques well known in the art, demonstrating the SWIB protein formulated with Montanide adjuvant induced a strong humoral immune response. T-cell proliferative responses were determined by a XTT-based assay (Scudiero, et al, *Cancer Research*, 1988, 48:4827). As shown in Fig. 5, splenocytes from mice immunized with the SWIB polypeptide plus Montanide elicited an antigen specific proliferative response. In addition, the capacity of splenocytes from immunized animals to secrete IFN- γ in response to soluble recombinant SWIB polypeptide was determined using the cytokine induction assay previously described. The splenocytes from all animals in the group immunized with SWIB polypeptide formulated with montanide adjuvant secreted IFN- γ in response to exposure to the SWIB Chlamydia antigen, demonstrating an *Chlamydia*-specific immune response.

In a further experiment, C3H mice were immunized at three separate time points at the base of the tail with 10 μ g of purified SWIB or S13 protein (*C. trachomatis*, SWIB protein, clone 1-B1-66, SEQ ID NO: 5, and S13 protein, clone 10-C10-31, SEQ ID NO: 4) formulated with the SBAS2 adjuvant (SmithKline Beecham, London, England). Antigen-specific antibody titers were measured by ELISA, showing both polypeptides induced a strong IgG response, ranging in titers from 1×10^{-4} to 1×10^{-5} . The IgG1 and IgG2a components of this response were present in fairly equal amounts. Antigen-specific T-cell proliferative responses, determined by standard ^3H -incorporation assays on spleen cells isolated from immunized mice, were quite strong for SWIB (50,000 cpm above the negative control) and even stronger for s13 (100,000 cpm above the negative control). The IFN γ production was assayed by standard ELISA techniques from supernatant from the proliferating culture. *In vitro* restimulation of the culture with S13 protein induced high levels of IFN γ production, approximately 25 ng/ml versus 2 ng/ml for the negative control. Restimulation with the SWIB protein also induced IFN γ , although to a lesser extent.

In a related experiment, C3H mice were immunized at three separate time points with 10 μ g of purified SWIB or S13 protein (*C. trachomatis*, SWIB protein, clone 1-B1-66, SEQ ID NO: 5, and S13 protein, clone 10-C10-31, SEQ ID NO: 4) mixed with 10 μ g of Cholera Toxin. Mucosal immunization was through intranasal inoculation. Antigen-specific antibody responses were determined by standard ELISA techniques. Antigen-specific IgG antibodies were present in the blood of SWIB-immunized mice, with titers

ranging from 1×10^{-3} to 1×10^{-4} , but non-detectable in the S13-immunized animals. Antigen-specific T-cell responses from isolated splenocytes, as measured by IFN γ production, gave similar results to those described immediately above for systemic immunization.

An animal study was conducted to determine the immunogenicity of the CT529 serovar LGVII CTL epitope, defined by the CT529 10mer consensus peptide (CSFIGGITYL – SEQ ID NO: 31), which was identified as an H2-Kd restricted CTL epitope. BALB/c mice (3 mice per group) were immunized three times with 25 μ g of peptide combined with various adjuvants. The peptide was administered systemically at the base of the tail in either SKB Adjuvant System SBAS-2'', SBAS-7 (SmithKline Beecham, London, England) or Montanide. The peptide was also administered intranasally mixed with 10ug of Cholera Toxin (CT). Naive mice were used as a control. Four weeks after the 3rd immunization, spleen cells were restimulated with LPS-blasts pulsed with 10ug/ml CT529 10mer consensus peptide at three different effector to LPS-blasts ratios : 6, 1.5 and 0.4 at 1×10^6 cell/ml. After 2 restimulations, effector cells were tested for their ability to lyse peptide pulsed P815 cells using a standard chromium release assay. A non-relevant peptide from chicken egg ovalbumin was used as a negative control. The results demonstrate that a significant immune response was elicited towards the CT529 10mer consensus peptide and that antigen-specific T-cells capable of lysing peptide-pulsed targets were elicited in response to immunization with the peptide. Specifically, antigen-specific lytic activities were found in the SBAS-7 and CT adjuvanted group while Montanide and SBAS-2'' failed to adjuvant the CTL epitope immunization.

EXAMPLE 6

EXPRESSION AND CHARACTERIZATION OF *CHLAMYDIA PNEUMONIAE* GENES

The human T-cell line, TCL-8, described in Example 1, recognizes *Chlamydia trachomatis* as well as *Chlamydia pneumonia* infected monocyte-derived dendritic cells, suggesting *Chlamydia trachomatis* and *pneumonia* may encode cross-reactive T-cell epitopes. To isolate the *Chlamydia pneumonia* genes homologous to *Chlamydia trachomatis* LGV II

clones 1B1-66, also referred to as SWIB (SEQ ID NO: 1) and clone 10C10-31, also referred to as S13 ribosomal protein (SEQ ID NO: 4), HeLa 229 cells were infected with *C. pneumonia* strain TWAR (CDC/CWL-029). After three days incubation, the *C. pneumonia*-infected HeLa cells were harvested, washed and resuspended in 200 μ l water and heated in a boiling water bath for 20 minutes. Ten microliters of the disrupted cell suspension was used as the PCR template.

C. pneumonia specific primers were designed for clones 1B1-66 and 10C10-31 such that the 5' end had a 6X-Histidine tag and a Nde I site inserted, and the 3' end had a stop codon and a BamHI site included (Fig. 6). The PCR products were amplified and sequenced by standard techniques well known in the art. The *C. pneumonia*-specific PCR products were cloned into expression vector pET17B (Novagen, Madison, WI) and transfected into *E. coli* BL21 pLysS for expression and subsequent purification utilizing the histidine-nickel chromatographic methodology provided by Novagen. Two proteins from *C. pneumonia* were thus generated, a 10-11 kDa protein referred to as CpSWIB (SEQ ID NO: 27, and SEQ ID NO: 78 having a 6X His tag, with the corresponding amino acid sequence provided in SEQ ID NO: 28, respectively), a 15 kDa protein referred to as CpS13 (SEQ ID NO: 29, and SEQ ID NO: 77, having a 6X His tag, with the corresponding amino acid sequence provided in SEQ ID NO: 30 and 91, respectively).

EXAMPLE 7

INDUCTION OF T CELL PROLIFERATION AND INTERFERON- γ PRODUCTION BY *CHLAMYDIA PNEUMONIAE* ANTIGENS

The ability of recombinant *Chlamydia pneumoniae* antigens to induce T cell proliferation and interferon- γ production is determined as follows.

Proteins are induced by IPTG and purified by Ni-NTA agarose affinity chromatography (Webb et al., *J. Immunology* 157:5034-5041, 1996). The purified polypeptides are then screened for the ability to induce T-cell proliferation in PBMC preparations. PBMCs from *C. pneumoniae* patients as well as from normal donors whose T-

cells are known to proliferate in response to *Chlamydia* antigens, are cultured in medium comprising RPMI 1640 supplemented with 10% pooled human serum and 50 µg/ml gentamicin. Purified polypeptides are added in duplicate at concentrations of 0.5 to 10 µg/mL. After six days of culture in 96-well round-bottom plates in a volume of 200 µl, 50 µl of medium is removed from each well for determination of IFN-γ levels, as described below. The plates are then pulsed with 1 µCi/well of tritiated thymidine for a further 18 hours, harvested and tritium uptake determined using a gas scintillation counter. Fractions that result in proliferation in both replicates three fold greater than the proliferation observed in cells cultured in medium alone are considered positive.

IFN-γ was measured using an enzyme-linked immunosorbent assay (ELISA). ELISA plates are coated with a mouse monoclonal antibody directed to human IFN-γ (PharMingen, San Diego, CA) in PBS for four hours at room temperature. Wells are then blocked with PBS containing 5% (W/V) non-fat dried milk for 1 hour at room temperature. The plates are washed six times in PBS/0.2% TWEEN-20 and samples diluted 1:2 in culture medium in the ELISA plates are incubated overnight at room temperature. The plates are again washed and a polyclonal rabbit anti-human IFN-γ serum diluted 1:3000 in PBS/10% normal goat serum is added to each well. The plates are then incubated for two hours at room temperature, washed and horseradish peroxidase-coupled anti-rabbit IgG (Sigma Chemical Co., St. Louis, MO) is added at a 1:2000 dilution in PBS/5% non-fat dried milk. After a further two hour incubation at room temperature, the plates are washed and TMB substrate added. The reaction is stopped after 20 min with 1 N sulfuric acid. Optical density is determined at 450 nm using 570 nm as a reference wavelength. Fractions that result in both replicates giving an OD two fold greater than the mean OD from cells cultured in medium alone, plus 3 standard deviations, are considered positive.

A human anti-*Chlamydia* T-cell line (TCL-8) capable of cross-reacting to *C. trachomatis* and *C. pneumonia* was used to determine whether the expressed proteins described in the example above, (i.e., CpSWIB, SEQ ID NO: 27, and SEQ ID NO: 78 having a 6X His tag, with the corresponding amino acid sequence provided in SEQ ID NO: 28, respectively, and the 15 kDa protein referred to as CpS13 SEQ ID NO: 29, and SEQ ID NO: 77, having a 6X His tag, with the corresponding amino acid sequence provided in SEQ ID

NO: 30 and 91, respectively), possessed T-cell epitopes common to both *C. trachomatis* and *C. pneumoniae*. Briefly, *E. coli* expressing *Chlamydial* proteins were titrated on 1×10^4 monocyte-derived dendritic cells. After two hours, the dendritic cells cultures were washed and 2.5×10^4 T cells (TCL-8) added and allowed to incubate for an additional 72 hours. The amount of INF- γ in the culture supernatant was then determined by ELISA. As shown in Figs. 7A and 7B, the TCL-8 T-cell line specifically recognized the S13 ribosomal protein from both *C. trachomatis* and *C. pneumoniae* as demonstrated by the antigen-specific induction of INF- γ , whereas only the SWIB protein from *C. trachomatis* was recognized by the T-cell line. To validate these results, the T cell epitope of *C. trachomatis* SWIB was identified by epitope mapping using target cells pulsed with a series of overlapping peptides and the T-cell line TCL-8. 3H-thymidine incorporation assays demonstrated that the peptide, referred to as C.t.SWIB 52-67, of SEQ ID NO: 39 gave the strongest proliferation of the TCL-8 line. The homologous peptides corresponding to the SWIB of *C. pneumoniae* sequence (SEQ ID NO: 40), the topoisomerase-SWIB fusion of *C. pneumoniae* (SEQ ID NO: 43) and *C. trachomatis* (SEQ ID NO: 42) as well as the human SWI domain (SEQ ID NO: 41) were synthesized and tested in the above assay. The T-cell line TCL-8 only recognized the *C. trachomatis* peptide of SEQ ID NO: 39 and not the corresponding *C. pneumoniae* peptide (SEQ ID NO: 40), or the other corresponding peptides described above (SEQ ID NO: 41-43).

Chlamydia-specific T cell lines were generated from donor CP-21 with a positive serum titer against *C. pneumoniae* by stimulating donor PBMC with either *C. trachomatis* or *C. pneumoniae*-infected monocyte-derived dendritic cells, respectively. T-cells generated against *C. pneumoniae* responded to recombinant *C. pneumoniae*-SWIB but not *C. trachomatis*-SWIB, whereas the T-cell line generated against *C. trachomatis* did not respond to either *C. trachomatis*- or *C. pneumoniae*-SWIB (see Fig. 9). The *C. pneumoniae*-SWIB specific immune response of donor CP-21 confirms the *C. pneumoniae* infection and indicates the elicitation of *C. pneumoniae*-SWIB specific T-cells during *in vivo C. pneumoniae* infection.

Epitope mapping of the T-cell response to *C. pneumoniae*-SWIB has shown that Cp-SWIB-specific T-cells responded to the overlapping peptides Cp-SWIB 32-51 (SEQ

ID NO: 101) and Cp-SWIB 37-56 (SEQ ID NO: 102), indicating a *C. pneumoniae*-SWIB-specific T-cell epitope Cp-SWIB 37-51 (SEQ ID NO: 100).

In additional experiments, T-cell lines were generated from donor CP1, also a *C. pneumoniae* seropositive donor, by stimulating PBMC with non-infectious elementary bodies from *C. trachomatis* and *C. pneumoniae*, respectively. In particular, proliferative responses were determined by stimulating 2.5×10^4 T-cells in the presence of 1×10^4 monocyte-derived dendritic cells and non-infectious elementary bodies derived from *C. trachomatis* and *C. pneumoniae*, or either recombinant *C. trachomatis* or *C. pneumoniae* SWIB protein. The T-cell response against SWIB resembled the data obtained with T-cell lines from CP-21 in that *C. pneumoniae*-SWIB, but not *C. trachomatis*-SWIB elicited a response by the *C. pneumoniae* T-cell line. In addition, the *C. trachomatis* T-cell line did not proliferate in response to either *C. trachomatis* or *C. pneumoniae* SWIB, though it did proliferate in response to both CT and CP elementary bodies. As described in Example 1, Clone 11-C12-91 (SEQ ID NO: 63), identified using the TCP-21 cell line, has a 269 bp insert that is part of the OMP2 gene (CT443) and shares homology with the 60 kDa cysteine rich outer membrane protein of *C. pneumoniae*, referred to as OMCB. To further define the reactive epitope(s), epitope mapping was performed using a series of overlapping peptides and the immunoassay previously described. Briefly, proliferative responses were determined by stimulating 2.5×10^4 TCP-21 T-cells in the presence of 1×10^4 monocyte-derived dendritic cells with either non-infectious elementary bodies derived from *C. trachomatis* and *C. pneumoniae*, or peptides derived from the protein sequence of *C. trachomatis* or *C. pneumoniae* OMCB protein (0.1 μ g/ml). The TCP-21 T-cells responded to epitopes CT-OMCB #167-186, CT-OMCB #171-190, CT-OMCB #171-186, and to a lesser extent, CT-OMCB #175-186 (SEQ ID NO: 249-252, respectively). Notably, the TCP-21 T-cell line also gave a proliferative response to the homologous *C. pneumoniae* peptide CP-OMCB #171-186 (SEQ ID NO: 253), which was equal to or greater than the response to the *C. trachomatis* peptides. The amino acid substitutions in position two (i.e., Asp for Glu) and position four (i.e., Cys for Ser) did not alter the proliferative response of the T-cells and therefore demonstrating this epitope to be a cross-reactive epitope between *C. trachomatis* and *C. pneumoniae*.

EXAMPLE 8

IMMUNE RESPONSES OF HUMAN PBMC AND T-CELL LINES AGAINST
CHLAMYDIA ANTIGENS

The examples provided herein suggest that there is a population of healthy donors among the general population that have been infected with *C. trachomatis* and generated a protective immune response controlling the *C. trachomatis* infection. These donors remained clinically asymptomatic and seronegative for *C. trachomatis*. To characterize the immune responses of normal donors against *chlamydial* antigens which had been identified by CD4 expression cloning, PBMC obtained from 12 healthy donors were tested against a panel of recombinant *chlamydial* antigens including *C. trachomatis*-, *C. pneumoniae*-SWIB and *C. trachomatis*-, *C. pneumoniae*-S13. The data are summarized in Table I below. All donors were seronegative for *C. trachomatis*, whereas 6/12 had a positive *C. pneumoniae* titer. Using a stimulation index of >4 as a positive response, 11/12 of the subjects responded to *C. trachomatis* elementary bodies and 12/12 responded to *C. pneumoniae* elementary bodies. One donor, AD104, responded to recombinant *C. pneumoniae*-S13 protein, but not to recombinant *C. trachomatis*-S13 protein, indicating a *C. pneumoniae*-specific response. Three out of 12 donors had a *C. trachomatis*-SWIB, but not a *C. pneumoniae*-SWIB specific response, confirming a *C. trachomatis* infection. *C. trachomatis* and *C. pneumoniae*- S13 elicited a response in 8/12 donors suggesting a chlamydial infection. These data demonstrate the ability of SWIB and S13 to elicit a T-cell response in PBMC of normal study subjects.

Table I.

Immune response of normal study subjects against <i>Chlamydia</i>										
onor	Sex	<i>Chlamydia</i> IgG titer	CT EB	CP EB	CT Swib	CP Swib	CT S13	CP S13	CT lpdA	CT TSA
D100	male	negative	++	+++	+	-	++	++	-	nt.
D104	female	negative	+++	++	-	-	-	++	-	nt.
D108	male	CP 1:256	++	++	+	+/-	+	+	+	nt.
D112	female	negative	++	++	+	-	+	-	+/-	nt.
D120	male	negative	-	+	-	-	-	-	-	nt.
D124	female	CP 1:128	++	++	-	-	-	-	-	nt.
D128	male	CP 1:512	+	++	-	-	++	+	++	-
D132	female	negative	++	++	-	-	+	+	-	-
D136	female	CP 1:128	+	++	-	-	+/-	-	-	-
D140	male	CP 1:256	++	++	-	-	+	+	-	-
D142	female	CP 1:512	++	++	-	-	+	+	+	-
D146	female	negative	++	++	-	-	++	+	+	-

CT= *Chlamydia trachomatis*; CP= *Chlamydia pneumoniae*; EB= *Chlamydia* elementary bodies; Swib= recombinant *Chlamydia* Swib protein; S13= recombinant *Chlamydia* S13 protein; lpdA= recombinant *Chlamydia* lpdA protein; TSA= recombinant *Chlamydia* TSA protein. Values represent results from standard proliferation assays. Proliferative responses were determined by stimulating 3×10^5 PBMC with 1×10^4 monocyte-derived dendritic cells pre-incubated with the respective recombinant antigens or elementary bodies (EB). Assays were harvested after 6 days with a ^3H -thymidine pulse for the last 18h.

SI: Stimulation index

+/-: SI ~ 4

+: SI > 4

++: SI 10-30

+++ : SI > 30

In a first series of experiments, T-cell lines were generated from a healthy female individual (CT-10) with a history of genital exposure to *C. trachomatis* by stimulating T-cells with *C. trachomatis* LGV II elementary bodies as previously described. Although the study subject was exposed to *C. trachomatis*, she did not seroconvert and did not develop clinical symptoms, suggesting donor CT-10 may have developed a protective immune response against *C. trachomatis*. As shown in Fig. 10, a primary *Chlamydia*-specific T-cell line derived from donor CT-10 responded to *C. trachomatis*-SWIB, but not *C. pneumoniae*-SWIB recombinant proteins, confirming the exposure of CT-10 to *C. trachomatis*. Epitope mapping of the T-cell response to *C. trachomatis*-SWIB showed that this donor responded to the same epitope Ct-SWIB 52-67 (SEQ ID NO: 39) as T-cell line TCL-8, as shown in Fig. 11.

Additional T-cell lines were generated as described above for various *C. trachomatis* patients. A summary of the patients' clinical profile and proliferative responses to various *C. trachomatis* and *C. pneumoniae* elementary bodies and recombinant proteins are summarized in Table II .

Proliferative response of <i>C. trachomatis</i> patients										
patients	Clinical manifestation	IgG titer	CT Tablet	CP EB	CT Swib	CP Swib	CT S13	CP S13	CT lpdA	CT TSA
CT-1	NGU	negative	+	+	-	-	++	++	++	+
CT-2	NGU	negative	++	++	-	-	+	+/-	-	-
CT-3	asymptomatic shed Eb Dx was HPV	Ct 1:512 Cp 1:1024 Cps 1:256	+	+	-	-	+	-	+	-
CT-4	asymptomatic shed Eb	Ct 1:1024	+	+	-	-	-	-	-	-
CT-5	BV	Ct 1:256 Cp 1:256	++	++	-	-	+	-	-	-
CT-6	perinial rash discharge	Cp 1:1024	+	+	-	-	-	-	-	-
CT-7	BV genital ulcer	Ct 1:512 Cp 1:1024	+	+	-	-	+	+	+	-
CT-8	Not known	Not tested	++	++	-	-	-	-	-	-
CT-9	asymptomatic	Ct 1:128 Cp 1:128	+++	++	-	-	++	+	+	-
CT-10	Itch mild vulvar	negative	++	++	-	-	-	-	-	-
CT-11	BV, abnormal pap	Ct 1: 512	+++	+++	-	-	+++	+/-	++	+
CT-12	asymptomatic	Cp 1: 512	++	++	-	-	++	+	+	-

NGU= Non-Gonococcal Urethritis; BV= Bacterial Vaginosis; CT= *Chlamydia trachomatis*; CP= *Chlamydia pneumoniae*; EB= *Chlamydia* elementary bodies; Swib= recombinant *Chlamydia* Swib protein; S13= recombinant *Chlamydia* S13 protein; lpdA= recombinant *Chlamydia* lpdA protein; TSA= recombinant *Chlamydia* TSA protein
 Values represent results from standard proliferation assays. Proliferative responses were determined by stimulating 3×10^5 PBMC with 1×10^4 monocyte-derived dendritic cells pre-

incubated with the respective recombinant antigens or elementary bodies (EB). Assays were harvested after 6 days with a ^3H -thymidine pulse for the last 18 hours.

SI: Stimulation index

+/-:	SI ~	4
+:	SI >	4
++:	SI	10-30
+++:	SI >	30

Using the panel of asymptomatic (as defined above) study subjects and *C. trachomatis* patients, as summarized in Tables I and II, a comprehensive study of the immune responses of PBMC derived from the two groups was conducted. Briefly, PBMCs from *C. pneumoniae* patients as well as from normal donors are cultured in medium comprising RPMI 1640 supplemented with 10% pooled human serum and 50 $\mu\text{g}/\text{mL}$ gentamicin. Purified polypeptides, a panel of recombinant *chlamydial* antigens including *C. trachomatis*-, *C. pneumoniae*-SWIB and S13, as well as *C. trachomatis* lpdA and TSA are added in duplicate at concentrations of 0.5 to 10 $\mu\text{g}/\text{mL}$. After six days of culture in 96-well round-bottom plates in a volume of 200 μL , 50 μL of medium is removed from each well for determination of IFN- γ levels, as described below. The plates are then pulsed with 1 $\mu\text{Ci}/\text{well}$ of tritiated thymidine for a further 18 hours, harvested and tritium uptake determined using a gas scintillation counter. Fractions that result in proliferation in both replicates three fold greater than the proliferation observed in cells cultured in medium alone are considered positive.

Proliferative responses to the recombinant *Chlamydiae* antigens demonstrated that the majority of asymptomatic donors and *C. trachomatis* patients recognized the *C. trachomatis* S13 antigen (8/12) and a majority of the *C. trachomatis* patients recognized the *C. pneumonia* S13 antigen (8/12), with 4/12 asymptomatic donors also recognizing the *C. pneumonia* S13 antigen. Also, six out of twelve of the *C. trachomatis* patients and four out of twelve of the asymptomatic donors gave a proliferative response to the lpdA antigen of *C. trachomatis*. These results demonstrate that the *C. trachomatis* and *C. pneumonia* S13 antigen, *C. trachomatis* Swib antigen and the *C. trachomatis* lpdA antigen are recognized by the asymptomatic donors, indicating these antigens were recognized during exposure to *Chlamydia* and an immune response elicited against them. This implies these antigens may

play a role in conferring protective immunity in a human host. In addition, the *C. trachomatis* and *C. pneumonia* S13 antigen is recognized equally well among the *C. trachomatis* patients, therefore indicating there may be epitopes shared between *C. trachomatis* and *C. pneumonia* in the S13 protein. Table III summarizes the results of these studies.

Table III.

Antigen	Normal Donors	C.t. Patients
C.t.-Swib	3/12	0/12
C.p.-Swib	0/12	0/12
C.t.-S13	8/12	8/12
C.p.-S13	4/12	8/12
lpdA	4/12	6/12
TSA	0/12	2/12

A series of studies were initiated to determine the cellular immune response to short-term T-cell lines generated from asymptomatic donors and *C. trachomatis* patients. Cellular immune responses were measured by standard proliferation assays and IFN- γ , as described in Example 7. Specifically, the majority of the antigens were in the form of single *E. coli* clones expressing Chlamydial antigens, although some recombinant proteins were also used in the assays. The single *E. coli* clones were titred on 1×10^4 monocyte-derived dendritic cells and after two hours, the culture was washed and 2.5×10^4 T-cells were added. The assay using the recombinant proteins were performed as previously described. Proliferation was determined after four days with a standard ^3H -thymidine pulse for the last 18 hours. Induction of IFN- γ was determined from culture supernatants harvested after four days using standard ELISA assays, as described above. The results show that all the *C. trachomatis* antigens tested, except for C.T. Swib, elicited a proliferative response from one or more different T-cell lines derived from *C. trachomatis* patients. In addition, proliferative responses were elicited from both the *C. trachomatis* patients and asymptomatic donors for

the following *Chlamydia* genes, CT622, groEL, pmpD, CT610 and rS13.

The 12G3-83 clone also contains sequences to CT734 and CT764 in addition to CT622, and therefore these gene sequence may also have immunoreactive epitopes. Similarly, clone 21G12-60 contains sequences to the hypothetical protein genes CT229 and CT228 in addition to CT875; and 15H2-76 also contains sequences from CT812 and CT088, as well as sharing homology to the sycE gene. Clone 11H3-61 also contains sequences sharing homology to the PGP6-D virulence protein.

Table IV.

Clone	C. t. Antigen (putative*)	TCL from Asymp. Donors	TCL from C. t. Patients	SEQ ID NO::
1B1-66 (E. coli)	Swib	2/2	0/4	5
1B1-66 (protein)	Swib	2/2	0/4	5
12G3-83 (E. coli)	CT622*	2/2	4/4	57
22B3-53 (E. coli)	groEL	1/2	4/4	111
22B3-53 (protein)	groEL	1/2	4/4	111
15H2-76 (E. coli)	PmpD*	1/2	3/4	87
11H3-61 (E. coli)	rL1*	0/2	3/4	60
14H1-4 (E. coli)	TSA	0/2	3/4	56
14H1-4 (protein)	TSA	0/2	3/4	56
11G10-46 (E. coli)	CT610	1/2	1/4	62
10C10-17 (E. coli)	rS13	1/2	1/4	62
10C10-17 (protein)	rS13	1/2	1/4	62
21G12-60 (E. coli)	CT875*	0/2	2/4	110
11H4-32 (E. coli)	dnaK	0/2	2/4	59
21C7-8 (E. coli)	dnaK	0/2	2/4	115
17C10-31 (E. coli)	CT858	0/2	2/4	114

EXAMPLE 9

PROTECTION STUDIES USING *CHLAMYDIA* ANTIGENS

Protection studies were conducted in mice to determine whether immunization with chlamydial antigens can impact on the genital tract disease resulting from chlamydial inoculation. Two models were utilized; a model of intravaginal inoculation that uses a human isolate containing a strain of *Chlamydia psittaci* (MTW447), and a model of intrauterine inoculation that involves a human isolate identified as *Chlamydia trachomatis*, serovar F (strain N11). Both strains induce inflammation in the upper genital tract, which resemble endometritis and salpingitis caused by *Chlamydia trachomatis* in women. In the first experiment, C3H mice (4 mice per group) were immunized three times with 100 µg of pcDNA-3 expression vector containing *C. trachomatis* SWIB DNA (SEQ ID NO: 1, with the corresponding amino acid sequence provided in SEQ ID NO: 5). Inoculations were at the base of the tail for systemic immunization. Two weeks after the last immunization, animals were progesterone treated and infected, either thru the vagina or by injection of the inoculum in the uterus. Two weeks after infection, the mice were sacrificed and genital tracts sectioned, stained and examined for histopathology. Inflammation level was scored (from + for very mild, to +++++ for very severe). Scores attributed to each single oviduct/ovary were summed and divided by the number of organs examined to get a mean score of inflammation for the group. In the model of uterine inoculation, negative control-immunized animals receiving empty vector showed consistent inflammation with an ovary/oviduct mean inflammation score of 6.12, in contrast to 2.62 for the DNA-immunized group. In the model of vaginal inoculation and ascending infection, negative control-immunized mice had an ovary/oviduct mean inflammation score of 8.37, versus 5.00 for the DNA-immunized group. Also, in the later model, vaccinated mice showed no signs of tubal occlusion while negative control vaccinated groups had inflammatory cells in the lumen of the oviduct

In a second experiment, C3H mice (4 mice per group) were immunized three times with 50 µg of pcDNA-3 expression vector containing *C. trachomatis* SWIB DNA (SEQ ID NO: 1, with the corresponding amino acid sequence provided in SEQ ID NO: 5) encapsulated in Poly Lactide co-Glycolide microspheres (PLG); immunizations were made

intra-peritoneally. Two weeks after the last immunization, animal were progesterone treated and infected by inoculation of *C. psittaci* in the vagina. Two weeks after infection, mice were sacrificed and genital tracts sectioned, stained and examined for histopathology. Inflammation level was scored as previously described. Scores attributed to each single oviduct /ovary were summed and divided by the number of examined organs to get a mean of inflammation for the group. Negative control-immunized animals receiving PLG-encapsulated empty vector showed consistent inflammation with an ovary /oviduct mean inflammation score of 7.28, versus 5.71 for the PLG-encapsulated DNA immunized group. Inflammation in the peritoneum was 1.75 for the vaccinated group versus 3.75 for the control.

In a third experiment, C3H mice (4 per group) were immunized three times with 10 µg of purified recombinant protein, either SWIB (SEQ ID NO: 1, with the corresponding amino acid sequence provided in SEQ ID NO: 5, or S13 (SEQ ID NO: 4, with the corresponding amino acid sequence provided in SEQ ID NO: 12) mixed with Cholera Toxin (CT); the preparation was administered intranasally upon anaesthesia in a 20 µL volume. Two weeks after the last immunization, animal were progesterone treated and infected, either by vaginal inoculation of *C. psittaci* or by injection of *C. trachomatis* serovar F in the uterus. Two weeks after infection, the mice were sacrificed and genital tracts sectioned, stained and examined for histopathology. The degree of inflammation was scored as described above. Scores attributed to each single oviduct /ovary were summed and divided by the number of examined organs to get a mean score of inflammation for the group. In the model of uterine inoculation, negative control- immunized animals receiving cholera toxin alone showed an ovary /oviduct mean inflammation score of 4.25 (only 2 mice analyzed ; 2 other died) versus 5.00 for the s13 plus cholera toxin-immunized group, and 1.00 for the SWIB plus cholera toxin. Untreated infected animals had an ovary /oviduct mean inflammation score of 7. In the model of vaginal inoculation and ascending infection, negative control-immunized mice had an ovary /oviduct mean inflammation score of 7.37 versus 6.75 for the s13 plus cholera toxin-immunized group and 5.37 for the SWIB plus cholera toxin-immunized group. Untreated infected animals had an ovary /oviduct mean inflammation score of 8.


The three experiments described above suggest that SWIB-specific protection is obtainable. This protective effect is more marked in the model of homologous infection but is still present when in a heterologous challenge infection with *C. psittaci*.

Although the present invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, changes and modifications can be carried out without departing from the scope of the invention which is intended to be limited only by the scope of the appended claims.

Claims


1. An isolated polypeptide comprising an immunogenic portion of a *Chlamydia* antigen, wherein said antigen comprises an amino acid sequence encoded by a polynucleotide sequence selected from the group consisting of: (a) sequences recited in SEQ ID NO: 1, 15, 21-25, 44-64, 66-76, 79-88, 110-119, 120, 122, 124, 126, 128, 130, 132, 134, 136, 169-174, 181-188, 263, 265 and 267-290 ; (b) sequences complementary to a sequence of (a); and (c) polynucleotide sequences that hybridize to a sequence of (a) or (b) under moderately stringent conditions.
2. The polypeptide of claim 1 wherein the polypeptide comprises a sequence selected from the group consisting of SEQ ID NO: 5, 26, 32, 65, 90, 92-98, 103-108, 121, 123, 125, 127, 129, 131, 133, 135, 137, 175-180, 189-196, 264 and 266.
3. An isolated polynucleotide molecule comprising a nucleotide sequence encoding a polypeptide according to any one of claims 1 and 2.
4. A recombinant expression vector comprising a polynucleotide molecule according to claim 3.
5. A host cell transformed with an expression vector according to claim 4.
6. The host cell of claim 5 wherein the host cell is selected from the group consisting of *E. coli*, yeast and mammalian cells.
7. A fusion protein comprising a polypeptide according to any one of claims 1 and 2.
8. A fusion protein according to claim 7, wherein the fusion protein comprises an expression enhancer that increases expression of the fusion protein in a host cell

1/10

*Fig. 1*

2/10

Retroviral vector
pBIB-KS



Kozak-Start

GA TCT	GCC GCC ACC	ATG	GAA TTC	GAT ATC	GGA TCC	CTG CAG	
A	CGG CGG TGG	TAC	ATT AAG	CTA TAG	CCT AGG	GAC GTC	

(BglII) EcoRI BamHI PstI

AAG CTT GAG CTC GAG CGC GGC CGC TAA TTA GGT GAG ReadingFrame 1
 TTC GAA CTC GAG CTC GCG CCG GCG ATT AAT CCA CTC AGC T KS1+
 HindIII XhoI NotI Stop Stop Stop (Sali)

Kozak-Start

GA TCT	GCC GCC ACC	ATG	GGA ATT	CGA TAT	CGG ATC	CCT GCA G	
A	CGG CGG TGG	TAC	CCT TAA	GCT ATA	GCC TAG	GGA CGT C	

(BglII) EcoRI BamHI PstI

AA GCT TGA GCT CGA GCG CGG CCG GTA ATT AGC TGA G ReadingFrame 1
 TT CGA ACT CGA GCT CGC GCC GGC GAT TAA TCG ACT CAG CT KS2+
 HindIII XhoI NotI Stop Stop Stop (Sali)

Kozak-Start


GA TCT	GCC GCC ACC	ATG	GGG AAT	TCG ATA	TCG GAT	CCC TGC AG	
A	CGG CGG TGG	TAC	CCC TTA	AGC TAT	AGC CTA	GGG ACG TC	

(BglII) EcoRI BamHI PstI

A AGC TTG AGC TCG AGC GCG GCC GGT AAT TAG GTG AG ReadingFrame 3
 T TCG AAC TCG AGC TCG GCG CGG CGA TTA ATC GAC TCA GCT KS3+
 HindIII XhoI NotI Stop Stop Stop (Sali)

Fig. 2

3/10

*Fig. 3*




Fig. 4A




Fig. 4B





Fig. 4C



5/10




Fig. 5

6/10

CP SWIB Nde (5' primer)

5' GATATACATATGCATCACCATCACCATCACATGAGTCAAAAAATAAAACTCT

CP SWIB EcoRI (3' primer)

5' CTCGAGGAATTCTTATTTACAATATGTTTGA

CP S13 Nde (5' primer)



5' GATATACATATGCATCACCATCACCATCACATGCCACGCATCATTGGAATGAT

CP S13 EcoRI (3' primer)


5' CTCGAGGAATTCTTATTTCTTCTTACCTGC

Fig. 6



7/10



*Fig. 7A**Fig. 7B*

8/10

*Fig. 8*

9/10

*Fig. 9B**Fig. 9A*

*Fig. 10**Fig. 11*

SEQUENCE LISTING

<110> Corixa Corporation
 Probst, Peter
 Bhatia, Ajay
 Skeiky, Yasir
 Fling, Steve
 Maisonneuve, Jeff

<120> COMPOSITIONS AND METHODS FOR TREATMENT AND
 DIAGNOSIS OF CHLAMYDIAL INFECTION

<130> 210121.469PC

<140> PCT

<141> 1999-12-08

<160> 303

<170> FastSEQ for Windows Version 3.0/4.0

<210> 1

<211> 481

<212> DNA

<213> Chlamydia trachomatis

<400> 1

```

ctgaagactt ggctatgttt tttattttga cgataaacctt agttaaggca taaaagagtt      60
gcgaaggaag agccctcaac ttttcttata acctctctta actaggagtc atccatgagt      120
caaaataaga actctgtctt catgcagcct gtgaacgtat cagctgattt agctgccatc      180
gttgggtgcag gacctatgcc tcgcaacagag atccttaaga aaatgaggga ttscattaaag      240
gagaatagtc ttcaagatcc tacaacacaa cgtaatatca atcccgatga taattggctt      300
aaagctttttg gaactgaaaa acctatcgat atgttccaaa tgacaaaaat ggttttctcaa      360
cacatcatta aataaaatag aaattgactc acgtgttctc cgtctttaag atgagggaact      420
agttcattct ttttgttcgt ttttgtgggt attactgtat ctttaacaac tatcttagca      480
g

```

<210> 2

<211> 183

<212> DNA

<213> Chlamydia trachomatis

<400> 2

```

atcgtgtgggt caggacctat gctctgcaca gagatcatta agaaaaatgtg ggattacatt      60
aaggagaata gtcttcaaga tcttacaacac aaacgtaatc tcaatcccgga tgataaattg      120
gctaaagttt ttggaactga aaaacctatc gatatgttcc aaatgacaaa aatggtttct      180
caa

```

<210> 3

<211> 110

<212> DNA

<213> Chlamydia trachomatis

<400> 3

```

gctgcgacat catgcgagct tgcaaaccaa catggacatc tccaatttcc ccttctaact    60
cgctctttgg aactaatgct gctaccgagt caatcacaat cacatcgacc    110

```

<210> 4
 <211> 555
 <212> DNA
 <213> Chlamydia trachomatis

```

<400> 4
cggcagcagc ctaagatgct tatactactt taaggaggcg ccttcgtatg ccgcgcacatca    60
ttggaataga tattcctgcg aaaaagaaat taaaaataag tcttacatat atttatggaa    120
tagggccagc tcttctaaa gagattattg ctagattgca gttgaatccc gaagctagag    180
ctgcagagtt gactgaggaa gaggttggtc gactaaacgc tcttttacag tcggattacg    240
ttgttgaagg ggatttgcgc cgtcgtgtgc aatcagatat caaacgtctg attractatcc    300
atgcttatcg tggacaaaaga catagacttt cttgcctgt tcgtgggtcag agaacasaaa    360
caaattctcg cagcgctaag ggtaaaacgt aactatttgc aggttaagaag aaataataat    420
ttttaggaga gagtgttttg gttaaaaatc aagcgcaaaa aagaggcgta aaaagaaaaac    480
aagtaaaaaa cattccttcg ggcgttgtcc atgttaaggc tacttttaat aaracaattg    540
taaccataac agacc    555

```

<210> 5
 <211> 86
 <212> PRT
 <213> Chlamydia trachomatis

```

<400> 5
Met Ser Gln Asn Lys Asn Ser Ala Phe Met Gln Pro Val Asn Val Ser
1      5      10      15
Ala Asp Leu Ala Ala Ile Val Gly Ala Gly Pro Met Pro Arg Thr Glu
20      25      30
Ile Ile Lys Lys Met Trp Asp Tyr Ile Lys Glu Asn Ser Leu Gln Asp
35      40      45
Pro Thr Asn Lys Arg Asn Ile Asn Pro Asp Asp Lys Leu Ala Lys Val
50      55      60
Phe Gly Thr Glu Lys Pro Ile Asp Met Phe Gln Met Thr Lys Met Val
65      70      75      80
Ser Gln His Ile Ile Lys
85

```

<210> 6
 <211> 61
 <212> PRT
 <213> Chlamydia trachomatis

```

<400> 6
Ile Val Gly Ala Gly Pro Met Pro Arg Thr Glu Ile Ile Lys Lys Met
1      5      10      15
Trp Asp Tyr Ile Lys Glu Asn Ser Leu Gln Asp Pro Thr Asn Lys Arg
20      25      30
Asn Ile Asn Pro Asp Asp Lys Leu Ala Lys Val Phe Gly Thr Glu Lys
35      40      45
Pro Ile Asp Met Phe Gln Met Thr Lys Met Val Ser Gln
50      55      60

```

<210> 7

<211> 36
 <212> PRT
 <213> Chlamydia trachomatis

<400> 7
 Ala Ala Thr Ser Cys Glu Leu Ala Asn Gln His Gly His Leu Gln Phe
 1 5 10 15
 Pro Leu Leu Thr Arg Ser Leu Glu Leu Met Leu Leu Pro Ser Gln Ser
 20 25 30
 Gln Ser His Arg
 35

<210> 8
 <211> 18
 <212> PRT
 <213> Chlamydia trachomatis

<400> 8
 Leu Arg His His Ala Ser Leu Gln Thr Asn Met Asp Ile Ser Asn Phe
 1 5 10 15
 Pro Phe

<210> 9
 <211> 5
 <212> PRT
 <213> Chlamydia trachomatis

<400> 9
 Leu Ala Leu Trp Asn
 1 5

<210> 10
 <211> 11
 <212> PRT
 <213> Chlamydia trachomatis

<400> 10
 Cys Cys Tyr Arg Val Asn His Asn His Ile Asp
 1 5 10

<210> 11
 <211> 36
 <212> PRT
 <213> Chlamydia trachomatis

<400> 11
 Val Asp Val Ile Val Ile Asp Ser Val Ala Ala Leu Val Pro Lys Ser
 1 5 10 15
 Glu Leu Glu Gly Glu Ile Gly Asp Val His Val Gly Leu Gln Ala Arg
 20 25 30
 Met Met Ser Gln
 35

<210> 12

<211> 122
 <212> PRT
 <213> Chlamydia trachomatis

<400> 12
 Met Pro Arg Ile Ile Gly Ile Asp Ile Pro Ala Lys Lys Lys Leu Lys
 1 5 10 15
 Ile Ser Leu Thr Tyr Ile Tyr Gly Ile Gly Pro Ala Leu Ser Lys Glu
 20 25 30
 Ile Ile Ala Arg Leu Gln Leu Asn Pro Glu Ala Arg Ala Ala Glu Leu
 35 40 45
 Thr Glu Glu Val Gly Arg Leu Asn Ala Leu Leu Gln Ser Asp Tyr
 50 55 60
 Val Val Glu Gly Asp Leu Arg Arg Arg Val Gln Ser Asp Ile Lys Arg
 65 70 75 80
 Leu Ile Thr Ile His Ala Tyr Arg Gly Gln Arg His Arg Leu Ser Leu
 85 90 95
 Pro Val Arg Gly Gln Arg Thr Lys Thr Asn Ser Arg Thr Arg Lys Gly
 100 105 110
 Lys Arg Lys Thr Ile Ala Gly Lys Lys Lys
 115 120

<210> 13
 <211> 20
 <212> PRT
 <213> Chlamydia trachomatis

<400> 13
 Asp Pro Thr Asn Lys Arg Asn Ile Asn Pro Asp Asp Lys Leu Ala Lys
 1 5 10 15
 Val Phe Gly Thr
 20

<210> 14
 <211> 20
 <212> PRT
 <213> Chlamydia trachomatis

<400> 14
 Asp Asp Lys Leu Ala Lys Val Phe Gly Thr Glu Lys Pro Ile Asp Met
 1 5 10 15
 Phe Gln Met Thr
 20

<210> 15
 <211> 161
 <212> DNA
 <213> Chlamydia trachomatis

<400> 15
 atctttgtgt gtctcataag cgcagagcgg ctgcggctgt ctgtagcttc atcggaggaa 60
 ttacctacct cgcgacattc ggagctatcc gtccgattct gttgtgcaac aaaatgctgg 120
 cgcaaccggt tcttctctcc caaactaaag caaatatggg a 161

<210> 16

<211> 897

<212> DNA

<213> Chlamydia trachomatis

<400> 16

```

atggcttcta tatgcggacg tttagggtct ggtacaggga atgctctaaa agcttttttt      60
acacagccca acaataaaat ggcaagggtg gtaataaaga cgaagggaat ggataagact      120
attaagggtg ccaagtctgc tgccgaattg accgcaaaata ttttggaaac agctggaggc      180
gcggggtctt ccgcacacat tacagcttcc caagtgtcca aaggattagg ggatgcgaga      240
actgttgctg ctttagggaa tgcccttaac ggagcggtgc caggaacact tcaaatgctg      300
caaggtttct ttcttcacat gaaagctgct agtcagaaaa cgcaagaagg ggatgagggg      360
ctcacagcag atcttttgtg gtctcataag cgcaagcggg ctgcggctgt ctgtagcatc      420
atcggaggaa ttacctacct cgcgacattc ggagctatcc gtccgattct gttgtccaac      480
aaaatgctgg caaaaccgtt tctttcttcc caaactaaag caaatatggg atcttctggt      540
agctatatta tggcgggtaa ccatgcagcg tctgtggtgg gtgctggact cgctatcagt      600
gcggaagagc cagattgcga agcccgcctg gctcgtattg cgagagaaga gtcgttactc      660
gaagtgccgg gagaggaaaa tgcttgcgag aagaaaagtc ctggagagaa agccaagacg      720
ttcacgcgca tcaagtatgc actcctcact atgctcgaga agtttttggg atgcggtggc      780
gacgttttca aattggtgcc gctgcctatt acaatgggta ttctgtcgat tgtggctgct      840
ggatgcactg tcacttctgc aattattgga ttgtgcactt tctgcgccag agcataaa      897

```

<210> 17

<211> 298

<212> PRT

<213> Chlamydia trachomatis

<400> 17

```

Met Ala Ser Ile Cys Gly Arg Leu Gly Ser Gly Thr Gly Asn Ala Leu
 1          5          10          15
Lys Ala Phe Phe Thr Gln Pro Asn Asn Lys Met Ala Arg Val Val Asn
 20          25          30
Lys Thr Lys Gly Met Asp Lys Thr Ile Lys Val Ala Lys Ser Ala Ala
 35          40          45
Glu Leu Thr Ala Asn Ile Leu Glu Gln Ala Gly Gly Ala Gly Ser Ser
 50          55          60
Ala His Ile Thr Ala Ser Gln Val Ser Lys Gly Leu Gly Asp Ala Arg
 65          70          75          80
Thr Val Val Ala Leu Gly Asn Ala Phe Asn Gly Ala Leu Pro Gly Thr
 85          90          95
Val Gln Ser Ala Gln Ser Phe Phe Ser His Met Lys Ala Ala Ser Gln
100          105          110
Lys Thr Gln Glu Gly Asp Glu Gly Leu Thr Ala Asp Leu Cys Val Ser
115          120          125
His Lys Arg Arg Ala Ala Ala Val Cys Ser Ile Ile Gly Gly Ile
130          135          140
Thr Tyr Leu Ala Thr Phe Gly Ala Ile Arg Pro Ile Leu Phe Val Asn
145          150          155          160
Lys Met Leu Ala Lys Pro Phe Leu Ser Ser Gln Thr Lys Ala Asn Met
165          170          175
Gly Ser Ser Val Ser Tyr Ile Met Ala Ala Asn His Ala Ala Ser Val
180          185          190
Val Gly Ala Gly Leu Ala Ile Ser Ala Glu Arg Ala Asp Cys Glu Ala
195          200          205
Arg Cys Ala Arg Ile Ala Arg Glu Glu Ser Leu Leu Glu Val Pro Gly
210          215          220

```

Glu Glu Asn Ala Cys Glu Lys Lys Val Ala Gly Glu Lys Ala Lys Thr
 225 230 235 240
 Phe Thr Arg Ile Lys Tyr Ala Leu Leu Thr Met Leu Glu Lys Phe Leu
 245 250 255
 Glu Cys Val Ala Asp Val Phe Lys Leu Val Pro Leu Pro Ile Thr Met
 260 265 270
 Gly Ile Arg Ala Ile Val Ala Ala Gly Cys Thr Phe Thr Ser Ala Ile
 275 280 285
 Ile Gly Leu Cys Thr Phe Cys Ala Arg Ala
 290 295

<210> 18
 <211> 18
 <212> PRT
 <213> Chlamydia trachomatis

<400> 16
 Arg Ala Ala Ala Ala Ala Val Cys Ser Phe Ile Gly Gly Ile Thr
 1 5 10 15
 Tyr Leu

<210> 19
 <211> 18
 <212> PRT
 <213> Chlamydia trachomatis

<400> 19
 Cys Ser Phe Ile Gly Gly Ile Thr Tyr Leu Ala Thr Phe Gly Ala Ile
 1 5 10 15
 Arg Pro

<210> 20
 <211> 216
 <212> PRT
 <213> Chlamydia trachomatis

<400> 20
 Met Arg Gly Ser Gln Gln Ile Phe Val Cys Leu Ile Ser Ala Glu Arg
 1 5 10 15
 Leu Arg Leu Ser Val Ala Ser Ser Glu Glu Leu Pro Thr Ser Arg His
 20 25 30
 Ser Glu Leu Ser Val Arg Phe Cys Leu Ser Thr Lys Cys Trp Gln Asn
 35 40 45
 Arg Phe Phe Leu Pro Lys Leu Lys Gln Ile Trp Asp Leu Leu Ala
 50 55 60
 Ile Leu Trp Arg Leu Thr Met Gln Arg Leu Trp Trp Val Leu Asp Ser
 65 70 75 80
 Leu Ser Val Arg Lys Glu Gln Ile Ala Lys Pro Ala Ala Leu Val Leu
 85 90 95
 Arg Glu Lys Ser Arg Tyr Ser Lys Cys Arg Glu Arg Lys Met Leu Ala
 100 105 110
 Arg Arg Lys Ser Leu Glu Arg Lys Pro Arg Arg Ser Arg Ala Ser Ser
 115 120 125

Met His Ser Ser Leu Cys Ser Arg Ser Phe Trp Asn Ala Leu Pro Thr
 130 135 140
 Phe Ser Asn Trp Cys Arg Cys Leu Leu Gln Trp Val Phe Val Arg Leu
 145 150 155 160
 Trp Leu Leu Asp Val Arg Ser Leu Leu Gln Leu Leu Asp Cys Ala Leu
 165 170 175
 Ser Ala Pro Glu His Lys Gly Phe Phe Lys Phe Leu Lys Lys Ala
 180 185 190
 Val Ser Lys Lys Lys Gln Pro Phe Leu Ser Thr Lys Cys Leu Ala Phe
 195 200 205
 Leu Ile Val Lys Ile Val Phe Leu
 210 215

<210> 21
 <211> 1256
 <212> DNA
 <213> Chlamydia trachomatis

<400> 21

ctcgtgcccgcg	cacgagcaaa	gaaatccctc	aaaaaatggc	cattattggc	gggtggtgtga	60
tcggttgcgga	attcgcttcc	ttattccata	cgtaggctc	cgaagtttct	gtgatcgag	120
caagctctca	aatccttgct	ttgaataatc	cagatatttc	aaaaaccatg	ttcgataaat	180
tcaccgcgaca	aggactccgt	ttcgactag	aagcctctgt	atcaaatatt	gaggatatag	240
gagatcgctg	tcggttaact	atcaatggga	atgtcgaaga	atacgattac	gttctcgat	300
ctataggacg	ccgtttgaat	acagaaaata	ttggcttgga	taaagctggt	gttattttgtg	360
atgaacgcgg	agtcacccct	accgatgcc	caatgcccac	aaacgtacct	aacatttatg	420
ctattggaga	tatcacagga	aaatggcaac	ttgcccatgt	agcttctcat	caaggaatca	480
ttgcagcagc	gaatataggt	ggccataaag	aggaataatcga	ttactctgct	gtcccttctg	540
tgatctttac	cttccctgaa	gtcgcttcag	taggcctctc	cccaacagca	gctcaacaac	600
atctccttct	tcgcttactt	tttctgaaaa	atttgataca	gaagaagaat	tcctcgaca	660
cttgcgagga	ggaggggcgtc	tggaaagacca	gttgaattta	gctaagtttt	ctgagcgcttt	720
tgattctttg	cgagaattat	ccgctaagct	tggttacgat	agcgatggag	agactggggga	780
tttcttcaac	gaggagtagc	acgacgaaga	agaggaaatc	aaacgaaga	aaactacgaa	840
acgtgtgacgt	aagaagagcc	gttcataagc	cttgctttta	agggttggtta	gttttaacttc	900
ttcaaaaatc	aaatggttgc	tgtgccaaaa	agtagtttgc	gtttccggat	agggcgtaaa	960
tgcgctgcac	gaagattgc	ttcgagagcg	gcactcgctg	ggagatcccg	gatactttct	1020
ttcagatacg	ataaagcata	gctgttccca	gaataaaaaa	ggccgacgct	aggaacaaca	1080
agatttagat	agagcttgtg	tagcaggtaa	actgggttat	atgttgctgg	gcggtttagt	1140
ttcagataac	ccaagttgcc	tccagttgtg	aatactcgat	acacttccct	agagccctct	1200
aatggatagg	ataagttccg	taatccatag	gccatagaag	ctaaacgaaa	cgtatt	1256

<210> 22
 <211> 601
 <212> DNA
 <213> Chlamydia trachomatis

<400> 22

ctcgtgcccgcg	cacgagcaaa	gaaatccctc	aaaaaatggc	cattattggc	gggtggtgtga	60
tcggttgcgga	attcgcttcc	ttattccata	cgtaggctc	cgaagtttct	gtgatcgag	120
caagctctca	aatccttgct	ttgaataatc	cagatatttc	aaaaaccatg	ttcgataaat	180
tcaccgcgaca	aggactccgt	ttcgactag	aagcctctgt	atcaaatatt	gaggatatag	240
gagatcgctg	tcggttaact	atcaatggga	atgtcgaaga	atacgattac	gttctcgat	300
ctataggacg	ccgtttgaat	acagaaaata	ttggcttgga	taaagctggt	gttattttgtg	360
atgaacgcgg	agtcacccct	accgatgcc	caatgcccac	aaacgtacct	aacatttatg	420
ctattggaga	tatcacagga	aaatggcaac	ttgcccatgt	agcttctcat	caaggaatca	480

ttgcagcacg	gaatataggt	ggccataaag	aggaaatcga	ttactctgct	gtccctcttg	540
tgatctttac	cttccttgaa	gtcgcttcag	taggcctctc	cccaacagca	gctcaacaac	600
a						601

<210> 23

<211> 270

<212> DNA

<213> *Chlamydia trachomatis*

<400> 23

acatctcctt	cttcgcttac	ttttctgaa	aaatttgata	cagaagaaga	attcctcgca	60
cacttgcgag	gaggaggcgc	tctggaagac	cagttgaatt	tagctaagtt	ttctgagcgt	120
tttgattctt	tgcgagaatt	atccgctaag	cttggttacg	atagcgatgg	agagactggg	180
gattttctta	acaggaggata	cgacgacgaa	gaaggaggaa	tcaaacccgaa	gaaaactacg	240
aaacgtggac	gtaagaagag	cogttcataa				270

<210> 24

<211> 363

<212> DNA

<213> *Chlamydia trachomatis*

<400> 24

ttactctctc	aaaatccaaa	tggttgctgt	gccaaaaagt	agtttgcggt	tcgggatagg	60
gcgtaaatgc	gctgcatgaa	agattgcttc	gagagcggca	tcgcgtggga	gattccggat	120
actttctttc	agatacgaat	aagcatagct	gttcccagaa	taaaaaacgc	cgacgcttag	180
aacaacaaga	tttagataga	gcttgtgtag	caggtaaact	gggttatatg	ttgctggggc	240
tgtagttctc	agaataccca	agtgctctcc	aggttgtaat	actcgataca	cttccctaa	300
agcctctaatt	ggataggata	agttccgtaa	tcctataggc	atagaagcta	aacgaaacgt	360
att						363

<210> 25

<211> 696

<212> DNA

<213> *Chlamydia trachomatis*

<400> 25

gctcgtgccg	gcacgagcaa	agaaatccct	caaaaaatgg	ccattatttg	cggtgggtgtg	60
atcggttgccg	aattcgcttc	cttatcccat	acgttaggct	ccgaagtttc	tgtgatcgaa	120
gcgaactctc	aaatccttgc	tttgaataat	ccagatattt	caaaaacatt	gttcgataaa	180
ttcaccgcag	aaggactcgc	tttcgtacta	gaagcctctg	tatcaaatat	tgaggatata	240
ggagatcgcg	ttcggttaac	tatcaatggg	aatgtcgaag	aatacgatta	cggtctcgta	300
tctataggac	gccgtttgaa	tacagaaaat	attgctgttg	ataaagctgg	tgttatttgt	360
gatgaacgcg	gagtcattcc	taccgatgcc	acaatgcgca	caaacgtacc	taacatttat	420
gctattggag	atatcacagg	aaaatggcaa	cttgcccatg	tagcttctca	tcaagggaatc	480
attgcagcac	ggaatatagg	tggccataaa	gaggaaatcg	attactctgc	tgctccctct	540
gtgactctta	ccctccctga	agtcgcttca	gtaggcctct	ccccaacagc	agctcaacaa	600
catctccttc	ttcgcttact	ttttctgaaa	aatttgatac	agaagaagaa	ttcctcgcac	660
acttcgcagg	aggaggcgct	ctggaagacc	agttga			696

<210> 26

<211> 231

<212> PRT

<213> *Chlamydia trachomatis*

<400> 26

Ala Arg Ala Gly Thr Ser Lys Glu Ile Pro Gln Lys Met Ala Ile Ile
 1 5 10 15
 Gly Gly Gly Val Ile Gly Cys Glu Phe Ala Ser Leu Phe His Thr Leu
 20 25 30
 Gly Ser Glu Val Ser Val Ile Glu Ala Ser Ser Gln Ile Leu Ala Leu
 35 40 45
 Asn Asn Pro Asp Ile Ser Lys Thr Met Phe Asp Lys Phe Thr Arg Gln
 50 55 60
 Gly Leu Arg Phe Val Leu Glu Ala Ser Val Ser Asn Ile Glu Asp Ile
 65 70 75 80
 Gly Asp Arg Val Arg Leu Thr Ile Asn Gly Asn Val Glu Glu Tyr Asp
 85 90 95
 Tyr Val Leu Val Ser Ile Gly Arg Arg Leu Asn Thr Glu Asn Ile Gly
 100 105 110
 Leu Asp Lys Ala Gly Val Ile Cys Asp Glu Arg Gly Val Ile Pro Thr
 115 120 125
 Asp Ala Thr Met Arg Thr Asn Val Pro Asn Ile Tyr Ala Ile Gly Asp
 130 135 140
 Ile Thr Gly Lys Trp Gln Leu Ala His Val Ala Ser His Gln Gly Ile
 145 150 155 160
 Ile Ala Ala Arg Asn Ile Gly Gly His Lys Glu Glu Ile Asp Tyr Ser
 165 170 175
 Ala Val Pro Ser Val Ile Phe Thr Phe Pro Glu Val Ala Ser Val Gly
 180 185 190
 Leu Ser Pro Thr Ala Ala Gln Gln His Leu Leu Leu Arg Leu Leu Phe
 195 200 205
 Leu Lys Asn Leu Ile Gln Lys Lys Asn Ser Ser His Thr Cys Glu Glu
 210 215 220
 Glu Gly Val Trp Lys Thr Ser
 225 230

<210> 27
 <211> 264
 <212> DNA
 <213> Chlamydia pneumoniae

<400> 27
 atgagtcaaa aaaataaaaa ctctgctttt atgcatcccg tgaatatctt cacagattta 60
 gcagtttatg ttggcaaggg acctatgccc agaaccgaaa ttgtaaagaa agtttgggaa 120
 tacattaaaa aacacaactg tcaggatcaa aaaaataaac gtaatatcct tcccgatgcg 180
 aatcttgcca aagtcctttg ctctagtgat cctatcgaca tgttccaaat gaccaaaagcc 240
 ctttccaaac atattgtataa ataa 264

<210> 28
 <211> 87
 <212> PRT
 <213> Chlamydia pneumoniae

<400> 28
 Met Ser Gln Lys Asn Lys Asn Ser Ala Phe Met His Pro Val Asn Ile
 1 5 10 15
 Ser Thr Asp Leu Ala Val Ile Val Gly Lys Gly Pro Met Pro Arg Thr
 20 25 30
 Glu Ile Val Lys Lys Val Trp Glu Tyr Ile Lys Lys His Asn Cys Gln
 35 40 45

Asp Gln Lys Asn Lys Arg Asn Ile Leu Pro Asp Ala Asn Leu Ala Lys
 50 55 60
 Val Phe Gly Ser Ser Asp Pro Ile Asp Met Phe Gln Met Thr Lys Ala
 65 70 75 80
 Leu Ser Lys His Ile Val Lys
 85

<210> 29
 <211> 369
 <212> DNA
 <213> Chlamydia pneumoniae

<400> 29
 atgccacgca tcattggaat tgatattcct gcaagaaaa agttaaaaaat aagctctgaca 60
 tatatttatg gaataggatc agctcgctct gatgaaatca ttaaaaaagt gaagttagat 120
 cctgaggcaa gagcctctga attaaactgaa gaagaagtag gacgactgaa ctctctgcta 180
 caatcagaat ataccgtaga aggggatttg cgacgtcgtg ttcaatcgga tatcaaaaga 240
 ttgatcgcca tccattctta tcgaggtcag agacatagac ttctttacc agtaagagga 300
 caacgtacaa aaactaatc tcgtactcga aaaggtaaaa gaaaaacagt cgcaggtaag 360
 aagaataa 369

<210> 30
 <211> 122
 <212> PRT
 <213> Chlamydia pneumoniae

<400> 30
 Met Pro Arg Ile Ile Gly Ile Asp Ile Pro Ala Lys Lys Lys Leu Lys
 1 5 10 15
 Ile Ser Leu Thr Tyr Ile Tyr Gly Ile Gly Ser Ala Arg Ser Asp Glu
 20 25 30
 Ile Ile Lys Lys Leu Lys Leu Asp Pro Glu Ala Arg Ala Ser Glu Leu
 35 40 45
 Thr Glu Glu Glu Val Gly Arg Leu Asn Ser Leu Leu Gln Ser Glu Tyr
 50 55 60
 Thr Val Glu Gly Asp Leu Arg Arg Arg Val Gln Ser Asp Ile Lys Arg
 65 70 75 80
 Leu Ile Ala Ile His Ser Tyr Arg Gly Gln Arg His Arg Leu Ser Leu
 85 90 95
 Pro Val Arg Gly Gln Arg Thr Lys Thr Asn Ser Arg Thr Arg Lys Gly
 100 105 110
 Lys Arg Lys Thr Val Ala Gly Lys Lys Lys
 115 120

<210> 31
 <211> 10
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Made in the lab

<400> 31
 Cys Ser Phe Ile Gly Gly Ile Thr Tyr Leu
 1 5 10

<210> 32
 <211> 53
 <212> PRT
 <213> Chlamydia trachomatis

<400> 32
 Leu Cys Val Ser His Lys Arg Arg Ala Ala Ala Val Cys Ser Phe
 1 5 10 15
 Ile Gly Gly Ile Thr Tyr Leu Ala Thr Phe Gly Ala Ile Arg Pro Ile
 20 25 30
 Leu Phe Val Asn Lys Met Leu Ala Gln Pro Phe Leu Ser Ser Gln Thr
 35 40 45
 Lys Ala Asn Met Gly
 50

<210> 33
 <211> 161
 <212> DNA
 <213> Chlamydia trachomatis

<400> 33
 atctttgtgt gtctcataag cgcagagcgg ctgcggcgtgt ctgtagcacc atcggaggaa 60
 ttacctacct cgcgacattc ggagctatcc gtccgattct gtttgtcaac aaaatgctgg 120
 caaaacccgtt tctttcttcc caaactaaag caaatatggg a 161

<210> 34
 <211> 53
 <212> PRT
 <213> Chlamydia trachomatis

<400> 34
 Leu Cys Val Ser His Lys Arg Arg Ala Ala Ala Val Cys Ser Ile
 1 5 10 15
 Ile Gly Gly Ile Thr Tyr Leu Ala Thr Phe Gly Ala Ile Arg Pro Ile
 20 25 30
 Leu Phe Val Asn Lys Met Leu Ala Lys Pro Phe Leu Ser Ser Gln Thr
 35 40 45
 Lys Ala Asn Met Gly
 50

<210> 35
 <211> 55
 <212> DNA
 <213> Chlamydia pneumoniae

<400> 35
 gatatacata tgcataccca tcaccatcac atgagtcгаа aaaaaataaaa actct 55

<210> 36
 <211> 33
 <212> DNA
 <213> Chlamydia pneumoniae

<400> 36

ctcgaggaat tcttatttta caatatgttt gga 33

<210> 37
 <211> 53
 <212> DNA
 <213> Chlamydia pneumoniae

<400> 37
 gataacata tgcatacca tcaccatcac atgccacgca tcattggaat gat 53

<210> 38
 <211> 30
 <212> DNA
 <213> Chlamydia pneumoniae

<400> 38
 ctcgaggaat tcttatttct tcttacctgc 30

<210> 39
 <211> 16
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Made in the lab

<400> 39
 Lys Arg Asn Ile Asn Pro Asp Asp Lys Leu Ala Lys Val Phe Gly Thr
 1 5 10 15

<210> 40
 <211> 16
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> made in the lab

<400> 40
 Lys Arg Asn Ile Leu Pro Asp Ala Asn Leu Ala Lys Val Phe Gly Ser
 1 5 10 15

<210> 41
 <211> 15
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> made in the lab

<400> 41
 Lys Glu Tyr Ile Asn Gly Asp Lys Tyr Phe Gln Gln Ile Phe Asp
 1 5 10 15

<210> 42
 <211> 16
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> made in the lab

<400> 42
 Lys Lys Ile Ile Ile Pro Asp Ser Lys Leu Gln Gly Val Ile Gly Ala
 1 5 10 15

<210> 43
 <211> 15
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> made in the lab

<400> 43
 Lys Lys Leu Leu Val Pro Asp Asn Asn Leu Ala Thr Ile Ile Gly
 1 5 10 15

<210> 44
 <211> 509
 <212> DNA
 <213> Chlamydia

<400> 44
 ggagctcgaa ttccggcacga gaggcgccat tggtttgcag gctttgtctg atgatagcga 60
 taccgtacgt gagattgctg tacaagtagc tggtagtat ggttctagtt gcttactgcg 120
 cgccgtgggc gatttagcga aaatgatgc tcttattcaa gtacgcacga ctgcttatcg 180
 tgctgcagcc gtgttgaga tacaagatct tggcctcat ttacgagttg tagtccaaaa 240
 tacacaatta gatggaacgg aaagaagaga agcttgaga tctttatgtg ttcttactcg 300
 gcctcatagt ggtgtattaa ctggcataga tcaagcttta atgacctgtg agatgtataa 360
 ggaatatcct gaaaagtgtg cggagaaga gattcgtaaa ttattggctg cagatcatcc 420
 agaagtgcag gtacgtacct tacagatcat tctgagagga ggtagagtat tccggtcatc 480
 ttctataatg gaatcgggtc tctgcccgg 509

<210> 45
 <211> 481
 <212> DNA
 <213> Chlamydia

<220>
 <221> unsure
 <222> (23)
 <223> n=A,T,C or G

<400> 45
 gatccgaatt cggcagcagg cantatttac tcccaacatt acggttccaa ataagcgata 60
 aggtcttcta ataaggaagt taatgtaaga ggctttttta ttgcttttcg taaggtagta 120
 ttgcaaccgc acgcgattga atgatacga agccatttcc atcatggaaa agaacccttg 180
 gacaaaaata caaaggaggt tcaactctaa ccagaaaaag ggagagttag ttccatggg 240

```

ttttccttat atacacccgt ttacacacat taggagccgc gtctagtatt tgggaatacaa 300
atttccccca agcgaatttt gttcctgttt cagggaatttc tctaatattgt tctgtcagcc 360
atccgcttat ggtaacgcaa tttagctgtag taggaagatc aactccaaac aggtcataga 420
aatcaaaaag ctcatagggt cctgcagcaa taacaacatt ctgtctcgag tgagcgaaat 480
g 481

```

```

<210> 46
<211> 427
<212> DNA
<213> Chlamydia

<220>
<221> unsure
<222> (20)
<223> n=A,T,C or G

```

```

<400> 46
gatccgaatt cggcagcaggn tttttcctgt tttttcttag tttttagtgt tcccggagca 60
ataacacaga tcaaaagaacg gccattcagt ttaggctctg actcaacaaa acctatgtctc 120
tctaagccct gacacattct ttgaacaacc ttatgcccgt gttcgggata agccaactct 180
cgcccccgaa acatacaaga aacctttact ttatttctct tctcaataaa ggctctagct 240
tgctttgctt tcgtaagaaa gtctgtatca tcatatttag gcttaagctt aacctctttg 300
atacgcaatt ggtgctgtgc tttcttacta tcttttctct ttttagttat gtcgtaacga 360
tacttcccggt agtccatgat ttgcacaca ggaggctctg agtttgaagc aacctctgtc 420
cgaattc 427

```

```

<210> 47
<211> 600
<212> DNA
<213> Chlamydia

<220>
<221> unsure
<222> (522)
<223> n=A,T,C or G

```

```

<400> 47
gatccgaatt cggcagcagga tgcttctatt acaattgggt tggatgcgga aaaagcttac 60
cagcttattc tagaaaagtt gggagatcaa attcttgggt gaattgctga tactattgtt 120
gatagtacag tccaagatat tttagacaaa atcacacacag acccttctct aggtttgtgt 180
aaagctttta acaactttcc aatcactaat aaaattcaat gcaacgggtt attcactccc 240
aggaacattg aaactttatt aggaggaact gaaataggaa aattcacagt cacaccocaa 300
agctctggga gcatgttctt agtctcagca gatattattg catcaagaat ggaaggcgcc 360
gttgttctag ttttggtagc agaaggtgat tctaagccct acgcgattag ttatggatac 420
tcatcagcgc ttctcaattt atgtagtcta agaaccagaa ttattaatac aggtttgact 480
ccgacaacgt attcattacg tgtaggcggt ttagaagcgc grngtggatg ggttaatgcc 540
ctttctaatt gcaatgatat tttaggaata acaaatcttc taatgtatct tttttggagg 600

```

```

<210> 48
<211> 600
<212> DNA
<213> Chlamydia

```

```

<400> 48
ggagctcgaa ttcggcacga gctctatgaa tatccaattc tctaaactgt tcggataaaa 60

```

```

atgatgcagg aattaggctc acactatctt tttttgttc gcaaatgatt gattttaaat 120
cgtttgatgt gtatactatg tcgtgtaagc ctttttggtt acttctgaca ctagccccc 180
atccagaaga taaattggat tgcgggtcta ggtcagcaag taacactttt ttccctaaaa 240
attggggcaa gttgcatccc acgttttagag aaagtgttgt ttttccagtt cctcccttaa 300
aagagcaaaa aactaagggt tgcaaatcaa ctccaacgtt agagtaagtt atctattcag 360
ccttggtaaa catgtctttt ctagacaaga taagcataat caaagccttt tttagcttta 420
aactgttate ctctaatttt tcaagaacag gagagctcgg gaataatcct aaagagtttt 480
ctatttgttg aagcagtcct agaattagtg agacactttt atggttagag tccaaggag 540
aatttaagaa agttactttt tccttgttta ctctgatttt taggtctaat tccgggaaat 600

```

<210> 49
 <211> 600
 <212> DNA
 <213> Chlamydia

```

<400> 49
gatccgaatt cggcacgaga tgcttctatt acaattggtt tggatgcgga aaaagcttac 60
cagcttattc tagaaaaagt gggagatcaa attcttggtg gaattgtgta tactattggt 120
gatagtacag tccaagatat tttagacaaa atcacacagc acccttctct aggtttgttg 180
aaagctttta acaactttcc aatcataatt aaaattcaat gcaacgggtt attcactccc 240
aggaacattg aaactttatt aggaggaact gaaattaggaa aattcacagt cacaccctaa 300
agctctggga gcatgtttctt agtctcaaga gatattattg catcaagaat ggaaggcggc 360
gttgttctag ctttggtacg agaaggtgat tctaagccct acgcgattag ttatggatac 420
tcatacggcg ttcctaatatt atgtagtcta agaaccagaa ttattaatac aggattgact 480
ccgacaacgt attcattacg tgtaggcggg ttagaagcgg gtgtgggtat gggttaatgcc 540
ctttctaatt gcaatgatat tttaggaata acaaatactt ctaattgtatc tttttggag 600

```

<210> 50
 <211> 406
 <212> DNA
 <213> Chlamydia

```

<400> 50
gatccgaatt cggcacgagt tcttagcttg ctttaattac taattaacca aactaaaggg 60
gcatcaaat agcttattca gtctttcatt agttaaaca tcttttctag ccatgactca 120
tcctatgttc ttacgtata aaaatacttc ttaaaacttg atatgctgta atcaatccat 180
cattaaccac aacataatca aattcgctag cggcagcaat ttgcacagcg ctatgctcta 240
atctttcttt ctctgtgaaa tctttctctg aatcccgagc attcaaacgg cgctcaagtt 300
ctctctgaga gggagcttga ataaaaatgt gactgccggc atttgcttct tcagagccaa 360
agctccttgc acatcaatca cggctatgca gtctcggtcc gaattc 406

```

<210> 51
 <211> 602
 <212> DNA
 <213> Chlamydia

```

<400> 51
gatccgaatt cggcacgaga tatttttagac aaaaatcaca cagacccttc tctaggtttg 60
ttgaaagctt ttaacaactt tccaatcact aataaaattc aatgcaacgg gttatccact 120
cccaggaaac ttgaaacttt attaggagga actgaaatag gaaaattcac agtcacaccc 180
aaaagcttgc ggaagcatgt cttagtctca gcagatatta ttgcattcaag aatggaaggc 240
ggcgttgttc tagcttttgt acgagaaggt gattctaaag cctacgcgat tagttatgga 300
taactcacag gcgttcccaa tttatgtagt ctaagaacca gaattattaa tacaggattg 360
actccgacaa cgtattcatt acgtgtaggc ggtttagaaa cggtgtggtt atgggttaat 420
gccctttcta atggcaatga tattttagga ataacaataa ctcttaagt atcttttttg 480

```

gaggtaatac ctcaaacaaa cgcttaaacaa attttttattg gatttttctt atagggtttta 540
tatttagaga aaaaagtctg aattacgggg tttgttatgc aaaataaact cgtgccgaat 600
tc 602

<210> 52
<211> 145
<212> DNA
<213> Chlamydia

<400> 52
gatccgaatt cggcagcagc tcgtgccgat gtgttcaaca gcatccatag gatgggcagt 60
caataatact ccaagtaatt cttttttctt ttccaacaac tccttaggag agcggtggat 120
aacattttca gtcgtgcccg aattc 145

<210> 53
<211> 450
<212> DNA
<213> Chlamydia

<400> 53
gatccgaatt cggcagcagc taatcggcac cgcactgctg acactcatct cctcgagctc 60
gatcaaaacc acacttggga caagtaccta caacataacg gtccgctaaa aacttccctt 120
cttcctcaga atacagctgt tcggtcacct gattctctac cagtcgcgct tcctgcaagt 180
ttcgatagaa atcttgcaca atagcaggat gataagcgtt cgtagtctcg gaaaagaaat 240
ctacagaaat tcccaatttc ttgaaggtat ctttatgaag cttatgatac atgtcgacat 300
attcttgata ccccatgcct gccaaactctg cattaagggt aattgcgatt cgtattatcat 360
cagaaccaca aatatacaaa acctctttgc cttgtagtct ctgaaaacgc gcataaacat 420
ctgcaggcaa ataagcctcg tgccgaattc 450

<210> 54
<211> 716
<212> DNA
<213> Chlamydia

<400> 54
gatcgaatt cggcagcagc ggcacgagtt ttctgatagc gatttacaat cctttattca 60
acttttgctt agagaggcac actatactaa gaagtcttct ggtgtgtggt cacagtcctg 120
tcgtcagggg attctgctag aggggtaggg gaaaaaaccc ttattactat gaccatgcgc 180
atgtgggaatt acattgccata gacttttcga tcattcccaa catttacaca gctctacacc 240
tcttaagaag aggtgacgtg gattgggtgg ggcagccttg gcaaccaagg attctctttg 300
agctctggac tacctctgct ctctacaccc attaccctgt agatggcaca ttctggccta 360
ttcttaattc caaagatcct gtaactttct ctctatctaa tcgtcagcga ttgattgctg 420
ccatccaaaa ggaaaaactg gtgaagcaag ctttaggaac acaatatcga gtacttgaaa 480
gctctccatc tcagagggga atcatagctc atcaagaagc ttctactcct ttctctggga 540
aaattacttt gatatactcc aataatatta cgcgctgtca gcgtttggcc gaggtatcca 600
aaaaatgatc gacaaggagc acgctaaatt tgtacatacc ccaaaatcaa tcagccatct 660
aggcaaatgg aatatcaaa gtaaacagtat acaactgggg atctcgtgcc gaattc 716

<210> 55
<211> 463
<212> DNA
<213> Chlamydia trachomatis

<400> 55
tctcaaatcc ttgctttgaa taatccagat atttcaaaaa ccatgttcca taaattcacc 60

```

cgacaaggag tcogtttcgt actagaagcc tctgtatcaa atattgagga tataggagat 120
cgcggttcggt taactatcaa tgggaatgtc gaagaatacg attacgttct cgtactctata 180
ggacgcgcgtt tgaatcacaga aaatatggc ttggataaag ctgggtttat ttgtgatgaa 240
cgcgaggatca tccctaccca tgccacaatg cgcacaaacg tacctaact ttatgctatt 300
ggagatatcca caggaaaatg gcaacttgcc catgtagctt ctcatcaagg aatcattgca 360
gcacggaata taggtggcca taaagaggaa atcgattact ctgctgtccc ttctgtgate 420
tttaccttcc ctgaagtgcg ttcagtaggc ctctcccaag cag 463

```

<210> 56

<211> 829

<212> DNA

<213> Chlamydia trachomatis

<400> 56

```

gtactatggg atcattagtt ggaagacagg ctccggattt ttctggtaaa gccgttgttt 60
gtggagaaga gaaagaaatc tctctagcag actttctggg taagtatgta gtgctcttct 120
tttactctaa agattttacc tatgtttgtc ctacagaatt acatgctttt caagatagat 180
tggttagatt tgaagagcat ggtgcagtcg tctctgggtg ctccgttgag gacattgaga 240
cacattctcg ttggtcact gtacgcagag atgcaggagg gatagaggga acagaaatca 300
ctctgttagc agaccctct tttaaaat cagaagcttt ttgtgttttg aatcctgaag 360
gtcgtctcgc tttaaagact actttcctta tcgataaaca tgggtttatt cgtcatcggt 420
ctataactga tcttccctta gggcggtcca ttgacgagga attgcgtatt tttagattca 480
tgatcttctt tgagaaccac ggaatggttt gtccagctaa ctggcgcttc ggagagcgtg 540
gaatgggtgc ttctgaagag ggattaaaag aatacttcca gacgatggat taagcatctt 600
tgaaaagtaag aaagtctac agatcttgat ctgaaaagag aagaaggctt tttaatcttc 660
tgacagagagc cagcagaggt tcaataatgt tgaagtctcc gacaccaggc aatgctaugg 720
cgacgatatt agttagtgaa gtctgagtat taaggaaatg aaggcccaag aaatagctat 780
caataaagaa gcttctctcc ttgactctaa agaatagtac gtctgtatcc 829

```

<210> 57

<211> 1537

<212> DNA

<213> Chlamydia trachomatis

<400> 57

```

acatcaagaa atagcggact cgcctttagt gaaaaaagct gaggagcaga ttaatcaagc 60
acaacaagat attcaaacga tcacacctag tggtttggat attcctatcg ttggtccgag 120
tggttcagct gcttcgcgag gaagtgcggc aggagcgttg aaatcctcta acaattcagg 180
aagaatttcc ttgttcttg atgatgtaga caatgaaatg gcacgcgatt caatgcaagg 240
tttctgactc atgatcgaac aatttaatgt aaacaactct gcaacagcta aagagctaca 300
agctatggag gctcagctga ctgcgagtgc agatcaactg gttggtgcgg atggcgagct 360
cccagccgaa atacaagcaa tcaaatagtc tcttgcccaa gctttgaaac aacctcagc 420
agatggttta gctacagcta tgggacaagt ggccttttga gctgccaaag ttggaggagg 480
ctccgcagga acagctggca ctgtccagat gaatgtaaaa cagctttaca agacagcgtt 540
tctctcagat tcttcagct ctlatgcagc agcactttcc gatggatatt ctgcttaca 600
aacactgaac tctttatatt ccgaaaagcag aagcggcggt cagtcagcta ttagtcaaac 660
tgcaaatccc gcgctttcca gaagcgtttc tctgtctggc atagaaagtc aaggacgcag 720
tgcatagct agccaaagag cagcagaaac tattgtcaga gatagccaaa cgttaggtga 780
tgtatagtc cgtttacagg ttctggattc ttgtatgctt acgatttgtg caaatccgca 840
agcaaatcaa gaagagatta tgacgaagct cagcgcatct attagcaaa gctccacaatt 900
tgggtatcct gctgttcaga attctgtgga tagctttcag aagtttgctg cacaaattgga 960
aagagagttt gttgtatggg aacgttagtct cgcagaactc caagagaatg cgtttagaaa 1020
acagcccgct ttcatcaac aggtgttggg aaacattgct tctctattct ctgggttatct 1080
ttcttaacgt gtgattgaag ttgtgaaat gagggggagc caaaaaagaa ttctcttttt 1140
ggctcttttt tcttttcaaa ggaatctcgt gtctacagaa gtcttttcaa taataagttc 1200

```

```

ttagtcccaa aagaagaaaa tatataaaag aaaaaactcc taattcattt aaaaagtgtc 1260
cggcagactt cgtgggaaaa gtctgtaaa gtcggaggga atcagcagaa agatgcaaga 1320
tatccgagaa aaaaggctca ggctcgtgcc gaattcggca cgagactacg aaagaaaggt 1380
ctttctcttc ggaatctgtc attggatctg cgtgaagactt aaggttcggc aacacagggc 1440
ctgtctcttc tttaggtttc ttgcgcgaga aaaattttct caagtaacaa gaagattttc 1500
ttttacagcc ggcattccggc ttctcgcgaa gtataac 1537

```

<210> 58

<211> 463

<212> DNA

<213> Chlamydia trachomatis

<400> 58

```

tctcaaatcc ttgctttgaa taatccagat atttcaaaaa ccattgttga taaattcacc 60
cgacaaggac tccgtttcgt actagaagcc tctgtatcaa atattgagga tataggagat 120
cgcgcttcggt taactatcaa tgggaatgtc gaagaatacg attacgtttc cgtatctata 180
ggacgccggtt tgaatacaga aaatattggc ttggataaag ctggtgtttat ttggtatgaa 240
cgccggagta cccctaccga tggcacaagt cgcacaaacg taactaacat ttactgtatt 300
ggagatatca caggaaaaat gcaacttgcc catgtagctt ctactcaagg aatcattgca 360
gcacgggaata taggtggcca taaagaggaa atcgattact ctgctgtccc ttctgtgac 420
tttactcttc ctgaagtgcg ttcatgtaggc ctctccccaa cag 463

```

<210> 59

<211> 552

<212> DNA

<213> Chlamydia trachomatis

<400> 59

```

acattctctc tgcctctcgc ggccatccac aaattgaggt aaccttcgat attgatgcca 60
acggaatttt acacgtttct gctaagaagt ctgctagtgg acggaacaa aaaatccgta 120
ttgaagcaag ctctggatta aaagaagatg aaattcaaca aacgatccgc gatgcagagc 180
ttcataaaga ggaagacaaa caacgaaaag aagcttctga tgtgaaaaat gaagccgatg 240
gaatgatctt tagagccgaa aaagctgtga aagattacca cgacaaaatt cctgcagaac 300
ttgttaaaga aattgaagag catattgaga aagtcagcca agcaatcaaa gaagatgctt 360
ccacaacagc tatcaaaaga gcttctgatg agttgagtac tcgtatgcaa aaaatcggag 420
aagctatgca ggtcaatcc gcattccgag cagcatcttc tgcagcgaat gctcaaggag 480
ggccaaacat taactccgaa gatctgaaaa aacatagttt cagcacagca cctccagcag 540
gaggaaagcg ct 552

```

<210> 60

<211> 1180

<212> DNA

<213> Chlamydia trachomatis

<400> 60

```

atctcagcgg taaaactgct tactggctcag ataaaatcca tacagaagca acacgtactt 60
cttttaggag aaaaaactta taatgctaga aaaatcctga gtaaggatca ctctctctca 120
acaaactttt catcttgagt agagttagtt tttagaacta agtcttctgc ttacaatgct 180
cttgcatatt acgagctttt tataaaacct cccaacccaa ctctacaaa agagtttcaa 240
tcgatccctc ataaatccgc atatatcttg gccgctagaa aaggcagatt aaaaaccaag 300
gtcgatgtga tagggaagat atgtggaatc tcgtgcgcaa ttccgcagca gcggcacgag 360
gatgtagagt aattagttaa agagctgcat aattatgaca aagcatggaa aacgcattcg 420
tggtatccaa gagactacg atttagctaa gtcgtattct ttgggtgaag cgatagatat 480
tttaaaacag gtgcctactg tgcgtttcga tcaaacggtt gatgtgtctg ttaaatagg 540
gatcgatcca agaaaagagt atcagcaaat tcgtggttcg gttctcttac ctacgggtac 600

```

```

aggtaaagtt ttgcgaattt tagttttttgc tgcaggagat aaggctgcag aggcatttga 660
agcaggagcg gactttgttg gtatgcgacga cttgtagtaa aaaatcaaaag gtggatgggt 720
tgacttcgat gttgcggttg ccactccgga tatgatgaga gaggtcggaa agctaggaaa 780
agtttttaggt ccaagaaacc ttatgcctac gcttaaaagc ggaactgtaa caacagatgt 840
ggtttaaaact attgcggaac tgcgaaaagg taaaattgaa tttaaagctg atcgagctgg 900
tgtatccaac tgcggagttg cgaagcttcc tttcgatagt gcgcgaatca aagaaaaatgt 960
tgaagcgttg tctgcagcct tagttaaagc taagcccgcga actgctaaag gacaaatatt 1020
agtttaatttc actatttccc cgaccatggg ccgaggggtt accgtggata ctaggaggtt 1080
gattcgcgtta taattctaaag ttaaaagagg aaaaatgaaa gaagagaaaa agttgctgct 1140
tcgcgaggtt gaagaaaaa taaccgcttc tcggcaccag 1180

```

<210> 61

<211> 1215

<212> DNA

<213> *Chlamydia trachomatis*

<400> 61

```

attacagcgt gtgcaggtaa cgacatcatt gcgatgatgct ttgatggca ttgatgcggc 60
attccttata gggtcagttc cttagaggccc aggaatggag agaagagatc ttctaagaaa 120
aaatggggag attgtttgcta cgcaaggaaa agctttgaac acaacagcca agcgggatgc 180
aaagattttt gttgttggga accctgtgaa taccaatgct tggatagcaa tgaatcatgc 240
tcccagatta ttgagaaga aactttcatgc gatgcacga ttggaccaga atcgatgca 300
tagcatgtta tcgcataag cagaagtacc tttatcggtc gtatcacaag ttgtggtttg 360
gggaaatcac tcgccaaac aagtcgctga ttttacgcaa gctctgatta atgaccgtcc 420
tatcgacag acgatagcgg atcgtagttg gttagagaat attatgggtc ctctgtaca 480
gagtcgtggt agtcagtaa ttgaagcacg agggaaagct tcggcagctt ctgcagcacg 540
agcttttagca gaggctgctc gatcaatata tcagccaaaa gaaggactcg tgccgaattc 600
ggcacaggtta tcgaattgac aggcattttct agtgaatggt cgtatgctta taactactgt 660
ggtagagact tgagctctca aaagtgttgc acagattctt acatcgaga cccttattct 720
aagaattatc actccctcca actatttggg tccctaaac aagaaaagga ttacgcattt 780
agttacctga aatatgagga ttttgactgg gaaggcgaca ctctttgca ccttcaaaa 840
gaaaaattc tcatttatga aatgcattgt cggctattca ccgagatcc gttctccag 900
gtttcccatc ctggaacttt ccttggtatc atcgaaaaaa tagaccacct caaacaacta 960
ggcggttcag cagttgaact ccttctatc ttogaattcg atgaaccgt ccattcattt 1020
aaaaactcag acttcccaca cctgtgtaac tattgggggt attcttcggt gaattttttc 1080
tgccctctc gccgtatac ttatggggca gaccttgcc ctccggccc agagttcaag 1140
actcttgta caacggttaca ccgtgcggga atcgaaagca ttctcgatgt cgttttcaat 1200
catcacggtt ttgaa 1215

```

<210> 62

<211> 688

<212> DNA

<213> *Chlamydia trachomatis*

<400> 62

```

gtggatccaa aaaagaattc aaaaagccat acaagattg cgttactctc tgcgatgctt 60
ctaactattt atcagcgtca tctttgagaa gcattctaat gagcgctttt tcttctctag 120
catgccgcac attcgtcttc tcatgttctg tgaatatgac atagctctca ggattggaaa 180
atccaaagta ctcagctaat ccacgaattt tctctctagc gatacgtgta attgactct 240
cataagaata caaagcagcc actcctgcag ctaagaatc tctgtacac caccgcgatg 300
tagctgctac tttcgctttt gctgcttcc taggtctcat agcctctaac tctctggag 360
taactcctag agcaaacaca aactgcttcc acaaatcaat atgattaggg taaccgttct 420
cttctccat caagttatct aacaataact tacgcgctc taaatcatcg caacgactat 480
gaatcgaga taaatattta ggaaggctt tgatatgtaa ataatagtct ttggcacgag 540
cctgaattg ctcttttagt agtccccct tcgaccattt cacataaaac gtgtgttcta 600

```

gcatatgctt attttgaata attaaatcta actgatctaa aaaattcata aacacctcca 660
tcattttctt tcttgactcc acgtaacc 688

<210> 63

<211> 269

<212> DNA

<213> *Chlamydia trachomatis*

<400> 63

atgttgaagt cacacaagct gttcctaagt atgtactcgt aggatctccc tatcctgttg 60
aaattactgc tacagggtaaa agggattgtg ttgatgttat cattactcag caattaccat 120
gtgaagcaga gttcgtacgc agtgatccag cgacaactcc tactgtctgt ggtaaagctag 180
tttggaaaat tgaccgctta ggacaaggcg aaaagagtaa tttactgtga tgggtaaaac 240
ctcttaaga aggttgctgc ttacagct 269

<210> 64

<211> 1339

<212> DNA

<213> *Chlamydia trachomatis*

<400> 64

cttttattat ggcttctggg gatgatgtca acgatatcga cctgctatct cgaggagatt 60
ttaaaattgt tatacagacg gctccagagg agatgcattg attagcgagc tttttggctc 120
ccccggcgaa ggatcttggg attctctccg cctgggaagc tggtagctg cgttacaacac 180
agctagttaa tctctaggaa acatttctgg acctatgcc atcacattg ctcctgtatc 240
cacatagaga gtttctcccg taattgcgct agctaggaga gagactaaga aggtctgctg 300
tgcgctact tgctcagctt ccattggaga aggtagtga gccagctct gtagtaactc 360
caccattctc tcaataaato caatagcttt tcttcgacgg ctagttaatg gccctgcgca 420
gatagtattc actcggactc cccaacgtcg gccgggtccc caagccagta cttttgtatc 480
acttctaaaa gcagcttttg ctggttcat tctcccgcca taccctggaa cagcacgcat 540
ggaagcaaga taagttagag agatggtgct agctcctgca ttcataaatt gcccacaaatg 600
agagagaagg ctgataaagg agtagctgga tgcacttaag gcggcaagat agcctttacg 660
agaggatcca agtaatgggt tagcaatttc cggactgttt gctaaagagt gaacaaagat 720
atcaatgtgt ccaaaatctt ttttcacctg tctacaact tgggatacag tgtaccacga 780
aagatctttg taacgtttat tttccaaaat tctctgagga atatctctg ggggtgtcga 840
actggcatcc atgggataga ttttagcgaa agttagcaat tctccattg agagttcacg 900
agatgcattg aattttctca actcccaaga ttgagagaaa attttataga taggaacca 960
ggctcccaaca agtatgggtg cgctgcttc tgctaactt tctggcaatg cccagccata 1020
cgtcttatca tgccttatga cggctatgaa agcaattttt cctgttaaat caattttcaa 1080
catgagctaa cccatttttg tcttcttgag agagagagat agcagattct ttattattga 1140
gaasgcggcc tcataataca taaggagtag attcactgac tggatccagg tttctagagt 1200
aaagagtttc cttgtcaaat tcttatatgg gttaggttaa tcaactgttt tcaagtgtat 1260
tatgtttatt ttaaaaataa ttgttttaac aactgtttaa tagttttaat ttttaaaagt 1320
tgaaaaacag gttttatat 1339

<210> 65

<211> 195

<212> PRT

<213> *Chlamydia trachomatis*

<400> 65

Met Gly Ser Leu Val Gly Arg Gln Ala Pro Asp Phe Ser Gly Lys Ala
5 10 15

Val Val Cys Gly Glu Glu Lys Glu Ile Ser Leu Ala Asp Phe Arg Gly

20	25	30
Lys Tyr Val Val Leu Phe Phe Tyr Pro Lys Asp Phe Thr Tyr Val Cys		
35	40	45
Pro Thr Glu Leu His Ala Phe Gln Asp Arg Leu Val Asp Phe Glu Glu		
50	55	60
His Gly Ala Val Val Leu Gly Cys Ser Val Asp Asp Ile Glu Thr His		
65	70	75
Ser Arg Trp Leu Thr Val Ala Arg Asp Ala Gly Gly Ile Glu Gly Thr		
85	90	95
Glu Tyr Pro Leu Leu Ala Asp Pro Ser Phe Lys Ile Ser Glu Ala Phe		
100	105	110
Gly Val Leu Asn Pro Glu Gly Ser Leu Ala Leu Arg Ala Thr Phe Leu		
115	120	125
Ile Asp Lys His Gly Val Ile Arg His Ala Val Ile Asn Asp Leu Pro		
130	135	140
Leu Gly Arg Ser Ile Asp Glu Glu Leu Arg Ile Leu Asp Ser Leu Ile		
145	150	155
Phe Phe Glu Asn His Gly Met Val Cys Pro Ala Asn Trp Arg Ser Gly		
165	170	175
Glu Arg Gly Met Val Pro Ser Glu Glu Gly Leu Lys Glu Tyr Phe Gln		
180	185	190
Thr Met Asp		
195		

<210> 66
 <211> 520
 <212> DNA
 <213> Chlamydia

<400> 66
 gatccgaatt cggcacgagg aggaatggaa gggccctccg attttaaatc tgctaccatg 60
 ccattcacta gaaactccat aacagcgggt ttctctgatg gcgagtaaga agcaagcatt 120
 tgatgtaaat tagcgcaatt agagggggat gaggttactt ggaatatataa ggagcgaagc 180
 gatgaaggag atgtatttgc tctggaagca aaggtttctg aagctaacag aacattgcgt 240
 cctccaacaa tcgcttgagg attctggctc atcagttgat gctttgcctg aatgagagcg 300
 gacttaagtt tcccatcaga gggagctatt tgaattagat aatcaagagc tagatccttt 360
 attgtgggat cagaaaattt acctgtgagc gcattcgagaa ttctcgcaga agaagaatca 420
 tcattcgaacg aatttttcaa tctctgaaaa tcttctccag agacttcgga aagatctctt 480
 gtgaaacgat cttcaagagg agtatcgccct ttttctctg 520

<210> 67
 <211> 276
 <212> DNA

<213> Chlamydia

<400> 67

```

gatccgaatt cggcaccgagg tattgaagga gaaggatctg actcgatcta tgaatcatg 60
atgcctatct atgaagttat gaatatggat ctagaacac gaagatcttt tgcggtacag 120
caagggcact atcaggaccc aagagcttca gattatgacc tcccacgtgc tagcgacctat 180
gatttgccata gaagcccata tcctactcca cctttgcctt ctatatatca gctacagaat 240
atggatgtag aagcagggtt ccgtgaggca gtttat

```

<210> 68

<211> 248

<212> DNA

<213> Chlamydia

<400> 68

```

gatccgaatt cggcaccgagg tgttcaagaa tatgtccttc aagaatgggt taaattgaaa 60
gatctaccgg tagaagagtt gctagaaaaa cgatatcaga aattccgaac gatagggtcta 120
tatgaaactt ctctgaaaag cgattctgag gcataagaag catttagttt tattcggttt 180
ttctctttta tccatattag ggctaacgat aacgtctcaa gcagaaaatt ttctcttagg 240
tcctatttg

```

<210> 69

<211> 715

<212> DNA

<213> Chlamydia

<220>

<221> unsure

<222> (34)

<223> n=A,T,C or G

<400> 69

```

gatccgaatt cggcaccgaga aggtagatcc gatntcagca aaagtgtccc taaaggaaga 60
ttccttcogg atcctcgagc aaataaagtg gcacactcca tctcgagacg tttagacttt 120
attttcatat agttttcgac ggaactcttt attaaactcc caaaaccgaa tgttagtcgt 180
gtgggtgatg cctatatggt aaggagggtt tttaggtctg agaatttggt tgatcatttt 240
ttgtacgaca aaattagcta atgcagggac ctctgggggg aagtatgcac ctgatgttcc 300
atctttttcg atgctagcaa cagggacaaa ataactctct atttggtagt gggatcttta 360
gcctccgac atgcccaaca tgatcgctgc ttagcattg ggaaggaaaag aacacagatc 420
tacggttaaga gctgctcctg gagagcctaa tttaaaatcg atgattgagg tgtgaatttg 480
aggcgcatgc gctgcgaaa acatggatcc tcgagaaaaca gggacctgat agatttcagc 540
gaaaacatcc acggttaatac cmaaatttag taagaaggag atagggctgg aactcttgaa 600
tggtagagcc ggtatagcgc tctagcatgt cacaggcgat tgtttctcgg ctgatttttt 660
tatgtctgat ggtcataaat cacagatatt ataagtgtta gagaactctt ttttc 715

```

<210> 70

<211> 323

<212> DNA

<213> Chlamydia

<400> 70

```

gatccgaatt cggcaccgagc agaacgtaaa cagcacactt aaaccgtgta tgaggtttaa 60
cactgtttgg caagcaaaaca accattctct ttccacacat gttcttacca atacctctga 120
ggagcaatcc aacattctct cctgcacgac ctctggggag ttctttttctg aacatttcaa 180
ccccagtaac aatcgtttct ttagtatctc taagaccgac caactgaact ttatcggaata 240

```

ctttaacaat tccacgctca atacgtccag ttactacagt tctcgtccg gagatagaga 300
acacgtctcc aatgggcatt aag 323

<210> 71

<211> 715

<212> DNA

<213> Chlamydia

<400> 71

gatccgaatt cggcagcagg aaaaaaagat tctctaacca ttataatc tgtgatttat 60
gacccatcaa cataaaaaaa tcagcgaaga aacaatcgcc tgtgacatgc tagagcggtc 120
ataccggctc taccattcaa gagttccgag cctatctcct tcttactaat ttgggtatt 180
acgtggatgt ttctcgtgaa atctatcagg tccctgttcc tcgaggatcc atgttttcgg 240
gcagcgcagc cgcccaaat tcacacctca atcatcgatt ttaaatagg cctccaggga 300
gcagctctta ccgtagatct gtgttcttcc cttcccaatg ctacagcagc gatcatgttg 360
ggcatgtgag gaggtctaa atccactac caaataggag attattttgt cctgtttgct 420
agcatccgaa aagatggaac atcagatgca tacttcccc cagaggtccc tgcattagct 480
aattttgtcg tcaaaaaaat gatcaccaat attctcgaag ccaaaaaacct cccttaccat 540
ataggcatca cccacacgac taacattcgg ttttgggagt ttaataaaga gttccgtcga 600
aaactatatg aaaataaagc tcaaacgtgc gagatggagt gtgccacctt atttgcgtga 660
ggataccgaa ggaatcttcc tttaggagca ctttgcgtga tatcggtatc acctt 715

<210> 72

<211> 641

<212> DNA

<213> Chlamydia

<220>

<221> unsure

<222> (550)

<223> n=A,T,C or G

<221> unsure

<222> (559)

<223> n=A,T,C or G

<221> unsure

<222> (575)

<223> n=A,T,C or G

<221> unsure

<222> (583)

<223> n=A,T,C or G

<221> unsure

<222> (634)

<223> n=A,T,C or G

<221> unsure

<222> (638)

<223> n=A,T,C or G

<400> 72

gatccgaatt cggcagcaga tctcctcgag ctccgatcaa cccacacttg ggacaagtac 60
ctacaacata acggtccgct aaaaacttcc cttcttctcc agaatacagc tgttcggcta 120
ctgattcttc taccagtcgc cgttctcgca agtttcgata gaaatcttgc acaatagcag 180
gatgataagc gttcgtagtt ctggaaaaga aatctacaga aattcccaat ttcttgaagg 240
tatctttatg aagcttatga tacatgtcga catattcttg ataccctatg cctgccaaat 300
ctgcattaa ggttaattgc attcctgatt catcagaacc acaaatatac aaaacctctt 360
tgccctgtag tctctgaaaa cgcgcataaa catctgcagg caaataaaga ccggtaatat 420

```

gtccaaaatg caaaggacca ttgcgctaag gcaacgcaga agtaataaga atacgggaag 480
attccactat ttccagtcgc tccagttgta cagagaagga tcttttcttc tggatgttcc 540
gaaaccttgn tctcttcgnc tctctcctgt agcanacaaa tgnctctctc gacatctctt 600
tcagcgtatt cggactgatg cccataagat cccnggangt t 641

```

```

<210> 73
<211> 584
<212> DNA
<213> Chlamydia

```

```

<220>
<221> unsure
<222> (460)
<223> n=A,T,C or G
<221> unsure
<222> (523)
<223> n=A,T,C or G
<221> unsure
<222> (541)
<223> n=A,T,C or G
<221> unsure
<222> (546)
<223> n=A,T,C or G

```

```

<400> 73
gaattcgcca cgagacattt ctagaatgga accggcaca aacaaaaact ttgtatctga 60
agatgacttt aagcaatctt tagataggga agatTTTTtTg gaatgggtct ttttatttgg 120
gactttattc ggaacgagta aggcggagat ttctagagtt ctgcaaaagg gtaagcactg 180
catagccgtg attgatgtac aaggagcttt ggctctgaag aagcaaatgc cggcagtcac 240
tatttttatt caagctccct ctcaagaaga acttgagcgc cgtttgaatg ctcggtattc 300
agagaaaagt ttccagaaga aagaaaagatt agagcatagc gctgtcgaaa ttgctgccgc 360
tagcgaattt gattatgttg tggtaaatga tgatttgatt acagcatatc aagttttaag 420
aagtattttt atagctgaag aacataggat gagtcatggn tagaaaaagt cgtttaacta 480
atgaaagact gaataagcta ttgtatagcc cctttagtgt ggntaattac gtaattaagc 540
nagctnagaa caaatgtgct agaggagatg ttctgtcttc taac 584

```

```

<210> 74
<211> 465
<212> DNA
<213> Chlamydia

```

```

<400> 74
gatccgaatt cggcacgagc tcgtgccgtt tgggacgtg taatcgcatc ggagaatggt 60
taagaaatta ttttcgagtg aaagagctag gcgtaatcat tacagatagc cataactactc 120
caatgcggcg tggagtagtg ggtatcgggc tgtgttggtt tggattttct ccattacaca 180
actatagag atcgcctagat tgtttcggtc gtcccttaca gatgacgcaa agtaactctg 240
tagatgcctt agcagttgcg gctgtgtttt gtatgggaga ggggaatgag caaacaccct 300
tagcgtgatg agagcaggca cctaataatg tctaccattc atatctact tctcgagaag 360
agtattgttc ttgcgcata gatgaaacag aggacttata cggacctttt ttgcaagcgg 420
ttaccgtgga gtcagaagaaa gaaatgatgg aggtgtttat gaatt 465

```

```

<210> 75
<211> 545
<212> DNA
<213> Chlamydia

```

<400> 75

```

gaattcggca cgagatgaaa agttagcgtc acaggggatt ctctaccaa agaattccga 60
aaagttttct tccaaaaacc tcttctctct ttgatttagt atccctctgc aactacttta 120
ctatatgttc tgtgaaatat gcatagtctt caggattgga aaatccaaag tactcagta 180
atccacgaat ttctctctta gcgatacgtg gaatttgact ctcatagaa tacaaagcag 240
ccactcctgc agctaagaaa tctcctgtac accaccgcgt gaaagttagct actttcgctt 300
ttgctgtctc actgagctca tgagcctcta actcttctgg agtaactcct agagcaaaaca 360
caaaactgctt ccacaataca atatgattag ggtaaccggt ctcttcatcc atcaagttat 420
ctaacaataa cttacgcgcc tctaatacat cgcaacgact atgaatcgca gataaatatt 480
taggaaagcg ttgatattgt aaataatagt ctttggcata cgcttgtaat tgcctcttag 540
taagc 545

```

<210> 76

<211> 797

<212> DNA

<213> Chlamydia

<220>

<221> unsure

<222> (788)

<223> n=A,T,C or G

<221> unsure

<222> (789)

<223> n=A,T,C or G

<400> 76

```

gatcgaatt cggcacgaga tacgctagat gcgataaatg cggataatga ggattatcct 60
aaaccagggt acttcccaag atcttctctc tctagtcacg ctctctcatg tccagtaact 120
caatctgaga ttccaaacgtc acctacctca acacagcctc catcacccta acttgtaaaa 180
actgtaataa aaagagcgcg cttctcttat gcaaaatcaa ttgaacaac tcttactga 240
attaggggact caaatcaaca gccctcttac tcttgattcc aataatgctc gtatagttcg 300
ctttgggata aacaatgttg ctgtacaaat tgaagaggat ggtaattcag gatttttagt 360
tctgtgagtc atgcttggaa aacttccaga gaataccttt agacaaaaaa ttttcaaaagc 420
tgctttgtct atcaatggat ctccgcaatc taatattaaa ggcaactctag gatacgggtga 480
aatctctaac caactctatc tctgtgatcg gcttaacatg acctatctaa atggagaaaa 540
gctcgcgcgt tacttagttc ttttttcgca gcataccaat atctggatgc aatctatctc 600
aaaaggagaa cttccagatt tacatgctct aggtatgtat cacctgtaaa ttatgcgcgt 660
attatcccaa tcccgacgta tcatccagca atcttccatt cgaaagattt ggaatcagat 720
agatactctt cctaagcatg ggggtgatcg taccggttat ttttctcttc atactcaaaa 780
aaagttgnng gggaata 797

```

<210> 77

<211> 399

<212> DNA

<213> Chlamydia

<400> 77

```

catatgcac accatcacca tcacatgcc a cgcatacttg gaattgatat tcttgcaaa 60
aaaaagttaa aataaagttc gacatatatt tatggaatag gatcagctcg ttctgatgaa 120
atcattaaaa agttgaagtt agatcctgag gcaagagcct ctgaattaac tgaagaagaa 180
gtaggacgac tgaactctct gctacaataca gaataaccg tagaagggga ttgacgacgt 240
cgtgttcaat cggatatcaa aagattgac gccatccatt ctatcgagg tcagagacat 300
agactttctt taccagtaag aggacaacgt acaaaaacta attctcgtac tcgaaaaggt 360
aaagaaaaaa cagtcgcagg taagaagaaa taagaattc 399

```

<210> 78
 <211> 285
 <212> DNA
 <213> Chlamydia

<400> 78
 atgcacaccc atcaccatca catgagtcac aaaaataaaa actctgcttt tatgcacccc 60
 gtgaattatt ccacagattt agcagttata gttggcaagg gacatatgcc cagaaccgaa 120
 attgtaaga aagtttggga atacattaaa aaacacaaact gtcaggatca aaaaaataaa 180
 cgtaatatcc ttcccgatgc gaattcttgc aaagtctttg gctctagtga tcctatcgac 240
 atgttccaaa tgaccaaagc cttttccaaa catattgtaa aataa 285

<210> 79
 <211> 950
 <212> DNA
 <213> Chlamydia

<400> 79
 aaattaaact gagcacaaat tacggcaatt gctgagcaaa agatgaagga catggatgtc 60
 gttcttttag agtccgcca gagaatgggt gaagggactg cccgaagcat ggggttagat 120
 gtgagtaatt tagtttaaga gctgcataat tatgacaaag catggaacac gcattcgtgg 180
 tatccaagag acttacgatt tagctaaagtc gtattctttg ggtgaagcga tagatatttt 240
 aaaaacagtg cctactgtgc gtttcgatca aacggttgat gtgtctgtta aattagggat 300
 cgtaccaaga aagagtgtac agcaaatcgc tgggttcggt tctttacccc acggtacagg 360
 taagttttg cgaatttttag tttttgctgc tggagataag gctgcagagg ctattgaagc 420
 aggagcggac ttgtttggta gcgacgactt ggtagaaaa atcaaaagggt gatgggttga 480
 ctccgatgtt gcggttgcca ctcccgatat gatgagagag gtcggaagac taggaaaaag 540
 tttaggtcca agaaacctta tgccatcgcc taaagccgga actgtaacaa cagatgtggt 600
 taaaactatt gcggaactgc gaaaaggtaa aattgaattt aaagctgtac gagctggtgt 660
 atgcaacgct ggagttgcga agctttcttt cgtagtgtgc caaatcaaa gaaatgttga 720
 agcggttgtt gcagccttag ttaagctaa gcccgcaact gctaaaggac aatatattag 780
 taatttctat atttccctga ccatggggcc aggggttacc gtgatacta gggagttgat 840
 tgcgttataa ttctaagttt aaagaggaaa aatgaagaa gagaaaaagt tgctgtctcg 900
 cgggttgaa gaaaagataa ccgcttctca aggttttatt ttgttgagat 950

<210> 80
 <211> 395
 <212> DNA
 <213> Chlamydia

<400> 80
 tttcaaggat tttgttttcc cgtatcatct actaaatgca gctccaacaa tcacatcatg 60
 ggctgggtta gcacttaagg caacagaagc tctctgtgtg taataagtag attcttcaga 120
 agtaggtgtt cctacttgcg atagcatcgt tcttagtctt gatatacaca ggttggtata 180
 gctaacctca tcaaacgcag ctgatttcat ttatcggtt agcaagcctt gtttgactgt 240
 gaccattgac atttgagatc ccagaatcga gttcgcata aaatgattgt ctctaggtag 300
 aataagccat tgcctataag agtcaaatct ccagagcgct gagatcgctt cattttgtag 360
 ttgatcagga tccagagtga gtgttctctg atacc 395

<210> 81
 <211> 2085
 <212> DNA
 <213> Chlamydia

<400> 81

```

atttggcgaa ggagtttggg ctacggctat taataaatca ttcgtgttcg ctgcctccaa 60
gaccagattg tgtactttct tatgaagaat ctccatttga gcaaatgttg cgttggggag 120
agtctcagtt agaaacaattt gctccaagtag gtttagatgc aagtgtggcaa gttgttttcg 180
atccagggaat aggattttggg aagactcccg ttccagtcgat gttattgatg gatggagtaa 240
agcagtttaa acgtgtttta gagtgtccctg tattaatagg ccattctaga aaatcgtgtt 300
tgagtatatt gggccgattt aatagtgcag atcgtgatgg ggaacgcac ggctgtctcg 360
tatctctcca tgcacgagga gttgattatc tacgtgtgca tcaggttgaa ggttaacagac 420
gtgccttagc cgctgctgct tgggctggta tgtttgtatg atccaagcaa caggtatcgt 480
tgctattgat cccagaggag tgatggggagc tttaggcaag ctcccttggg gttatccga 540
agatctacgt ttttttcgag aaaccattcg aaatcatccc atcattatgg gacgaaagac 600
ttgggagttc tctccagaca agtataagca tgggcgggat atcgttgtct ttcttcgag 660
gatgcattca ccacaatgca taggagtttc ttcccttggc agtatggga cactatcttt 720
gaatcatccg tttttaaatt ggggagcggg gctctttgaa agttttttcc aacaaaacct 780
tctgaagcct tgttttgtca cacatatcaa aaagaaatat tggggcgata ctttctctcc 840
tatcacggca ttatcaggat ggaagaagga atgtatttgt aatacagagg atttcagtat 900
ttattattat gaaaataact ccgatcaaaa cagctaaagt atttgcacat gatccgttc 960
aagagatctt gcaagaggct ttgccgcttc tgcaagaacg gagtgtggta gttgctctt 1020
caagagattg gagtttatgt gaaggcgctg tgcgtgatgc aagaatgtgc aaagcagagt 1080
tgataaaaaa agaagcggat gcttatttgt ttgttgagaa aagcgggata tatctaagca 1140
aaaaagaagg tattttgatt ccttctgcag ggattgatga atcgaatagc gaccagcctt 1200
ttgttttata tcttaagat attttgggat cgtgtaatcg catcgagaaa tgggttaagaa 1260
attattttcg agtgaaagag ctaggcgtaa tcatcacaga tagccatct actccaatgc 1320
ggcgtggagt actgggtgtt ggctgtggtt ggtatggatt ttctccatta cacaactata 1380
taggatcgct agattgttc ggtcgtccct tacagatgac gcaagtaat ctgtagatg 1440
ccttagcagt tgcgctggtt gtttgtattg gagaggggaa tgagcaaaac ccgttagcgt 1500
tgatagagca ggcacccaat atggtctacc attcatatcc tacttctcga gaagagtatt 1560
gtctttttgc catagatgaa acagaggact tatcggacc ttttttgcga gcggttacgt 1620
ggagtaagaa aaagaaatga tggaggtgtt tatgaatttt ttagatcagt tagatttaat 1680
tattcaaaaat aagcatatgc tagaacacac gttttatgtg aaatggtcga agggggagct 1740
tactaaaggc caattacagc cgtatgccc aaagctattat ttacatatca aagcctttcc 1800
taaaattatg tcttcgattc atagtctgtt cgtatgatta gaggcgcgtg agttattgtt 1860
agataaactg atggatgaag aagacgggta ccctaatacat atcgatttgt ggaagcagtt 1920
tgtgtttgct ctaggagtta ctccagaaga gttagaggct catgagccta gtgaagcagc 1980
aaaagcgaaa gtactactt tcatgcgggtg gttacagga gattctttag ctgcaggagt 2040
ggctgctttg tattcttatg agagtcaaat tccacgtatc gcctc 2085

```

<210> 82

<211> 405

<212> DNA

<213> Chlamydia

<400> 82

```

ttcatcggtc tagttcgcta ttctactctc caatgggtcc gcatattttg gcagagcttc 60
gcaatcattt tgcaacgagt ggtttgaaaa gcgggtacaa tatgtggagt accgatgggt 120
ttctccctgt catcgagcct gttatatggg agtcggaggg tcttttcgcg gcttatattt 180
ctcgggtgac tgatggggat ggtaagagcc ataaagttag atttctaaga attcctacat 240
atagtgtggca ggaatggaa gattttgatc ctccaggacc gctctctgg gaagaattgt 300
attggctcca taaagggagg agaaaacttc gatataggga atcgtatcaa ggtgaaagta 360
gcaaaaaata aattagcttc tccattccga actgcagaat ttgat 405

```

<210> 83

<211> 379

<212> DNA

<213> Chlamydia

<400> 83

tataccattc gtttgaaggt gcccttgacg ggagaaagt tttttgaaga tcaatgcaa 60
 ggtcgtgctg ttttcccttg ggcagatggt gacgatcaag ttttggtaa atcagacggg 120
 ttccctacgt atcacttttg taatgtagtt gatgatcatt tgatgggat taccatgtg 180
 ttgcgagggg aagagtgggt aagtcttaca cctaacaacc ttctcttta caaagctttt 240
 gggggggagc ctccgcagtt ttcccatatg ccgctctctt taaatcctga tggagtaag 300
 ctttccaaga gaagaatcc tacttctatt ttttactatc gggatgctgg atacaaaaa 360
 gaagcgttca tgaattttc 379

<210> 84

<211> 715

<212> DNA

<213> Chlamydia

<400> 84

tcaatcctgt attaataatt ctggttctta gactacataa attaggaacg cctgatgagt 60
 atccataact aatcgcgtag ggcttagaat cactctctcg taccaaagct agaacaacgc 120
 cgccttccat tcttgatgca ataatactcg ctgagactaa gaacatgctc ccagagcttt 180
 tgggtgtgac tgtgaatttt cctatttcag ttccctctaa taaagtttca atgtctctgg 240
 gagtgaataa ccctgtgcat tgaattttat tagtgattgg aaagtgttta aaagctttca 300
 acaaaccttag agaagggtct gttgtgattt tgtctaaaa atcttggact gtactatcaa 360
 caatagatgc agcaattcca ccaagaattt gatctcccaa ctttctaga ataagctggt 420
 aagctttttc cgcattccaaa ccaattgtaa tagaagcatt ggtgatgga ttattggaga 480
 ctgttaaaaga tattccatca gaagctgtca ttttggctgc gacaggtgtt gatgtgtgcc 540
 caaggattat ttgctggtcc ttgagcggct ctgtcatttg cccaactttg atattatcag 600
 caaagacgca gttttgagt ttatacaaat aaaaaccaga atttccatt tcaaaactct 660
 tttttatttt gagctttana taaattaggt ttttagtttc aagtttgcta ttaat 715

<210> 85

<211> 476

<212> DNA

<213> Chlamydia

<400> 85

ctcgtgccgc tctgtccgct cgtgccggtc ttttagaaga cgtgaagct ttaataatt 60
 cgattacgtt tatcatggat aagcgtatatt ggtatagaac cgagtctgaa caggatcaag 120
 tggttttcag agatagtaca gcttgcctag gaggaggcgc tattgcagct caagaattgt 180
 ttctattaca gaacaatcag gctgggattt ccttcgagg aggtgaagct agtttcggag 240
 gaggtattgc gtgtggaatct ttttcttccg caggcgggtc ttctgtttta gggactattg 300
 atatttcgaa gaatttaggc gcgatttcgt tctctcgtac ttatgtacg acctgaagtt 360
 taggacaaat ggagtaccag ggaggaggag ctctatttgg tgaataatt tctctttctg 420
 agaattgctg tgtgctcacc tttaaagaca acattgtgaa gacttttgc tccaat 476

<210> 86

<211> 1551

<212> DNA

<213> Chlamydia

<400> 86

gcgtatcgat atttctctg ttacattctt tatagggatt ctgttggctg ttaatgcgct 60
 aacctactct catgtattac gggattttat tgtgagtat gatgcgctgt tttctcgtaa 120
 cagcgttctg gttcttttag gtttagcttc tagcgtttta gataatgtgc cattagtgcg 180
 tgcacaataa ggtatgtat acttacctat gaacgatcct ctttggaaac tcattgccta 240
 tacagcagcg acagggggaa gtattctcat cattgattcc gctgcagggt ttgcctacat 300

```

gggaatggaa  aagatgagtt  tcggctggta  tgtcaaacac  gctctctgga  ttgcttttagc  360
cagttatttt  ggaggtcctag  cagttctattt  tctaatggaa  aattgtgtga  atttgttcgt  420
ttgagtgagt  cagtagggca  gaggttctttt  aaaaattcttt  ttaataaaaag  ggttctctgc  480
ctattctagg  cccttttttg  aatggaaaaaa  tgggttttttg  gagaacatcg  attatgaaaa  540
tgaataggat  ttggctatta  ctgcttacct  ttctctctgc  catacattct  cctgtacgag  600
gagaaaagctt  ggtttgcaag  aatgctcttc  aagatttgag  ttttttagag  cattttattac  660
aggttaataa  tgcctctaaa  acatggaaaag  agcaataact  aggatgggat  ctctgttcaa  720
ctgcctgttt  tgcacagcag  aagcttcgta  cacaagaaaa  tccatcaaca  agtttttgcc  780
agcaggtctc  tgcgtatttt  atcggaggat  taaatgacct  tcacgtcgga  gtaactttct  840
ttgcgtatga  aagtgcttac  ctctcttata  ccgtacaaaa  aagtagtgac  ggccgtttct  900
actttgtaga  tatcatgact  tttctctcag  agatcogtgt  tggagatgag  ttgctagagg  960
tggatggggc  gcctgtccaa  gatgtgctcg  ctactctata  tggaaagcaat  cacaaaggga  1020
ctgcagctga  agagtcggct  gctttaagaa  cactattttc  tcgcaagccc  tcttagggc  1080
acaaagtacc  ttctgggcgc  actactttaa  agattcgtcg  tctcttttgt  actacgagag  1140
aagttcgtgt  gaaatggcgt  tatgttcctg  aaggtgtag  agatttggtc  accatagctc  1200
ctctcatcag  ggctccacag  ttacagaaat  cgtagagaag  ctcttctcct  aagaaagatc  1260
atgcgtttca  tcggtctagt  tcgctatttc  actctccaat  ggttcgcgat  ggttcggcag  1320
agcttcgcaa  tcattatgca  acgagtggtt  tgaaaagcgg  gtacaatatt  gggagtagcc  1380
atgggtttct  ccctgtcaat  gggcctgtta  tatgggagtc  ggaggggtct  ttcgcgctt  1440
atatcttctc  ggtgactgat  ggggagtgtt  agagccataa  agtaggattt  ctaagaattc  1500
ctacatatag  ttggcaggac  atggaagatt  ttgatctctc  aggaccgcct  c  1551

```

<210> 87
 <211> 3031
 <212> DNA
 <213> Chlamydia

```

<400> 87
atgtaggccc  tcaagcgggt  ttattgttag  accaaattcg  agatctattc  gttgggtcta  60
aagatagtca  ggctgaagga  cagrataggt  taattgtagg  agatccaagt  tctttccaag  120
agaaagatgc  agatactctt  ccgggaagag  tagagcaaa  tactttgttc  tcagtaacca  180
atcccggtgt  ttccaaggt  gtggaccaac  aggatcaagt  ctcttcccaa  gggtaatttt  240
gtagttttac  gagcagcaac  ctgtattctc  ccctgtagcg  agaactcttt  tttaggtatt  300
ctttttgtgg  gगतtagtag  aagcgtggaa  tcacattaac  tgacgtgaaa  gcttctttgt  360
ctggagcgcc  ttatatctct  acagaagatc  ttactcttga  aaagattaa  ggtgatttgg  420
aatttgcatc  atgttctctc  ctagaacagg  ggggagcttg  tgcagctcaa  agttatttga  480
ttcatgtagt  tcaaggattg  caggttaaac  actgtactac  acccgtaat  gctgaggggt  540
ctagtgcgaa  tgatcatctt  ggatttggag  gaggcgcttt  ctttgttacc  ggttctcttt  600
ctggagagaa  aagtctctat  atgcctgcag  gagatatggt  agttgcgaat  tgtgatgggg  660
ctatatcttt  tgaaggaaac  agcgcgaact  ttgctaatcg  aggagcgatt  gctgcctctt  720
ggaaagtgc  ttttgtcgct  aatgataaaa  agactctctt  tataggaac  ctagctttgt  780
ctggaggagc  gattgcagcc  tcttctgata  ttgctttca  aaactgcgca  gaactagttt  840
tcaaaaggcaa  ttgtgcaatt  ggaacagagg  ataaaaggtt  tttaggtaga  ggggctatat  900
ctctctcagg  caccgtctt  ttgcaaggga  atcacgggat  aacttgtgat  aataatgagt  960
ctgcttcgca  aggagcgcc  atttttggca  aaaattgtca  gatttctgac  aacgagggcg  1020
cagtggtttt  cagagatgac  acagcttgct  taggaggagg  cgctatttgc  gctcaagaaa  1080
ttgtttctat  tcagaaacat  caggctggga  ttctcttca  gggaggttaa  gctagtttcg  1140
tggagggat  tgcgtgtgga  tctttttctt  ccgcaggcgg  tgccttgtgt  ttagggacta  1200
ttgatatttc  gaagaattta  ggcgcgattt  taactttctg  tctttatgt  acgacctcag  1260
atttaggaca  aagtgagatc  caggggagg  gagctctatt  ttgtgaaaa  atttctcttt  1320
ctgagaaatc  ttgtgtgctc  accctttaa  acaacattgt  gaagactttt  gcttcgaagt  1380
ggaaaattct  gggaggagg  gcgattttag  ctactggtaa  ggtggaattt  accataaatt  1440
ccggaggaa  ttcttttaca  ggaatgcga  gagcttcaca  agctcttcca  actcaaggag  1500
agtttctctt  attcagcaaa  aaaaaggggc  gaccaacttc  ttcaggatat  tctgggggag  1560
gagcgatttt  aggaagagaa  gtactatttc  tccacaacgc  tgcagtatga  tttagagaaa  1620

```

```

atcgttttgc gtgcagcgaa gaagaagcga cattattagg ttgttgtgga ggagggcgctg 1680
ttcatgggat ggaatagcact tcgattgttg gcaactcttc agtaagattt ggtaataatt 1740
acgcaatggg acaaggagtc tcaggaggag ctcttttatt taaaacagtg cagttagctg 1800
gaataggagg cgtcgatttt tctcgaaata ttgctagttt gggaggagcgc aatgtttctgt 1860
tagcttcaga aacctttgtc tccagagcaa atacatctcc ttcatcgctt cgtcctctat 1920
atttccaaat aacctctacc cctctcaatt gcgctaattt acatcaaatg cttgtctctt 1980
actcgcctac agagaaaacc gctgttatgg agttcttagt gaatggcatg gtgacgagat 2040
taaaatcgga gggcccttcc attcctctcg caaaattgca agtataatg acggaaactaa 2100
gcaatctcca agccttacac tctgtagata gcttttttga tagaataatt gggaaacttg 2160
aaaatagctt aaagcatgaa ggacatgccc ctattccate cttaacgaca ggaattttaa 2220
ctaaaaacct cttacaatta gtagaagata aattcccttc ctctccaaa gctcaaaagg 2280
cattaaatga actggtaggc ccagatactg gtctcaaac tgaagtttta aacttattct 2340
tccgcgctct taatggctgt tcgcttagaa tattctctgg agctgaaaaa aaacagcagc 2400
tggcatcggt tatcacaaat acgtctagat cgtataatgc ggataatgag gattatccta 2460
aaacagggtg cttcccaaga tcttctcttc ctagtacgca tctctatgct ccagtaacct 2520
aatctgagat tccaaactga cctacctcaa cacagcctcc atcaccctaa cttgtaaaaa 2580
ctgtataaaa aagagcgcggt tctctttatg caaaatcaat ttgaacaaat ccttactgaa 2640
ttaggagact aaatcaacag cctcttact cctgattcca ataatgcctg tatagttctgc 2700
tttgatatac acaatgttgc tgtacaaatt gaaggagatg gtaattcagg atttttagtt 2760
gctggagcca tgccttgaaa acttccagag aataccttta gacaaaaaat ttccaagat 2820
gctttgtcta tcaatggatc tccgcaatct aatattaaag gcactctagg atacgggtgaa 2880
atctctaacc aactctatct ctgtgatgg cttaacatga cctatctaaa tggagaaaag 2940
ctcgccggtt acttagttct tttttcgag catgccataa tctggatgca atctatctca 3000
aaaggagaac ttccagattt acatgctcta g
3031

```

<210> 88

<211> 976

<212> DNA

<213> Chlamydia

<400> 88

```

agggtggatgg ggcgcctgtc caagatgtgc tcgctactct atatggaagc aatcacaaag 60
ggactgcagc tgaagagtcg gctgcttttaa gaacactatt tctctcgcatg gcctcttttag 120
ggcacaagaat acctctctgg cgcactactt taaagattcg tctgcttttt ggtactacga 180
gagaagttcg tgtgaaatgg cgttatgttc ctgaaaggtgt aggagatttg gctaccatag 240
ctcctcttat cagggtctcca cagttacaga aatcgatgag aagctttttc cctaagaaga 300
atgatgcggt tcatcggtct agttcgctat tctactctcc aatggtttcg caattttggg 360
cagagctctcg caatcattat gcaacagatg gtttgaaaag cgggtacaat attgggagta 420
ccgatgggtt tctccctgtc attgggcctg ttatatggga gtcggaggggt cttttccgcg 480
cttatatttc ttcggtgact gatgggggatg gtaagagcca taaagttaga tttctaagaa 540
tctctacata tagttggcag gacatggaag attttgatcg ttcaggaccg cctccttggg 600
aagaattttgc taagattatt caagtatttt cttctaatac agaagctttg attatcgacc 660
aaacgaacaa cccaggtgtg agtgtccttt atctttatgc actgcttttc atgttgacag 720
accgctcttt agaactctct aaacatagaa tgattctgac tcaggatgaa gtggtttgat 780
ctttagattg gttaacctcg ttggaaaacg tagacacaaa cgtcgaggtct cgcctttgctc 840
ttggagacaa catgggaagg tatactgtgg attctacagt tcgcgagtat ttaaaaagct 900
ttggagctca agtattgaat tgttggagta aaggggatat cgagttatca acacctatc 960
ctctttttgg ttttga
976

```

<210> 89

<211> 94

<212> PRT

<213> Chlamydia

<400> 89

Met	His	His	His	His	His	His	Met	Ser	Gln	Lys	Asn	Lys	Asn	Ser	Ala
				5					10					15	
Phe	Met	His	Pro	Val	Asn	Ile	Ser	Thr	Asp	Leu	Ala	Val	Ile	Val	Gly
			20					25					30		
Lys	Gly	Pro	Met	Pro	Arg	Thr	Glu	Ile	Val	Lys	Lys	Val	Trp	Glu	Tyr
		35					40					45			
Ile	Lys	Lys	His	Asn	Cys	Gln	Asp	Gln	Lys	Asn	Lys	Arg	Asn	Ile	Leu
		50				55					60				
Pro	Asp	Ala	Asn	Leu	Ala	Lys	Val	Phe	Gly	Ser	Ser	Asp	Pro	Ile	Asp
		65			70					75					80
Met	Phe	Gln	Met	Thr	Lys	Ala	Leu	Ser	Lys	His	Ile	Val	Lys		
			85					90							

```
<210> 90
<211> 474
<212> PRT
<213> Chlamydia
```

<400> 90																	
Met	Ala	Ser	His	His	His	His	His	His	Met	Asn	Glu	Ala	Phe	Asp	Cys		
			5						10			15					
Val	Val	Ile	Gly	Ala	Gly	Pro	Gly	Gly	Tyr	Val	Ala	Ala	Ile	Thr	Ala		
			20						25			30					
Ala	Gln	Ala	Gly	Leu	Lys	Thr	Ala	Leu	Ile	Glu	Lys	Arg	Glu	Ala	Gly		
			35						40			45					
Gly	Thr	Cys	Leu	Asn	Arg	Gly	Cys	Ile	Pro	Ser	Lys	Ala	Leu	Leu	Ala		
			50						55			60					
Gly	Ala	Glu	Val	Val	Thr	Gln	Ile	Arg	His	Ala	Asp	Gln	Phe	Gly	Ile		
			65						70			75			80		
His	Val	Glu	Gly	Phe	Ser	Ile	Asn	Tyr	Pro	Ala	Met	Val	Gln	Arg	Lys		
			85						90			95					
Asp	Ser	Val	Val	Arg	Ser	Ile	Arg	Asp	Gly	Leu	Asn	Gly	Leu	Ile	Arg		
			100						105			110					
Ser	Asn	Lys	Ile	Thr	Val	Phe	Ser	Gly	Arg	Gly	Ser	Leu	Ile	Ser	Ser		
			115						120			125					
Thr	Glu	Val	Lys	Ile	Leu	Gly	Glu	Asn	Pro	Ser	Val	Ile	Lys	Ala	His		
			130						135			140					
Ser	Ile	Ile	Leu	Ala	Thr	Gly	Ser	Glu	Pro	Arg	Ala	Phe	Pro	Gly	Ile		
			145						150			155			160		

Pro Phe Ser Ala Glu Ser Pro Arg Ile Leu Cys Ser Thr Gly Val Leu
 165 170 175
 Asn Leu Lys Glu Ile Pro Gln Lys Met Ala Ile Ile Gly Gly Gly Val
 180 185 190
 Ile Gly Cys Glu Phe Ala Ser Leu Phe His Thr Leu Gly Ser Glu Val
 195 200 205
 Ser Val Ile Glu Ala Ser Ser Gln Ile Leu Ala Leu Asn Asn Pro Asp
 210 215 220
 Ile Ser Lys Thr Met Phe Asp Lys Phe Thr Arg Gln Gly Leu Arg Phe
 225 230 235 240
 Val Leu Glu Ala Ser Val Ser Asn Ile Glu Asp Ile Gly Asp Arg Val
 245 250 255
 Arg Leu Thr Ile Asn Gly Asn Val Glu Glu Tyr Asp Tyr Val Leu Val
 260 265 270
 Ser Ile Gly Arg Arg Leu Asn Thr Glu Asn Ile Gly Leu Asp Lys Ala
 275 280 285
 Gly Val Ile Cys Asp Glu Arg Gly Val Ile Pro Thr Asp Ala Thr Met
 290 295 300
 Arg Thr Asn Val Pro Asn Ile Tyr Ala Ile Gly Asp Ile Thr Gly Lys
 305 310 315 320
 Trp Gln Leu Ala His Val Ala Ser His Gln Gly Ile Ile Ala Ala Arg
 325 330 335
 Asn Ile Gly Gly His Lys Glu Glu Ile Asp Tyr Ser Ala Val Pro Ser
 340 345 350
 Val Ile Phe Thr Phe Pro Glu Val Ala Ser Val Gly Leu Ser Pro Thr
 355 360 365
 Ala Ala Gln Gln Gln Lys Ile Pro Val Lys Val Thr Lys Phe Pro Phe
 370 375 380
 Arg Ala Ile Gly Lys Ala Val Ala Met Gly Glu Ala Asp Gly Phe Ala
 385 390 395 400
 Ala Ile Ile Ser His Glu Thr Thr Gln Gln Ile Leu Gly Ala Tyr Val
 405 410 415
 Ile Gly Pro His Ala Ser Ser Leu Ile Ser Glu Ile Thr Leu Ala Val
 420 425 430
 Arg Asn Glu Leu Thr Leu Pro Cys Ile Tyr Glu Thr Ile His Ala His
 435 440 445
 Pro Thr Leu Ala Glu Val Trp Ala Glu Ser Ala Leu Leu Ala Val Asp

```

450
Thr Pro Leu His Met Pro Pro Ala Lys Lys
465
470
<210> 91
<211> 129
<212> PRT
<213> Chlamydia
<400> 91
Met His His His His His Met Pro Arg Ile Ile Gly Ile Asp Ile
5 10 15
Pro Ala Lys Lys Lys Leu Lys Ile Ser Leu Thr Tyr Ile Tyr Gly Ile
20 25 30
Glu Ser Ala Arg Ser Asp Glu Ile Ile Lys Lys Leu Lys Leu Asp Pro
35 40 45
Glu Ala Arg Ala Ser Glu Leu Thr Glu Glu Glu Val Gly Arg Leu Asn
50 55 60
Ser Leu Leu Gln Ser Glu Tyr Thr Val Glu Gly Asp Leu Arg Arg Arg
65 70 75 80
Val Gln Ser Asp Ile Lys Arg Leu Ile Ala Ile His Ser Tyr Arg Gly
85 90 95
Gln Arg His Arg Leu Ser Leu Pro Val Arg Gly Gln Arg Thr Lys Thr
100 105 110
Asn Ser Arg Thr Arg Lys Gly Lys Arg Lys Thr Val Ala Gly Lys Lys
115 120 125

```

Lys

```
<210> 92  
<211> 202  
<212> FRT  
<213> Chlamydia  
  
<400> 92  
Met His His His His His Met Gly Ser Leu Val Gly Arg Gln Ala  
                    5                      10                      15  
Pro Asp Phe Ser Gly Lys Ala Val Val Cys Gly Glu Glu Lys Glu Ile  
                20                  25                  30  
Ser Leu Ala Asp Phe Arg Gly Lys Tyr Val Val Leu Phe Phe Tyr Pro  
    35              40              45
```

Lys Asp Phe Thr Tyr Val Cys Pro Thr Glu Leu His Ala Phe Gln Asp
 50 55 60
 Arg Leu Val Asp Phe Glu Glu His Gly Ala Val Leu Leu Gly Cys Ser
 65 70 75 80
 Val Asp Asp Ile Glu Thr His Ser Arg Trp Leu Thr Val Ala Arg Asp
 85 90 95
 Ala Gly Gly Ile Glu Gly Thr Glu Tyr Pro Leu Leu Ala Asp Pro Ser
 100 105 110
 Phe Lys Ile Ser Glu Ala Phe Gly Val Leu Asn Pro Glu Gly Ser Leu
 115 120 125
 Ala Leu Arg Ala Thr Phe Leu Ile Asp Lys His Gly Val Ile Arg His
 130 135 140
 Ala Val Ile Asn Asp Leu Pro Leu Gly Arg Ser Ile Asp Glu Glu Leu
 145 150 155 160
 Arg Ile Leu Asp Ser Leu Ile Phe Phe Glu Asn His Gly Met Val Cys
 165 170 175
 Pro Ala Asn Trp Arg Ser Gly Glu Arg Gly Met Val Pro Ser Glu Glu
 180 185 190
 Gly Leu Lys Glu Tyr Phe Gln Thr Met Asp
 195 200

<210> 93
 <211> 19
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> made in a lab

<400> 93
 Glu Asn Ser Leu Gln Asp Pro Thr Asn Lys Arg Asn Ile Asn Pro Asp
 1 5 10 15
 Asp Lys Leu

<210> 94
 <211> 20
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Made in a lab

<400> 94

Asp Pro Thr Asn Lys Arg Asn Ile Asn Pro Asp Asp Lys Leu Ala Lys
1 5 10 15
Val Phe Gly Thr
20

<210> 95
<211> 20
<212> PRT
<213> Artificial Sequence

<220>
<223> Made in a lab

<400> 95
Lys Arg Asn Ile Asn Pro Asp Asp Lys Leu Ala Lys Val Phe Gly Thr
1 5 10 15
Glu Lys Pro Ile
20

<210> 96
<211> 20
<212> PRT
<213> Artificial Sequence

<220>
<223> Made in a lab

<400> 96
Asp Asp Lys Leu Ala Lys Val Phe Gly Thr Glu Lys Pro Ile Asp Met
1 5 10 15
Phe Gln Met Thr
20

<210> 97
<211> 20
<212> PRT
<213> Artificial Sequence

<220>
<223> Made in a lab

<400> 97
Lys Val Phe Gly Thr Glu Lys Pro Ile Asp Met Phe Gln Met Thr Lys
1 5 10 15
Met Val Ser Gln
20

<210> 98
<211> 20
<212> PRT
<213> Artificial Sequence

<220>
<223> Made in a lab

<400> 98

Asn	Lys	Arg	Asn	Ile	Asn	Pro	Asp	Asp	Lys	Leu	Ala	Lys	Val	Phe	Gly
1				5					10					15	
Thr	Glu	Lys	Pro												
				20											

<210> 99

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> Made in a lab

<400> 99

Asn	Lys	Arg	Asn	Ile	Leu	Pro	Asp	Ala	Asn	Leu	Ala	Lys	Val	Phe	Gly
1				5					10					15	

<210> 100

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> Made in a lab

<400> 100

Lys	Met	Trp	Asp	Tyr	Ile	Lys	Glu	Asn	Ser	Leu	Gln	Asp	Pro	Thr
1				5					10					15

<210> 101

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> Made in a lab

<400> 101

Thr	Glu	Ile	Val	Lys	Lys	Val	Trp	Glu	Tyr	Ile	Lys	Lys	His	Asn	Cys
1				5					10					15	
Gln	Asp	Gln	Lys												
				20											

<210> 102

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> Made in a lab

<400> 102

Lys	Val	Trp	Glu	Tyr	Ile	Lys	Lys	His	Asn	Cys	Gln	Asp	Gln	Lys	Asn
1					5					10				15	

Lys Arg Asn Ile
20

<210> 103
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> Made in a lab

<400> 103
Lys Val Trp Glu Tyr Ile Lys Lys His Asn Cys Gln Asp Gln Lys
1 5 10 15

<210> 104
<211> 20
<212> PRT
<213> Artificial Sequence

<220>
<223> Made in a lab

<400> 104
Ala Glu Leu Thr Glu Glu Glu Val Gly Arg Leu Asn Ala Leu Leu Gln
1 5 10 15
Ser Asp Tyr Val
20

<210> 105
<211> 21
<212> PRT
<213> Artificial Sequence

<220>
<223> Made in a lab

<400> 105
Leu Gln Ser Asp Tyr Val Val Glu Gly Asp Leu Arg Arg Arg Val Gln
1 5 10 15
Ser Asp Ile Lys Arg
20

<210> 106
<211> 20
<212> PRT
<213> Artificial Sequence

<220>
<223> Made in a lab

<400> 106
Met Pro Arg Ile Ile Gly Ile Asp Ile Pro Ala Lys Lys Lys Leu Lys
1 5 10 15
Ile Ser Leu Thr

20

<210> 107
 <211> 20
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Made in a lab

<400> 107
 Ala Glu Leu Thr Glu Glu Val Gly Arg Leu Asn Ala Leu Leu Gln
 1 5 10 15
 Ser Asp Tyr Val
 20

<210> 108
 <211> 20
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Made in a lab

<400> 108
 Leu Asn Ala Leu Leu Gln Ser Asp Tyr Val Val Glu Gly Asp Leu Arg
 1 5 10 15
 Arg Arg Val Gln
 20

<210> 109
 <211> 20
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Made in a lab

<400> 109
 Leu Asn Ser Leu Leu Gln Ser Glu Tyr Thr Val Glu Gly Asp Leu Arg
 1 5 10 15
 Arg Arg Val Gln
 20

<210> 110
 <211> 1461
 <212> DNA
 <213> Chlamydia

<400> 110
 ctatctatga agttatgaat atggatctag aaacacgaag atcttttgcg gtacagcaag 60
 ggcactatca ggacccaaga gcttcagatt atgacctccc acgtgctagc gactatgatt 120
 tgcctagaag cccatatcct actccacctt tgccttctag atatcagcta cagaatatgg 180
 atgtagaagc aggggtccgt gaggcagttt atgcttcttt ttagtcagga atgtacaatt 240
 atgtagtgc acagccgcaa gagcgtattc ccaatagtc gcaggtggaa gggattctgc 300

```

gtgatatgct  taccacacggg  tcacagacat  ttgcaacct  gatgcagcgt  tgggatagag  360
aagtcgatag  ggaataaact  ggtatctacc  ataggtttgt  atcaaaaaac  taagcccacc  420
aagaaagaat  tctcttttgt  gggcttcttt  ttttatccaa  aaaagaaagc  cctcttcaag  480
attatctcgt  gccgctcgtg  ccgaattcgg  cagcagcgcc  acgaggagct  gtaagtaagt  540
attgccaaag  gttggaagaa  aaaatattag  atttgttaa  gcgtcatgcc  gcaacaattt  600
gctccattga  ggaggatgct  aacaagaaga  ttcgtcatca  gacagaaagg  ttaaacacgc  660
ggttgcaca  aaatcagaac  acttcagtc  aattaacagc  agagtgtgt  aaattgagat  720
ctgagaataa  ggcattatcg  gagcggctgc  aggtgcaggc  atcccgtcgt  aaaaaataat  780
taaagactcc  tcagatattg  catctgagag  ttagggggtc  cttttgccta  cgccgcttta  840
gttctgcatt  ttgcggattt  atagtattt  gcgagtaaa  cgccgttcgt  atacagtatt  900
tcgccttaa  aataaaaaag  gtgaaaaaat  gagtactact  attagcggag  acgcttcttc  960
ttaccgctg  ccaacagctt  cctgcgtaga  gacaaaatct  acttcgtctt  caacaaaagg  1020
gaataactgt  tccaaaattt  tggatatagc  tttagctatc  gtaggcgctt  tagtttgtgt  1080
cgctggggta  tttagcttgg  ttttgtgcgc  tagcaatgct  atatttactg  taataggat  1140
tcctgcatta  attattggat  ctgcttgtgt  gggtcgggga  atatctcgtc  ttatgtatcg  1200
atctcttat  ctgactctag  aagcaaaaa  tgttttgtct  gagcaacgtt  tgcgtaacct  1260
ttcagaagg  aeggaacgct  ttgctcctg  ctctttcatt  aataagatgt  ttctgcgagg  1320
tcttacggac  gatctccaag  ctttggaagc  taaggtaatg  gaatttgaga  ttgattgttt  1380
ggacagatta  gagaaaaatg  agcaagcttt  attgtccgat  gtgcgcttag  ttttatctag  1440
ctacacaaga  tggttggata  g

```

<210> 111

<211> 267

<212> DNA

<213> Chlamydia

<400> 111

```

gtctctttct  tattatagca  gaagacattg  aaggcgaagc  tttagctact  ttggctcgtg  60
acagaattcg  tggaggattc  cgggttttgc  cagttaaaag  tccaggcttt  ggagatagaa  120
gaaaaagctat  gttggaagac  atcgctatct  taactggcgg  tcaactcatt  agcgaagagt  180
tgggcattgaa  attagaaaa  gctaacttag  ctatgttagg  taaagctaaa  aaagtattcg  240
tttctaaga  agacacgacc  atcgctgc

```

<210> 112

<211> 698

<212> DNA

<213> Chlamydia

<400> 112

```

tgataagcaa  gcaaccgctc  aactagcagc  tctaactatt  aaaaaaatcc  tctgttttga  60
tgaaaattcc  tacgagaagg  agctggcatg  cttagaaaaa  aaacgcagta  gcgtacaaaa  120
agatctgagc  caactgaaaa  aatacacagt  tctctacatc  aagaagctgc  tcgaaaccta  180
cagacaactc  gggcatcgaa  agacaaaaat  tgcaaaaatt  gatgacctac  acccagagat  240
agtctccgct  cataagaagg  caaaagaact  cgctcgctgc  gatcaagaag  agaacttcta  300
aaacgtgact  cggcccttga  gatccttaaa  ctctcgggac  aaaaagacta  cagctcttct  360
gagaagaaaa  acggtgttag  aaaataacgc  cgctaagact  ttctctaaca  atgactcaaa  420
aagctgtaaa  cgtatcagtt  taccgctctt  ccataatttc  taggctgact  ttcacattat  480
ctcgactcgc  tacggaaccc  aataaagtac  ggatagcctt  aatagtcgct  cctcttttac  540
cgataatttt  accgatatct  cccttagcaa  cagtcatttc  gtatagataac  gtattggttc  600
cctgcaccct  tttcagatgc  acttctctct  gcttatcaac  aagatttttt  acaatgtacg  660
ctaaaaactc  tttctgcgga  agcaaatctt  acacaagc

```

<210> 113

<211> 1142

<212> DNA

<213> Chlamydia

<400> 113

```

ctcttcaaaag attgtgaggt tatgtgaagg cgtctgcgt gatgcaagaa tgtgcaaaagc 60
agagttgata aaaaaaaga cggatgctta ttgttttgt gaaaaagcg ggatatactct 120
aacgaaaaaa gaaggtatatt tgattccttc tgcagggaatt gatgaatcga atacggacca 180
gccttttgtt ttatatccta aagataatttt gggatcgtgt aatcgatcg gagaatgggt 240
aagaaattat ttctgagtg aagagctagg cgtaatcatt acagatagcc atactactcc 300
aatgcggcgt ggagtactcg gtatcgggct gtgttggtat ggattttctc cattacacaa 360
ctatatagga tcgctagatt gtttcgggtc gcccttacag atgacgcaaa gtaactcttgt 420
agatgcccta gcagttgcgg ctgttgtttg tatgggagag ggaatgagc aaacacgggt 480
agcgggtgata gcagggcac ctaatatggg ctaccattca tatcctact ctcgagaaga 540
gtattgtctt ttgcgcatag atgaacacaga ggaactatcc ggaccttttt tgcaagcgggt 600
tacgtggagt caagaaaaa aatgatggag gtgtttatga attttttaga tcagttagat 660
ttaattattc aaaaataagca tatgctagaa cacacgtttt atgtgaaatg gtcgaagggt 720
gagcttacta aagagcaatt acaggcgat gccaagaact attatttaca tatcaaaagg 780
tttcccaaat atttactcgc gattcatagt cgttgcgatg atttagaggc gcgtaagtta 840
ttgttagata acctgatgga tgaagagpac ggttacccta atcatattga ttgttggaag 900
cagtttgtgt ttgcctcagg agttactcca gaagagttag aggtcatga gccagtga 960
gcagcaaaa cgaagtagtc tactttcatg cgggtgggta caggagatcc tttagctgca 1020
ggagtggcgt ctttgtatcc ttatgagagt caaattccac gtatcgtag agagaaaatt 1080
cgtggattga ctgagtactt tggattttcc aatcctgaag actatgcata ttccacagaa 1140
ca 1142

```

<210> 114

<211> 976

<212> DNA

<213> Chlamydia

<400> 114

```

aggtggatgg ggcgcctgtc caagatgtgc tcgctactct atatggaagc aatcacaaag 60
ggactgcagc tgaagagtcg gctgctttaa gaacactatt ctctgcagc gccctcttag 120
ggcacaaaat acctctctgg cgcactactt taagatttcg tcgtctcttt ggtactacga 180
gagaagttcg tgtgaaatgg cgttatgttc ctgaagggtg aggagatttg gctaccatag 240
ctccttctat cagggtccca cagttacaga aatcgatgag aagctttttc cctaagaaag 300
atgatgcggt tcacggtctc agttcgctat tctactctcc aatggtctcg catttttggg 360
cagagcttcg caatcattat gcaacgagtg gtttgaaaag cgggtacaat attgggagta 420
ccgattgggt tctccctgtc attgggctcg ttatatggga gtcggagggt ctttctccgg 480
cttatatttc tccgggtgact gatgggagtg taaagagcca taaagttaga ttctaaagaa 540
ttctacata tagttggcag gacatggaag attttgatcc ttcaggaccg cctccttggg 600
aagaatttgc taagattatt caagtatttt ctctaatc agaaactttg attatcgacc 660
aaacgaacaa cccagttgtg agtgcctttt atcttatgac actgctttcc atgttgacag 720
accgtccttt agaacttctc aaacatagaa tgattctgac ctgagtgaa gtcggttgatg 780
cttttagatt gttaaccttg ttggaaaacg tagacacaaa cgtggagctc cgccttgctc 840
tgggagacaa catggaagga tatactgtgg atctacaggt tgcgagatg ttaaaaaagt 900
ttggacgtca agtatggaat tgttggagta aaggggatat cgagttatca acacctatct 960
ctctttttgg ttttga 976

```

<210> 115

<211> 995

<212> DNA

<213> Chlamydia

<400> 115

```

ttatcctaga aatttggtgt tcaatatgag cgaaaaaaga aagtctaaca aaattattgg 60

```

```

tatcgaccta gggacgacca actcttgctt ctcgtttatg gaaggtggcc aacctaaagt 120
tattgctctt tctgaaggaa ctgcgtactac tctctctatc gttgctttta aaggtggcga 180
aactctctgtt ggaattctctg caaaacgtca ggcagtaacc aatctgaaa aaacattggc 240
ttctactaag cgattcatcg gtatgaaatt cctcgaagtc gaattctgaaa ttaaaacagt 300
ccctacaaaa gttgctccta actcgaaagg agatcggttc tttgatgtgg aacaaaaact 360
gtacactcca gaagaaatcg gcgctcagat cctcatgaag atgaaggaaa ctgctgaggg 420
ttatctcggg gaaacagtaa cggaaagcagt cattaccgta ccagcttact ttaacgattc 480
tcaaagagct tctacaaaag atgctggacg tatcgcagga tttagatgta aacgcattat 540
tcttgaaacca acagcgcccg ctcttgctta tggatttgat aaggaaaggag ataaaaaat 600
cgcgctcttc gacttaggag gaggaacttt cgatatttct atcttggaaa tcggtgacgg 660
agtttttgaa gttctctcaa ccaacgggga tactcacttg ggaggagacg acttcgacgg 720
agtcacatc aactggatgc ttgatgaatt caaaaaacaa gaaggcattg atcttaagcaa 780
agataacatg gctttgcaaa gattgaaaga tgctgctgaa aaagcaaaaa tagaattgtc 840
tggtgtatcg tctactgaaa tcaatcagcc attcatcact atcgacgcta atggacctaa 900
acatttggtt ttaactctaa ctgcgctca attcgaacac ctagcttctt ctctcattga 960
ggaacacaaa caactcttg gtcaggcttt aaag 995

```

<210> 116

<211> 437

<212> DNA

<213> Chlamydia

<400> 116

```

gtcacagcta aaggcggtgg gctttatct gataagaatc ttcgattac taacatcaca 60
gggaattatcg aaattgcaaa taacaaagcg acagatgttg gaggtgtgct ctacgtaaaa 120
gggaacctta cttgtaaaaa ctctcacctg ctacaatttt tgaaaaaact ttcgataaaa 180
caaggtggag gaattctacg agaagacac atcacctat ctattctgac agggaaagac 240
ctattccaag agaatactgc caaaaaagag ggcggtggac tcttcataaa aggtcacagt 300
aaagctctta caatgcacgg actggatag ttctgtttaa ttaataacac atcagaaaaa 360
catggttggt gagcctttgt taccaaagaa atctctcaga ctacacctc tgatgtggaa 420
acaattccag gaatcac 437

```

<210> 117

<211> 446

<212> DNA

<213> Chlamydia

<400> 117

```

aagtttacct agaccaaact gaagatgacg aaggaaaagt tgttttatcc agagaaaaag 60
caacaagaca acgacaatgg gaatacattc ttgctcactg cgaggaaagt tctattgtta 120
agggacaaat tacccgaaaa gtttaagggtg gtttgatcgt agatattgg atggaagcct 180
tctctccagg atcccaataa gacaataaga agatcaagaa cttagatgat tacgtaggca 240
aggtttgtga gttcaaaatt ctcaaaatca actggatcg tcggaacggt gttgtatcta 300
gaagagaact tctcgaagct gaacgcattt ctaagaaagc agatgtgat gagcaaatca 360
ctatcggtga acgtcgcaaa ggtatcgtaa agaatacac agatttcgga gtattctctg 420
attctgatgg cattgacggc ctactc 446

```

<210> 118

<211> 951

<212> DNA

<213> Chlamydia

<400> 118

```

agtattgcga aatattactg tgagaagcaa tgctgagacg ggttctagta aaagtgaagg 60
gagagctgtc agaaggatc gctcaggaag cgagacaacg tgtggtgat ttattaggaa 120

```

```

gattccctct tttacctgaa atcgatctgg aaacgctagt ttagtgggag actctatgcc 180
tgaaggggaa atgatgcata agttgcaaga tgcctatgat agaaagtgtg tggattctcg 240
tcgtattttc ttctccgaac ctgtaacgga gaaaagtgtc gcagaagcca tcaaaaagct 300
ttggattttg gaactcacca atctcgggca gccaaattgta ttgtcattta atagccctcg 360
agggctctgt gatgctgggt ttgctgtttg ggaccaaaatt aaaatgatct ctctcctctt 420
gactacagtt gttacaggtt tagcagcatc tatgggagct gtattgagtt ttgtgtctgt 480
tccaggaaaga cgttttgcta cgcctcatgc gcgcattatg attcaccagc ctctctattg 540
aggaaccatt actggctcaag ccacggactt ggatattcat gctcgtgaaa ttttaaaac 600
aaaagcacgc attattgatg tgtatgtcga ggcacactgga caatctccag aggtgataga 660
gaaagctatc gatcgagata tgtggatgag tgcaaatgaa gcaatggagt ttggactgtt 720
agatggggatt ctctctctt ttaacgactt gtatagatct tttatattct ggagcaggaa 780
acagtttcat ttgggggaa tcatgacctt ctcttgagga tgttctgttt ttatgccagg 840
aagagatggg tgatgggttt ttatgtgtag agtctcttga aatagcagat gctaaacctca 900
ctgtctttaa tagtgatgga tctatcgctt ctatgtcgcg gaatgggtgt c 951

```

<210> 119

<211> 953

<212> DNA

<213> Chlamydia

<400> 119

```

atatcaaaagt tgggcaaatg acagagccgc tcaaggacca gcaataatc ctggggacaa 60
catcaacacc tgtcgcagcc aaaatgacag ctctcgatgg aatatcttta acagtctcca 120
ataatccatc aaccaatgct tctattacaa ttggtttgga tgcggaaaaa gcttaccagc 180
ttattctaga aaagtgggga gatcaaatc ttggtggaat tgctgatact attgttgata 240
gtcactgccaa agatatttta gacaaaaatca caacagaccc ttctctaggt ttgttgaaag 300
cttttaacaa ctttccaatc actaataaaa ttcaatgcaa cgggttattc actcccagga 360
acattgaaac ttatattagga ggaactgaaa taggaaaaat cacagtcaaa cccaaaagct 420
ctgggagcat gttctctatc tcagcagata ttattgcata aagaatggaa ggccggcttg 480
ttctagcttt ggtacgagaa ggtgattcta agccctacgc gattagttat ggatactcat 540
caggcgcttc taatttatgt agtctaagaa ccagaattat taatacagga ttgactccga 600
caacgtatc attacgtgta ggcgggttag aaagcgggtg ggtatgggtt aatgcctctt 660
ctaattggcaa tgatatttta ggaataacaa atacttctaa tgtatcttt ttggaggtaa 720
tcactcaaac aaacgcttaa acaattttta ttggattttt ctatagctt ttatatttag 780
agaaaaaagt tcgaattacg ggggtttgta tgcaaaaaaa aagcaaaagt agggacgatt 840
ttattaaaat tgttaaagat tcttggatc ggtctgcgat tccgactcgt ccaactcaaa 900
tacaacctat taatttcccc tcgtcaaaaa taagggtatc aagtggagaa tca 953

```

<210> 120

<211> 897

<212> DNA

<213> Chlamydia

<400> 120

```

atggctctta tatcgcgagc tttagggctc ggtacaggga atgctctaaa agcttttttt 60
acacagccca gcaataaaat ggcaagggtta gtaaataga cgaagggaat ggataagact 120
gttaaggtcg ccaagtctgc tgcgcaattg accgcaata tttggaaaca agctggaggc 180
gcgggctctt ccgcacacat tacagcttcc caagtgtcca aaggattagg ggaatcgaga 240
actgtttctg cttaggggaa tgcctttaac ggagcgttgc caggaaacgt tcaaaagtgc 300
caaagctctt tctcttacct gaaagctgct agtcagaaac cgcaagaagg ggaatgaggg 360
ctcgtagcac atcttttgtt gtctcataag cgcanaagcg ctgcggctgt ctgtagcttc 420
atcggaggaa ttacctacct ccgcacattc ggcagctacc tccgactctt gtttgtcaac 480
aaaatctcgg ccgaaccggt tctttctccc caaattaaag caaatatggg atctctgttt 540
agctatatta tggcggctta ccatgcagcg ttgtgtgtgg gttctggact cgctatcagt 600

```

```

gcggaagag cagattgcga agcccgtgc gctcgtattg cgagagaaga gtcgtcactc 660
gaattgtcgg gagaggaaaa tgcttgcgag agggagagtcg ctggagagaa agccaagacg 720
ttcacgcgca tcaagtatgc actcctcact atgctcgaga agtttttggg atgcgttgcc 780
gacgttttca aattggtgcc gttgcctatt acaatgggta ttctgccaat tgtggctgcg 840
ggatgtacgt tcactctctg agttattgga ttgtggactt tctgcgccag agcataa 897

```

<210> 121
 <211> 298
 <212> PRT
 <213> Chlamydia

```

<400> 121
Met Ala Ser Ile Cys Gly Arg Leu Gly Ser Gly Thr Gly Asn Ala Leu
1      5      10      15
Lys Ala Phe Phe Thr Gln Pro Ser Asn Lys Met Ala Arg Val Val Asn
20     25     30
Lys Thr Lys Gly Met Asp Lys Thr Val Lys Val Ala Lys Ser Ala Ala
35     40     45
Glu Leu Thr Ala Asn Ile Leu Glu Gln Ala Gly Gly Ala Gly Ser Ser
50     55     60
Ala His Ile Thr Ala Ser Gln Val Ser Lys Gly Leu Gly Asp Ala Arg
65     70     75     80
Thr Val Leu Ala Leu Gly Asn Ala Phe Asn Gly Ala Leu Pro Gly Thr
85     90     95
Val Gln Ser Ala Gln Ser Phe Phe Ser Tyr Met Lys Ala Ala Ser Gln
100    105    110
Lys Pro Gln Glu Gly Asp Glu Gly Leu Val Ala Asp Leu Cys Val Ser
115    120    125
His Lys Arg Arg Ala Ala Ala Ala Val Cys Ser Phe Ile Gly Gly Ile
130    135    140
Thr Tyr Leu Ala Thr Phe Gly Ala Ile Arg Pro Ile Leu Phe Val Asn
145    150    155    160
Lys Met Leu Ala Gln Pro Phe Leu Ser Ser Gln Ile Lys Ala Asn Met
165    170    175
Gly Ser Ser Val Ser Tyr Ile Met Ala Ala Asn His Ala Ala Phe Val
180    185    190
Val Gly Ser Gly Leu Ala Ile Ser Ala Glu Arg Ala Asp Cys Glu Ala
195    200    205
Arg Cys Ala Arg Ile Ala Arg Glu Glu Ser Ser Leu Glu Leu Ser Gly
210    215    220
Glu Glu Asn Ala Cys Glu Arg Arg Val Ala Gly Glu Lys Ala Lys Thr
225    230    235    240
Phe Thr Arg Ile Lys Tyr Ala Leu Leu Thr Met Leu Glu Lys Phe Leu
245    250    255
Glu Cys Val Ala Asp Val Phe Lys Leu Val Pro Leu Pro Ile Thr Met
260    265    270
Gly Ile Arg Ala Ile Val Ala Ala Gly Cys Thr Phe Thr Ser Ala Val
275    280    285
Ile Gly Leu Trp Thr Phe Cys Ala Arg Ala
290    295

```

<210> 122
 <211> 897
 <212> DNA
 <213> Chlamydia

<400> 122

atggtctcta	tatgcggaag	tttaggggtct	ggtagagggga	atgctctaaa	agcttttttt	60
acacagccca	gcaataaaat	ggcaagggtta	gtaataaaga	cgaaggggaat	ggataagact	120
gttaaggctcg	ccaagctctgc	tgccgaattg	accgcaaata	ttttggaaca	agctgggagc	180
cggggctctt	ccgcacacat	tacagcttcc	caagtgtcca	aaggattagg	ggatcacgaga	240
actgttctgc	ctttagggaat	tgcttttaac	ggagcgttgc	caggaacagt	tcaaagtgcg	300
caaagcttct	tctctcacat	gaaagctgct	agtcaaaaaa	cgcaagaagg	ggatgagggg	360
ctcacagcag	atctttgtgt	gtctcataag	cgcagagcgg	ctgcggctgt	ctgtggcttc	420
atcggaggaa	ttacctacct	cgcacattc	ggagttatcc	gtccgattct	gtttgtcaac	480
aaaaagctgg	tgaaccogtt	tctttcttcc	caaaactaaa	caaatatggg	atctcttgtt	540
agctatatta	tggcggctaa	ccatgcagcg	tctgtggtgg	gtgctggact	cgctatcagt	600
gcgaaaagag	cagattgcga	agcccgctgc	gctcgtattg	cgagagaaga	gtcgttactc	660
gaagtgtcgg	gagaggaanaa	tgcttgcgag	aagagagctg	ctggagagaa	agccaagacg	720
ttcacgcgca	tcaagtatgc	actctcact	atgctcgaga	agtttttgga	atgcgttgc	780
gacgttttca	aattgggtcc	gctgcctatt	acaatgggta	ttcgtgcgat	tgtggctgct	840
ggatgtacgt	tcactttctgc	aattattgga	ttgtgcactt	tctgcgcag	agcataa	897

<210> 123

<211> 298

<212> PRT

<213> Chlamydia

<400> 123

Met	Ala	Ser	Ile	Cys	Gly	Arg	Leu	Gly	Ser	Gly	Thr	Gly	Asn	Ala	Leu
1			5						10					15	
Lys	Ala	Phe	Phe	Thr	Gln	Pro	Ser	Asn	Lys	Met	Ala	Arg	Val	Val	Asn
			20					25					30		
Lys	Thr	Lys	Gly	Met	Asp	Lys	Thr	Val	Lys	Val	Ala	Lys	Ser	Ala	Ala
			35				40					45			
Glu	Leu	Thr	Ala	Asn	Ile	Leu	Glu	Gln	Ala	Gly	Gly	Ala	Gly	Ser	Ser
	50				55						60				
Ala	His	Ile	Thr	Ala	Ser	Gln	Val	Ser	Lys	Gly	Leu	Gly	Asp	Thr	Arg
65					70				75					80	
Thr	Val	Val	Ala	Leu	Gly	Asn	Ala	Phe	Asn	Gly	Ala	Leu	Pro	Gly	Thr
				85					90				95		
Val	Gln	Ser	Ala	Gln	Ser	Phe	Phe	Ser	His	Met	Lys	Ala	Ala	Ser	Gln
			100					105				110			
Lys	Thr	Gln	Glu	Gly	Asp	Glu	Gly	Leu	Thr	Ala	Asp	Leu	Cys	Val	Ser
			115				120				125				
His	Lys	Arg	Arg	Ala	Ala	Ala	Ala	Val	Cys	Gly	Phe	Ile	Gly	Gly	Ile
	130				135					140					
Thr	Tyr	Leu	Ala	Thr	Phe	Gly	Val	Ile	Arg	Pro	Ile	Leu	Phe	Val	Asn
145				150					155					160	
Lys	Met	Leu	Val	Asn	Pro	Phe	Leu	Ser	Ser	Gln	Thr	Lys	Ala	Asn	Met
				165					170				175		
Gly	Ser	Ser	Val	Ser	Tyr	Ile	Met	Ala	Ala	Asn	His	Ala	Ala	Ser	Val
			180				185					190			
Val	Gly	Ala	Gly	Leu	Ala	Ile	Ser	Ala	Glu	Arg	Ala	Asp	Cys	Glu	Ala
	195						200				205				
Arg	Cys	Ala	Arg	Ile	Ala	Arg	Glu	Glu	Ser	Leu	Leu	Glu	Val	Ser	Gly
	210				215						220				
Glu	Glu	Asn	Ala	Cys	Glu	Lys	Arg	Val	Ala	Gly	Glu	Lys	Ala	Lys	Thr
225				230					235					240	
Phe	Thr	Arg	Ile	Lys	Tyr	Ala	Leu	Leu	Thr	Met	Leu	Glu	Lys	Phe	Leu

245 250 255
 Glu Cys Val Ala Asp Val Phe Lys Leu Val Pro Leu Pro Ile Thr Met
 260 265 270
 Gly Ile Arg Ala Ile Val Ala Ala Gly Cys Thr Phe Thr Ser Ala Ile
 275 280 285
 Ile Gly Leu Cys Thr Phe Cys Ala Arg Ala
 290 295

<210> 124

<211> 897

<212> DNA

<213> Chlamydia

<400> 124

```

atggcttcta tatgcggagc tttagggctc ggtacaggga atgctctaaa agcttttttt 60
acacagccca acaataaaat ggcaagggtg gtaataaga cgaagggaat ggataagact 120
attaaggttg ccaagctctg tgccgaattg accgaaata ttttggaaac agctggaggc 180
gcgggctctt ccgcacacat tacagcttcc caagtgtcca aaggattagg ggaatgcgaga 240
actgttgctc ctttagggaa tgcttttaac ggagcgttgc caggaacagt tcaaagtgcg 300
caaagctctt tctctacat gaaagctgct agtcagaaaa cgcaagaagg ggaatgagggg 360
ctcacagcag atctttgtgt gtctcataag cgcagagcgg ctgcggctgt ctgtagcctc 420
atcggaggaa ttacctacct cgcgacattc ggagctatcc gtccgattct gtttgcacac 480
aaaatgctgg caaaacggtt tctttctccc caaactaaag caaatatggg atctctctgt 540
agctatatta tggcggctaa ccatgcagcg tctgtggtgg gtgctggact cgctatcagt 600
gcggaaaagag cagattgcga agcccgcgtc gctcgtattg cgagagaaga gtcgttactc 660
gaagtgcggg gagaggaaaa tgcttgcgag aagaaaagtc ctggagagaa agccaagacg 720
ttcacgcgca tcaagtatgc actcctcact atgctcgaga agtttttggg atgcgttccc 780
gacgttttca aattggtgcc gctgcctatt acaatgggta ttctgtcgat tgtggtcgtc 840
ggatgtacgt tcacttctgc aattattgga ttgtgcactt tctgcgcagc agcataaa 897

```

<210> 125

<211> 298

<212> PRT

<213> Chlamydia

<400> 125

```

Met Ala Ser Ile Cys Gly Arg Leu Gly Ser Gly Thr Gly Asn Ala Leu
  1      5      10      15
Lys Ala Phe Phe Thr Gln Pro Asn Asn Lys Met Ala Arg Val Val Asn
  20      25      30
Lys Thr Lys Gly Met Asp Lys Thr Ile Lys Val Ala Lys Ser Ala Ala
  35      40      45
Glu Leu Thr Ala Asn Ile Leu Glu Gln Ala Gly Gly Ala Gly Ser Ser
  50      55      60
Ala His Ile Thr Ala Ser Gln Val Ser Lys Gly Leu Gly Asp Ala Arg
  65      70      75      80
Thr Val Val Ala Leu Gly Asn Ala Phe Asn Gly Ala Leu Pro Gly Thr
  85      90      95
Val Gln Ser Ala Gln Ser Phe Phe Ser His Met Lys Ala Ala Ser Gln
  100     105     110
Lys Thr Gln Gln Gly Asp Glu Gly Leu Thr Ala Asp Leu Cys Val Ser
  115     120     125
His Lys Arg Arg Ala Ala Ala Val Cys Ser Ile Ile Gly Gly Ile
  130     135     140
Thr Tyr Leu Ala Thr Phe Gly Ala Ile Arg Pro Ile Leu Phe Val Asn

```

145					150					155				160	
Lys	Met	Leu	Ala	Lys	Pro	Phe	Leu	Ser	Ser	Gln	Thr	Lys	Ala	Asn	Met
				165					170					175	
Gly	Ser	Ser	Val	Ser	Tyr	Ile	Met	Ala	Ala	Asn	His	Ala	Ala	Ser	Val
			180					185					190		
Val	Gly	Ala	Gly	Leu	Ala	Ile	Ser	Ala	Glu	Arg	Ala	Asp	Cys	Glu	Ala
		195					200					205			
Arg	Cys	Ala	Arg	Ile	Ala	Arg	Glu	Glu	Ser	Leu	Leu	Glu	Val	Pro	Gly
		210				215					220				
Glu	Glu	Asn	Ala	Cys	Glu	Lys	Lys	Val	Ala	Gly	Glu	Lys	Ala	Lys	Thr
225					230					235				240	
Phe	Thr	Arg	Ile	Lys	Tyr	Ala	Leu	Leu	Thr	Met	Leu	Glu	Lys	Phe	Leu
			245						250					255	
Glu	Cys	Val	Ala	Asp	Val	Phe	Lys	Leu	Val	Pro	Leu	Pro	Ile	Thr	Met
		260						265				270			
Gly	Ile	Arg	Ala	Ile	Val	Ala	Ala	Gly	Cys	Thr	Phe	Thr	Ser	Ala	Ile
		275					280					285			
Ile	Gly	Leu	Cys	Thr	Phe	Cys	Ala	Arg	Ala						
290						295									

<210> 126
<211> 897
<212> DNA
<213> Chlamydia

<400> 126						
atgcccttcta	tatgccgagc	tttaggggtct	ggtacacggga	atgctctaaa	agcttttttt	60
accagcccca	acataaataa	ggcaagggta	gtaaataaga	cgaaggagga	gataagaact	120
atcaaggtgt	ccaagctctc	tgcgcgaattg	accgcataa	ttttggaaca	agctggaggc	180
gcgggctctt	cgcacacgat	tacagctcttc	caaggtgtcca	aaggattagg	ggatgcgaga	240
actgttgtct	cttttagggaa	tgccctttaac	cgagcaacagt	cgaagcactg	tcaaatgtcg	300
caaaagtctt	ct.ctctacat	gaaaagctgct	agtcagaaaa	cgcgaagaag	ggatggaggg	360
ctccacagac	actcttgtgt	gtctcataag	cgcagagcgct	ctcggcgctt	ctgtagatc	420
atcggaggaa	ttacctactc	cgcgacattc	ggagctatcc	gtccgattct	gtttgtcaac	480
aaaactgctg	caaaaaccgtt	ttctttcttc	caactataag	caatctagg	atctcttgtt	540
agcatatata	tgcggcgctgc	ccatcgacgcy	gtctggtgtg	gctgtatggc	cgctactcagt	600
ggcgaagaag	catagtgcga	agcccgctgc	gctcgtatct	cgaagaaga	gctgtactc	660
gaagtcgccg	gagaggaaaa	tctctcgag	aagaaagatgc	ctggagagaa	agccaagacg	720
ttcacgcgca	tcaagtatgc	acctctcaat	atgctcgaga	agtttttggg	atgcgttgcc	780
gcagctttta	aattggtgcg	gctgcctatt	acaatgggta	ttcgtgcgat	tgtggtcgtc	840
ggatgtacgt	tctactctgc	aattatttqga	ttctgcactt	ttcgcagaca	acacataa	897

```
<210> 127
<211> 298
<212> PRT
<213> Chlamydia
```

<400> 127															
Met	Ala	Ser	Ile	Cys	Gly	Arg	Leu	Gly	Ser	Gly	Thr	Gly	Asn	Ala	Leu
1				5					10					15	
Lys	Ala	Phe	Phe	Thr	Gln	Pro	Asn	Asn	Lys	Met	Ala	Arg	Val	Val	Asn
			20					25					30		
Lys	Thr	Lys	Gly	Met	Asp	Lys	Thr	Ile	Lys	Val	Ala	Lys	Ser	Ala	Ala
			35				40					45			
Glu	Leu	Thr	Ala	Asn	Ile	Leu	Glu	Gln	Ala	Gly	Gly	Ala	Gly	Ser	Ser

50	55	60
Ala His Ile Thr Ala Ser Gln Val Ser Lys Gly Leu Gly Asp Ala Arg		
65	70	75
Thr Val Val Ala Leu Gly Asn Ala Phe Asn Gly Ala Leu Pro Gly Thr		80
	85	90
Val Gln Ser Ala Gln Ser Phe Phe Ser His Met Lys Ala Ala Ser Gln		95
	100	105
Lys Thr Gln Glu Gly Asp Glu Gly Leu Thr Ala Asp Leu Cys Val Ser		110
	115	120
His Lys Arg Arg Ala Ala Ala Ala Val Cys Ser Ile Ile Gly Gly Ile		125
	130	135
Thr Tyr Leu Ala Thr Phe Gly Ala Ile Arg Pro Ile Leu Phe Val Asn		140
	145	150
Lys Met Leu Ala Lys Pro Phe Leu Ser Ser Gln Thr Lys Ala Asn Met		155
	165	170
Gly Ser Ser Val Ser Tyr Ile Met Ala Ala Asn His Ala Ala Ser Val		175
	180	185
Val Gly Ala Gly Leu Ala Ile Ser Ala Glu Arg Ala Asp Cys Glu Ala		190
	195	200
Arg Cys Ala Arg Ile Ala Arg Glu Glu Ser Leu Leu Gly Val Pro Gly		205
	210	215
Glu Glu Asn Ala Cys Glu Lys Lys Val Ala Gly Glu Lys Ala Lys Thr		220
	225	230
Phe Thr Arg Ile Lys Tyr Ala Leu Leu Thr Met Leu Glu Lys Phe Leu		235
	245	250
Glu Cys Val Ala Asp Val Phe Lys Leu Val Pro Leu Pro Ile Thr Met		255
	260	265
Gly Ile Arg Ala Ile Val Ala Ala Gly Cys Thr Phe Thr Ser Ala Ile		270
	275	280
Ile Gly Leu Cys Thr Phe Cys Ala Arg Ala		285
	290	295

<210> 128

<211> 897

<212> DNA

<213> Chlamydia

<400> 128

atggcttcta	tatgtggagc	tttagggctc	ggtagcagga	atgctctaaa	agcttttttt	60
acacagccca	gcaataaaat	ggcaagggtg	gtaataaaga	cgaagggaat	ggataagact	120
gttaaagtcg	ccaagctcgc	tgccgaattg	accgcaata	ttttggaaca	agctggaggg	180
gcgggctctt	ccgcacacat	tacagcttcc	caagtgtcca	aaggattagg	ggatcacgaga	240
actgttgtcg	ctttagggaa	tgcccttaac	ggagcggtgc	caggaacagt	tcaaaagtgcg	300
caaagctctc	tctctcacat	gaaagctgct	agtcagaaaa	cgaagaagg	ggatgagggg	360
ctccagcagc	atcttttgtg	gtctcataag	cgcagagcgg	ctgcggctgt	ctgtggcttc	420
atccagaggaa	ttaactacct	cgcgacattc	ggagttatcc	gtccgattct	gtttgtcaac	480
aaaatgctgg	tgaaccocgt	tctttcttcc	caaactaaag	caaatatggg	atcttctgtt	540
agcttatatta	tggcgggctaa	ccatgcagcg	tctgtgggtg	gtgctggact	cgctatcagt	600
gcggaaagag	cagatttcga	agcccgctgc	gctcgtattg	cgagagaaga	gtcgttactc	660
gaagtgtcgg	gagaggaaaa	tgcttgcgag	aagagagtgc	ctggagagaa	agccaagacg	720
ttcacgcgca	tcaagtatgc	actcctcact	atgctcgaga	agtttttgga	atgcgttgcc	780
gacgttttca	aatttggtgcc	gctgcctatt	acaatgggta	ttcgtgcgat	tgtggtgct	840
ggatgtacgt	tcactctctgc	aattatttga	ttgtgcactt	tctgcgcagc	agcataaa	897

<210> 129

<211> 298
 <212> PRT
 <213> Chlamydia

<400> 129
 Met Ala Ser Ile Cys Gly Arg Leu Gly Ser Gly Thr Gly Asn Ala Leu
 1 5 10 15
 Lys Ala Phe Phe Thr Gln Pro Ser Asn Lys Met Ala Arg Val Val Asn
 20 25 30
 Lys Thr Lys Gly Met Asp Lys Thr Val Lys Val Ala Lys Ser Ala Ala
 35 40 45
 Glu Leu Thr Ala Asn Ile Leu Glu Gln Ala Gly Gly Ala Gly Ser Ser
 50 55 60
 Ala His Ile Thr Ala Ser Gln Val Ser Lys Gly Leu Gly Asp Thr Arg
 65 70 75 80
 Thr Val Val Ala Leu Gly Asn Ala Phe Asn Gly Ala Leu Pro Gly Thr
 85 90 95
 Val Gln Ser Ala Gln Ser Phe Phe Ser His Met Lys Ala Ala Ser Gln
 100 105 110
 Lys Thr Gln Glu Gly Asp Glu Gly Leu Thr Ala Asp Leu Cys Val Ser
 115 120 125
 His Lys Arg Arg Ala Ala Ala Val Cys Gly Phe Ile Gly Gly Ile
 130 135 140
 Thr Tyr Leu Ala Thr Phe Gly Val Ile Arg Pro Ile Leu Phe Val Asn
 145 150 155 160
 Lys Met Leu Val Asn Pro Phe Leu Ser Ser Gln Thr Lys Ala Asn Met
 165 170 175
 Gly Ser Ser Val Ser Tyr Ile Met Ala Ala Asn His Ala Ala Ser Val
 180 185 190
 Val Gly Ala Gly Leu Ala Ile Ser Ala Glu Arg Ala Asp Cys Glu Ala
 195 200 205
 Arg Cys Ala Arg Ile Ala Arg Glu Glu Ser Leu Leu Glu Val Ser Gly
 210 215 220
 Glu Glu Asn Ala Cys Glu Lys Arg Val Ala Gly Glu Lys Ala Lys Thr
 225 230 235 240
 Phe Thr Arg Ile Lys Tyr Ala Leu Leu Thr Met Leu Glu Lys Phe Leu
 245 250 255
 Glu Cys Val Ala Asp Val Phe Lys Leu Val Pro Leu Pro Ile Thr Met
 260 265 270
 Gly Ile Arg Ala Ile Val Ala Ala Gly Cys Thr Phe Thr Ser Ala Ile
 275 280 285
 Ile Gly Leu Cys Thr Phe Cys Ala Arg Ala
 290 295

<210> 130
 <211> 897
 <212> DNA
 <213> Chlamydia

<400> 130
 atggctgcta tatgtggagc ttttagggctt ggtacaggga atgctctaaa agcttttttt 60
 acacagccca gcaataaaaat ggcaagggtta gtaataaaga cgaagggaat ggataagact 120
 gtttaaggtcg ccaagttctgc tgccgaattg accgcaataa ttttggaaaca agctggagac 180
 gcgggctctt ccgcacacat tacagcttcc caagtgtcca aaggattagg ggaatgcgaga 240
 actgttctcg ctttagggaa tgctttaac ggagcgttgc caggaacagt tcaaagtgcg 300

```

caaagcttct tctcttacat gaaagctgct agtcagaaac cgcaagaagg ggaatgagggg 360
ctcgtagcag atcttttgtgt gtctcataag cgcagagcgg ctgcggctgt ctgtagcttc 420
atcggaggaa ttacctaacct cgcgacattc ggaagctatcc gtccgattct gtttgcacac 480
aaaatgctgg cgcaacogtt tctttcttcc caaactaaag caaatatggg atctctctgtt 540
agctatatta tggcgggctaa ccatgcagcg tttgtggtgg gtctcggaact cgctatcaagt 600
gcggaagaag cagattgcga agcccgctgc gctcgtattg cgagagaaga gtcgtcactc 660
gaattgtcgg gagaggaataa tgcttgcgag agggggagtcg ctggagagaa agccaagacg 720
ttcacgcgca tcaagtatgc actcctcact atgctcgaga agtttttgga atgcgttgcc 780
gacgttttca aattgggtgcc gttgcctatt acaatgggta ttcgtgcaat tgtggtcgcg 840
ggatgtacgt tcacttctgc agttattgga ttgtggactt tctgcaacag agtataa 897

```

<210> 131

<211> 298

<212> PRT

<213> Chlamydia

<400> 131

```

Met Ala Ala Ile Cys Gly Arg Leu Gly Ser Gly Thr Gly Asn Ala Leu
 1          5          10          15
Lys Ala Phe Phe Thr Gln Pro Ser Asn Lys Met Ala Arg Val Val Asn
 20          25          30
Lys Thr Lys Gly Met Asp Lys Thr Val Lys Val Ala Lys Ser Ala Ala
 35          40          45
Glu Leu Thr Ala Asn Ile Leu Glu Gln Ala Gly Gly Ala Gly Ser Ser
 50          55          60
Ala His Ile Thr Ala Ser Gln Val Ser Lys Gly Leu Gly Asp Ala Arg
 65          70          75          80
Thr Val Leu Ala Leu Gly Asn Ala Phe Asn Gly Ala Leu Pro Gly Thr
 85          90          95
Val Gln Ser Ala Gln Ser Phe Phe Ser Tyr Met Lys Ala Ala Ser Gln
100          105          110
Lys Pro Gln Glu Gly Asp Glu Gly Leu Val Ala Asp Leu Cys Val Ser
115          120          125
His Lys Arg Arg Ala Ala Ala Val Cys Ser Phe Ile Gly Gly Ile
130          135          140
Thr Tyr Leu Ala Thr Phe Gly Ala Ile Arg Pro Ile Leu Phe Val Asn
145          150          155          160
Lys Met Leu Ala Gln Pro Phe Leu Ser Ser Gln Thr Lys Ala Asn Met
165          170          175
Gly Ser Ser Val Ser Tyr Ile Met Ala Ala Asn His Ala Ala Phe Val
180          185          190
Val Gly Ser Gly Leu Ala Ile Ser Ala Glu Arg Ala Asp Cys Glu Ala
195          200          205
Arg Cys Ala Arg Ile Ala Arg Glu Glu Ser Ser Leu Glu Leu Ser Gly
210          215          220
Glu Glu Asn Ala Cys Glu Arg Gly Val Ala Gly Glu Lys Ala Lys Thr
225          230          235          240
Phe Thr Arg Ile Lys Tyr Ala Leu Leu Thr Met Leu Glu Lys Phe Leu
245          250          255
Glu Cys Val Ala Asp Val Phe Lys Leu Val Pro Leu Pro Ile Thr Met
260          265          270
Gly Ile Arg Ala Ile Val Ala Ala Gly Cys Thr Phe Thr Ser Ala Val
275          280          285
Ile Gly Leu Trp Thr Phe Cys Asn Arg Val
290          295

```

<210> 132
<211> 897
<212> DNA
<213> Chlamydia

<400> 132
atggctgcta tatgctggagc tttaggggtct ggtacaggga atgctctaaa agcttttttt 60
acacagccca gcaataaaat ggcaagggtta gtaataaaga cgaaggggaat ggataagact 120
gttaaggctcg ccaagctctgc tgccgaattg accgcaataa ttttggaaac agctggaggcg 180
gctggctctct ccgcacacat tacagctctcc caagtgtcca aaggattagg ggaatcgaga 240
actgttctcg ctttagggaa tgcccttaac ggagcgttgc caggaacagt tcaaagtcgc 300
caaagctctct tctcttcatat gaaagctgct agtcagaaac cgaagaagg ggaatgagggg 360
ctcgtagcag atctttgtgt gtctcataag cgcagagcgg ctgcggctgt ctgtagcttc 420
atcggaggaa ttacctacct cgcgacattc ggagctatcc gtccgattct gtttgtcaac 480
aaaatgctgg cgcaaccgtt tctttcttcc caaactaaag caaatatggg atctctctgt 540
agctatatata tggcggctaa ccattgcagc tttgtggtgg gttctggact cgctatcagt 600
gcggaaggcg cagattgcga agcccgctgc gctcgtattg cgagagaaga gctcgtcactc 660
gaatttgcgg gagagggaaa tgcttctgag aggagagctg ctggagagaa agccaagacg 720
ttcacgcgca tcaagtatgc actctcact atgctcgaga agtttttggg atgcgttggc 780
gacgttttca taattggtgcc gttgcttatt acaatgggta ttctgtcaat tgtggctgag 840
ggatgtacgt tcacttctgc agttattgga ttgtggactt tctgcaacag agtataa 897

<210> 133
<211> 298
<212> PRT
<213> Chlamydia

<400> 133
Met Ala Ala Ile Cys Gly Arg Leu Gly Ser Gly Thr Gly Asn Ala Leu
1 5 10 15
Lys Ala Phe Phe Thr Gln Pro Ser Asn Lys Met Ala Arg Val Val Asn
20 25 30
Lys Thr Lys Gly Met Asp Lys Thr Val Lys Val Ala Lys Ser Ala Ala
35 40 45
Glu Leu Thr Ala Asn Ile Leu Glu Gln Ala Gly Gly Ala Gly Ser Ser
50 55 60
Ala His Ile Thr Ala Ser Gln Val Ser Lys Gly Leu Gly Asp Ala Arg
65 70 75 80
Thr Val Leu Ala Leu Gly Asn Ala Phe Asn Gly Ala Leu Pro Gly Thr
85 90 95
Val Gln Ser Ala Gln Ser Phe Phe Ser Tyr Met Lys Ala Ala Ser Gln
100 105 110
Lys Pro Gln Glu Gly Asp Glu Gly Leu Val Ala Asp Leu Cys Val Ser
115 120 125
His Lys Arg Arg Ala Ala Ala Val Cys Ser Phe Ile Gly Gly Ile
130 135 140
Thr Tyr Leu Ala Thr Phe Gly Ala Ile Arg Pro Ile Leu Phe Val Asn
145 150 155 160
Lys Met Leu Ala Gln Pro Phe Leu Ser Ser Gln Thr Lys Ala Asn Met
165 170 175
Gly Ser Ser Val Ser Tyr Ile Met Ala Ala Asn His Ala Ala Phe Val
180 185 190
Val Gly Ser Gly Leu Ala Ile Ser Ala Glu Arg Ala Asp Cys Glu Ala
195 200 205

Arg Cys Ala Arg Ile Ala Arg Glu Glu Ser Ser Leu Glu Leu Ser Gly
 210 215 220
 Glu Glu Asn Ala Cys Glu Arg Arg Val Ala Gly Glu Lys Ala Lys Thr
 225 230 235 240
 Phe Thr Arg Ile Lys Tyr Ala Leu Leu Thr Met Leu Glu Lys Phe Leu
 245 250 255
 Glu Cys Val Ala Asp Val Phe Lys Leu Val Pro Leu Pro Ile Thr Met
 260 265 270
 Gly Ile Arg Ala Ile Val Ala Ala Gly Cys Thr Phe Thr Ser Ala Val
 275 280 285
 Ile Gly Leu Trp Thr Phe Cys Asn Arg Val
 290 295

<210> 134

<211> 897

<212> DNA

<213> Chlamydia

<400> 134

atggccttcta tatcgccgacg ttttagggctc ggtacagggga atgctctaaa agcttttttt 60
 acacagccc acaataaaat ggcaagggtta gtaastaaga cgaaggggaat ggataagact 120
 attaaagttg ccaagctctgc tgccgaattg accgcaataa ttttggaaca agctggagggc 180
 cggggctctt ccgcacacat tacagcttcc caagtgtcca aaggattagg ggaatgcgaga 240
 actgtgtctg ctttagggaa tgccctttaac ggagcgttgc caggaacagt tcaaagtgcg 300
 caaagctctc tctctcacat gaaagctgct agtcagaaaa cgaagaagg ggaatgagggg 360
 ctcacagcag atcttttgtgt gtctcataag cgcagagcgg ctgcggctgt ctgtagcacc 420
 atcggaggaa ttacctacct cgcgacattc ggaagctatcc gtccgattct gtttgtcaac 480
 aaaatgctgg caaaaccgtt tctttcttcc caaactaaag caaatatggg atcttctgtt 540
 agctatatca tggcggctaa ccatgcagcg tctgtgtggg gtgctggact cgctatcagt 600
 cgggaagaag cagattgcga agcccgcgtc gctcgtattg cgagagaaga gtcgttactc 660
 gaaatgccgg gagaggaaaa tgcttgcgag aagaaagtcg ctggagagaa agccaagacg 720
 ttcacgcgca tcaagtatgc actcctcact atgctcgaga agtttttggg atgcgttgcc 780
 gacgttttca aattgggtgc gctgcctatt acaatgggta ttcgtgcgat tgggtgctgt 840
 ggatgtacgt tcaactctgc aattattgga ttgtgcactt tctgcgccag agcataa 897

<210> 135

<211> 298

<212> PRT

<213> Chlamydia

<400> 135

Met Ala Ser Ile Cys Gly Arg Leu Gly Ser Gly Thr Gly Asn Ala Leu
 1 5 10 15
 Lys Ala Phe Phe Thr Gln Pro Asn Asn Lys Met Ala Arg Val Val Asn
 20 25 30
 Lys Thr Lys Gly Met Asp Lys Thr Ile Lys Val Ala Lys Ser Ala Ala
 35 40 45
 Glu Leu Thr Ala Asn Ile Leu Glu Gln Ala Gly Gly Ala Gly Ser Ser
 50 55 60
 Ala His Ile Thr Ala Ser Gln Val Ser Lys Gly Leu Gly Asp Ala Arg
 65 70 75 80
 Thr Val Val Ala Leu Gly Asn Ala Phe Asn Gly Ala Leu Pro Gly Thr
 85 90 95
 Val Gln Ser Ala Gln Ser Phe Phe Ser His Met Lys Ala Ala Ser Gln
 100 105 110

Lys Thr Gln Glu Gly Asp Glu Gly Leu Thr Ala Asp Leu Cys Val Ser
 115 120 125
 His Lys Arg Arg Ala Ala Ala Val Cys Ser Ile Ile Gly Gly Ile
 130 135 140
 Thr Tyr Leu Ala Thr Phe Gly Ala Ile Arg Pro Ile Leu Phe Val Asn
 145 150 155 160
 Lys Met Leu Ala Lys Pro Phe Leu Ser Ser Gln Thr Lys Ala Asn Met
 165 170 175
 Gly Ser Ser Val Ser Tyr Ile Met Ala Ala Asn His Ala Ala Ser Val
 180 185 190
 Val Gly Ala Gly Leu Ala Ile Ser Ala Glu Arg Ala Asp Cys Glu Ala
 195 200 205
 Arg Cys Ala Arg Ile Ala Arg Glu Glu Ser Leu Leu Glu Met Pro Gly
 210 215 220
 Glu Glu Asn Ala Cys Glu Lys Lys Val Ala Gly Glu Lys Ala Lys Thr
 225 230 235 240
 Phe Thr Arg Ile Lys Tyr Ala Leu Leu Thr Met Leu Glu Lys Phe Leu
 245 250 255
 Glu Cys Val Ala Asp Val Phe Lys Leu Val Pro Leu Pro Ile Thr Met
 260 265 270
 Gly Ile Arg Ala Ile Val Ala Ala Gly Cys Thr Phe Thr Ser Ala Ile
 275 280 285
 Ile Gly Leu Cys Thr Phe Cys Ala Arg Ala
 290 295

<210> 136

<211> 882

<212> DNA

<213> Chlamydia

<400> 136

atggcttctg tatgtgggagc attaagtgcg ggggtgggga acagatttaa cgcatttttc 60
 acgcgtcccg gtaacaagct atcacggttt gtaaatagcg caaaaggatt agacagatca 120
 ataaagggtg ggaagtctgc tgcctgaatta acggcgagta ttttagagca aactgggggg 180
 gcagggactg atgcacatgt tacggcggcc aaggtgtcta aagcacttgg ggacgcgcga 240
 acagtaatgg ctctagggaa tgtcttcaat gggctctgtgc cagcaacocat tcaaaagtgcg 300
 cgaagctgtc tcgcccattt acgagcgccc ggcaaaagaag aagaacatcg ctccaagggtg 360
 aaagatctct gtgttttcca tagacgaaga gctgcggcg aggccttgtaa tgttattgga 420
 ggagcaactt atattacaac ttctggagcg attcgtccga cattactcgt taacaagcctt 480
 cttgccaaac cattcctttc ctcccaagcc aaagaagggt tgggagcttc tgttggttat 540
 atcatggcag cgaaccatgc ggcactctgt cttgggtctg ctttaagtat tagcgcagaa 600
 agagcgactc gtgaagagcg gtgtgatcgc attcgtatga gtgaggatgg tgaatttgc 660
 gaaggcaata aattaacagc tatttcggaa gagaaggcta gatcatggac tctcataagg 720
 tacagattcc ttactatgat agaaaaacta ttgagatgg tggcggatat ctccaagtta 780
 attcctttgc caatttcgca tggaaattcg gctattgttg ctgcgggatg tacgttgact 840
 tctgcagtta ttggcttagg tacttttttg tctagagcat aa 882

<210> 137

<211> 293

<212> PRT

<213> Chlamydia

<400> 137

Met Ala Ser Val Cys Gly Arg Leu Ser Ala Gly Val Gly Asn Arg Phe
 1 5 10 15

```

Asn Ala Phe Phe Thr Arg Pro Gly Asn Lys Leu Ser Arg Phe Val Asn
      20      25
Ser Ala Lys Gly Leu Asp Arg Ser Ile Lys Val Gly Lys Ser Ala Ala
      35      40      45
Glu Leu Thr Ala Ser Ile Leu Glu Gln Thr Gly Gly Ala Gly Thr Asp
      50      55      60
Ala His Val Thr Ala Ala Lys Val Ser Lys Ala Leu Gly Asp Ala Arg
      65      70      75      80
Thr Val Met Ala Leu Gly Asn Val Phe Asn Gly Ser Val Pro Ala Thr
      85      90      95
Ile Gln Ser Ala Arg Ser Cys Leu Ala His Leu Arg Ala Ala Gly Lys
      100      105      110
Glu Glu Glu Thr Cys Ser Lys Val Lys Asp Leu Cys Val Ser His Arg
      115      120      125
Arg Arg Ala Ala Glu Ala Cys Asn Val Ile Gly Gly Ala Thr Tyr
      130      135      140
Ile Thr Thr Phe Gly Ala Ile Arg Pro Thr Leu Leu Val Asn Lys Leu
      145      150      155      160
Leu Ala Lys Pro Phe Leu Ser Ser Gln Ala Lys Glu Gly Leu Gly Ala
      165      170      175
Ser Val Gly Tyr Ile Met Ala Ala Asn His Ala Ala Ser Val Leu Gly
      180      185      190
Ser Ala Leu Ser Ile Ser Ala Glu Arg Ala Asp Cys Glu Glu Arg Cys
      195      200      205
Asp Arg Ile Arg Cys Ser Glu Asp Gly Glu Ile Cys Glu Gly Asn Lys
      210      215      220
Leu Thr Ala Ile Ser Glu Glu Lys Ala Arg Ser Trp Thr Leu Ile Lys
      225      230      235      240
Tyr Arg Phe Leu Trp Met Ile Glu Lys Leu Phe Glu Met Val Ala Asp
      245      250      255
Ile Phe Lys Leu Ile Pro Leu Pro Ile Ser His Gly Ile Arg Ala Ile
      260      265      270
Val Ala Ala Gly Cys Thr Leu Thr Ser Ala Val Ile Gly Leu Gly Thr
      275      280      285
Phe Trp Ser Arg Ala
      290

```

<210> 138

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> Made in a lab

<400> 138

```

Asp Leu Cys Val Ser His Lys Arg Arg Ala Ala Ala Val Cys Ser
  1           5           10          15

```

<210> 139

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> Made in a lab

<400> 139

Arg	Ala	Ala	Ala	Ala	Val	Cys	Ser	Phe	Ile	Gly	Gly	Ile	Thr	Tyr	Leu
1				5					10					15	

<210> 140

<211> 18

<212> PRT

<213> Artificial Sequence

<220>

<223> Made in a lab

<400> 140

Cys	Ser	Phe	Ile	Gly	Gly	Ile	Thr	Tyr	Leu	Ala	Thr	Phe	Gly	Ala	Ile
1				5					10					15	

Arg Pro

<210> 141

<211> 18

<212> PRT

<213> Artificial Sequence

<220>

<223> Made in a lab

<400> 14

Tyr	Leu	Ala	Thr	Phe	Gly	Ala	Ile	Arg	Pro	Ile	Leu	Phe	Val	Asn	Lys
1				5					10					15	

Met Leu

<210> 142

<211> 18

<212> PRT

<213> Artificial Sequence

<220>

<223> Made in a lab

<400> 142

Arg	Pro	Ile	Leu	Phe	Val	Asn	Lys	Met	Leu	Ala	Gln	Pro	Phe	Leu	Ser
1				5					10					15	

Ser Gln

<210> 143

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> Made in a lab

<400> 143
Met Leu Ala Gln Pro Phe Leu Ser Ser Gln Thr Lys Ala Asn Met Gly
1 5 10 15
Ser

<210> 144
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Made in a lab

<400> 144
Cys Ser Phe Ile Gly Gly Ile Thr Tyr Leu
1 5 10

<210> 145
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Made in a lab

<400> 145
Ser Phe Ile Gly Gly Ile Thr Tyr Leu
1 5

<210> 146
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Made in a lab

<400> 146
Phe Ile Gly Gly Ile Thr Tyr Leu
1 5

<210> 147
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Made in a lab

<400> 147
Cys Ser Phe Ile Gly Gly Ile Thr Tyr
1 5

<210> 148
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Made in a lab

<400> 148
Cys Ser Phe Ile Gly Gly Ile Thr
1 5

<210> 149
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Made in a lab

<400> 149
Cys Ser Ile Ile Gly Gly Ile Thr Tyr Leu
1 5 10

<210> 150
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Made in a lab

<400> 150
Cys Gly Phe Ile Gly Gly Ile Thr Tyr Leu
1 5 10

<210> 151
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Made in a lab

<400> 151
Gly Phe Ile Gly Gly Ile Thr Tyr Leu
1 5

<210> 152
<211> 20
<212> PRT
<213> Artificial Sequence

<220>
<223> Made in a lab

<400> 152
Gln Ile Phe Val Cys Leu Ile Ser Ala Glu Arg Leu Arg Leu Arg Leu
1 5 10 15
Ser Val Ala Ser
20

<210> 153
<211> 20
<212> PRT
<213> Artificial Sequence

<220>
<223> Made in a lab

<400> 153
Glu Arg Leu Arg Leu Arg Leu Ser Val Ala Ser Ser Glu Glu Leu Pro
1 5 10 15
Thr Ser Arg His
20

<210> 154
<211> 20
<212> PRT
<213> Artificial Sequence

<220>
<223> Made in a lab

<400> 154
Ala Ser Ser Glu Glu Leu Pro Thr Ser Arg His Ser Glu Leu Ser Val
1 5 10 15
Arg Phe Cys Leu
20

<210> 155
<211> 20
<212> PRT
<213> Artificial Sequence

<220>
<223> Made in a lab

<400> 155
Arg His Ser Glu Leu Ser Val Arg Phe Cys Leu Ser Thr Lys Cys Trp
1 5 10 15
Arg Asn Arg Phe
20

<210> 156
<211> 20
<212> PRT
<213> Artificial Sequence

<220>

<223> Made in a lab

<400> 156

Leu Ser Thr Lys Cys Trp Arg Asn Arg Phe Phe Leu Pro Lys Leu Lys
 1 5 10 15
 Gln Ile Trp Asp
 20

<210> 157

<211> 53

<212> PRT

<213> Artificial Sequence

<220>

<223> Made in a lab

<400> 157

Ile Phe Val Cys Leu Ile Ser Ala Glu Arg Leu Arg Leu Ser Val Ala
 1 5 10 15
 Ser Ser Glu Glu Leu Pro Thr Ser Arg His Ser Glu Leu Ser Val Arg
 20 25 30
 Phe Cys Leu Ser Thr Lys Cys Trp Arg Asn Arg Phe Phe Leu Pro Lys
 35 40 45
 Leu Lys Gln Ile Trp
 50

<210> 158

<211> 52

<212> PRT

<213> Artificial Sequence

<220>

<223> Made in a lab

<400> 158

Leu Cys Val Ser His Lys Arg Arg Ala Ala Ala Val Cys Ser Phe
 1 5 10 15
 Ile Gly Gly Ile Thr Tyr Leu Ala Thr Phe Gly Ala Ile Arg Pro Ile
 20 25 30
 Leu Phe Val Asn Lys Met Leu Ala Gln Pro Phe Leu Ser Ser Gln Ile
 35 40 45
 Lys Ala Asn Met
 50

<210> 159

<211> 24

<212> DNA

<213> Chlamydia

<400> 159

ttttgaagca ggtagggtgaa tatg

24

<210> 160

<211> 24

<212> DNA

<213> Chlamydia
 <400> 160
 ttaagaaatt taaaaaatcc cttta 24
 <210> 161
 <211> 24
 <212> DNA
 <213> Chlamydia
 <400> 161
 ggtataatat ctctctaaat ttg 24
 <210> 162
 <211> 19
 <212> DNA
 <213> Chlamydia
 <400> 162
 agataaaaaa ggctgtttc 19
 <210> 163
 <211> 24
 <212> DNA
 <213> Chlamydia
 <400> 163
 ttttgaagca ggtagtgaa tatg 24
 <210> 164
 <211> 29
 <212> DNA
 <213> Chlamydia
 <400> 164
 ttacataaa gaaaagctaa gcactttgt 29
 <210> 165
 <211> 20
 <212> DNA
 <213> Chlamydia
 <400> 165
 ccttacacag tctgtgtgac 20
 <210> 166
 <211> 20
 <212> DNA
 <213> Chlamydia
 <400> 166
 gtttcgggc cctcacattg 20
 <210> 167
 <211> 9

<212> PRT
<213> Artificial Sequence

<220>
<223> Made in a lab

<400> 167
Ser Phe Ile Gly Gly Ile Thr Tyr Leu
1 5

<210> 168
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Made in a lab

<400> 168
Ser Ile Ile Gly Gly Ile Thr Tyr Leu
1 5

<210> 169
<211> 2643
<212> DNA
<213> Chlamydia

```

<400> 169
gcaatcatgc gacctgatca tatgaacttc tgtgtcttat gtgctgctat ttgtctatcc      60
acagcggtcc tctttggcca ggcacccctta ggtgaaaccg cctcctcac taaaaatcct      120
aatcatgtcg tctgtacatt ttttgaggac tgtaccatgg agagcctctt tctgtctctt      180
tgtgtctcat catcacaaga cgatcctttg tatgtacttg gaaattccta ctgttggttc      240
gtatctaaac tccatcatcac ggaccccaaa gaggctcttt ttaaagaaaa aggagatctt      300
tcattctaaa actttcgctt cctttccttc acagattgct ctccaagga aagctctcct      360
tctattatcc atcaaaagaa tggtcagtta tccctgcgca ataattgtag catgagtttc      420
tgtcgaaatc atgctgaagg ctctggagga gccatctctg cgatgccttt ttctctacag      480
cacaactatc ttctcacagc ttttgaagag aattcttcta aaggaaatgg cggagccatt      540
caggctcaaa cctctctctt atctagaaat gtgtcgccca ttctcttcgc cgtaatcgt      600
gcggatttaa atggcgggcg tatttgctgt agtaatctta ttgttccagg gaatgtaaac      660
cctctctttt tcaactggaaa ctccgccacg aatggaggcg ctatttgttg tatcagcgat      720
ctaaacacct cagaaaaagg ctctctctct ctgtcttgta accaagaaac gctatttgca      780
agcaattctg ctaaaagaaa agcgggggct atttatgcca agcacatggt attgcgttat      840
aacggtcctg ttctctcat taacaacagc gctaaaaatg gtggagctat cgccatccag      900
tccggaggga gtctctctat ccttgacagg gaaggatctg ttctgttcca gaataactcc      960
caacgcacct ccgaccaagg tctagtaaga aacgccatct acttaragaa agatgcgatt      1020
ctttcttctt tagaagctcg caacggagat attcttttct ttgactctat tgtacaagaa      1080
agttagcagca aagaatcgcc tcttccctcc tctttgcaag ccagcgtgac ttctccacc      1140
ccagccaccc catctccttt agttattcag acaagtgcaa accgttcaqt gattttctcg      1200
agcgaacgct ttctggaaga agaaaaaact cctgataacc tcacttccca actacagcag      1260
cctatcgaac tgaatccggc agcgttagtt ttaaagatc gcgctgtcct ttccgcgcct      1320
tctctctctt aggatcctca agctctcctc attatggaag cgggaacttc ttaaaaaact      1380
tctctgattt tgaagttagc tacgctaagt attccctctc attccttaga tactgaaaaa      1440
agcgtaacta tccacgcccc taatctttct atccaaaaga tcttctcttc taactctgga      1500
gatgagaatt tttatgaaaa tgtagagctt ctacagtaaa agcaaaaaca tattctcttc      1560
cttactctcc ctaagagaca atctcattta catcttctcg atgggaacct ctctctcac      1620

```

tttggatatac	aaggagattg	gactttttct	tggaaaagatt	ctgatgaagg	gcattctctg	1580
attgctaatt	ggacgcctaa	aaactatgtg	cctcatccag	aacgtcaatc	tacactcggt	1740
gcgaacactc	tttggaaacac	ctattccgat	atgcaagctg	tgcagtcgat	gattaataca	1800
acagcgacg	gaggagccta	tctatttggg	acgtggggat	ctgctgtttc	taatttattc	1860
tatgttcaag	acagctcttg	gaaacctatc	gataattggc	atcatagaag	ccttgagctac	1920
ctattcggtg	tcagttactca	cagttttagat	gaccattctt	tctgcttgcc	tgcaggacaa	1980
ttactcggga	aatcgctcga	ttcctttatt	acgtctacag	aaacgacctc	ctatatagct	2040
actgtacaag	cgcaactcgc	tacctctcta	atgaaaatct	ctgcacagcg	attgctacaat	2100
gaaagtatcc	atgagctaaa	aacaaaaat	cgctccttct	ctaaagaagg	attcggaatc	2160
tggcatagcg	ttgcagtatc	cggagaagtg	tgcgcatacg	ttcctattgt	attccaatggt	2220
tccggactgt	tcagctcctt	ctctattttc	tctaactcgc	aaggattttc	aggaacacag	2280
gacgggtttg	aggagagttc	gggagagatt	cggtcctttt	ctgccagctc	tttcagaaat	2340
atttcacttc	ctatagggaat	aacatttgaa	aaaaaatccc	aaaaaacacg	aacctactat	2400
tactttctag	gagcctacat	ccaagacctg	aaacgtgatg	tggaaatcggg	acctgtagtgt	2460
ttactcaaaa	atgcgctctc	ctgggatgct	cctatggcga	acttggattc	acgagcctac	2520
atgttccggc	ttacgaatca	aagagctcta	cacagacttc	agacgctgtt	aaatgtgtct	2580
tgtgtgctgc	gtgggcaagg	ccatagttac	tcctcggatc	tggggaccac	ttacaggttc	2640
tag						2643

<210> 170

<211> 2949

<212> DNA

<213> Chlamydia

<400> 170

atgattcctc	aaggaattta	cgatggggag	acgttaactg	tatcatttcc	ctatactggt	60
ataggagatc	cgagtggggac	tactgttttt	tctgcaggag	agttaacatt	aaaaaatctt	120
gacaattctga	ttgcagcttt	gcctttaagt	tgttttggga	acttatttag	gagtttactc	180
gtttttaggga	gaggacactc	gttgactttc	gagaaacatac	agacttccga	aaatggggca	240
gctctaagta	atagcctctg	tgatggactg	tttactattg	agggttttaa	agaattatcc	300
ttttccaagt	gcattctatt	acttgcgcta	ctgcctgctg	caacgactaa	taagggttagc	360
cagactccga	cgacaacatc	tacaccgtct	aatggtacta	tttatctcaa	aacagatctt	420
ttgttactca	ataatgagaa	gttctcattc	tatagtaatt	tagtctctgg	agatgggggga	480
gctatagatg	ctaagagctt	aacggttcaa	ggaattagca	agctttgtgt	cttccaagaa	540
aatactgctc	aagctgatgg	gggagcttgt	caagtagtca	ccagttttctc	tgctatggct	600
aacgaggctc	ctattgcctt	tgtagcgaat	gttgcaggag	taagaggggg	agggattgct	660
gctgttcagg	atgggcagca	gggagtgctc	tcatctactt	caacagaaga	tccagtagta	720
agttttttcca	gaaatactgc	ggtagagttt	gatgggaacg	tagcccgagt	agggaggagg	780
atttactcct	acgggaacgt	tgctttccgt	aataatggaa	aaaccttgtt	tctcaacaat	840
gttgctcttc	ctgtttacat	tgctgctaag	caaccaacaa	gtggacagcg	ttctaatatcg	900
agtaataaat	acggagatgg	aggagctatc	ttctgttaaga	atggtgcgca	agcaggatcc	960
aataactctg	gatcagtttc	ctttgatgga	gaggggagtag	ttttctttag	tagcaatgta	1020
gctgcctggga	aagggggagc	tatttatgcc	aaaaagctct	cggttgctaa	ctgtggccct	1080
gtacaatttt	taagggaatat	gcctaagat	gggtggagcga	tttatttagg	agaactctgga	1140
gagctcagtt	tatctgctga	ttatggagat	attattttct	atgggaatct	taaaagaaca	1200
gccaaagaga	atgctgcctga	tgttaatggc	gtaactgtgt	ctccacaagc	catttcgagt	1260
ggatcggggg	ggaaaataac	gacatttaaga	gctaagacag	ggcatcagat	ctctcttaat	1320
gatccctatg	agatggcaca	cggaaaataac	cagccagcgc	agctctccaa	actctctaaa	1380
attaacgatg	gtgaaggata	cacaggggat	attgtttttg	ctaattggaag	cagtaactttg	1440
taccaaaatg	tatcagataga	gcaagggaag	attgttcttc	gtgaaaaggc	aaaattatca	1500
gtgaattctc	taagctcagac	aggtgggagt	ctgtatatgg	aagctgggag	tacatttgag	1560
tttgttaact	cacaaccacc	acaacagcct	cctgccctga	atcagttgat	cacgctttacc	1620
aatctgcttc	tgtctctctt	ttcttttgta	gcaaaacaatg	cagtttacgaa	tcctctctac	1680
aatcctccag	cgcaagattc	tcatctctga	gtcattggta	gcacaactgc	tggttctggt	1740
acaattagtg	ggcctatctt	ttttgaggat	ttggatgata	cagcttatga	taggtatgat	1800

tggctagagtt	ctaatacaaaa	aatacaatgtc	ctgaataatc	agttaggagc	taagccccca	1860
gctaagtcgcc	catcagattt	gactcttagg	aatgagatgc	ctaagtatgg	ctatcaagga	1920
agctgggaagc	ttgcgctggga	tctaataaca	gcaataatg	gtccttatac	tctgaagact	1980
acatggacta	aaactgggtt	taatacctggg	cctgagcgag	tagctctctt	gggtccaaat	2040
agtttatggg	gatccatttt	agataacaga	tctgcgcatt	cagcaattca	agcaagtggtg	2100
gatggggcgt	cttattgtcg	aggattatgg	gtttctggag	tttcgaattt	cttctatcat	2160
gacgcgcatg	ctttaggcta	gggatctcgg	tatattatgt	ggggttatcc	cttagggagca	2220
aactctctact	ttggatctac	gatgtttggg	ctgactatta	ccgaagtatt	tctgagatct	2280
aaagattatg	tagtgtgtcg	ttccaatcat	catgcttgca	taggatccgt	ttatctatct	2340
acccaacaag	ctttatgtgg	atcctaattg	ttcggagatg	cgtttatccg	tctgactgac	2400
gggtttggga	ctcagcatat	gaaaacctca	tatacatttg	cagaggagag	cgatgttctg	2460
tgggataaat	actgtctggc	tggagagatt	ggagcgggat	tacgattgtg	gattactcca	2520
tctaagctct	atttgaatga	gttgctgctt	ttcgtgcaag	ctgagttctt	ttatgccgat	2580
catgaatctt	ttacagagga	agggcatcaa	gctcggggat	tcaagagcgg	acatctccta	2640
aatctatcag	tctctgttgg	agtgaagttt	gatcgatgtt	ctagtacaca	tcttaataaa	2700
tatagcttta	tggcggtcta	tatctgtgat	gcttatcgca	ccatctctgg	tactgagaca	2760
acgctcttaa	cccatcaaga	gacatggaca	acagatgcct	ttcattttgc	aagacatgga	2820
gttctgggta	gaggatctat	gtatgcttct	ctaacaagta	atatagaagt	atatggccat	2880
ggaagatatg	agtatcgaga	tgttctctga	ggctatgggt	tgagtgcagg	magtaaagtc	2940
yggctctaa						2949

<210> 171

<211> 2895

<212> DNA

<213> Chlamydia

<400> 171

atgaaaaaag	cgtttttctt	tttctctatc	ggaaaactccc	tatcaggact	agctagagag	60
gtctcttcta	gaactcttct	tatgcccac	tcagttccag	atcctacgaa	agagtcgcta	120
tcaataaaaa	ttagtttgac	aggagacact	cacaactcca	ctaactgccta	tctcgataac	180
ctacgctaca	tactggctat	tctacaaaaa	actccaatg	aaggagctgc	tgctacaata	240
acagattacc	taagcttttt	tgatacacia	aaagaaggtta	tttattttgc	aaaaaatccc	300
acccctgaaa	gtgggtggcg	gattggttat	gcgagtccca	attctctcac	cgctggagatt	360
cgtagataaa	taggtcctgt	aatctttgaa	aataataact	gttgacagat	atttactatgg	420
agaaatctct	atgctgccta	taaaaataaga	gaaggcggag	ccattcatgc	tcaaaatctt	480
tacataaatc	ataatcatga	tgtgctcgga	tttatgaaga	acttttctta	gtgccaagga	540
ggagccatta	gtaccgccta	tacctttgtt	gtgagcgaga	atcagttctg	ttttctcttt	600
atggacaaca	tctgtattca	aactaataca	gcaggaaaaa	gtggcgctat	ctatgctgga	660
acggagcaatt	ctttttgagag	taataaactgc	gatctctctt	tcatcaataa	cgctgttgtt	720
gcaggaggag	cgatcttctc	ccctatctgt	tcttcaacag	gaaatcgctg	taacatcggt	780
ttctataaca	atcgctgctt	taaaaatgta	gaaacagctt	cttcagaaag	tcttgatgga	840
ggagcaatta	aagtaactac	tcgcctagat	gttacaggca	atcgttggtg	gatctttttt	900
agtgacaata	tcacaaaaaa	ttatggcgga	gctatttacg	ctcctgtagt	taccctagtgt	960
gataatggcc	ctacctactt	tataaacaat	atcgccaata	ataagggggg	cgctatctat	1020
atagacagaa	ccagtaactc	caaaatttct	gcgcagccgc	atctgattat	ttttaataga	1080
aatatttgga	ctaattgtta	taatgcaaat	ggtaccagta	cgtcagctaa	tctcctagta	1140
agaaatgcga	taacagtagc	aagctcctct	gggtgaaatt	tattaggagc	agggagtagc	1200
caaaatttaa	ttttttatga	tcttattgaa	gttagcaatg	cagggtctct	tgtgtctctc	1260
aataaggga	ctgatcaaac	aggctctgta	gtatttttcg	gagctactgt	taattctgca	1320
gattttctat	aacgcgaatt	acaaacaaaa	acacctgcac	cccttactct	cagtaatggt	1380
tttctatgta	tcgaaatgca	tgtctcagct	acagtgaaat	gattcacaca	actgggggtg	1440
gtgtgtttct	ctgggaatgg	agcagttctg	agttgtcata	aaaatggtag	aggagattct	1500
cttagcaatg	cctctataac	actgaagcat	attggattga	atcttctctc	cattctgaaa	1560
agtggtgctg	agattctctt	attgtgggta	gagcctacaa	ataacagcaa	taactataca	1620
gcagatactg	cagctacctt	ttcatttaag	gatgtaaaaa	tctcactcat	tgatgactac	1680

gggaaactctc	cttatgaatc	cacagatctg	accatgctc	tgtcatcaca	gcctatgcta	1740
tctattttctg	aagctagcga	taaccagcta	caatcagaaa	atatagattt	ttcggggacta	1800
aatgtccctc	attatggatg	gcaaggactt	tggacttggg	gctgggcaaa	aactcaagat	1860
ccagaaccag	catcttcacg	aaacatcact	gatccacaaa	aagccaatag	attcatagata	1920
accttactac	taacatggct	tctcgccggg	tatgttctca	gcccaaaaca	cagaagctccc	1980
ctcatagcta	acaccttatg	ggggaatatg	ctgcttgcaa	cagaaagctt	aaaaaatagt	2040
gcagagctga	caaccttagtg	tcctcctttc	tggggaatta	caggaggagg	actaggcatg	2100
atgtgttacc	aagatctctg	agaaaatcat	ctcgattccc	atatgcgctc	tccgggatac	2160
tctcggggga	tgatagcagg	gcagacacac	accttctcat	tgaatttcag	tcagacctac	2220
accaactca	atgagcgctt	cgcaaaaaac	aacgtatctt	ctaaaaatta	ctcatgccaa	2280
ggagagatgc	tcttctcatt	gcagaagagg	ttcttctgta	ctaaatttagt	tgggctttac	2340
agctatggag	accataaactg	tcaccatttc	tatactcaag	gagaaaaatct	aaactctcaa	2400
gggacgttcc	gcagctcaaac	gatgggagggt	gctgtctttt	ttgatctccc	tatgaaaccc	2460
tttggatcaa	cgcatatact	gacagctccc	tttttaggtg	ctcttgggat	ttaattctag	2520
ctgtctcaact	ttactgaggt	gggagcctat	ccgcgaagct	ttctacaaa	gactcctttg	2580
atacaatgct	tagtccotat	tggagttaaa	ggttagcttta	tgaatgctac	ccacagacct	2640
caagccttgg	ctgtagaatt	ggcataccaa	cccgctctgt	atagacaaa	accaggggatc	2700
gcgaccacag	tctatgcccag	taaaggattt	tgggttggtta	gtggaagccc	ctcatcgctg	2760
catgccatgt	cctataaaat	ctcacagcaa	acacaacctt	tgagtttggt	aactctccat	2820
ttccagtatc	atggattctta	ctcctcttca	acctctgtga	attatctcaa	tggggaaatt	2880
gctctcgcat	tctag					2895

<210> 172

<211> 4593

<212> DNA

<213> Chlamydia

<400> 172

atgagttccg	agaaagatat	aaaaagcacc	tgttctaagt	tttttttgct	tgtagtagca	60
gctatccttg	cctctgttag	cggttagctt	agttagctag	atctctatcg	tggaggacag	120
tctgtaaatg	agctgggtata	tgtaggccct	caagcggttt	tattgttaga	ccaaattcca	180
gatctattgg	ttgggtctaa	agatagtcag	gctgaaggac	agtataggtt	aattgttaga	240
gatecaagtt	ctttccaaga	gaaagatgca	gatactcttc	ccgggaaggt	agagcaaatg	300
actttgttct	cagtacaacaa	tcccggtggt	ttccaagggt	tggaccaaca	gatatcaagtc	360
tcttcccaag	gggttaatttg	tagtttttacg	agcagcaacc	ttgattcttc	ccgtgacgga	420
gaatcttttt	taggtattgc	ttttgttggg	gatagtagta	ggcctgaaat	caacttaact	480
gacgtgaaag	cttctttgtc	tggagcggct	ttatatctca	cagaagatct	tatctttgaa	540
aagatttaagg	gtggattgga	atttgcatca	tgttctctc	tagaacaggg	gggagcttgt	600
gcagctcaaa	gtattttgat	tcattgattgt	caaggattgc	aggttaaaac	ctgtactaca	660
gccgtgaatg	ctgaggggtc	tagtgcgaat	gatcatcttg	gatttggagg	aggcgctttc	720
tttgttacgg	gttctctttc	tggagagaaa	agttctcata	tgccctgcag	agatatggta	780
gttgcgaaat	gtgatggggc	tatatctttt	gaaggaaaac	gcgcgaactt	tgcataaggta	840
ggagcgattg	ctgcctctgg	gaaagtgcct	tttgcgcta	atgataaaaa	gacctctttt	900
atagagaacc	gagctttgtc	tggaggagcg	attgcagcct	cttctgatat	tgccttccaa	960
aactgcgcag	aactagtttt	caaaaggcaat	tgtgcaattg	gaacagagga	taaaagttct	1020
ttaggttgag	gggcttatct	ttctctagcg	acogtctctt	tgcaagggaa	tcacgggata	1080
actttgtgata	agaatgagtc	tgcttcgcaa	ggaggcgcca	tttttggcaa	aaattgtcag	1140
atttctgaca	acgaggggac	agtggttttc	agagatagta	cagcttgcct	aggaggaggc	1200
gctattgcag	ctcaagaana	tgtttctatt	cagaacaatc	aggctgggat	ttctctcgag	1260
ggaggttaagg	ctagttttcg	aggaggtatt	gcgtgtggat	ctttttcttc	ccgacgcggt	1320
gctcttgctt	taggagactat	tgatattttc	aagaatttag	gcgcgatttc	gttctctcgt	1380
actttatgta	cgacctcaga	tttaggacaa	atggagatcc	agggaggagg	agctctattt	1440
gttgaaaata	tttctctttc	tgagaatgct	ggtgtgctca	cctttaagaa	caacattgtg	1500
aagacttttg	cttcgaatgg	gaaaattctg	ggaggaggag	cgatttttag	tactggttaag	1560
gtggaaatta	ccaataattc	cggagggaatt	tctttttacag	gaaatgcgag	agctccacaa	1620

gctcttccaa	ctcaagagga	gtttccttta	ttcagcaaaa	aagaaggcg	accactctct	1680
tcaggatatt	ctgggggagg	agcgatttta	ggaagagaag	tagctattct	ccacaacgct	1740
gcagtagtat	ttgagcaaaa	tcgtttgcag	tgcaagcgaag	aagaagcgac	attatttaggt	1800
tggttggagg	gaggcgctgt	tcatgggagt	gatagcactt	cgattgttgg	caactcttca	1860
gtaagatttg	gtaataatta	cgcaatggga	caaggagtct	caggaggagc	tcttttatct	1920
aaaacagtgc	agttagctgg	aaatggaagc	gtcgattttt	ctcgaaatat	tgctagtgtt	1980
ggaggaggag	ctcttcaagg	ttctgaagga	aattgtgagc	tagttgataa	cggctatgtg	2040
ctattcagag	ataatcgagg	gagggtttat	gggggtgcta	ttcttgcgtt	acgtggagat	2100
gtagtcattt	ctggaaccaa	gggttagagtt	gaatttaaa	acaacatagc	aacacgctct	2160
tatgtggaag	aaactgtaga	aaagggttaa	gaggtagagc	cagctcctga	gcacaaaagac	2220
aataatgagc	tttctttctt	agggagtgta	gaacagagtt	ttattactgc	agctaataca	2280
gctctttctg	catctgaaga	tggggattta	tcactctgag	catccattct	ttctgaagaa	2340
cttgcgaaaa	gaagagagtg	tgctggagga	gctatttttt	caaaaacgggt	tcgtatttga	2400
gataaccaa	agggcgttgt	attctcgaat	aactctctct	atatattatg	cggcgccatt	2460
tttacgggtt	ctcttcgaga	agaggataag	ttagatgggc	aaatccctga	agctttgatc	2520
tcaggcaatg	caggggagtg	tggttttttc	ggaatttctt	cgaagcgtga	tgagcatctt	2580
cctcatcacg	gtgggggagc	catttgtact	caaaatttga	cgattttctc	gcacacaggg	2640
aatgttctgt	tttataacaa	cgtggcctgt	tcgggaggag	ctgttcgtat	agaggatcat	2700
ggtaatgttc	ttttgaagc	ttttggagga	gatattgttt	ttaaaggaaa	ttctcttctt	2760
agagcacaag	gactcgatgc	tattctatttt	gcaggtaaa	aatcgcatat	tacagccctg	2820
gaatgctacg	aaggacatgc	tattgttttc	cacgagcat	tagtttttga	aaatctaaaa	2880
aaaaggaaag	ctgctgaagt	attgttaatc	aatagtcgag	aaaatccagg	ttacactgga	2940
tctattcgat	ttttgaagc	agaaagtaaa	gttctcctaa	gtattctatg	acacaagga	3000
agccttgagt	tgctaagtgt	agctacatta	tgtagtattg	gttttaacaa	agatcgtgga	3060
gctaagtgtg	tattggctgc	tggatctaaa	ctgaagattt	tagattcagy	aactccgtga	3120
caagggcgag	ctatcagtaa	acctgaagca	gaatctgagt	catcttctga	accagagggg	3180
gcacatttct	tttggattgc	gaagaatgct	caacaacag	ttcctattgt	tgatatccat	3240
actattcttg	tagattttagc	ctcctctctt	tctagtcaac	aggaagggag	agttagaagt	3300
ctccaggtta	ttgttctctg	aggaagttat	gttcgatctg	gagcgcttaa	tttggagtta	3360
gttaacacaa	caggctactgg	ttatgaaaa	catgctttgt	tgaagaatga	ggctaagaat	3420
ccatttagtg	ctttcgttgc	ttctagtgt	gaagcttcag	ccgaatcag	taactgtctg	3480
gtttctgatt	tacagattca	tgtagcaact	ccagagattg	aagaagacac	atacggccat	3540
atgggagatt	ggctcgagc	taaaattcaa	gatggaactc	ttgtcattaa	ttggaatcct	3600
actggatctc	gattagatct	tcaaaaagca	ggggctttag	tattttaatgc	attatgggaa	3660
gaaggggctg	tcttctctgc	tctgaaaaat	gcacgctttg	ctcataatct	cactgtccag	3720
cgtatggagt	tcgatttact	tacaaaatgt	tggggatttc	cctttgggtg	tttccgaagt	3780
ctatctcgag	agaatctggt	tgctattgat	ggatacaaa	gagcttatgg	tggtgcttct	3840
ctggagtgct	atattcaact	gatggaagat	tttgtttctg	gagtttagtg	agctgtcttc	3900
ctaggtcaaaa	tggatagctc	gaagtttgat	gcggaggttt	ctcggaaagg	agttgttggt	3960
tctgtatata	caggattttt	agctggatcc	tggtttctca	aaggacaata	tagccttgga	4020
gaacacaga	acgatattga	aacgcgttat	ggagtactag	gagagtcgag	tgcttcttgg	4080
acatctcgag	gagtactggc	agatgcttta	gttgaatacc	gaagtttagt	tggtcctgtg	4140
agacctactt	tttatgcttt	gcatttcaat	ccttatgtcg	aaglatctta	tgcttctatg	4200
aaattctctg	gctttacaga	acaaggaaga	gaagcgctgt	cttttgaaga	cgcttccctt	4260
accaatctca	ccattctctt	agggtagaag	tttgaattgg	cgttcaataa	aggacagttt	4320
tccaggttga	actctttggg	ataaagttat	gcattcgaaa	agttagaagg	agtagaagg	4380
ggcgcggctg	agctttttaga	agctgggttt	gattgggaag	gagctccaat	ggatcttctt	4440
agacaggagc	tcgctgtctg	tctggaaaa	aatacggagt	ggagttctta	cttcagcaca	4500
gtcttaggat	taacagcttt	tttggaggga	tttacttcta	cagatagtaa	actaggatat	4560
gaggcgaaata	ctggattcgc	attgatcttt	taa			4593

<210> 173

<211> 5331

<212> DNA

<213> Chlamydia

<400> 173

gcaatcatga	aattttatgtc	agctactgct	gtatttgcgt	cagtactctc	ctccggtact	60
gaggcgagct	cgatccaaga	tcaataaag	aatccgact	gcaatgttag	caaagtagga	120
tattcaactt	ctcaagcatt	tactgatatg	atgctagcag	acaacacaga	gtatcgagct	180
gctgatagtg	tttcatctta	tgacttttcc	acatcttccg	gattacctag	aaaacatctt	240
agtagagtag	gtgaagcttc	tccaacgaca	gaaggagtgt	cttcatcttc	atctggagaa	300
aatactgaga	attcacaaga	ttcagctccc	ttctctggag	aaactgataa	gaaacacaga	360
gaagaactag	acaatggcgg	aatcatttat	gctagagaga	aactaactat	ctcagaatct	420
caggactctc	tctctaacc	aagcatagaa	ctccatgaca	atagtttttt	cttcggagaa	480
ggtagagttt	tctttgatca	cagagttgcc	ctcaaaaacg	gaggagctat	ttatggagag	540
aaagaggtag	cttttgaaa	cataaaatct	ctactgtag	aagtaaatat	ctcggtcgag	600
aaagggggtg	gcgtctatgc	aaaaaacya	gtatctttag	aaaatgttac	cgaagcaacc	660
ttctctccca	atgggtggga	acaaggggtg	ggtagaatct	atccagaaca	agatattgta	720
atcagtgatt	gcaacaatgt	acatttccaa	gggaatgctg	caggagcaac	acagctaaaa	780
caatgtctgg	atgaagaaat	gatcgtattg	ctcacagaat	gcgttgatag	cttatccgaa	840
gtacactggg	atagcactcc	agaaacggaa	cagactaagt	caaatgaaa	tcaagatggt	900
tcgtctgaaa	caaaagatac	acaagtatca	gaatcaccag	aatcaactcc	tagcccccag	960
gctgtttttg	gtaaaaggtg	tggtatctat	acagaaaaat	ctttgacctat	caactggaatt	1020
acaggggacta	tagattttgt	cagtaacata	gctaccgatt	cttggagcagg	tgatttcaact	1080
aaagaaaact	tgtcttgac	caacacgaat	agctacagat	ttttgaaaaa	ctcggcaggt	1140
gagagtgagg	gaggagccta	cgttactcaa	accatgtctg	ttactaatac	aactagtgaa	1200
agttataacta	ctccccctct	cgttagagaa	gtgattttct	ttgaaaaact	agctaaaggg	1260
ccagtggtgt	gtatctgcac	taacaaaact	tcttttctta	attaaaaaac	ggtagactct	1320
actaaaact	ctgcaaaagg	gtctggagga	gctattttta	cagattctagc	gtctatacca	1380
acaaacagata	ccccagagtc	ttctcccccc	ttctctctct	cgcttgcaag	cactccccga	1440
gtagttgctt	ctgctaaaat	aaatcgattc	tttgctctta	cggcagaaac	cgacgcccct	1500
ttctctaacag	aggttgagtc	tgatcaaacg	gatcaaacag	aaacttctga	taactaatagc	1560
gatatacagc	tgtcgattgc	gaacattttg	aatgtcgcta	tcnatcaaaa	caacttctgcg	1620
aaaaaaggag	gggtatttta	cgggaaaaaa	gctaaacttt	ccggtattaa	caatcttgaa	1680
ctttcaggga	attcatccca	ggatgtagga	ggaggtctct	gttaacttga	aagcgtagaa	1740
tttgatgcga	ttggatcgct	cttatcccac	tataactctg	ctgctaaaaga	aggtggggtt	1800
attcatttcta	aaacggttac	tctatctaac	ctcaagtcta	ccttcaactt	tgacagataac	1860
actgtttaaag	caatagttaga	aagcactcct	gaagctccag	aagagattcc	ttccagttaga	1920
ggagaacagt	ctacagcaac	agaaaatccg	aattcttaata	cagaaggaag	ttcggctaac	1980
actaaactgt	aaggatctca	aggggatact	gctgatacag	gnaactgggt	tgtaaacact	2040
gagttctcaag	acacatcaga	tactggaac	gctgaactctg	gagaacaact	acaagattct	2100
acacaaacta	atgaagaaaa	tacccttccc	aatagtagta	ttgatcaatc	taacgaaaaa	2160
acagaggaat	catctgtatag	ccacactgag	gaaataactg	acagagagct	ctcactgcctc	2220
ctcaaaagt	gatcatctac	tctccaagat	ggagggagcag	cttcttcagg	ggctccctca	2280
ggagatacaat	ctatctctgc	aaacgcttgt	ttagctaaaa	gctatgctgc	gagtaactgat	2340
agctccccctg	tatctaattc	ttcaggttca	gaagttactg	catcttctga	taattccagac	2400
tcttctctac	ctggagatag	cgtcggagac	cttgaggagac	cgactgagcc	agaagctggt	2460
tctcaacacag	aaactcctac	tttaatagga	gaaggtgcta	tctatggaga	aactgttaag	2520
attgagaact	tctctggcca	aggaatatatt	tctggaaca	aagctatcga	taacaccaca	2580
gaaggctcct	cttccaaatc	taacgtctct	ggaggtgcgg	tctatgctaa	aactgtgttt	2640
aatctcgata	gcgggagctc	tagacgaact	gtcaccttct	ccgggaatad	tgctctctct	2700
caactctaca	caggctcaggt	tgctggagga	gctactact	ctctactgtg	aaccttgcct	2760
actcctgtag	tattttcttaa	aaactctgca	acaaacaatg	ctaataacgc	tacagatact	2820
cagagaaaacg	aaacctttgg	aggagctatc	ggagctactt	ctgctgtttc	tctatcagaa	2880
ctctgctcaat	tcttagaaaa	cgttgctgac	ctcggaactg	ctattgggtt	gggtccagag	2940
acacaaaaat	cagaacacgt	gaaatttagag	tctggctctct	actacttcta	aaaaataaaa	3000
gctttaaaac	gagctactat	ttacgcacct	gtcgtttccc	ttaaaagctg	ctctgcgaca	3060
tttaaccaaa	acagatctct	agaagaagga	agcgcgattt	actttacaaa	agaagcatct	3120
attgagctctt	taggctctgt	tctcttcaaa	ggaaacttag	taaccccaac	gctaagcaca	3180

actacaaga	gcacaccagc	cacaacctca	ggagatgtaa	caaaatatgg	tgctgctatc	3240
tttggacaaa	tagcaagctc	aaacggatct	cagacggata	accttcccc	gaaactcatt	3300
gcttcggag	gaaatatttg	tttcgaaac	aatgaatacc	gtcctatctc	ttctgatacc	3360
ggaaacctcta	ctttctgtag	tattgcgga	gatgttaaat	taacctatga	agctgcaaaa	3420
gggaaaaacga	tcagttctt	tgatgcaatc	cggacctcta	ctaagaaaa	aggtacacag	3480
gcaactcgct	acgatattct	cgatattaat	aaatctgagg	attcagaaa	tgtaaactct	3540
gcgtttacag	gaacgattct	gttctctct	gaattacatg	aaaataaact	ctatatccca	3600
caaaacgtag	ttctacacag	tggatctctt	gtattgaagc	caaataccga	gttctatgtc	3660
atttcttttg	agcagaaga	aggctcttct	ctcgttatga	cacctggatc	tgttctttcg	3720
aaccagactg	ttgctgtatg	agctttgggc	ataaataaca	tgaccattga	tttatccagg	3780
gtagagaaaa	atggtattgc	tgaaggaaat	atctttactc	ctccagaatt	gagaatcata	3840
garactacta	caagtggaa	cgggtggaac	ccatctacag	atagtgaag	taaccagaat	3900
agtgatgata	ccaaggagca	aaataataat	gacgcctcga	atcaaggaga	aagcgcgaat	3960
ggatcgctct	ctcctgcagt	agctgctgca	cacacatctc	gtacaagaaa	ctttgcgcgt	4020
gcagctacag	ccacacctac	gacaacacca	acggctacaa	ctacaacaag	caaccaagta	4080
atcctaggag	gagaaatcaa	actcatcgat	cctaattggga	ctttcttcca	gaaccttgca	4140
ttaagatccg	accaacaaat	ctccttggtt	gtgctcccta	cagactcttc	aaaaatgcaa	4200
gctcagaaaa	tagtactgac	gggtgatatt	gctctccaga	aaggatatcc	aggaacactc	4260
actctggatc	gcgttcaatc	acaaaatgga	acgatctcag	cgctctggaa	atttgacctc	4320
tatatgacaat	gggtttatgt	acctagagac	aatcatcttc	atgcgaactc	gattctggga	4380
ttcctaaatgt	caatggctcac	agtnaaacaa	ggcttgctca	acgataaaat	gaatctagct	4440
cgctttgatg	aagtttagcta	taacaacctg	tggatatcag	gactaggaa	gatgctatcg	4500
caagtaggaa	caactacttc	tgaagaattc	acttatcata	gcagaggagc	ttctgttgcc	4560
ttagatgcta	aaccagccca	tgatgtgatt	gttggagctg	catttagtaa	gatgatcggt	4620
aaaaaataat	ccctgaaagg	agsgaataac	tacactcata	aaggatccga	atattctcac	4680
caacgatcgg	tatacggagg	caaacacctc	caactttgta	tcaataaaaa	aacggaaaaa	4740
tcgctaccgc	tattgttaca	aggagctcac	tcttacggat	atatcaaaac	tgatcacagt	4800
actcactatc	caacgatccg	tgaacgaaac	caaggagaat	gggaagactt	aggatggctg	4860
acagctctcc	gtgctctctc	tgtcttaaga	actctgcac	aaggggatcc	taaacgtatc	4920
actgtttacg	gagaattgga	atactccagt	atccgctcga	aacaaatcac	agaaacagaa	4980
taogatctct	gttactctga	caactgcacc	tatagaact	tagraattcc	tatggggtta	5040
gcattcgag	gagagctctc	tggtaacgat	attttgatgt	acaacagatt	ctctgtagca	5100
tacatgccat	caattctatc	aaattctcca	acatgcaaat	accaagtgtc	ctcttcagga	5160
gaaggcggag	aaattatttg	tggagtaccg	acaagaaact	cagctgcggg	agaatacagc	5220
acgcagctgt	acccgggacc	tttgtggact	ctgtatggat	ctcacacgat	agaagcagac	5280
gcacatacac	tagctcatat	gatgaactgc	ggtgctcgta	tgacattcta	a	5331

<210> 174

<211> 5265

<212> DNA

<213> Chlamydia

<400> 174

gcaatcatga	aatggctgtc	agctactgcy	gtgtttgtgt	ctgtttctcc	ctcagtttca	60
gggttttgg	tccagaaacc	taagaatta	aatttctctc	gcgtagaaa	ttcttctctc	120
accactttta	ctgaacaaat	tggagaagct	ggggcagaat	atactgtctc	tggttaacgca	180
cttttccaaa	aatttaccaa	cattctctact	accgatatac	caactcccac	gaactcaaac	240
ttctcttagt	ctagcggaga	aactgcttcc	gtttctgagg	atagtgaact	tacaacaacg	300
actctcgatc	ctaaaggtgg	cggcgcttct	tataaacgcy	actccggagt	ttgtctcttt	360
atgacacgat	caggaaacga	aggttcccta	actctgtctg	agataaaaa	gactggtgaa	420
ggcgggtgcta	cttctctca	aggagagctg	ctattttacag	atctgacaa	cttaaccatc	480
caaaaataact	tatccacgtc	atccggagga	gcgatttttg	gaggatctac	aatctcccta	540
tccgggatta	ctaaagcgac	tttctctctc	aactctgcag	aagttctctg	ttctgttaag	600

aaacctacag	aacctaaagc	tcaaacagca	agcgaaacgt	cgggttctag	tagttctagc	660
ggaatgatt	cgggtctctc	ccccagttcc	agttagagctg	aaccgcgagc	agctaatctt	720
caaatgcact	ttattttgtg	tacagctact	cctgctgctc	aaaccgatac	agaaacatca	780
actccctctc	ataagccagg	atctggggga	gctatctatg	ctaaagcgga	ccttactact	840
gcagactctc	aagaggttact	attctcaata	aataaaagcta	ctaaagatgg	aggagcgatc	900
tttctgtaga	aagatgtttc	tttcgagaat	attacatcat	taaaagtaca	aactaacggt	960
gctgaagaaa	agggaggagc	tatctatgct	aaaggtgacc	tctcaattca	atcttctaaa	1020
cagagctctt	ttaatctctaa	ctacagtaaa	caaggtgggg	gggctctata	tgttgaagga	1080
ggtataaaat	tccaagatct	tgaagaat	cgcattaaat	acaataaagc	tggaaagcttc	1140
gaaacaaaaa	aaatcacttt	accttcttta	aaagctcaag	catctgcagg	aaatgcagat	1200
gcttggggct	cttctctctc	tcaatctggt	tctggagcaa	ctacagtctc	cgaactcagga	1260
gactctagct	ctggctcagc	ctcggatacc	tcgaaaacag	ttccagtccac	agctaagggc	1320
ggtgggcttt	atactgataa	gaatctttcg	attactaaca	tcacaggaat	tatcgaaatt	1380
gaaataaaca	aagcgacaga	tgttggagggt	ggtgcttacc	taaaaggaaac	ccttacttgt	1440
gaaaactctc	accgtctaca	atttttgaaa	aactcttccg	ataaacaagg	tggagggaatc	1500
tacggagaga	acaaactcac	cctatctaat	ttgacagggga	agactctatt	ccaagagaat	1560
actgccaaag	aagagggcgg	tggactcttc	ataaaaggtt	cagataaagc	tcttacaagt	1620
acaggactgg	atagtttctg	tttaattaat	aacacatcag	aaaaacatgg	tgggtggagcc	1680
tttgtatcca	aaagaatctc	tcagacttac	acctctgatg	tggaaaacat	tccaggaatc	1740
accgcgtgac	atgggtgaac	agtcattact	ggcaataaat	ctacaggagg	taatggttga	1800
ggcgtgtgta	caaaacgtct	tgccttatct	aacctctcaa	gcatttctat	atccgggaat	1860
tctgcagcag	aaaatgctgg	tggagccacc	acatgccagc	atagctctcc	aacggcgagat	1920
actgcagaac	agcccgagcg	agcttctgcc	gcgactctct	ctcccaaatc	tgcctccggtc	1980
tcaactgctc	taagcacacc	ttcatctctt	acctgtctct	cttaaacctt	actagcagcc	2040
tcttcaacag	cctctctctc	aacctctaat	aaggaaactc	aagatcctaa	tgtctgatac	2100
gacttattga	tcgattatgt	agttgatagc	actatcagca	aaaacactgc	taagaagggc	2160
tgttgaattct	atgctaaaaa	agccaaagat	tccgcataag	acaaactgaa	tatctctgag	2220
actcccgcta	cagagatagg	tggaggatct	tgtctgtaag	aatctttaga	actagatgct	2280
ctagtctctt	tatctgtaac	agagaacctt	gttgggaaag	aaggtggagg	cttacctgct	2340
aaaactgttaa	atatttctaa	tctgaaatca	ggcttctctt	tctcgaaaca	caaagcaaac	2400
tctcatcaca	caggagctgc	acaaacagct	tcagcacctg	ctcgcagctgc	tgcttcccta	2460
caagcagccg	cagcagccgc	accatcatct	ccagcaaac	caacttatrc	aggtgtagta	2520
ggaggagcta	tctatggaga	aaaggttaca	ttctctcaat	gtagcgggac	ttgtcagttc	2580
tctgggaaac	aagctatcga	taacaatccc	tccaatcat	cgttgaacgt	caaggaggga	2640
gccatctcta	ccaaaacctc	tttgtctatt	ggatcttccg	atgtcggaac	ctctcatatt	2700
tcttcgggga	acaggttctc	cactgggaaa	tctcaaaaca	cagggcacat	agcgggaggga	2760
gcgatctact	cccctactgt	tacattgaat	tgtcctgcga	cattctctaa	caatcacagc	2820
tctatagcta	caccgaagac	ttcttctgaa	gatggatcct	caggaaatct	tattaaagat	2880
accatttgag	gagccattgc	agggacagcc	attacctat	ctggagctct	tcgattttca	2940
gggaatacgg	ctgattttagg	agctgcaata	ggaaactctag	ctaagtcaaa	tacaccaggt	3000
cgaactagcg	gatctcaaaa	tagcattaca	gaaaaaaaga	cttttagaaa	cggttctctt	3060
atttttgaaa	gaaaccagcg	taataaacgt	ggagcgattt	actctcctag	cgttctccatt	3120
aaagggaaata	atattacctt	caatcaaaat	acatccactc	atgatggaag	cgctatctac	3180
tttcaaaaag	atgctacgat	tgagctctta	tgcactgttc	tttttacagg	aaataacggt	3240
acagctacac	aagctagttc	tgcacatctt	ggacaaaata	caaatactgc	caactatggg	3300
gcagccatct	ttggagatcc	aggaaccaact	caatcgtctc	acaacagatc	caattttacg	3360
ctctctgctt	cttctggaaa	cattactttt	agcaacaaca	gtttacagaa	tataccaagt	3420
gatactcccg	ctagcaagtt	ttgtagtatt	gcaggatcac	tcaaaactct	tcataaacgc	3480
gctaaagggga	agactattag	ctttttcgat	tgtgtgcaca	cctctaccaa	aaaaacaggt	3540
tcaaacaaaa	acgtttatga	aaactttagat	attaataaag	aagagaacag	taatccatat	3600
acaggaacta	ttgtgtcttc	ttctgaatta	catgaaaaca	aatctttacg	cccacagaat	3660
gcaatctctc	acaaaggaaac	tttagttctt	aaagagaaaa	cagaactcca	cgtaactctc	3720
tttgtagcga	aagaagggtc	taaatattt	atggaaacccg	gagctgtgtt	atcttaacca	3780
aaatagcta	acggagctct	agctatcaat	gggttaacga	ttgatcttct	cagtatgggg	3840
actcctcaag	caggggaaat	cttctctcct	ccagaattac	gtatcgttgc	cagacactct	3900

```

agtgcattccg gaggaagcgg ggtcagcagt agtatacca caaatcctaa aaggattttct 3960
gcagcagtgcc ctctcaggttc tgcgcgaact actccaacta tgagcgcagaa caaagtttttc 4020
ctaacaggag acccttacttt aatagatcct aatggaaact tttaccaaaa ccctatgtta 4080
ggaagcgatc tagatgtacc actaattaa gctccgacta acacaaagta cgtccaagtc 4140
tatgatttaa ctttatctgg ggaatctttt cctcagaaag ggtacatggg aacctggaca 4200
ttgatttcta atccacaac agggaaactt caagccagat ggacattcga tacctatcgt 4260
cgctgggtat acatacctag ggataatcat ttttatcgga actctatctt aggtcccaa 4320
aactcaatga tgttgtgaa gcaagggtct atcaacaaca tgttgaataa tgcccgttc 4380
gatgatctcg cttacaataa cttctgggtt tcagagtagt gaactttctt agctcaacaa 4440
ggaactctct tttccgaaga attcagttac tacagccgcg gaacttcagt tgccatcgat 4500
gccaaaccta gacaagattt tatcctagga gctgcattta gtaagatagt ggggaaaacc 4560
aaagccatca aaaaatgca taattacttc cataagggtc ctgagtactc ttaccaagct 4620
tctgtctatg gaggtaaatt cctgtatttc ttgctcaata agcaacatgg ttgggcactt 4680
cctttcctaa tacaaggagt cgtgtcctat ggacatatta aacatgatac aacacactt 4740
taccttcta tccatgaag aataaaagga gattgggaag atttaggatg gttacgggat 4800
cttcgtatct ctatggatct taagaacct tctaaagatt cttctaaac gatcactgtc 4860
tatggggaac tggagtattc cagcattcgc cagaaacagt tcacagaaat cgattacgat 4920
ccaagacact tcatgatgtg tgcctacaga aatctgtcgc ttctgtggg atgcgctgtc 4980
gaaggagact tcatgaactg taatattctt atgtataata agcttgcat agcctacatg 5040
cctcttatct acagaaataa tctgtctgt aaatatcggg tatgtcttc gaatgaagct 5100
ggccaagata tctcggaggt gccaaactaga acctctgcta gagcagaata cagtactcaa 5160
ctatatcttg gtccctctg gactctctac ggaaactata ctatcgatgt aggcattgat 5220
acgctatcgc aaatgactag ctgcggtgct cgcattgatct tctaa 5265

```

<210> 175

<211> 880

<212> PRT

<213> Chlamydia

<220>

<221> VARIANT

<222> (1)...(880)

<223> Xaa = Any Amino Acid

<400> 175

```

Ala Ile Met Arg Pro Asp His Met Asn Phe Cys Cys Leu Cys Ala Ala
 1             5             10             15
Ile Leu Ser Ser Thr Ala Val Leu Phe Gly Gln Asp Pro Leu Gly Glu
 20             25             30
Thr Ala Leu Leu Thr Lys Asn Pro Asn His Val Val Cys Thr Phe Phe
 35             40             45
Glu Asp Cys Thr Met Glu Ser Leu Phe Pro Ala Leu Cys Ala His Ala
 50             55             60
Ser Gln Asp Asp Pro Leu Tyr Val Leu Gly Asn Ser Tyr Cys Trp Phe
 65             70             75             80
Val Ser Lys Leu His Ile Thr Asp Pro Lys Glu Ala Leu Phe Lys Glu
 85             90             95
Lys Gly Asp Leu Ser Ile Gln Asn Phe Arg Phe Leu Ser Phe Thr Asp
100            105            110
Cys Ser Ser Lys Glu Ser Ser Pro Ser Ile Ile His Gln Lys Asn Gly
115            120            125
Gln Leu Ser Leu Arg Asn Asn Gly Ser Met Ser Phe Cys Arg Asn His
130            135            140

```

Ala Glu Gly Ser Gly Gly Ala Ile Ser Ala Asp Ala Phe Ser Leu Gln
 145 150 155 160
 His Asn Tyr Leu Phe Thr Ala Phe Glu Glu Asn Ser Ser Lys Gly Asn
 165 170 175
 Gly Gly Ala Ile Gln Ala Gln Thr Phe Ser Leu Ser Arg Asn Val Ser
 180 185 190
 Pro Ile Ser Phe Ala Arg Asn Arg Ala Asp Leu Asn Gly Gly Ala Ile
 195 200 205
 Cys Cys Ser Asn Leu Ile Cys Ser Gly Asn Val Asn Pro Leu Phe Phe
 210 215 220
 Thr Gly Asn Ser Ala Thr Asn Gly Gly Ala Ile Cys Cys Ile Ser Asp
 225 230 235 240
 Leu Asn Thr Ser Glu Lys Gly Ser Leu Ser Leu Ala Cys Asn Gln Glu
 245 250 255
 Thr Leu Phe Ala Ser Asn Ser Ala Lys Glu Lys Gly Gly Ala Ile Tyr
 260 265 270
 Ala Lys His Met Val Leu Arg Tyr Asn Gly Pro Val Ser Phe Ile Asn
 275 280 285
 Asn Ser Ala Lys Ile Gly Gly Ala Ile Ala Ile Gln Ser Gly Gly Ser
 290 295 300
 Leu Ser Ile Leu Ala Gly Glu Gly Ser Val Leu Phe Gln Asn Asn Ser
 305 310 315 320
 Gln Arg Thr Ser Asp Gln Gly Leu Val Arg Asn Ala Ile Tyr Leu Xaa
 325 330 335
 Lys Asp Ala Ile Leu Ser Ser Leu Glu Ala Arg Asn Gly Asp Ile Leu
 340 345 350
 Phe Phe Asp Pro Ile Val Gln Glu Ser Ser Lys Glu Ser Pro Leu
 355 360 365
 Pro Ser Ser Leu Gln Ala Ser Val Thr Ser Pro Thr Pro Ala Thr Ala
 370 375 380
 Ser Pro Leu Val Ile Gln Thr Ser Ala Asn Arg Ser Val Ile Phe Ser
 385 390 395 400
 Ser Glu Arg Leu Ser Glu Glu Glu Lys Thr Pro Asp Asn Leu Thr Ser
 405 410 415
 Gln Leu Gln Gln Pro Ile Glu Leu Lys Ser Gly Arg Leu Val Leu Lys
 420 425 430
 Asp Arg Ala Val Leu Ser Ala Pro Ser Leu Ser Gln Asp Pro Gln Ala
 435 440 445
 Leu Leu Ile Met Glu Ala Gly Thr Ser Leu Lys Thr Ser Ser Asp Leu
 450 455 460
 Lys Leu Ala Thr Leu Ser Ile Pro Leu His Ser Leu Asp Thr Glu Lys
 465 470 475 480
 Ser Val Thr Ile His Ala Pro Asn Leu Ser Ile Gln Lys Ile Phe Leu
 485 490 495
 Ser Asn Ser Gly Asp Glu Asn Phe Tyr Glu Asn Val Glu Leu Leu Ser
 500 505 510
 Lys Glu Gln Asn Asn Ile Pro Leu Leu Thr Leu Pro Lys Glu Gln Ser
 515 520 525
 His Leu His Leu Pro Asp Gly Asn Leu Ser Ser His Phe Gly Tyr Gln
 530 535 540
 Gly Asp Trp Thr Phe Ser Trp Lys Asp Ser Asp Glu Gly His Ser Leu
 545 550 555 560
 Ile Ala Asn Trp Thr Pro Lys Asn Tyr Val Pro His Pro Glu Arg Gln
 565 570 575
 Ser Thr Leu Val Ala Asn Thr Leu Trp Asn Thr Tyr Ser Asp Met Gln

```

      580                      585                      590
Ala Val Gln Ser Met Ile Asn Thr Thr Ala His Gly Gly Ala Tyr Leu
      595                      600                      605
Phe Gly Thr Trp Gly Ser Ala Val Ser Asn Leu Phe Tyr Val His Asp
      610                      615                      620
Ser Ser Gly Lys Pro Ile Asp Asn Trp His His Arg Ser Leu Gly Tyr
      625                      630                      635
Leu Phe Gly Ile Ser Thr His Ser Leu Asp Asp His Ser Phe Cys Leu
      645                      650                      655
Ala Ala Gly Gln Leu Leu Gly Lys Ser Ser Asp Ser Phe Ile Thr Ser
      660                      665                      670
Thr Glu Thr Thr Ser Tyr Ile Ala Thr Val Gln Ala Gln Leu Ala Thr
      675                      680                      685
Ser Leu Met Lys Ile Ser Ala Gln Ala Cys Tyr Asn Glu Ser Ile His
      690                      695                      700
Glu Leu Lys Thr Lys Tyr Arg Ser Phe Ser Lys Glu Gly Phe Gly Ser
      705                      710                      715
Trp His Ser Val Ala Val Ser Gly Glu Val Cys Ala Ser Ile Pro Ile
      725                      730                      735
Val Ser Asn Gly Ser Gly Leu Phe Ser Ser Phe Ser Ile Phe Ser Lys
      740                      745                      750
Leu Gln Gly Phe Ser Gly Thr Gln Asp Gly Phe Glu Glu Ser Ser Gly
      755                      760                      765
Glu Ile Arg Ser Phe Ser Ala Ser Ser Phe Arg Asn Ile Ser Leu Pro
      770                      775                      780
Ile Gly Ile Thr Phe Glu Lys Lys Ser Gln Lys Thr Arg Thr Tyr Tyr
      785                      790                      795
Tyr Phe Leu Gly Ala Tyr Ile Gln Asp Leu Lys Arg Asp Val Glu Ser
      805                      810                      815
Gly Pro Val Val Leu Leu Lys Asn Ala Val Ser Trp Asp Ala Pro Met
      820                      825                      830
Ala Asn Leu Asp Ser Arg Ala Tyr Met Phe Arg Leu Thr Asn Gln Arg
      835                      840                      845
Ala Leu His Arg Leu Gln Thr Leu Leu Asn Val Ser Cys Val Leu Arg
      850                      855                      860
Gly Gln Ser His Ser Tyr Ser Leu Asp Leu Gly Thr Thr Tyr Arg Phe
      865                      870                      875                      880

```

<210> 176

<211> 982

<212> PRT

<213> Chlamydia

<220>

<221> VARIANT

<222> (1)...(982)

<223> Xaa = Any Amino Acid

<400> 176

```

Met Ile Pro Gln Gly Ile Tyr Asp Gly Glu Thr Leu Thr Val Ser Phe
  1                      5                      10                      15
Pro Tyr Thr Val Ile Gly Asp Pro Ser Gly Thr Thr Val Phe Ser Ala
      20                      25                      30
Gly Glu Leu Thr Leu Lys Asn Leu Asp Asn Ser Ile Ala Ala Leu Pro
      35                      40                      45

```

Leu Ser Cys Phe Gly Asn Leu Leu Gly Ser Phe Thr Val Leu Gly Arg
 50 55 60
 Gly His Ser Leu Thr Phe Glu Asn Ile Arg Thr Ser Thr Asn Gly Ala
 65 70 75 80
 Ala Leu Ser Asn Ser Ala Ala Asp Gly Leu Phe Thr Ile Glu Gly Phe
 85 90 95
 Lys Glu Leu Ser Phe Ser Asn Cys Asn Ser Leu Leu Ala Val Leu Pro
 100 105 110
 Ala Ala Thr Thr Asn Lys Gly Ser Gln Thr Pro Thr Thr Thr Ser Thr
 115 120 125
 Pro Ser Asn Gly Thr Ile Tyr Ser Lys Thr Asp Leu Leu Leu Leu Asn
 130 135 140
 Asn Glu Lys Phe Ser Phe Tyr Ser Asn Leu Val Ser Gly Asp Gly Gly
 145 150 155 160
 Ala Ile Asp Ala Lys Ser Leu Thr Val Gln Gly Ile Ser Lys Leu Cys
 165 170 175
 Val Phe Gln Glu Asn Thr Ala Gln Ala Asp Gly Gly Ala Cys Gln Val
 180 185 190
 Val Thr Ser Phe Ser Ala Met Ala Asn Glu Ala Pro Ile Ala Phe Val
 195 200 205
 Ala Asn Val Ala Gly Val Arg Gly Gly Gly Ile Ala Ala Val Gln Asp
 210 215 220
 Gly Gln Gln Gly Val Ser Ser Ser Thr Ser Thr Glu Asp Pro Val Val
 225 230 235 240
 Ser Phe Ser Arg Asn Thr Ala Val Glu Phe Asp Gly Asn Val Ala Arg
 245 250 255
 Val Gly Gly Gly Ile Tyr Ser Tyr Gly Asn Val Ala Phe Leu Asn Asn
 260 265 270
 Gly Lys Thr Leu Phe Leu Asn Asn Val Ala Ser Pro Val Tyr Ile Ala
 275 280 285
 Ala Lys Gln Pro Thr Ser Gly Gln Ala Ser Asn Thr Ser Asn Asn Tyr
 290 295 300
 Gly Asp Gly Gly Ala Ile Phe Cys Lys Asn Gly Ala Gln Ala Gly Ser
 305 310 315 320
 Asn Asn Ser Gly Ser Val Ser Phe Asp Gly Glu Gly Val Val Phe Phe
 325 330 335
 Ser Ser Asn Val Ala Ala Gly Lys Gly Gly Ala Ile Tyr Ala Lys Lys
 340 345 350
 Leu Ser Val Ala Asn Cys Gly Pro Val Gln Phe Leu Arg Asn Ile Ala
 355 360 365
 Asn Asp Gly Gly Ala Ile Tyr Leu Gly Glu Ser Gly Glu Leu Ser Leu
 370 375 380
 Ser Ala Asp Tyr Gly Asp Ile Ile Phe Asp Gly Asn Leu Lys Arg Thr
 385 390 395 400
 Ala Lys Glu Asn Ala Ala Asp Val Asn Gly Val Thr Val Ser Ser Gln
 405 410 415
 Ala Ile Ser Met Gly Ser Gly Gly Lys Ile Thr Thr Leu Arg Ala Lys
 420 425 430
 Ala Gly His Gln Ile Leu Phe Asn Asp Pro Ile Glu Met Ala Asn Gly
 435 440 445
 Asn Asn Gln Pro Ala Gln Ser Ser Lys Leu Leu Lys Ile Asn Asp Gly
 450 455 460
 Glu Gly Tyr Thr Gly Asp Ile Val Phe Ala Asn Gly Ser Ser Thr Leu
 465 470 475 480
 Tyr Gln Asn Val Thr Ile Glu Gln Gly Arg Ile Val Leu Arg Glu Lys

[illegible]

Trp Thr Thr Asp Ala Phe His Leu Ala Arg His Gly Val Val Val Arg
 930 935 940
 Gly Ser Met Tyr Ala Ser Leu Thr Ser Asn Ile Glu Val Tyr Gly His
 945 950 955 960
 Gly Arg Tyr Glu Tyr Arg Asp Ala Ser Arg Gly Tyr Gly Leu Ser Ala
 965 970 975
 Gly Ser Lys Val Xaa Phe
 980

<210> 177

<211> 964

<212> PRT

<213> Chlamydia

<400> 177

Met Lys Lys Ala Phe Phe Phe Phe Leu Ile Gly Asn Ser Leu Ser Gly
 1 5 10 15
 Leu Ala Arg Glu Val Pro Ser Arg Ile Phe Leu Met Pro Asn Ser Val
 20 25 30
 Pro Asp Pro Thr Lys Glu Ser Leu Ser Asn Lys Ile Ser Leu Thr Gly
 35 40 45
 Asp Thr His Asn Leu Thr Asn Cys Tyr Leu Asp Asn Leu Arg Tyr Ile
 50 55 60
 Leu Ala Ile Leu Gln Lys Thr Pro Asn Glu Gly Ala Ala Val Thr Ile
 65 70 75 80
 Thr Asp Tyr Leu Ser Phe Phe Asp Thr Gln Lys Glu Gly Ile Tyr Phe
 85 90 95
 Ala Lys Asn Leu Thr Pro Glu Ser Gly Gly Ala Ile Gly Tyr Ala Ser
 100 105 110
 Pro Asn Ser Pro Thr Val Glu Ile Arg Asp Thr Ile Gly Pro Val Ile
 115 120 125
 Phe Glu Asn Asn Thr Cys Cys Arg Leu Phe Thr Trp Arg Asn Pro Tyr
 130 135 140
 Ala Ala Asp Lys Ile Arg Glu Gly Gly Ala Ile His Ala Gln Asn Leu
 145 150 155 160
 Tyr Ile Asn His Asn His Asp Val Val Gly Phe Met Lys Asn Phe Ser
 165 170 175
 Tyr Val Gln Gly Gly Ala Ile Ser Thr Ala Asn Thr Phe Val Val Ser
 180 185 190
 Glu Asn Gln Ser Cys Phe Leu Phe Met Asp Asn Ile Cys Ile Gln Thr
 195 200 205
 Asn Thr Ala Gly Lys Gly Gly Ala Ile Tyr Ala Gly Thr Ser Asn Ser
 210 215 220
 Phe Glu Ser Asn Asn Cys Asp Leu Phe Phe Ile Asn Asn Ala Cys Cys
 225 230 235 240
 Ala Gly Gly Ala Ile Phe Ser Pro Ile Cys Ser Leu Thr Gly Asn Arg
 245 250 255
 Gly Asn Ile Val Phe Tyr Asn Asn Arg Cys Phe Lys Asn Val Glu Thr
 260 265 270
 Ala Ser Ser Glu Ala Ser Asp Gly Gly Ala Ile Lys Val Thr Thr Arg
 275 280 285
 Leu Asp Val Thr Gly Asn Arg Gly Arg Ile Phe Phe Ser Asp Asn Ile
 290 295 300
 Thr Lys Asn Tyr Gly Gly Ala Ile Tyr Ala Pro Val Val Thr Leu Val
 305 310 315 320

Asp Asn Gly Pro Thr Tyr Phe Ile Asn Asn Ile Ala Asn Asn Lys Gly
 325 330 335
 Gly Ala Ile Tyr Ile Asp Gly Thr Ser Asn Ser Lys Ile Ser Ala Asp
 340 345 350
 Arg His Ala Ile Ile Phe Asn Glu Asn Ile Val Thr Asn Val Thr Asn
 355 360 365
 Ala Asn Gly Thr Ser Thr Ser Ala Asn Pro Pro Arg Arg Asn Ala Ile
 370 375 380
 Thr Val Ala Ser Ser Ser Gly Glu Ile Leu Leu Gly Ala Gly Ser Ser
 385 390 395 400
 Gln Asn Leu Ile Phe Tyr Asp Pro Ile Glu Val Ser Asn Ala Gly Val
 405 410 415
 Ser Val Ser Phe Asn Lys Glu Ala Asp Gln Thr Gly Ser Val Val Phe
 420 425 430
 Ser Gly Ala Thr Val Asn Ser Ala Asp Phe His Gln Arg Asn Leu Gln
 435 440 445
 Thr Lys Thr Pro Ala Pro Leu Thr Leu Ser Asn Gly Phe Leu Cys Ile
 450 455 460
 Glu Asp His Ala Gln Leu Thr Val Asn Arg Phe Thr Gln Thr Gly Gly
 465 470 475 480
 Val Val Ser Leu Gly Asn Gly Ala Val Leu Ser Cys Tyr Lys Asn Gly
 485 490 495
 Thr Gly Asp Ser Ala Ser Asn Ala Ser Ile Thr Leu Lys His Ile Gly
 500 505 510
 Leu Asn Leu Ser Ser Ile Leu Lys Ser Gly Ala Glu Ile Pro Leu Leu
 515 520 525
 Trp Val Glu Pro Thr Asn Asn Ser Asn Asn Tyr Thr Ala Asp Thr Ala
 530 535 540
 Ala Thr Phe Ser Leu Ser Asp Val Lys Leu Ser Leu Ile Asp Asp Tyr
 545 550 555 560
 Gly Asn Ser Pro Tyr Glu Ser Thr Asp Leu Thr His Ala Leu Ser Ser
 565 570 575
 Gln Pro Met Leu Ser Ile Ser Glu Ala Ser Asp Asn Gln Leu Gln Ser
 580 585 590
 Glu Asn Ile Asp Phe Ser Gly Leu Asn Val Pro His Tyr Gly Trp Gln
 595 600 605
 Gly Leu Trp Thr Trp Gly Trp Ala Lys Thr Gln Asp Pro Glu Pro Ala
 610 615 620
 Ser Ser Ala Thr Ile Thr Asp Pro Gln Lys Ala Asn Arg Phe His Arg
 625 630 635 640
 Thr Leu Leu Leu Thr Trp Leu Pro Ala Gly Tyr Val Pro Ser Pro Lys
 645 650 655
 His Arg Ser Pro Leu Ile Ala Asn Thr Leu Trp Gly Asn Met Leu Leu
 660 665 670
 Ala Thr Glu Ser Leu Lys Asn Ser Ala Glu Leu Thr Pro Ser Gly His
 675 680 685
 Pro Phe Trp Gly Ile Thr Gly Gly Gly Leu Gly Met Met Val Tyr Gln
 690 695 700
 Asp Pro Arg Glu Asn His Pro Gly Phe His Met Arg Ser Ser Gly Tyr
 705 710 715 720
 Ser Ala Gly Met Ile Ala Gly Gln Thr His Thr Phe Ser Leu Lys Phe
 725 730 735
 Ser Gln Thr Tyr Thr Lys Leu Asn Glu Arg Tyr Ala Lys Asn Asn Val
 740 745 750
 Ser Ser Lys Asn Tyr Ser Cys Gln Gly Glu Met Leu Phe Ser Leu Gln

755 760 765
 Glu Gly Phe Leu Leu Thr Lys Leu Val Gly Leu Tyr Ser Tyr Gly Asp
 770 775 780
 His Asn Cys His His Phe Tyr Thr Gln Gly Glu Asn Leu Thr Ser Gln
 785 790 795 800
 Gly Thr Phe Arg Ser Gln Thr Met Gly Gly Ala Val Phe Phe Asp Leu
 805 810 815
 Pro Met Lys Pro Phe Gly Ser Thr His Ile Leu Thr Ala Pro Phe Leu
 820 825 830
 Gly Ala Leu Gly Ile Tyr Ser Ser Leu Ser His Phe Thr Glu Val Gly
 835 840 845
 Ala Tyr Pro Arg Ser Phe Ser Thr Lys Thr Pro Leu Ile Asn Val Leu
 850 855 860
 Val Pro Ile Gly Val Lys Gly Ser Phe Met Asn Ala Thr His Arg Pro
 865 870 875 880
 Gln Ala Trp Thr Val Glu Leu Ala Tyr Gln Pro Val Leu Tyr Arg Gln
 885 890 895
 Glu Pro Gly Ile Ala Thr Gln Leu Leu Ala Ser Lys Gly Ile Trp Phe
 900 905 910
 Gly Ser Gly Ser Pro Ser Ser Arg His Ala Met Ser Tyr Lys Ile Ser
 915 920 925
 Gln Gln Thr Gln Pro Leu Ser Trp Leu Thr Leu His Phe Gln Tyr His
 930 935 940
 Gly Phe Tyr Ser Ser Ser Thr Phe Cys Asn Tyr Leu Asn Gly Glu Ile
 945 950 955 960
 Ala Leu Arg Phe

<210> 178

<211> 1530

<212> PRT

<213> Chlamydia

<400> 178

Met Ser Ser Glu Lys Asp Ile Lys Ser Thr Cys Ser Lys Phe Ser Leu
 1 5 10 15
 Ser Val Val Ala Ala Ile Leu Ala Ser Val Ser Gly Leu Ala Ser Cys
 20 25 30
 Val Asp Leu His Ala Gly Gly Gln Ser Val Asn Glu Leu Val Tyr Val
 35 40 45
 Gly Pro Gln Ala Val Leu Leu Leu Asp Gln Ile Arg Asp Leu Phe Val
 50 55 60
 Gly Ser Lys Asp Ser Gln Ala Glu Gly Gln Tyr Arg Leu Ile Val Gly
 65 70 75 80
 Asp Pro Ser Ser Phe Gln Glu Lys Asp Ala Asp Thr Leu Pro Gly Lys
 85 90 95
 Val Glu Gln Ser Thr Leu Phe Ser Val Thr Asn Pro Val Val Phe Gln
 100 105 110
 Gly Val Asp Gln Gln Asp Gln Val Ser Ser Gln Gly Leu Ile Cys Ser
 115 120 125
 Phe Thr Ser Ser Asn Leu Asp Ser Pro Arg Asp Gly Glu Ser Phe Leu
 130 135 140
 Gly Ile Ala Phe Val Gly Asp Ser Ser Lys Ala Gly Ile Thr Leu Thr
 145 150 155 160
 Asp Val Lys Ala Ser Leu Ser Gly Ala Ala Leu Tyr Ser Thr Glu Asp

				165					170					175	
Leu	Ile	Phe	Glu	Lys	Ile	Lys	Gly	Gly	Leu	Glu	Phe	Ala	Ser	Cys	Ser
			180						185					190	
Ser	Leu	Glu	Gln	Gly	Gly	Ala	Cys	Ala	Ala	Gln	Ser	Ile	Leu	Ile	His
		195					200						205		
Asp	Cys	Gln	Gly	Leu	Gln	Val	Lys	His	Cys	Thr	Thr	Ala	Val	Asn	Ala
		210					215					220			
Glu	Gly	Ser	Ser	Ala	Asn	Asp	His	Leu	Gly	Phe	Gly	Gly	Gly	Ala	Phe
		225				230				235				240	
Phe	Val	Thr	Gly	Ser	Leu	Ser	Gly	Glu	Lys	Ser	Leu	Tyr	Met	Pro	Ala
			245						250					255	
Gly	Asp	Met	Val	Val	Ala	Asn	Cys	Asp	Gly	Ala	Ile	Ser	Phe	Glu	Gly
		260						265					270		
Asn	Ser	Ala	Asn	Phe	Ala	Asn	Gly	Gly	Ala	Ile	Ala	Ala	Ser	Gly	Lys
		275					280						285		
Val	Leu	Phe	Val	Ala	Asn	Asp	Lys	Lys	Thr	Ser	Phe	Ile	Glu	Asn	Arg
		290				295						300			
Ala	Leu	Ser	Gly	Gly	Ala	Ile	Ala	Ala	Ser	Ser	Asp	Ile	Ala	Phe	Gln
		305				310				315				320	
Asn	Cys	Ala	Glu	Leu	Val	Phe	Lys	Gly	Asn	Cys	Ala	Ile	Gly	Thr	Glu
			325					330						335	
Asp	Lys	Gly	Ser	Leu	Gly	Gly	Gly	Ala	Ile	Ser	Ser	Leu	Gly	Thr	Val
			340					345					350		
Leu	Leu	Gln	Gly	Asn	His	Gly	Ile	Thr	Cys	Asp	Lys	Asn	Glu	Ser	Ala
		355					360					365			
Ser	Gln	Gly	Gly	Ala	Ile	Phe	Gly	Lys	Asn	Cys	Gln	Ile	Ser	Asp	Asn
		370				375					380				
Glu	Gly	Pro	Val	Val	Phe	Arg	Asp	Ser	Thr	Ala	Cys	Leu	Gly	Gly	Gly
		385				390				395				400	
Ala	Ile	Ala	Ala	Gln	Glu	Ile	Val	Ser	Ile	Gln	Asn	Asn	Gln	Ala	Gly
			405						410					415	
Ile	Ser	Phe	Glu	Gly	Gly	Lys	Ala	Ser	Phe	Gly	Gly	Gly	Ile	Ala	Cys
		420						425					430		
Gly	Ser	Phe	Ser	Ser	Ala	Gly	Gly	Ala	Ser	Val	Leu	Gly	Thr	Ile	Asp
		435					440					445			
Ile	Ser	Lys	Asn	Leu	Gly	Ala	Ile	Ser	Phe	Ser	Arg	Thr	Leu	Cys	Thr
		450				455					460				
Thr	Ser	Asp	Leu	Gly	Gln	Met	Glu	Tyr	Gln	Gly	Gly	Gly	Ala	Leu	Phe
		465				470			475					480	
Gly	Glu	Asn	Ile	Ser	Leu	Ser	Glu	Asn	Ala	Gly	Val	Leu	Thr	Phe	Lys
			485						490					495	
Asp	Asn	Ile	Val	Lys	Thr	Phe	Ala	Ser	Asn	Gly	Lys	Ile	Leu	Gly	Gly
			500					505					510		
Gly	Ala	Ile	Leu	Ala	Thr	Gly	Lys	Val	Glu	Ile	Thr	Asn	Asn	Ser	Gly
		515					520					525			
Gly	Ile	Ser	Phe	Thr	Gly	Asn	Ala	Arg	Ala	Pro	Gln	Ala	Leu	Pro	Thr
		530				535				540					
Gln	Glu	Glu	Phe	Pro	Leu	Phe	Ser	Lys	Lys	Glu	Gly	Arg	Pro	Leu	Ser
		545				550				555				560	
Ser	Gly	Tyr	Ser	Gly	Gly	Gly	Ala	Ile	Leu	Gly	Arg	Glu	Val	Ala	Ile
			565						570					575	
Leu	His	Asn	Ala	Ala	Val	Val	Phe	Glu	Gln	Asn	Arg	Leu	Gln	Cys	Ser
			580					585					590		
Glu	Glu	Glu	Ala	Thr	Leu	Leu	Gly	Cys	Cys	Gly	Gly	Gly	Ala	Val	His
		595					600						605		

Gly Met Asp Ser Thr Ser Ile Val Gly Asn Ser Ser Val Arg Phe Gly
 610 615 620
 Asn Asn Tyr Ala Met Gly Gln Gly Val Ser Gly Gly Ala Leu Leu Ser
 625 630 635 640
 Lys Thr Val Gln Leu Ala Gly Asn Gly Ser Val Asp Phe Ser Arg Asn
 645 650 655
 Ile Ala Ser Leu Gly Gly Gly Ala Leu Gln Ala Ser Glu Gly Asn Cys
 660 665 670
 Glu Leu Val Asp Asn Gly Tyr Val Leu Phe Arg Asp Asn Arg Gly Arg
 675 680 685
 Val Tyr Gly Gly Ala Ile Ser Cys Leu Arg Gly Asp Val Val Ile Ser
 690 695 700
 Gly Asn Lys Gly Arg Val Glu Phe Lys Asp Asn Ile Ala Thr Arg Leu
 705 710 715 720
 Tyr Val Glu Glu Thr Val Glu Lys Val Glu Glu Val Glu Pro Ala Pro
 725 730 735
 Glu Gln Lys Asp Asn Asn Glu Leu Ser Phe Leu Gly Ser Val Glu Gln
 740 745 750
 Ser Phe Ile Thr Ala Ala Asn Gln Ala Leu Phe Ala Ser Glu Asp Gly
 755 760 765
 Asp Leu Ser Pro Glu Ser Ser Ile Ser Ser Glu Glu Leu Ala Lys Arg
 770 775 780
 Arg Glu Cys Ala Gly Gly Ala Ile Phe Ala Lys Arg Val Arg Ile Val
 785 790 795 800
 Asp Asn Gln Glu Ala Val Val Phe Ser Asn Asn Phe Ser Asp Ile Tyr
 805 810 815
 Gly Gly Ala Ile Phe Thr Gly Ser Leu Arg Glu Glu Asp Lys Leu Asp
 820 825 830
 Gly Gln Ile Pro Glu Val Leu Ile Ser Gly Asn Ala Gly Asp Val Val
 835 840 845
 Phe Ser Gly Asn Ser Ser Lys Arg Asp Glu His Leu Pro His Thr Gly
 850 855 860
 Gly Gly Ala Ile Cys Thr Gln Asn Leu Thr Ile Ser Gln Asn Thr Gly
 865 870 875 880
 Asn Val Leu Phe Tyr Asn Asn Val Ala Cys Ser Gly Gly Ala Val Arg
 885 890 895
 Ile Glu Asp His Gly Asn Val Leu Leu Glu Ala Phe Gly Gly Asp Ile
 900 905 910
 Val Phe Lys Gly Asn Ser Ser Phe Arg Ala Gln Gly Ser Asp Ala Ile
 915 920 925
 Tyr Phe Ala Gly Lys Glu Ser His Ile Thr Ala Leu Asn Ala Thr Glu
 930 935 940
 Gly His Ala Ile Val Phe His Asp Ala Leu Val Phe Glu Asn Leu Lys
 945 950 955 960
 Glu Arg Lys Ser Ala Glu Val Leu Leu Ile Asn Ser Arg Glu Asn Pro
 965 970 975
 Gly Tyr Thr Gly Ser Ile Arg Phe Leu Glu Ala Glu Ser Lys Val Pro
 980 985 990
 Gln Cys Ile His Val Gln Gln Gly Ser Leu Glu Leu Leu Asn Gly Ala
 995 1000 1005
 Thr Leu Cys Ser Tyr Gly Phe Lys Gln Asp Ala Gly Ala Lys Leu Val
 1010 1015 1020
 Leu Ala Ala Gly Ser Lys Leu Lys Ile Leu Asp Ser Gly Thr Pro Val
 1025 1030 1035 1040
 Gln Gly His Ala Ile Ser Lys Pro Glu Ala Glu Ile Glu Ser Ser Ser

1045 1050 1055
 Glu Pro Glu Gly Ala His Ser Leu Trp Ile Ala Lys Asn Ala Gln Thr
 1060 1065 1070
 Thr Val Pro Met Val Asp Ile His Thr Ile Ser Val Asp Leu Ala Ser
 1075 1080 1085
 Phe Ser Ser Ser Gln Gln Glu Gly Thr Val Glu Ala Pro Gln Val Ile
 1090 1095 1100
 Val Pro Gly Gly Ser Tyr Val Arg Ser Gly Glu Leu Asn Leu Glu Leu
 1105 1110 1115 1120
 Val Asn Thr Thr Gly Thr Gly Tyr Glu Asn His Ala Leu Leu Lys Asn
 1125 1130 1135
 Glu Ala Lys Val Pro Leu Met Ser Phe Val Ala Ser Ser Asp Glu Ala
 1140 1145 1150
 Ser Ala Glu Ile Ser Asn Leu Ser Val Ser Asp Leu Gln Ile His Val
 1155 1160 1165
 Ala Thr Pro Glu Ile Glu Glu Asp Thr Tyr Gly His Met Gly Asp Trp
 1170 1175 1180
 Ser Glu Ala Lys Ile Gln Asp Gly Thr Leu Val Ile Asn Trp Asn Pro
 1185 1190 1195 1200
 Thr Gly Tyr Arg Leu Asp Pro Gln Lys Ala Gly Ala Leu Val Phe Asn
 1205 1210 1215
 Ala Leu Trp Glu Glu Gly Ala Val Leu Ser Ala Leu Lys Asn Ala Arg
 1220 1225 1230
 Phe Ala His Asn Leu Thr Ala Gln Arg Met Glu Phe Asp Tyr Ser Thr
 1235 1240 1245
 Asn Val Trp Gly Phe Ala Phe Gly Gly Phe Arg Thr Leu Ser Ala Glu
 1250 1255 1260
 Asn Leu Val Ala Ile Asp Gly Tyr Lys Gly Ala Tyr Gly Gly Ala Ser
 1265 1270 1275 1280
 Ala Gly Val Asp Ile Gln Leu Met Glu Asp Phe Val Leu Gly Val Ser
 1285 1290 1295
 Gly Ala Ala Phe Leu Gly Lys Met Asp Ser Gln Lys Phe Asp Ala Glu
 1300 1305 1310
 Val Ser Arg Lys Gly Val Val Gly Ser Val Tyr Thr Gly Phe Leu Ala
 1315 1320 1325
 Gly Ser Trp Phe Phe Lys Gly Gln Tyr Ser Leu Gly Glu Thr Gln Asn
 1330 1335 1340
 Asp Met Lys Thr Arg Tyr Gly Val Leu Gly Glu Ser Ser Ala Ser Trp
 1345 1350 1355 1360
 Thr Ser Arg Gly Val Leu Ala Asp Ala Leu Val Glu Tyr Arg Ser Leu
 1365 1370 1375
 Val Gly Pro Val Arg Pro Thr Phe Tyr Ala Leu His Phe Asn Pro Tyr
 1380 1385 1390
 Val Glu Val Ser Tyr Ala Ser Met Lys Phe Pro Gly Phe Thr Glu Gln
 1395 1400 1405
 Gly Arg Glu Ala Arg Ser Phe Glu Asp Ala Ser Leu Thr Asn Ile Thr
 1410 1415 1420
 Ile Pro Leu Gly Met Lys Phe Glu Leu Ala Phe Ile Lys Gly Gln Phe
 1425 1430 1435 1440
 Ser Glu Val Asn Ser Leu Gly Ile Ser Tyr Ala Trp Glu Ala Tyr Arg
 1445 1450 1455
 Lys Val Glu Gly Gly Ala Val Gln Leu Leu Glu Ala Gly Phe Asp Trp
 1460 1465 1470
 Glu Gly Ala Pro Met Asp Leu Pro Arg Gln Glu Leu Arg Val Ala Leu
 1475 1480 1485

Glu Asn Asn Thr Glu Trp Ser Ser Tyr Phe Ser Thr Val Leu Gly Leu
 1490 1495 1500
 Thr Ala Phe Cys Gly Gly Phe Thr Ser Thr Asp Ser Lys Leu Gly Tyr
 1505 1510 1515 1520
 Glu Ala Asn Thr Gly Leu Arg Leu Ile Phe
 1525 1530

<210> 179
 <211> 1776
 <212> PRT
 <213> Chlamydia

<400> 179
 Ala Ile Met Lys Phe Met Ser Ala Thr Ala Val Phe Ala Ala Val Leu
 1 5 10 15
 Ser Ser Val Thr Glu Ala Ser Ser Ile Gln Asp Gln Ile Lys Asn Thr
 20 25 30
 Asp Cys Asn Val Ser Lys Val Gly Tyr Ser Thr Ser Gln Ala Phe Thr
 35 40 45
 Asp Met Met Leu Ala Asp Asn Thr Glu Tyr Arg Ala Ala Asp Ser Val
 50 55 60
 Ser Phe Tyr Asp Phe Ser Thr Ser Ser Gly Leu Pro Arg Lys His Leu
 65 70 75 80
 Ser Ser Ser Ser Glu Ala Ser Pro Thr Thr Glu Gly Val Ser Ser Ser
 85 90 95
 Ser Ser Gly Glu Asn Thr Glu Asn Ser Gln Asp Ser Ala Pro Ser Ser
 100 105 110
 Gly Glu Thr Asp Lys Lys Thr Glu Glu Leu Asp Asn Gly Gly Ile
 115 120 125
 Ile Tyr Ala Arg Glu Lys Leu Thr Ile Ser Glu Ser Gln Asp Ser Leu
 130 135 140
 Ser Asn Pro Ser Ile Glu Leu His Asp Asn Ser Phe Phe Phe Gly Glu
 145 150 155 160
 Gly Glu Val Ile Phe Asp His Arg Val Ala Leu Lys Asn Gly Gly Ala
 165 170 175
 Ile Tyr Gly Glu Lys Glu Val Val Phe Glu Asn Ile Lys Ser Leu Leu
 180 185 190
 Val Glu Val Asn Ile Ser Val Glu Lys Gly Gly Ser Val Tyr Ala Lys
 195 200 205
 Glu Arg Val Ser Leu Glu Asn Val Thr Glu Ala Thr Phe Ser Ser Asn
 210 215 220
 Gly Gly Glu Gln Gly Gly Gly Ile Tyr Ser Glu Gln Asp Met Leu
 225 230 235 240
 Ile Ser Asp Cys Asn Asn Val His Phe Gln Gly Asn Ala Ala Gly Ala
 245 250 255
 Thr Ala Val Lys Gln Cys Leu Asp Glu Glu Met Ile Val Leu Leu Thr
 260 265 270
 Glu Cys Val Asp Ser Leu Ser Glu Asp Thr Leu Asp Ser Thr Pro Glu
 275 280 285
 Thr Glu Gln Thr Lys Ser Asn Gly Asn Gln Asp Gly Ser Ser Glu Thr
 290 295 300
 Lys Asp Thr Gln Val Ser Glu Ser Pro Glu Ser Thr Pro Ser Pro Asp
 305 310 315 320
 Asp Val Leu Gly Lys Gly Gly Gly Ile Tyr Thr Glu Lys Ser Leu Thr
 325 330 335

Ile Thr Gly Ile Thr Gly Thr Ile Asp Phe Val Ser Asn Ile Ala Thr
 340 345 350
 Asp Ser Gly Ala Gly Val Phe Thr Lys Glu Asn Leu Ser Cys Thr Asn
 355 360 365
 Thr Asn Ser Leu Gln Phe Leu Lys Asn Ser Ala Gly Gln His Gly Gly
 370 375 380
 Gly Ala Tyr Val Thr Gln Thr Met Ser Val Thr Asn Thr Thr Ser Glu
 385 390 395 400
 Ser Ile Thr Thr Pro Leu Val Gly Glu Val Ile Phe Ser Glu Asn
 405 410 415
 Thr Ala Lys Gly His Gly Gly Gly Ile Cys Thr Asn Lys Leu Ser Leu
 420 425 430
 Ser Asn Leu Lys Thr Val Thr Leu Thr Lys Asn Ser Ala Lys Glu Ser
 435 440 445
 Gly Gly Ala Ile Phe Thr Asp Leu Ala Ser Ile Pro Thr Thr Asp Thr
 450 455 460
 Pro Glu Ser Ser Thr Pro Ser Ser Ser Ser Pro Ala Ser Thr Pro Glu
 465 470 475 480
 Val Val Ala Ser Ala Lys Ile Asn Arg Phe Phe Ala Ser Thr Ala Glu
 485 490 495
 Pro Ala Ala Pro Ser Leu Thr Glu Ala Glu Ser Asp Gln Thr Asp Gln
 500 505 510
 Thr Glu Thr Ser Asp Thr Asn Ser Asp Ile Asp Val Ser Ile Glu Asn
 515 520 525
 Ile Leu Asn Val Ala Ile Asn Gln Asn Thr Ser Ala Lys Lys Gly Gly
 530 535 540
 Ala Ile Tyr Gly Lys Lys Ala Lys Leu Ser Arg Ile Asn Asn Leu Glu
 545 550 555 560
 Leu Ser Gly Asn Ser Ser Gln Asp Val Gly Gly Leu Cys Leu Thr
 565 570 575
 Glu Ser Val Glu Phe Asp Ala Ile Gly Ser Leu Leu Ser His Tyr Asn
 580 585 590
 Ser Ala Ala Lys Glu Gly Gly Val Ile His Ser Lys Thr Val Thr Leu
 595 600 605
 Ser Asn Leu Lys Ser Thr Phe Thr Phe Ala Asp Asn Thr Val Lys Ala
 610 615 620
 Ile Val Glu Ser Thr Pro Glu Ala Pro Glu Glu Ile Pro Pro Val Glu
 625 630 635 640
 Gly Glu Glu Ser Thr Ala Thr Glu Asn Pro Asn Ser Asn Thr Glu Gly
 645 650 655
 Ser Ser Ala Asn Thr Asn Leu Glu Gly Ser Gln Gly Asp Thr Ala Asp
 660 665 670
 Thr Gly Thr Gly Val Val Asn Asn Glu Ser Gln Asp Thr Ser Asp Thr
 675 680 685
 Gly Asn Ala Glu Ser Gly Glu Gln Leu Gln Asp Ser Thr Gln Ser Asn
 690 695 700
 Glu Glu Asn Thr Leu Pro Asn Ser Ser Ile Asp Gln Ser Asn Glu Asn
 705 710 715 720
 Thr Asp Glu Ser Ser Asp Ser His Thr Glu Glu Ile Thr Asp Glu Ser
 725 730 735
 Val Ser Ser Ser Ser Lys Ser Gly Ser Ser Thr Pro Gln Asp Gly Gly
 740 745 750
 Ala Ala Ser Ser Gly Ala Pro Ser Gly Asp Gln Ser Ile Ser Ala Asn
 755 760 765
 Ala Cys Leu Ala Lys Ser Tyr Ala Ala Ser Thr Asp Ser Ser Pro Val

770	775	780
Ser Asn Ser Ser Gly Ser	Asp Val Thr Ala Ser	Ser Ser Asp Asn Pro Asp
785	790	795
Ser Ser Ser Ser Gly Asp	Ser Ala Gly Asp Ser	Glu Gly Pro Thr Glu
	805	810
Pro Glu Ala Gly Ser Thr	Thr Glu Thr Pro Thr	Leu Ile Gly Gly Gly
	820	825
Ala Ile Tyr Gly Glu Thr	Val Lys Ile Glu Asn Phe	Ser Gly Gln Gly
	835	840
Ile Phe Ser Gly Asn Lys	Ala Ile Asp Asn Thr	Thr Glu Gly Ser Ser
	850	855
Ser Lys Ser Asn Val Leu	Gly Gly Ala Val Tyr	Ala Lys Thr Leu Phe
	865	870
Asn Leu Asp Ser Gly Ser	Ser Arg Arg Thr Val	Thr Phe Ser Gly Asn
	885	890
Thr Val Ser Ser Gln Ser	Thr Thr Gly Gln Val	Ala Gly Gly Ala Ile
	900	905
Tyr Ser Pro Thr Val Thr	Ile Ala Thr Pro Val	Val Phe Ser Lys Asn
	915	920
Ser Ala Thr Asn Asn Ala	Asn Asn Ala Thr Asp	Thr Gln Arg Lys Asp
	930	935
Thr Phe Gly Gly Ala Ile	Gly Ala Thr Ser Ala	Val Ser Leu Ser Gly
	945	950
Gly Ala His Phe Leu Glu	Asn Val Ala Asp Leu	Gly Ser Ala Ile Gly
	965	970
Leu Val Pro Asp Thr Gln	Asn Thr Glu Thr Val	Lys Leu Glu Ser Gly
	980	985
Ser Tyr Tyr Phe Glu Lys	Asn Lys Ala Leu Lys	Arg Ala Thr Ile Tyr
	995	1000
Ala Pro Val Val Ser Ile	Lys Ala Tyr Thr Ala	Thr Phe Asn Gln Asn
	1010	1015
Arg Ser Leu Glu Glu Gly	Ser Ala Ile Tyr Phe	Thr Lys Glu Ala Ser
	1025	1030
Ile Glu Ser Leu Gly Ser	Val Leu Phe Thr Gly	Asn Leu Val Thr Pro
	1045	1050
Thr Leu Ser Thr Thr Thr	Glu Gly Thr Pro Ala	Thr Thr Ser Gly Asp
	1060	1065
Val Thr Lys Tyr Gly Ala	Ala Ile Phe Gly Gln	Ile Ala Ser Ser Asn
	1075	1080
Gly Ser Gln Thr Asp Asn	Leu Pro Leu Lys Leu	Ile Ala Ser Gly Gly
	1090	1095
Asn Ile Cys Phe Arg Asn	Asn Glu Tyr Arg Pro	Thr Ser Ser Asp Thr
	1105	1110
Gly Thr Ser Thr Phe Cys	Ser Ile Ala Gly Asp	Val Lys Leu Thr Met
	1125	1130
Gln Ala Ala Lys Gly Lys	Thr Ile Ser Phe Phe	Asp Ala Ile Arg Thr
	1140	1145
Ser Thr Lys Lys Thr Gly	Thr Gln Ala Thr Ala	Tyr Asp Thr Leu Asp
	1155	1160
Ile Asn Lys Ser Glu Asp	Ser Glu Thr Val Asn	Ser Ala Phe Thr Gly
	1170	1175
Thr Ile Leu Phe Ser Ser	Glu Leu His Glu Asn	Lys Ser Tyr Ile Pro
	1185	1190
Gln Asn Val Val Leu His	Ser Gly Ser Leu Val	Leu Lys Pro Asn Thr
	1205	1210
		1215

Glu Leu His Val Ile Ser Phe Glu Gln Lys Glu Gly Ser Ser Leu Val
 1220 1225 1230
 Met Thr Pro Gly Ser Val Leu Ser Asn Gln Thr Val Ala Asp Gly Ala
 1235 1240 1245
 Leu Val Ile Asn Asn Met Thr Ile Asp Leu Ser Ser Val Glu Lys Asn
 1250 1255 1260
 Gly Ile Ala Glu Gly Asn Ile Phe Thr Pro Pro Glu Leu Arg Ile Ile
 1265 1270 1275 1280
 Asp Thr Thr Thr Ser Gly Ser Gly Gly Thr Pro Ser Thr Asp Ser Glu
 1285 1290 1295
 Ser Asn Gln Asn Ser Asp Asp Thr Lys Glu Gln Asn Asn Asn Asp Ala
 1300 1305 1310
 Ser Asn Gln Gly Glu Ser Ala Asn Gly Ser Ser Ser Pro Ala Val Ala
 1315 1320 1325
 Ala Ala His Thr Ser Arg Thr Arg Asn Phe Ala Ala Ala Thr Ala
 1330 1335 1340
 Thr Pro Thr Thr Thr Pro Thr Ala Thr Thr Thr Thr Ser Asn Gln Val
 1345 1350 1355 1360
 Ile Leu Gly Gly Glu Ile Lys Leu Ile Asp Pro Asn Gly Thr Phe Phe
 1365 1370 1375
 Gln Asn Pro Ala Leu Arg Ser Asp Gln Gln Ile Ser Leu Leu Val Leu
 1380 1385 1390
 Pro Thr Asp Ser Ser Lys Met Gln Ala Gln Lys Ile Val Leu Thr Gly
 1395 1400 1405
 Asp Ile Ala Pro Gln Lys Gly Tyr Thr Gly Thr Leu Thr Leu Asp Pro
 1410 1415 1420
 Asp Gln Leu Gln Asn Gly Thr Ile Ser Ala Leu Trp Lys Phe Asp Ser
 1425 1430 1435 1440
 Tyr Arg Gln Trp Ala Tyr Val Pro Arg Asp Asn His Phe Tyr Ala Asn
 1445 1450 1455
 Ser Ile Leu Gly Ser Gln Met Ser Met Val Thr Val Lys Gln Gly Leu
 1460 1465 1470
 Leu Asn Asp Lys Met Asn Leu Ala Arg Phe Asp Glu Val Ser Tyr Asn
 1475 1480 1485
 Asn Leu Trp Ile Ser Gly Leu Gly Thr Met Leu Ser Gln Val Gly Thr
 1490 1495 1500
 Pro Thr Ser Glu Glu Phe Thr Tyr Tyr Ser Arg Gly Ala Ser Val Ala
 1505 1510 1515 1520
 Leu Asp Ala Lys Pro Ala His Asp Val Ile Val Gly Ala Ala Phe Ser
 1525 1530 1535
 Lys Met Ile Gly Lys Thr Lys Ser Leu Lys Arg Glu Asn Asn Tyr Thr
 1540 1545 1550
 His Lys Gly Ser Glu Tyr Ser Tyr Gln Ala Ser Val Tyr Gly Gly Lys
 1555 1560 1565
 Pro Phe His Phe Val Ile Asn Lys Lys Thr Glu Lys Ser Leu Pro Leu
 1570 1575 1580
 Leu Leu Gln Gly Val Ile Ser Tyr Gly Tyr Ile Lys His Asp Thr Val
 1585 1590 1595 1600
 Thr His Tyr Pro Thr Ile Arg Glu Arg Asn Gln Gly Glu Trp Glu Asp
 1605 1610 1615
 Leu Gly Trp Leu Thr Ala Leu Arg Val Ser Ser Val Leu Arg Thr Pro
 1620 1625 1630
 Ala Gln Gly Asp Thr Lys Arg Ile Thr Val Tyr Gly Glu Leu Glu Tyr
 1635 1640 1645
 Ser Ser Ile Arg Gln Lys Gln Phe Thr Glu Thr Glu Tyr Asp Pro Arg

1650 1655 1660
 Tyr Phe Asp Asn Cys Thr Tyr Arg Asn Leu Ala Ile Pro Met Gly Leu
 1665 1670 1675 1680
 Ala Phe Glu Gly Glu Leu Ser Gly Asn Asp Ile Leu Met Tyr Asn Arg
 1685 1690 1695
 Phe Ser Val Ala Tyr Met Pro Ser Ile Tyr Arg Asn Ser Pro Thr Cys
 1700 1705 1710
 Lys Tyr Gln Val Leu Ser Ser Gly Glu Gly Gly Glu Ile Ile Cys Gly
 1715 1720 1725
 Val Pro Thr Arg Asn Ser Ala Arg Gly Glu Tyr Ser Thr Gln Leu Tyr
 1730 1735 1740
 Pro Gly Pro Leu Trp Thr Leu Tyr Gly Ser Tyr Thr Ile Glu Ala Asp
 1745 1750 1755 1760
 Ala His Thr Leu Ala His Met Met Asn Cys Gly Ala Arg Met Thr Phe
 1765 1770 1775

<210> 180

<211> 1752

<212> PRT

<213> Chlamydia

<400> 180

Met Lys Trp Leu Ser Ala Thr Ala Val Phe Ala Ala Val Leu Pro Ser
 1 5 10 15
 Val Ser Gly Phe Cys Phe Pro Glu Pro Lys Glu Leu Asn Phe Ser Arg
 20 25 30
 Val Glu Thr Ser Ser Ser Thr Thr Thr Thr Glu Thr Ile Gly Glu Ala
 35 40 45
 Gly Ala Glu Tyr Ile Val Ser Gly Asn Ala Ser Phe Thr Lys Phe Thr
 50 55 60
 Asn Ile Pro Thr Thr Asp Thr Thr Thr Pro Thr Asn Ser Asn Ser Ser
 65 70 75 80
 Ser Ser Ser Gly Glu Thr Ala Ser Val Ser Glu Asp Ser Asp Ser Thr
 85 90 95
 Thr Thr Thr Thr Pro Asp Pro Lys Gly Gly Gly Ala Phe Tyr Asn Ala His
 100 105 110
 Ser Gly Val Leu Ser Phe Met Thr Arg Ser Gly Thr Glu Gly Ser Leu
 115 120 125
 Thr Leu Ser Glu Ile Lys Met Thr Gly Glu Gly Gly Ala Ile Phe Ser
 130 135 140
 Gln Gly Glu Leu Leu Phe Thr Asp Leu Thr Ser Leu Thr Ile Gln Asn
 145 150 155 160
 Asn Leu Ser Gln Leu Ser Gly Gly Ala Ile Phe Gly Gly Ser Thr Ile
 165 170 175
 Ser Leu Ser Gly Ile Thr Lys Ala Thr Phe Ser Cys Asn Ser Ala Glu
 180 185 190
 Val Pro Ala Pro Val Lys Lys Pro Thr Glu Pro Lys Ala Gln Thr Ala
 195 200 205
 Ser Glu Thr Ser Gly Ser Ser Ser Ser Ser Gly Asn Asp Ser Val Ser
 210 215 220
 Ser Pro Ser Ser Ser Arg Ala Glu Pro Ala Ala Ala Asn Leu Gln Ser
 225 230 235 240
 His Phe Ile Cys Ala Thr Ala Thr Pro Ala Ala Gln Thr Asp Thr Glu
 245 250 255
 Thr Ser Thr Pro Ser His Lys Pro Gly Ser Gly Gly Ala Ile Tyr Ala

	260		265		270
Lys Gly Asp	Leu Thr Ile Ala Asp	Ser Gln Glu Val Leu Phe Ser Ile			
	275	280		285	
Asn Lys Ala Thr Lys Asp Gly Gly Ala Ile Phe Ala Glu Lys Asp Val					
	290	295		300	
Ser Phe Glu Asn Ile Thr Ser Leu Lys Val Gln Thr Asn Gly Ala Glu					
	305	310		315	320
Glu Lys Gly Gly Ala Ile Tyr Ala Lys Gly Asp Leu Ser Ile Gln Ser					
	325	330		335	
Ser Lys Gln Ser Leu Phe Asn Ser Asn Tyr Ser Lys Gln Gly Gly Gly					
	340	345		350	
Ala Leu Tyr Val Glu Gly Gly Ile Asn Phe Gln Asp Leu Glu Glu Ile					
	355	360		365	
Arg Ile Lys Tyr Asn Lys Ala Gly Thr Phe Glu Thr Lys Lys Ile Thr					
	370	375		380	
Leu Pro Ser Leu Lys Ala Gln Ala Ser Ala Gly Asn Ala Asp Ala Trp					
	385	390		395	400
Ala Ser Ser Ser Pro Gln Ser Gly Ser Gly Ala Thr Thr Val Ser Asp					
	405	410		415	
Ser Gly Asp Ser Ser Ser Gly Ser Asp Ser Asp Thr Ser Glu Thr Val					
	420	425		430	
Pro Val Thr Ala Lys Gly Gly Gly Leu Tyr Thr Asp Lys Asn Leu Ser					
	435	440		445	
Ile Thr Asn Ile Thr Gly Ile Ile Glu Ile Ala Asn Asn Lys Ala Thr					
	450	455		460	
Asp Val Gly Gly Gly Ala Tyr Val Lys Gly Thr Leu Thr Cys Glu Asn					
	465	470		475	480
Ser His Arg Leu Gln Phe Leu Lys Asn Ser Ser Asp Lys Gln Gly Gly					
	485	490		495	
Gly Ile Tyr Gly Glu Asp Asn Ile Thr Leu Ser Asn Leu Thr Gly Lys					
	500	505		510	
Thr Leu Phe Gln Glu Asn Thr Ala Lys Glu Glu Gly Gly Gly Leu Phe					
	515	520		525	
Ile Lys Gly Thr Asp Lys Ala Leu Thr Met Thr Gly Leu Asp Ser Phe					
	530	535		540	
Cys Leu Ile Asn Asn Thr Ser Glu Lys His Gly Gly Gly Ala Phe Val					
	545	550		555	560
Thr Lys Glu Ile Ser Gln Thr Tyr Thr Ser Asp Val Glu Thr Ile Pro					
	565	570		575	
Gly Ile Thr Pro Val His Gly Glu Thr Val Ile Thr Gly Asn Lys Ser					
	580	585		590	
Thr Gly Gly Asn Gly Gly Gly Val Cys Thr Lys Arg Leu Ala Leu Ser					
	595	600		605	
Asn Leu Gln Ser Ile Ser Ile Ser Gly Asn Ser Ala Ala Glu Asn Gly					
	610	615		620	
Gly Gly Ala His Thr Cys Pro Asp Ser Phe Pro Thr Ala Asp Thr Ala					
	625	630		635	640
Glu Gln Pro Ala Ala Ser Ala Ala Thr Ser Thr Pro Lys Ser Ala					
	645	650		655	
Pro Val Ser Thr Ala Leu Ser Thr Pro Ser Ser Ser Thr Val Ser Ser					
	660	665		670	
Leu Thr Leu Leu Ala Ala Ser Ser Gln Ala Ser Pro Ala Thr Ser Asn					
	675	680		685	
Lys Glu Thr Gln Asp Pro Asn Ala Asp Thr Asp Leu Leu Ile Asp Tyr					
	690	695		700	

Val Val Asp Thr Thr Ile Ser Lys Asn Thr Ala Lys Lys Gly Gly Gly
 705 710 715 720
 Ile Tyr Ala Lys Lys Ala Lys Met Ser Arg Ile Asp Gln Leu Asn Ile
 725 730 735
 Ser Glu Asn Ser Ala Thr Glu Ile Gly Gly Gly Ile Cys Cys Lys Glu
 740 745 750
 Ser Leu Glu Leu Asp Ala Leu Val Ser Leu Ser Val Thr Glu Asn Leu
 755 760 765
 Val Gly Lys Glu Gly Gly Glu Leu His Ala Lys Thr Val Asn Ile Ser
 770 775 780
 Asn Leu Lys Ser Gly Phe Ser Phe Ser Asn Asn Lys Ala Asn Ser Ser
 785 790 795 800
 Ser Thr Gly Val Ala Thr Thr Ala Ser Ala Pro Ala Ala Ala Ala Ala
 805 810 815
 Ser Leu Gln Ala Ala Ala Ala Ala Pro Ser Ser Pro Ala Thr Pro
 820 825 830
 Thr Tyr Ser Gly Val Val Gly Gly Ala Ile Tyr Gly Glu Lys Val Thr
 835 840 845
 Phe Ser Gln Cys Ser Gly Thr Cys Gln Phe Ser Gly Asn Gln Ala Ile
 850 855 860
 Asp Asn Asn Pro Ser Gln Ser Ser Leu Asn Val Gln Gly Gly Ala Ile
 865 870 875 880
 Tyr Ala Lys Thr Ser Leu Ser Ile Gly Ser Ser Asp Ala Gly Thr Ser
 885 890 895
 Tyr Ile Phe Ser Gly Asn Ser Val Ser Thr Gly Lys Ser Gln Thr Thr
 900 905 910
 Gly Gln Ile Ala Gly Gly Ala Ile Tyr Ser Pro Thr Val Thr Leu Asn
 915 920 925
 Cys Pro Ala Thr Phe Ser Asn Asn Thr Ala Ser Ile Ala Thr Pro Lys
 930 935 940
 Thr Ser Ser Glu Asp Gly Ser Ser Gly Asn Ser Ile Lys Asp Thr Ile
 945 950 955 960
 Gly Gly Ala Ile Ala Gly Thr Ala Ile Thr Leu Ser Gly Val Ser Arg
 965 970 975
 Phe Ser Gly Asn Thr Ala Asp Leu Gly Ala Ala Ile Gly Thr Leu Ala
 980 985 990
 Asn Ala Asn Thr Pro Ser Ala Thr Ser Gly Ser Gln Asn Ser Ile Thr
 995 1000 1005
 Glu Lys Ile Thr Leu Glu Asn Gly Ser Phe Ile Phe Glu Arg Asn Gln
 1010 1015 1020
 Ala Asn Lys Arg Gly Ala Ile Tyr Ser Pro Ser Val Ser Ile Lys Gly
 1025 1030 1035 1040
 Asn Asn Ile Thr Phe Asn Gln Asn Thr Ser Thr His Asp Gly Ser Ala
 1045 1050 1055
 Ile Tyr Phe Thr Lys Asp Ala Thr Ile Glu Ser Leu Gly Ser Val Leu
 1060 1065 1070
 Phe Thr Gly Asn Asn Val Thr Ala Thr Gln Ala Ser Ser Ala Thr Ser
 1075 1080 1085
 Gly Gln Asn Thr Asn Thr Ala Asn Tyr Gly Ala Ala Ile Phe Gly Asp
 1090 1095 1100
 Pro Gly Thr Thr Gln Ser Ser Gln Thr Asp Ala Ile Leu Thr Leu Leu
 1105 1110 1115 1120
 Ala Ser Ser Gly Asn Ile Thr Phe Ser Asn Asn Ser Leu Gln Asn Asn
 1125 1130 1135
 Gln Gly Asp Thr Pro Ala Ser Lys Phe Cys Ser Ile Ala Gly Tyr Val

1140 1145 1150
 Lys Leu Ser Leu Gln Ala Ala Lys Gly Lys Thr Ile Ser Phe Phe Asp
 1155 1160 1165
 Cys Val His Thr Ser Thr Lys Lys Thr Gly Ser Thr Gln Asn Val Tyr
 1170 1175 1180
 Glu Thr Leu Asp Ile Asn Lys Glu Glu Asn Ser Asn Pro Tyr Thr Gly
 1185 1190 1195 1200
 Thr Ile Val Phe Ser Ser Glu Leu His Glu Asn Lys Ser Tyr Ile Pro
 1205 1210 1215
 Gln Asn Ala Ile Leu His Asn Gly Thr Leu Val Leu Lys Glu Lys Thr
 1220 1225 1230
 Glu Leu His Val Val Ser Phe Glu Gln Lys Glu Gly Ser Lys Leu Ile
 1235 1240 1245
 Met Glu Pro Gly Ala Val Leu Ser Asn Gln Asn Ile Ala Asn Gly Ala
 1250 1255 1260
 Leu Ala Ile Asn Gly Leu Thr Ile Asp Leu Ser Ser Met Gly Thr Pro
 1265 1270 1275 1280
 Gln Ala Gly Glu Ile Phe Ser Pro Pro Glu Leu Arg Ile Val Ala Thr
 1285 1290 1295
 Thr Ser Ser Ala Ser Gly Gly Ser Gly Val Ser Ser Ser Ile Pro Thr
 1300 1305 1310
 Asn Pro Lys Arg Ile Ser Ala Ala Val Pro Ser Gly Ser Ala Ala Thr
 1315 1320 1325
 Thr Pro Thr Met Ser Glu Asn Lys Val Phe Leu Thr Gly Asp Leu Thr
 1330 1335 1340
 Leu Ile Asp Pro Asn Gly Asn Phe Tyr Gln Asn Pro Met Leu Gly Ser
 1345 1350 1355 1360
 Asp Leu Asp Val Pro Leu Ile Lys Leu Pro Thr Asn Thr Ser Asp Val
 1365 1370 1375
 Gln Val Tyr Asp Leu Thr Leu Ser Gly Asp Leu Phe Pro Gln Lys Gly
 1380 1385 1390
 Tyr Met Gly Thr Trp Thr Leu Asp Ser Asn Pro Gln Thr Gly Lys Leu
 1395 1400 1405
 Gln Ala Arg Trp Thr Phe Asp Thr Tyr Arg Arg Trp Val Tyr Ile Pro
 1410 1415 1420
 Arg Asp Asn His Phe Tyr Ala Asn Ser Ile Leu Gly Ser Gln Asn Ser
 1425 1430 1435 1440
 Met Ile Val Val Lys Gln Gly Leu Ile Asn Asn Met Leu Asn Asn Ala
 1445 1450 1455
 Arg Phe Asp Asp Ile Ala Tyr Asn Asn Phe Trp Val Ser Gly Val Gly
 1460 1465 1470
 Thr Phe Leu Ala Gln Gln Gly Thr Pro Leu Ser Glu Glu Phe Ser Tyr
 1475 1480 1485
 Tyr Ser Arg Gly Thr Ser Val Ala Ile Asp Ala Lys Pro Arg Gln Asp
 1490 1495 1500
 Phe Ile Leu Gly Ala Ala Phe Ser Lys Ile Val Gly Lys Thr Lys Ala
 1505 1510 1515 1520
 Ile Lys Lys Met His Asn Tyr Phe His Lys Gly Ser Glu Tyr Ser Tyr
 1525 1530 1535
 Gln Ala Ser Val Tyr Gly Gly Lys Phe Leu Tyr Phe Leu Leu Asn Lys
 1540 1545 1550
 Gln His Gly Trp Ala Leu Pro Phe Leu Ile Gln Gly Val Val Ser Tyr
 1555 1560 1565
 Gly His Ile Lys His Asp Thr Thr Thr Leu Tyr Pro Ser Ile His Glu
 1570 1575 1580

Arg Asn Lys Gly Asp Trp Glu Asp Leu Gly Trp Leu Ala Asp Leu Arg
 1585 1590 1595 1600
 Ile Ser Met Asp Leu Lys Glu Pro Ser Lys Asp Ser Ser Lys Arg Ile
 1605 1610 1615
 Thr Val Tyr Gly Glu Leu Glu Tyr Ser Ile Arg Gln Lys Gln Phe
 1620 1625 1630
 Thr Glu Ile Asp Tyr Asp Pro Arg His Phe Asp Asp Cys Ala Tyr Arg
 1635 1640 1645
 Asn Leu Ser Leu Pro Val Gly Cys Ala Val Glu Gly Ala Ile Met Asn
 1650 1655 1660
 Cys Asn Ile Leu Met Tyr Asn Lys Leu Ala Leu Ala Tyr Met Pro Ser
 1665 1670 1675 1680
 Ile Tyr Arg Asn Asn Pro Val Cys Lys Tyr Arg Val Leu Ser Ser Asn
 1685 1690 1695
 Glu Ala Gly Gln Val Ile Cys Gly Val Pro Thr Arg Thr Ser Ala Arg
 1700 1705 1710
 Ala Glu Tyr Ser Thr Gln Leu Tyr Leu Gly Pro Phe Trp Thr Leu Tyr
 1715 1720 1725
 Gly Asn Tyr Thr Ile Asp Val Gly Met Tyr Thr Leu Ser Gln Met Thr
 1730 1735 1740
 Ser Cys Gly Ala Arg Met Ile Phe
 1745 1750

<210> 181

<211> 2601

<212> DNA

<213> Chlamydia

<400> 181

atggctagcc	atcaccatca	ccatcacctc	tttgccagg	atcccttagg	tgaaccggcc	60
ctcccaacta	aaaatectaa	tcattgtcgtc	tgtacatttt	ttgaggactg	taccattggag	120
agcctctttc	ctgctctttg	tgtctcatgca	tcacaagaag	atcctttgta	tgtacttgga	180
aattctctact	gttggttcgt	atctaaactc	catatcacgg	accccaaaag	ggctcttttt	240
aaagaaaaag	gagatctttc	cattcaaaac	tttcgtcttc	tttctctcac	agattgctct	300
tccaaaggaaa	gcctctcttc	tattattcat	caaaagaatg	gtcagttatc	cttgcgcaat	360
aattgttagca	tgagtttctg	tcgaatacat	gctgaaggct	ctggaggaggc	catctctcgcg	420
gatgcctttt	ctctacagca	caactatctt	ttcacagctt	ttgaagagaa	ttcttctaaa	480
ggaaatggcg	gagccattca	ggctcaaaac	ttctctttat	ctagaaatgt	gtcgctcatt	540
tctttcgccc	gtaatcgtgc	ggattttaaat	ggcggcgcta	tttctgttag	taattcttatt	600
tgttcaggga	atgtaaaccc	tctctttttc	actggaaact	cgcacraaa	tgagggcsct	660
atttgttgta	tcagcgatct	aaacacctca	gaaaaaggct	ctctctctct	tgcttgtaac	720
caaraaacgc	tatttgcaag	caattctgct	aaagaaaaag	gcggggctat	ttatgcccaag	780
cacatgggat	tgctttataa	cggctctggt	tccttcatta	acaacagcgc	taaaatagggt	840
ggagctatcg	ccatccagtc	cggaggggagt	ctctctatcc	ttgcagggtga	aggactctggt	900
ctgttcagaa	ataaactccc	acgcacctcc	gaccaaaggtc	tagtaagaaa	cgccatctac	960
ttagagaaag	atgcgattct	ttcttctcta	gaagctcgca	acggagatat	tctttttttt	1020
gatcctattg	tacaagaaag	tagcagcaaa	gaatcgcttc	ttccctctct	tttgcaagcc	1080
agcgtgactt	ctcccaaccc	agccaccgca	tctcttttag	ttattcagac	aagtgcacac	1140
cgttcacgtga	ttttctcgag	cgaacgtctt	tctgaagaag	aaaaaacctc	tgataacctc	1200
acttcccaac	tacagcagcc	tatcgaaact	aaatccggag	gcttagtttt	aaaagatgac	1260
gctgtctctt	ccgsgccttc	tctctctcag	gatctctcaag	ctctctctac	tatggaagcg	1320
ggaaactctt	taaaaacctc	ctytgatttg	aagtttagsta	cgstaagtat	tcctctctac	1380
tctcttagata	ctgaaaaag	cgtaactatc	cacgccccta	atctttctat	ccaaaagatc	1440
ttcctctcta	actctggaga	tgagaatttt	tatgaaaatg	tagagctctc	cagtaagag	1500
caaaaacaata	ttcctctcct	tactctcctc	aaagagcaat	ctcatttaca	tcttctctgat	1560

gggaacctct	cttctcactt	tggatatcaa	ggagattgga	ctttttcttg	gaaagattct	1620
gatgaagggc	atctctctgat	tgtcaattgg	acgcctaaaa	actatgtccc	tcatccagaa	1680
cgtcaatcta	caactcgttg	gaacactctt	tggaaacact	attccgcatat	gcaagctgtg	1740
cagtcgatga	ttaatacaac	acgcgcacga	ggagcctatc	tatttggaa	gtgggggatct	1800
gctgtttcta	atttattcta	tgttcacgac	agctctggga	aacctatcga	taattggcat	1860
catagaagcc	ttggctcact	attcgggtatc	agtactcaca	gtttagatga	ccattctttc	1920
tgtttggctg	caggacaatt	actcggggaaa	tgttcggatt	ccctttattac	gtctacagaa	1980
cgacactcct	atctagctat	tgtacaagcg	caactcgtca	ccctctccta	ccaaactctct	2040
gcacaggcat	gctacaatga	aagtatccat	gagctaaaaa	caaaatatcg	ctcctctctc	2100
aaagaaggat	tggatcctg	gcatacggtt	gcagtatccg	gagaagtgtg	cgcactgatt	2160
ccatttggat	ccaatgggtc	cggactgttc	agctccttct	ctattttctc	taactgcgaa	2220
ggattttcag	gaacacagga	cggttttgag	gagagtccg	gagagattcg	gtccttttct	2280
gcagctctct	tgcagaataa	tctacttctc	ataggaaata	catttgaaaa	aaaaatccca	2340
aaaaacagaa	cctactatta	ctttcttagga	gctacatcc	aagacctgaa	acgtgatgtg	2400
gaatcgggac	ctgtagtgtt	actcaaaaat	gcctgtctct	gggatgctcc	tatggcgaa	2460
ttggattcac	gagcctacat	gttcgggctt	acgaatcaaa	gagctctaca	cagacttcag	2520
acgctgttaa	atgtgtcttg	tgtgtcgtgt	gggcaagcc	atagttactc	cctggatctg	2580
gggaccactt	acaggttcta	g				2601

<210> 182

<211> 3021

<212> DNA

<213> Chlamydia

<400> 182

atggcttagca	tgactgggtg	acegcaaatg	ggctgggatt	caagcttggt	accgcatcac	60
catcacactc	acatgatctc	tcaaggaatt	tacgatgggg	agacgttaac	tgtatcattt	120
ccctatactg	ttataggaga	tccgagtggt	actactgttt	ttctgcagg	agagttaa	180
ttaaaaaatc	ttgacaattc	tattgcagct	tgtcctttaa	gttgtttgg	gaacttatta	240
gggagtttta	ctgttttagg	gagaggacac	tcgttgactt	tcgagaacat	acggacttct	300
acaaatgggg	cagctctaag	taatagcgct	gctgatggac	tgtttactat	tgagggtttt	360
aaagaattat	ccctttccaa	ttgcaattca	ttacttgccg	tactgcctcg	tgcacagact	420
aataagggtta	gccagactcc	gacgacaaca	tctacacgtg	ctaagtgtac	tattttattc	480
aaaaacagat	ttttgttact	caataatgag	aagttctcat	tctatagtaa	tttagtctct	540
ggagatgggg	gagctataga	tgtcaagagc	ttaacgggtc	aaggaaattag	caagctttgt	600
gtcttccaag	aaaataactc	tcaagctgat	gggggagctt	gtcaagtagt	ccacagtttc	660
tctgctatgg	ctaacgagcc	tcctattgcc	tttgttagca	attgttcagg	agtaagaggg	720
ggaggaggtg	tgcgtgttca	ggatggggcag	cagggaagtgt	catcatctac	tccaacagaa	780
gatccagtag	taagtttttc	cagaaatact	gcggtagagt	ttgatgggaa	cgtagccgca	840
gtcaggaggag	ggatttactc	ctacgggaac	gttgcttttc	tgaataatgg	aaaaaccttg	900
ttctccaaca	atgttgcttc	tcctgtttac	attgctgcta	agcaaccaac	aagtcgacag	960
gcttctaata	cgaatataaa	ttaacggagat	ggaggagcta	tcttctgtaa	gaatgggtcg	1020
caagcaggat	ccaataactc	tggatcagtt	tcctttgatg	gagagggagt	agttttctct	1080
agttagcaatg	tagctgctgg	gaaaggggga	gctatttatg	ccaaaaagct	ctcgggttgc	1140
aactgtggcc	ctgtacaatt	tttaaggaa	atcgctaagt	atggtggagc	gatttatbta	1200
ggagaaactg	gagagctcag	tttatctgct	gattatggag	attatttttt	cgatgggaat	1260
cttaaaagaa	cagccaaaga	gaatgctgcc	gatgttaagt	gcgtaactgt	gtcctcaaca	1320
gccatttctga	tgggatcggg	agggaaaata	acgacattaa	gagctaaagc	agggcatcag	1380
attctcttta	atgactccat	cngatggcca	aacgggaata	acagccagc	cgcagctctc	1440
aaacttctaa	aaattaaaga	tgggtgaagga	tacacagggg	atatgttttt	tgtcataatga	1500
agcagctaat	tgtaccaaaa	tgtttacgata	gagcaaggaa	ggattgttct	tcgtgaaaag	1560
gcaaaattat	cagtgaattc	tctaatgtcag	acaggtggga	gtctgtatat	ggaagctggg	1620
agtcacattg	attttgtaac	tcacacaacca	ccacaacagc	ctcctgcgcg	aactcagttg	1680
atcacgcttt	ccaatctgca	tttgtctctt	tcttctttgt	tagcaaacaa	tgcagttacg	1740
aatcctccta	ccaatctctc	agcgcgaagt	tctcatctcg	cagtcatttg	tagcacaact	1800

```

gctgggtctg ttacaattag tgggcctatc ttttttgagg atttggatga tacagcttat 1860
gataggtatg attggctagg ttctaatcaa aaaatcaatg tcttgaattt acagttaggg 1920
actaagccccc cagctaatgc cccatcagat ttgactctag ggaatgagat gcctaaagtat 1980
ggctatcaag gaagctggaa gcttgcgtgg gatcctaata cagcaaaata tggctccttat 2040
actctgaaag ctacatggac taaaactggg tataactctg gcctcgagcg agtagctctt 2100
ttgggtccaa atagtttatg gggatccatt ttgatatata gatctgcgca ttacagcaatt 2160
caagcaagtg tggatggggc ctcttattgt cgaggattat ggggttctgg agtttgcgat 2220
ttcttctatc attgaccgca tgcctttaggt cagggatata ggtatattag tgggggttat 2280
tccttaggag caaactccta ctttggatca tgcagtgttg gtctagcatt taccgaagta 2340
tttggtagat ctaaaagatta tgtagtgtgt cgttccaatc atcatgcttg cataggatoc 2400
gtttatctat caccccaaca agctttatgt ggatcctatt tgttcggaga tgcgtttatc 2460
cgtgctagct acgggtttgg gaatcagcat atgaaaacct catatacat ttccagaggag 2520
agcgatgttc gttgggataa taactgtctg gctggagaga ttggagcggg attaccgatt 2580
gtgattactc catctaagct ctatttgaat gagtgcgtc ctttctgcca agctgagttt 2640
tccttagcgc atcatgaatc ttttacagag gaaggcgatc aagctcgggc attcaagagc 2700
ggacatctcc taaatctatc agttctctgt ggagtgaagt ttgatcgatg ttctatgata 2760
catcctaata aatatagctt tatggcggct tatatctgtg atgcttatcg caccatctct 2820
ggtactcgga caargctcct atcccatcaa ggcacatgga caacagatgc ctttcattta 2880
gcaagacatg gagtgtgtgt tagaggatct atgtatgctt ctctaaacag taatatagaa 2940
gtatatggcc atggaagata tgagtatcga gatgctcttc gagggctatgg tttagtgca 3000
ggaagttaag tccggttcta a 3021

```

<210> 183

<211> 2934

<212> DNA

<213> Chlamydia

<400> 193

```

atggctagca tgactggtgg acagcaaatg ggtcgggatt caagcttggt accgagctcg 60
gatccacatc accatcacca tcacggacta gctagagagg ttccctctag aatctttctt 120
atgcccaact cagttccaga tctacgaaa gagtgcgtat caaataaaat tagtttgaca 180
ggagacactc acaatctcac taactgctat ctcgataacc tacgctacat actggctatt 240
ctacaaaaaa ctccaatga agagagctgt gtacacataa cagattacct aagctttttt 300
gatacacaaa aagaaggatg ttattttgca aaaaatctca cccctgaaa tgggtggtcg 360
atttggttat cgagtcacca ttctctacc gtggagatcc gtgatacaat aggtcctgtg 420
atctttgaaa ataatacttg ttgcagacta ttacatgga gaaatccta tgcgcgatg 480
aaaaatagag aaggcggagc cattcatgct caaaatcttt acataaatca taatcatgat 540
gtggctcgat ttatgaagaa ctcttcttat gtccaaggag gagccattag taaccgtaat 600
acccttgttg tgagcgagaa tcagctctgt ttctctttaa tggacaacat ctgtattcaa 660
actaatacag caggaaaagg tggcgctatc tatgctgaa cgagcaattc ttttgagagt 720
aatcaactcg atctcttctt catcaataac gcctgttgtg caggaggagc gatcttctcc 780
cctatctgtt ctctaacagg aaatcgtggt aacatcggtt tctataacaa tgcgtgcttt 840
aaaaatgtag aaaaagcttc ttccaagagt tctgatggag gagcaatcaa agtaactacc 900
cgcttagatg ttacaggcaa tctggttagg atctttttaa gtgacaatat cacaaaaaat 960
tatggcgagg ctattttacg tctgtagtt accctagtgg ataatggccc tactactttt 1020
ataaacaata tgcaccaata taaggggggc gctatctata tagacggaac cagtaactcc 1080
aaaaattctg cgcaccgca tgcattatt tttaatgaaa atattgtgac taatgtaact 1140
aatgcaaatg gtaccagatc gtcagcta at cctcctagaa gaaatgcaat aacagtagca 1200
agctcctctg gtgaaattct attaggagca gggagtagcc aaatttfaat tttttatgat 1260
cctattgaag tttagcaatgc aggggtctct gtgtccttca atagggaagc tgatcaaaaa 1320
ggctctgtag tattttcagg agctactggt aattctgcag attttcatca acgcaattta 1380
caaacaaaaa caccctgccc ccttactctc agtaatgggt ttctatgtat cgaagatcat 1440
ctcagcttca cagtgaatcg attcacacia actgggggtg ttgttctctc tgggaatgga 1500
gcagtctcga gttgctataa aaatggtaca ggagattctg ctacgaatgc ctctataaca 1560
ctgaagcata ttggattgaa tctttcttcc attctgaaaa gtgggtgctga gattccttta 1620

```

ttgtgggtag	agcctacaaa	taacagcaat	aactatacag	cagatactgc	agctacccttt	1680
tcattaagt	atgtaaaaat	ctcactcatt	gatgactacg	ggaactctcc	ttatgaaatcc	1740
acagatctga	cccatgctct	gtcatcacag	cctatgctat	ctatttctga	agctatgcgt	1800
aaccagctac	aatcagaaaa	tatagatttt	tcgggactaa	atgtccctca	ttatggatgg	1860
caaggacttt	ggacttgggg	ctgggcacaa	actcaagatc	cagaaccagc	actctcagca	1920
acaatcactg	atccacaaaa	agccaataga	tttcatagaa	ccttactact	aacatggcct	1980
cctgccgggt	atgttctctag	cccaaaacac	agaagtcccc	tcatagctaa	ccaccttatgg	2040
gggaatatgc	tgcttgcac	agaaagctta	aaaaatagtg	cagagctgac	acctatgtgt	2100
catcctttct	ggggaattac	aggaggagga	ctaggcatga	tggtttacca	agatcctcga	2160
gaaaatcatc	ctggattcca	tatgcgctct	tcgggatact	ctgcggggat	gatagcaggg	2220
cagacacaca	ccttctcatt	gaattcagtg	cagacctaca	ccaaactcaa	tgagcgttac	2280
gcaaaaaaca	acgtatcttc	taaaaattac	tcatgccaa	gagaaatgct	cttctcattg	2340
caagaagggt	tcttgcctgac	taaaattagt	gggctttaca	gctatggaga	ccataactgt	2400
caccatttct	atactcaagg	agaaaatcta	acatctcaag	ggacgttccg	cagtcaaacg	2460
atgggaggtg	ctgtcttttt	tgatctccct	atgaaacctt	ttggatcaac	gcataatact	2520
acagctccct	tttttaggtgc	tcttggtatt	tattctagtc	tgctcacttt	tactggaggtg	2580
ggagcctatc	cgcgaagctt	ttctacaaag	actccttga	ccaatgtctc	agtcctctatt	2640
ggagttaaa	gtagctttat	gaatgtctacc	cacgcacctc	aagcctgggc	tgtagaattg	2700
gcataccaa	cogtctctga	tagacaagaa	ccagggatgc	cgacccagct	cctagccagt	2760
aaagggtatt	ggtttggtag	tggaaagccc	tcatcgcgtc	atgccatgtc	ttataaaatc	2820
tcacagcaaa	cacaaacctt	gagttggtta	actctcattt	tccagtatca	tggattctac	2880
tctcttca	ccttctgtaa	ttatctcaat	ggggaaattg	ctctgcgatt	ctag	2934

<210> 184

<211> 2547

<212> DNA

<213> Chlamydia

<400> 184

atggctagcc	atcaccatca	ccatcacggt	gctatttctt	gcttacgtgg	agatgtagtc	60
atttctggaa	acaagggtag	agttgaattt	aaagacaaca	tagcaaacac	tctttatgtg	120
gaagaaactg	tagaaaaagt	tgaagaggta	gagccagctc	ctgagcaaaa	agacaataat	180
gagctttctt	tcttagggag	tgtagaacag	agttttatta	ctgcagctaa	tcaagctctt	240
ttcgcatctg	aagatgggga	tttatcacct	gagtcaccca	ttcttctctg	agaacttgcg	300
aaaaagaag	agtggtgctg	aggagctatt	tttgcaaaa	gggttcgctt	tgtagataac	360
caaggagccg	ttgtattctc	gaataacttc	tctgatattt	atggccgcgc	ttcttttaca	420
ggttctcttc	gagaaagaga	taagtttagat	gggcaaatcc	ctgaagtctt	gatctcaggc	480
aatgcagggg	atgttgtttt	ttccggaaat	tcttcgaagc	gtgatgagca	tcttctcat	540
acaggtgggg	gagccatttg	tactcaaaat	ttgacgattt	ctcagaatgt	agggaaatgt	600
ctgttttata	acaacgtggc	ctgttcggga	ggagctgttc	gtatagagga	tcatgggtaa	660
gtcttttttg	aagcttttgg	aggagatatt	gtttttaaag	gaaattcttc	tttcagagca	720
caaggatccg	atgctatctc	ttttcgaggt	aaagaatcgc	atattacagc	cctgaatgct	780
acggaaggac	atgctattgt	tttcacgac	gcattagttt	ttgaaatctt	aaaagaaagg	840
aaatctgctg	aagatttgtt	aatcaatagt	cgagaaaatc	caggtttacac	tggactattt	900
cgattttttg	aagcagaaag	taaagtctct	caatgtattc	atgtacaaca	aggaagcctt	960
gagttgctaa	atggagctac	attatgtagt	tatggtttta	aacaagatgc	tggagctaa	1020
ttggtatttg	ctgctggatc	taaaactga	attttagatt	caggaaactcc	tgtacaaagg	1080
catgcatatc	gtaaaactga	agcagaatc	gagtcactct	ctgaaccaga	gggtgcacat	1140
tctcttttga	ttgcgaagaa	tgctcaaaac	acagttccta	tggttgatat	ccatactatt	1200
tctgtagatt	tagcctcctt	ctctctagtg	caacaggagg	ggacagtaga	agctcctcag	1260
gttatgttgc	ctggaggaga	ttatgttcga	ttctggagagc	ttaatttga	gttaagttaa	1320
acaacaggta	ctggttatga	aaatcatgct	ttgttgaaga	atgaggctaa	agttccattg	1380
atgtctcttc	ttgctctcag	tgtatgaagt	tcagccgaaa	tcagtaattc	gtcggtttct	1440
gattttacaga	ttcatgtagc	aactccagag	attgaagaag	acacatacgg	ccatattggga	1500
gatttggtctg	aggctaaaa	tcaagatgga	actcttgtca	ttaatttggaa	tcctactgga	1560

tatcgattag	atcctcaaaa	agcaggggct	ttagtattta	atgcattatg	ggaagaaggg	1620
gctgtcttgc	ctgctctgaa	aaatgcacgc	tttgcctata	atctcaactgc	tcagcgtatg	1680
gaattcggatt	attctacaaa	tgtgtgggga	ttcgctcttg	gtgggttctg	aaactctatct	1740
gcagagaatc	tgggtgctat	tgatggatac	aaaggagcct	atggtgggtg	ttctgctgga	1800
gtcgatatcc	aattgatgga	agattttggt	ctaggagtta	gtggagctgc	tttcttaggt	1860
aaaatggata	gtcagaagtt	tgatgcggag	gtttctcgga	aggagagtgt	tgggtctgta	1920
tatcacaggat	ttttatgcgg	atcctgggtc	ttcaaggagc	aatatagctt	tggagaaacc	1980
cagaacgata	tgaaacgcgc	ttatggagta	ctaggagagt	cgagtgtctc	ttggacatct	2040
cgaggagatc	tggcagatgc	tttagttgaa	taccgaagtt	tagttgggtc	tgtgagacct	2100
actttttatg	ctttgcattt	caatccttat	gtcgaagtat	cttatgcttc	tatgaaattc	2160
cctggcttta	cagacaagcg	aagagaagcg	cgttcttttg	aagacgcttc	ccttaccatt	2220
atcacattcc	cttttagggat	gaagtttgaa	ttggcgttca	taaaaggaca	gtttccagag	2280
gtgaactctt	tgggaataag	ttatgcatgg	gaagcttatt	gaaaagttag	aggaggcgcg	2340
gtgcagcttt	tagaagctgg	gtttgattgg	gagggagctc	caatggatct	tccatagacg	2400
gagctcgctg	tcgctctgga	aaataatacg	gaatggagtt	cttacttcag	ccagctctta	2460
ggattaacag	ctttttgtgg	aggatttact	tctacagata	gtaaactagg	atatgaggcg	2520
aatactggat	tgcgattgat	cttttaa				2547

<210> 185

<211> 2337

<212> DNA

<213> Chlamydia

<400> 185

atgcataacc	atcaccatca	cggttagact	agttgcgtag	atcttctatgc	tggaggacag	60
tctgtaaatg	agcttggata	tgtaggccct	caagcggttt	tatttgttaga	ccaaatttga	120
gactcattcg	tgggtgtctaa	agatagtcag	gctgaaggac	agtatagggtt	aattgttagga	180
gactccaagt	ctttccaaga	gaagatgcca	gatactcttc	cggggaaggt	agagcaaatg	240
ttcttgtctc	cagtaaaccaa	tcccggtggt	ttccaaaggt	tggaccaacat	gagatcaagtc	300
tcttcccaag	ggtaattttg	tagttttacg	agcagcaacc	ttgattctcc	cgtgacgga	360
gaatcctttt	taggtatttg	ttttgttggg	gatagttaga	aggctggaat	cacattaact	420
gacgtgaaag	cttctttgtc	tggagcggtc	ttatatctta	cagaagatct	tatatcttga	480
aagatttaagg	gtggatttga	atttgcatca	tgttcttctc	tagaacacggg	gggagcttgt	540
gcagctcaaa	gtattttgat	tcatgattgt	caaggattgc	aggttaaacat	ctgtactaca	600
cccggtgaatg	ctgagggggtc	tagtgcgaat	gatcatcttg	gatttggagg	aggcgctttc	660
tgttctgcgg	gttctctttc	tggagagaaa	agtcctctata	tgcctgcagg	agatatggta	720
gttgcggaatt	gtgatggggc	tatatctttt	gaaggaaaac	gcgcgaactt	tgctaattgga	780
ggagcgattg	ctgcctctgg	gaaagtgttt	tttgtcgcta	atgataaaaa	gacttctttt	840
atagagaacc	gagcttttgtc	tggaggagcg	attgcagcct	cttctgatatt	tgcctttcaa	900
aaactgcgcag	aactagttttt	caaaaggcaat	tgtgcaattg	gaacagaggga	taaaagttctt	960
ttaggtggag	gggctatatc	ttctctaggc	acogttcttt	tgcgaaggaa	tcacgggata	1020
acttttgata	agaatgagtc	tgcttgcgaa	ggaggcgcca	tttttgcgaa	aaattgtcag	1080
atttctgaca	acgaggggcc	agtggttttc	agagatagta	cagcttgctt	aggaggaggc	1140
gctattgcag	ctcaagaaat	tgtttctatt	cagaacaatc	aggctgggat	ttccttcagag	1200
ggaggttaagg	ctagttttcgg	aggaggtatt	gcgtgtggat	cttttctctc	cgcaggcggt	1260
tcttctgttt	tagggactatt	tataatttgc	aaagattttg	gcgcgatttc	gttctctcgt	1320
actttatgta	cgactctcaga	tttaggacaa	atggagtaac	agggaggagg	agctctattt	1380
gtgaaataa	tttctctttc	tgagaatgct	ggtgtcctca	cttttaaaaga	caacatgtgt	1440
aagacttttg	cttcgaatgg	gaaaattctg	ggaggaggag	cgatttttagc	tacttggttaag	1500
gtggaaatata	ccaataatc	cggaggaatt	ctttttacag	gaatgcgag	agctccacaa	1560
gctcttccaa	ctcaagagga	gtttctctta	ttcagacaaa	aagaaggggc	accaactctc	1620
tcaggatata	ctggggggag	agcgaattta	ggaagagaag	tagctattctc	cccacacgct	1680
gcagtagtat	ttagacaaaa	tcgtttgcag	tgacgcgaag	aagaagcgac	attattaggt	1740
tgttgcggag	gaggcgctgt	tcatgggatg	gatagcaact	cgattgttgg	caactcttca	1800
gtaagatttg	gtaataatta	cgcaattggga	caaggagctc	caggaggagc	tcttttatct	1860

aaaacagctgc	agtttagctgg	aaatggaagc	gtcgattttt	ctcgaaatat	tgctagtttg	1920
ggaggaggag	ctcttcaagc	ttctgaaaga	aattgtgagc	tagttgataa	cggctatgtg	1980
ctatttcagag	ataatcgagg	gaggggttat	gggggtgcta	ttctctgtct	acgtggagat	2040
gtagtctatt	ctggaacaaa	gggttagagtt	gaatttaaa	acaacatagc	aacacgctct	2100
tatgtggag	aaactgtaga	aaaggttgaa	gaggttagagc	cagctctctga	gcataaagag	2160
aataatgagc	tttctttctt	agggagtgta	gaacagagtt	ttattactgc	agctaatcaa	2220
gctctttctg	catctgaaga	tggggattta	tcacctgagc	catccatttc	ttctgaagaa	2280
ctgcgaaaa	gaagagagtg	tgctggagga	gctgactcga	gcagatccgg	ctgctaa	2337

<210> 186

<211> 2847

<212> DNA

<213> Chlamydia

<400> 186

atgggtagca	tgcatccca	tcccatcac	gttaagattg	agaactcttc	tggccaagga	60
atattttctg	gaacaaaagc	tatcgataac	accacagaag	gctctctctc	caaatctaac	120
gtcctcggag	gtcgggtcta	tgctaaaaca	ttgtttaatc	tcgatagcgg	gagctctaga	180
cgaactgtca	cctctccgg	gaatactgtc	tcttctcaat	ctacacacag	tcaggttgct	240
ggaggagcta	tcactctctc	tactgttaac	attgtctact	ctgtagtatt	ttcttaaaac	300
ctcgcaacaa	acaatgtctaa	taacgtctaca	gatactcaga	gaaaagacac	ctttggagga	360
gctatcggag	ctactctctg	tggtttctcta	tcaggagggg	ctcattttctt	agaaaaagctt	420
gctgacctcg	gatctgctat	tgggttggtg	ccagacacac	aaatacacaga	aacagtgaag	480
ttagagtctg	gctctactta	ctttgaaaaa	aataaagctt	taaaaacgagc	tactatttac	540
gcacctgtcg	tttccattaa	agcctatact	gcgacattta	accaaaacag	atctctagaa	600
gaggaagagc	cgatttactt	tacaaaagaa	gcatttatgt	agtcctttagg	ctctgttctc	660
ttccaggaaa	acttagtaac	cccaacgcta	agcccaacta	cagaaggcac	accagccaca	720
acctcaggag	atgtaacaaa	atatggtgct	gctatctttg	gacaaatagc	aagctcaaac	780
ggatctcaga	cggataacct	tcctctgaac	ctcattgtct	caggaggaaa	tattgttttc	840
cgaacaatg	aatacgtctc	tacttctctt	gataccggaa	cctctacttt	ctgtagtatt	900
gcgggaagat	ttaaatgaac	catgcaagct	gcaaaaggga	aaacgctcag	ttcttttgat	960
gcaatccgga	cctctactaa	gaaaacaggt	acacaggcaa	ctgcctacga	tactctcgat	1020
attaataaat	ctgaggattc	agaaactgta	aactctgcgt	ttacaggaaac	gattctgttc	1080
tcctctgaat	tacatgaaaa	taaatctctat	attccacaaa	acgtagtctt	acacagtgga	1140
tcctcttgat	tgaagccaaa	taccgagctt	catgtcattt	cttttgagca	gaagaaggcg	1200
tcctctctgc	ttatgacacc	tggatctgtt	ctttcgaaac	agactgtgtg	tgatggagct	1260
ttggtcataa	ataacatgac	cattgattta	tcacgcgtag	agaaaaatgg	tattgtctgaa	1320
ggaaataatc	ttactctctc	agaattgaga	atcatagaca	ctactacaaa	tggaaagcgg	1380
ggaaacccat	ctacagatag	tgaagtaaac	cagaatagtg	atgataccag	ggagcaaaaat	1440
aataatgagc	cctcgaatca	aggagaaaagc	gcgaatggat	cgtcttctct	tgacgtagct	1500
gctgcacaca	catctcgtaac	aagaaacttt	gcgcgtgcag	ctacagccac	acctcagaca	1560
acaccaacgg	ctacaaactac	aacaagcaac	caagtaatcc	taggaggaga	aatacaactc	1620
atcgatccta	atgggacctt	cttcagaaac	cctgcattaa	gatccgacca	acaaactctc	1680
ttgttagtgc	tcctcacaga	ctcatcaaaa	atgcaagctc	agaaaaatgt	actgacgggt	1740
gatattgtct	ctcagacagg	atatacagga	acactcactc	tggtactcta	tcaactacaaa	1800
aatggaaacga	ctcagagcgt	ctggaaaattt	gactcttata	gacaaatggg	ttatgtctct	1860
agagacaatc	atttctatgc	gaactcgatt	ctgggactct	aaatgtcaat	ggtcacagtc	1920
aaacaaaggc	tgtccacaga	taaaatgaat	ctagctcgct	ttgatgaagt	tagctataac	1980
aacctgtgga	tatcaggact	aggaacgatg	ctatcgcaag	taggaacacc	tacttctgaa	2040
gaattccact	attacagcag	aggagcttct	gttcgcttag	atgctaaaac	agcccatgat	2100
gtgatgttgg	gagctgcatt	tagtaagatg	atcgggaaaa	caaaaactctt	gaaaagagag	2160
aataactaca	ctcaaaaagg	atccgaaatat	ctttaccaa	catcggtata	cggaggcaaa	2220
ccattccact	ttgtaactcaa	taaaaaaacg	gaaaaaatcg	taccgctatt	gttcaaggga	2280
gtcatctctt	acggatatac	caaacatgat	acagtgactc	actatccaac	gatccgtgaa	2340
cgaaaccaac	gagaatggga	agacttagga	tggtgtgacag	ctctccgtgt	ctcctctgtc	2400

ttaagaactc	ctgcacaagg	ggatactaaa	cgtatcactg	tttacggaga	attggaatac	2460
tccagtatcc	gtcagaaaca	attcacagaa	acagaatacy	atccctcgta	cttcagacaac	2520
tgcacctata	gaaacttagc	aattcctatg	gggttagcat	tcgaaggaga	gctctctggt	2580
aacgatattt	tgatgtacca	cagattctct	gtagcataca	tgccatcaat	ctatcgaaat	2640
tctccaacat	gcaaatacca	agtgctctct	tcaggagaag	gcggagaaat	tatttctgga	2700
gtaccgacaa	gaaactcagc	tcgcggagaa	tacagcacgc	agctgtaccc	gggacctttg	2760
tggactctgt	atggatccta	cacgatagaa	gcagacgcac	atacactagc	tcatatgatg	2820
aactgcgggt	ctcgtatgac	attctaa				2847

<210> 187

<211> 2466

<212> DNA

<213> Chlamydia

<400> 187

atgcacaccc	atcaccatca	cgaggcgagc	tcgatccaag	atcaaaataa	gaataccgac	60
tgcagtgtta	gcaaaagtagg	atatccaact	tctcaagcat	ttactgatat	gatgctagca	120
gacaaacacag	agtatcgagc	tgtctgtagt	gcttcattct	atgacttttc	gacatcttcc	180
ggattaccta	gaaaacatct	tagtagtagt	agtgaagctt	ctecaacgac	agaaggagtg	240
tcttcattctt	ctatctggaga	aaatactgag	aattcacaa	attcagctcc	ctctcttgga	300
gaaactgata	agaaaacaga	agaagaacta	gacaatggcg	gaatcattta	tgctagagag	360
aaactacata	tctcagaatc	tcaggactct	ctctctaact	caagcataga	actccatgac	420
aatagttttt	tcttcggaga	aggtgaagtt	atctttgac	acagagttgc	ctcctaaaaa	480
ggaggagcta	tttatcgaga	gaaagaggta	gtctttgaaa	acataaaact	tctactagta	540
gaagtataata	tctcgggtcga	gaaagggggg	agcgtctatg	caaaagaacy	agtatcttta	600
gaaaatgtta	cgaagcaaac	cttctctctc	aatggtgggg	aacaaggtgg	tgggtggaatc	660
tattcagaac	aagatatggt	aatcagtgat	tgcaacaatg	tacatttcca	agggaaatgct	720
gcaggagcaga	cagcagtaaa	acaatgtctg	gatgaagaaa	tgatcgattt	gctcacagaa	780
tgcggttgata	gcttatccga	agatacacatg	gatagcactc	cagaaacgga	acagactaag	840
tcaaatggaaa	atcaagatgg	tctgtctgaa	acaaaagata	cacaagtatc	agaaatcacca	900
gaatcaactc	ctagccccga	cgatgtttta	ggtaaagggt	gtggatatcta	tacagaaaaa	960
tctttgacca	tcaactggaat	tacaggggact	atagattttg	tcaagtaaat	agtaaccgat	1020
tctggagcag	gtgtattcac	taaaagaaac	ttgtcttgca	ccaacacgaa	tagctctacag	1080
ttttttgaaaa	actcggcgag	tcaacatgga	ggaggagccct	acgttactca	aacctgtctc	1140
gttactaata	caactagtga	aagtataaact	actccccctc	tcgtaggaga	agtgattttc	1200
tctgaaaata	cagctaaaag	gcacggtggg	ggtatctgca	ctaaacaaact	ttctttatct	1260
aattttaaaaa	cggtgactct	cactaaaaac	tctgcgaaag	agctcggagg	agctattttt	1320
acagactctag	cgtctctacc	aacaacagat	accccgagat	cttctacccc	ctctctctcc	1380
tcgctcgcaa	gcaactccga	agtagttgct	tctgctaaga	taaatcgatt	ctttgctctc	1440
acggcgagac	cggcagcccc	tctctcaaca	gaggctgagt	ctgatcaaac	ggatcaaaaa	1500
gaaactctgt	ataactaatg	cgatataagc	gtgtcgattg	agaaactttt	gaatgtcgct	1560
atcaatcaaa	acactctctg	gaaaaaagga	ggggtctatt	acgggaaaaa	agctaaactt	1620
tcccgattta	acaactctga	actttcaggg	aattctccc	aggatgtagg	aggaggtctc	1680
tgtttgacctg	aaagcgtaga	atttgatga	atttgatccc	tcttatccca	ctgataactct	1740
gctgtctaaag	aaggtggggg	tattctattc	aaaacgggta	ctctatctaa	ctcctaagctt	1800
accttcactt	tctgagataa	cactgtttaa	gcaatagtag	aagcactctc	tgaagctcca	1860
gaagagattc	ctccagtaga	aggagaagag	tctacagcaa	cagaaaaatc	gaattctaat	1920
acagaaggaa	gttcggctaa	cactaacctt	gaaggatctc	aagggaatc	tgctgataca	1980
gggactcggg	tgtttaacaa	tgagtctcaa	gacactcag	atactggaaa	cgtggaatct	2040
gggagaacac	tacaagattc	tacacaactc	aatgaagaaa	ataccctctc	caatagtagt	2100
attgatcta	ctaacgaaaa	cacagacgaa	tcatctgata	gccacactga	ggaaataact	2160
gacgagagtg	tctcatcgct	ctctaaaagt	ggatcatcta	ctcctcaaga	tggaggagca	2220
gcttctccag	gggctccctc	aggagatcaa	tctatctctg	caaacgcttg	tctagctaaa	2280
agctatcgctg	cgagactgga	tagctcccct	gtatctaatt	cttcagggtc	agacgttaact	2340
gcactctctg	ataatccaga	ctctctctca	tctggagata	gcgctggaga	ctctgaagga	2400

cggactgagc cagaagctgg ttctacaaca gaaactccta ctttaatagg aggaggtgct 2460
atctga 2466

<210> 188

<211> 1578

<212> DNA

<213> Chlamydia

<400> 188

atgcatcacc atcaccatca caggcgccgc tccgataact tccagctgtc ccagggtggg 60
cagggaatcg ccattccgat cgggcaggcg atggcgatcg cgggccagat caagcttccc 120
accgttcata tcgggcctac cgccttcctc ggcttgggtg ttgtcgacaa caacggcaac 180
ggcgacgag tccaacgctg ggtcgggagc gctcggcgcg caagtctcgg catctccacc 240
ggcgacgtga tccacgcggt cgcgcgcgct ccgatcaact cggccaccgc gatggcggac 300
gcgcttaacg ggcatactcc cggtagcgtc atctcgggtg cttggcaaac caagtgggc 360
ggcacgcgta cagggaacgt gacattggcc gagggaaccc cggccgaatt cccgctagta 420
cctagaggtt caccgctgcc cgtgggggaa ccagctgaac caagtttatt aatcgatggc 480
actatgtggg aaggtctctc aggagatcct tgcgatcctt gcgactactg gtgtgacgcc 540
attagcatcc cgcgaggata ctacggagat tatgttttcg atcgtgtatt aaaagtgtat 600
gtgaataaaa ctttttagcg catggctgca actcctacgc aggcataagg taacgcgaagt 660
aacactaatc agccagaagc aaatggcaga ccgaacatcg cttacgggaag gcataatgcaa 720
gatgcagagt gggttttcaa tgcagccttc ctagccttaa acatttggga gtgcttcgac 780
attttctgca ccttaggggc atccaatgga tacttcaaac caagtttcggc tgcattcaac 840
ttggttgggt taatagggtt ttcagctgca agctcaatct ctaccgatct tccaatgcaa 900
cttcctaacg taggcattac ccaaggtgtt gtggaatttt atacagacac atcattttct 960
ttgagcgtgag gtgcacgtgg agctttatgg gaattgtggt gtgcacacct agggagctgag 1020
tcccaatcgc tccaatctaa tcttaagatt yagatgctca acgtcacttc aagccacga 1080
caatttgtga ttcacaaacc aagaggctat aaaggagcta gctcgaattt tcccttaacct 1140
ataacgctg gaacaacaga agctacagac accaaatcag ctacaattaa ataccatgaa 1200
tggcaagtga gcttcgccct gtcttacaga tgaatatgc ttgtccata tatggcgta 1260
aactggtcaa gagcaacttt tgatgctgat actatccgca ttgctcaaac taaattaaaa 1320
tcggagattc ttaacattac tacatggaac ccaagcctta taggatcaac cactgctttg 1380
cccaataata gtgtaagga tgttctatct gatgtcttcg aaattgcttc gattcagatc 1440
aacaataatga agtctagaaa agcttgtggt gtactgttg gtgcaacgtt aatcgacgct 1500
gacaaatggt caatcactgg tgaagcacgc ttaatcaatg aaagagctgc tcacatgaat 1560
gcacaattcc gcttctaa 1578

<210> 189

<211> 866

<212> PRT

<213> Chlamydia

<220>

<221> VARIANT

<222> (1)...(866)

<223> Xaa = Any Amino Acid

<400> 189

Met Ala Ser His His His His His His Leu Phe Gly Gln Asp Pro Leu
1 5 10 15
Gly Glu Thr Ala Leu Leu Thr Lys Asn Pro Asn His Val Val Cys Thr
20 25 30
Phe Phe Glu Asp Cys Thr Met Glu Ser Leu Phe Pro Ala Leu Cys Ala
35 40 45
His Ala Ser Gln Asp Asp Pro Leu Tyr Val Leu Gly Asn Ser Tyr Cys

50	55	60
Trp Phe Val Ser Lys Leu His Ile Thr Asp Pro Lys Glu Ala Leu Phe		
65	70	75
Lys Glu Lys Gly Asp Leu Ser Ile Gln Asn Phe Arg Phe Leu Ser Phe		80
	85	90
Thr Asp Cys Ser Ser Lys Glu Ser Ser Pro Ser Ile Ile His Gln Lys		95
100	105	110
Asn Gly Gln Leu Ser Leu Arg Asn Asn Gly Ser Met Ser Phe Cys Arg		
115	120	125
Asn His Ala Glu Gly Ser Gly Gly Ala Ile Ser Ala Asp Ala Phe Ser		
130	135	140
Leu Gln His Asn Tyr Leu Phe Thr Ala Phe Glu Glu Asn Ser Ser Lys		
145	150	155
Gly Asn Gly Gly Ala Ile Gln Ala Gln Thr Phe Ser Leu Ser Arg Asn		
	165	170
Val Ser Pro Ile Ser Phe Ala Arg Asn Arg Ala Asp Leu Asn Gly Gly		175
	180	185
Ala Ile Cys Cys Ser Asn Leu Ile Cys Ser Gly Asn Val Asn Pro Leu		190
	195	200
Phe Phe Thr Gly Asn Ser Ala Thr Asn Gly Gly Xaa Ile Cys Cys Ile		205
210	215	220
Ser Asp Leu Asn Thr Ser Glu Lys Gly Ser Leu Ser Leu Ala Cys Asn		
225	230	235
Gln Xaa Thr Leu Phe Ala Ser Asn Ser Ala Lys Glu Lys Gly Gly Ala		240
	245	250
Ile Tyr Ala Lys His Met Val Leu Arg Tyr Asn Gly Pro Val Ser Phe		255
260	265	270
Ile Asn Asn Ser Ala Lys Ile Gly Gly Ala Ile Ala Ile Gln Ser Gly		
	275	280
Gly Ser Leu Ser Ile Leu Ala Gly Glu Gly Ser Val Leu Phe Gln Asn		285
290	295	300
Asn Ser Gln Arg Thr Ser Asp Gln Gly Leu Val Arg Asn Ala Ile Tyr		
305	310	315
Leu Glu Lys Asp Ala Ile Leu Ser Ser Leu Glu Ala Arg Asn Gly Asp		320
	325	330
Ile Leu Phe Phe Asp Pro Ile Val Gln Glu Ser Ser Ser Lys Glu Ser		335
340	345	350
Pro Leu Pro Ser Ser Leu Gln Ala Ser Val Thr Ser Pro Thr Pro Ala		
	355	360
Thr Ala Ser Pro Leu Val Ile Gln Thr Ser Ala Asn Arg Ser Val Ile		365
370	375	380
Phe Ser Ser Glu Arg Leu Ser Glu Glu Glu Lys Thr Pro Asp Asn Leu		
385	390	395
Thr Ser Gln Leu Gln Gln Pro Ile Glu Leu Lys Ser Gly Arg Leu Val		400
	405	410
Leu Lys Asp Arg Ala Val Leu Ser Xaa Pro Ser Leu Ser Gln Asp Pro		415
	420	425
Gln Ala Leu Leu Ile Met Glu Ala Gly Thr Ser Leu Lys Thr Ser Xaa		430
435	440	445
Asp Leu Lys Leu Xaa Thr Xaa Ser Ile Pro Leu His Ser Leu Asp Thr		
450	455	460
Glu Lys Ser Val Thr Ile His Ala Pro Asn Leu Ser Ile Gln Lys Ile		
465	470	475
Phe Leu Ser Asn Ser Gly Asp Glu Asn Phe Tyr Glu Asn Val Glu Leu		480
	485	490
		495

Leu Ser Lys Glu Gln Asn Asn Ile Pro Leu Leu Thr Leu Pro Lys Glu
 500 505 510
 Gln Ser His Leu His Leu Pro Asp Gly Asn Leu Ser Ser His Phe Gly
 515 520 525
 Tyr Gln Gly Asp Trp Thr Phe Ser Trp Lys Asp Ser Asp Glu Gly His
 530 535 540
 Ser Leu Ile Ala Asn Trp Thr Pro Lys Asn Tyr Val Pro His Pro Glu
 545 550 555 560
 Arg Gln Ser Thr Leu Val Ala Asn Thr Leu Trp Asn Thr Tyr Ser Asp
 565 570 575
 Met Gln Ala Val Gln Ser Met Ile Asn Thr Thr Ala His Gly Gly Ala
 580 585 590
 Tyr Leu Phe Gly Thr Trp Gly Ser Ala Val Ser Asn Leu Phe Tyr Val
 595 600 605
 His Asp Ser Ser Gly Lys Pro Ile Asp Asn Trp His His Arg Ser Leu
 610 615 620
 Gly Tyr Leu Phe Gly Ile Ser Thr His Ser Leu Asp Asp His Ser Phe
 625 630 635 640
 Cys Leu Ala Ala Gly Gln Leu Leu Gly Lys Ser Ser Asp Ser Phe Ile
 645 650 655
 Thr Ser Thr Glu Thr Thr Ser Tyr Ile Ala Thr Val Gln Ala Gln Leu
 660 665 670
 Ala Thr Ser Leu Met Lys Ile Ser Ala Gln Ala Cys Tyr Asn Glu Ser
 675 680 685
 Ile His Glu Leu Lys Thr Lys Tyr Arg Ser Phe Ser Lys Glu Gly Phe
 690 695 700
 Gly Ser Trp His Ser Val Ala Val Ser Gly Glu Val Cys Ala Ser Ile
 705 710 715 720
 Pro Ile Val Ser Asn Gly Ser Gly Leu Phe Ser Ser Phe Ser Ile Phe
 725 730 735
 Ser Lys Leu Gln Gly Phe Ser Gly Thr Gln Asp Gly Phe Glu Glu Ser
 740 745 750
 Ser Gly Glu Ile Arg Ser Phe Ser Ala Ser Ser Phe Arg Asn Ile Ser
 755 760 765
 Leu Pro Ile Gly Ile Thr Phe Glu Lys Lys Ser Gln Lys Thr Arg Thr
 770 775 780
 Tyr Tyr Tyr Phe Leu Gly Ala Tyr Ile Gln Asp Leu Lys Arg Asp Val
 785 790 795 800
 Glu Ser Gly Pro Val Val Leu Leu Lys Asn Ala Val Ser Trp Asp Ala
 805 810 815
 Pro Met Ala Asn Leu Asp Ser Arg Ala Tyr Met Phe Arg Leu Thr Asn
 820 825 830
 Gln Arg Ala Leu His Arg Leu Gln Thr Leu Leu Asn Val Ser Cys Val
 835 840 845
 Leu Arg Gly Gln Ser His Ser Tyr Ser Leu Asp Leu Gly Thr Thr Tyr
 850 855 860
 Arg Phe
 865

<210> 190

<211> 1006

<212> PRT

<213> Chlamydia

<400> 190

Met Ala Ser Met Thr Gly Gly Gln Gln Met Gly Arg Asp Ser Ser Leu
 1 5 10 15
 Val Pro His His His His His Met Ile Pro Gln Gly Ile Tyr Asp
 20 25 30
 Gly Glu Thr Thr Val Ser Phe Pro Tyr Thr Val Ile Gly Asp Pro
 35 40 45
 Ser Gly Thr Thr Val Phe Ser Ala Gly Glu Leu Thr Leu Lys Asn Leu
 50 55 60
 Asp Asn Ser Ile Ala Ala Leu Pro Leu Ser Cys Phe Gly Asn Leu Leu
 65 70 75 80
 Gly Ser Phe Thr Val Leu Gly Arg Gly His Ser Leu Thr Phe Glu Asn
 85 90 95
 Ile Arg Thr Ser Thr Asn Gly Ala Ala Leu Ser Asn Ser Ala Ala Asp
 100 105 110
 Gly Leu Phe Thr Ile Glu Gly Phe Lys Glu Leu Ser Phe Ser Asn Cys
 115 120 125
 Asn Ser Leu Leu Ala Val Leu Pro Ala Ala Thr Thr Asn Lys Gly Ser
 130 135 140
 Gln Thr Pro Thr Thr Ser Thr Pro Ser Asn Gly Thr Ile Tyr Ser
 145 150 155 160
 Lys Thr Asp Leu Leu Leu Leu Asn Asn Glu Lys Phe Ser Phe Tyr Ser
 165 170 175
 Asn Leu Val Ser Gly Asp Gly Gly Ala Ile Asp Ala Lys Ser Leu Thr
 180 185 190
 Val Gln Gly Ile Ser Lys Leu Cys Val Phe Gln Glu Asn Thr Ala Gln
 195 200 205
 Ala Asp Gly Gly Ala Cys Gln Val Val Thr Ser Phe Ser Ala Met Ala
 210 215 220
 Asn Glu Ala Pro Ile Ala Phe Val Ala Asn Val Ala Gly Val Arg Gly
 225 230 235 240
 Gly Gly Ile Ala Ala Val Gln Asp Gly Gln Gln Gly Val Ser Ser Ser
 245 250 255
 Thr Ser Thr Glu Asp Pro Val Val Ser Phe Ser Arg Asn Thr Ala Val
 260 265 270
 Glu Phe Asp Gly Asn Val Ala Arg Val Gly Gly Gly Ile Tyr Ser Tyr
 275 280 285
 Gly Asn Val Ala Phe Leu Asn Asn Gly Lys Thr Leu Phe Leu Asn Asn
 290 295 300
 Val Ala Ser Pro Val Tyr Ile Ala Ala Lys Gln Pro Thr Ser Gly Gln
 305 310 315 320
 Ala Ser Asn Thr Ser Asn Asn Tyr Gly Asp Gly Gly Ala Ile Phe Cys
 325 330 335
 Lys Asn Gly Ala Gln Ala Gly Ser Asn Asn Ser Gly Ser Val Ser Phe
 340 345 350
 Asp Gly Glu Gly Val Val Phe Phe Ser Ser Asn Val Ala Ala Gly Lys
 355 360 365
 Gly Gly Ala Ile Tyr Ala Lys Lys Leu Ser Val Ala Asn Cys Gly Pro
 370 375 380
 Val Gln Phe Leu Arg Asn Ile Ala Asn Asp Gly Gly Ala Ile Tyr Leu
 385 390 395 400
 Gly Glu Ser Gly Glu Leu Ser Leu Ser Ala Asp Tyr Gly Asp Ile Ile
 405 410 415
 Phe Asp Gly Asn Leu Lys Arg Thr Ala Lys Glu Asn Ala Ala Asp Val
 420 425 430
 Asn Gly Val Thr Val Ser Ser Gln Ala Ile Ser Met Gly Ser Gly Gly

435 440 445
 Lys Ile Thr Thr Leu Arg Ala Lys Ala Gly His Gln Ile Leu Phe Asn
 450 455 460
 Asp Pro Ile Glu Met Ala Asn Gly Asn Asn Gln Pro Ala Gln Ser Ser
 465 470 475 480
 Lys Leu Leu Lys Ile Asn Asp Gly Glu Gly Tyr Thr Gly Asp Ile Val
 485 490 495
 Phe Ala Asn Gly Ser Ser Thr Leu Tyr Gln Asn Val Thr Ile Glu Gln
 500 505 510
 Gly Arg Ile Val Leu Arg Glu Lys Ala Lys Leu Ser Val Asn Ser Leu
 515 520 525
 Ser Gln Thr Gly Gly Ser Leu Tyr Met Glu Ala Gly Ser Thr Leu Asp
 530 535 540
 Phe Val Thr Pro Gln Pro Pro Gln Gln Pro Ala Ala Asn Gln Leu
 545 550 555 560
 Ile Thr Leu Ser Asn Leu His Leu Ser Leu Ser Ser Leu Leu Ala Asn
 565 570 575
 Asn Ala Val Thr Asn Pro Pro Thr Asn Pro Pro Ala Gln Asp Ser His
 580 585 590
 Pro Ala Val Ile Gly Ser Thr Thr Ala Gly Ser Val Thr Ile Ser Gly
 595 600 605
 Pro Ile Phe Phe Glu Asp Leu Asp Asp Thr Ala Tyr Asp Arg Tyr Asp
 610 615 620
 Trp Leu Gly Ser Asn Gln Lys Ile Asn Val Leu Lys Leu Gln Leu Gly
 625 630 635 640
 Thr Lys Pro Pro Ala Asn Ala Pro Ser Asp Leu Thr Leu Gly Asn Glu
 645 650 655
 Met Pro Lys Tyr Gly Tyr Gln Gly Ser Trp Lys Leu Ala Trp Asp Pro
 660 665 670
 Asn Thr Ala Asn Asn Gly Pro Tyr Thr Leu Lys Ala Thr Trp Thr Lys
 675 680 685
 Thr Gly Tyr Asn Pro Gly Pro Glu Arg Val Ala Ser Leu Val Pro Asn
 690 695 700
 Ser Leu Trp Gly Ser Ile Leu Asp Ile Arg Ser Ala His Ser Ala Ile
 705 710 715 720
 Gln Ala Ser Val Asp Gly Arg Ser Tyr Cys Arg Gly Leu Trp Val Ser
 725 730 735
 Gly Val Ser Asn Phe Phe Tyr His Asp Arg Asp Ala Leu Gly Gln Gly
 740 745 750
 Tyr Arg Tyr Ile Ser Gly Gly Tyr Ser Leu Gly Ala Asn Ser Tyr Phe
 755 760 765
 Gly Ser Ser Met Phe Gly Leu Ala Phe Thr Glu Val Phe Gly Arg Ser
 770 775 780
 Lys Asp Tyr Val Val Cys Arg Ser Asn His His Ala Cys Ile Gly Ser
 785 790 795 800
 Val Tyr Leu Ser Thr Gln Gln Ala Leu Cys Gly Ser Tyr Leu Phe Gly
 805 810 815
 Asp Ala Phe Ile Arg Ala Ser Tyr Gly Phe Gly Asn Gln His Met Lys
 820 825 830
 Thr Ser Tyr Thr Phe Ala Glu Glu Ser Asp Val Arg Trp Asp Asn Asn
 835 840 845
 Cys Leu Ala Gly Glu Ile Gly Ala Gly Leu Pro Ile Val Ile Thr Pro
 850 855 860
 Ser Lys Leu Tyr Leu Asn Glu Leu Arg Pro Phe Val Gln Ala Glu Phe
 865 870 875 880

Ser Tyr Ala Asp His Glu Ser Phe Thr Glu Glu Gly Asp Gln Ala Arg
 885 890 895
 Ala Phe Lys Ser Gly His Leu Leu Asn Leu Ser Val Pro Val Gly Val
 900 905 910
 Lys Phe Asp Arg Cys Ser Ser Thr His Pro Asn Lys Tyr Ser Phe Met
 915 920 925
 Ala Ala Tyr Ile Cys Asp Ala Tyr Arg Thr Ile Ser Gly Thr Glu Thr
 930 935 940
 Thr Leu Leu Ser His Gln Glu Thr Trp Thr Thr Asp Ala Phe His Leu
 945 950 955 960
 Ala Arg His Gly Val Val Val Arg Gly Ser Met Tyr Ala Ser Leu Thr
 965 970 975
 Ser Asn Ile Glu Val Tyr Gly His Gly Arg Tyr Glu Tyr Arg Asp Ala
 980 985 990
 Ser Arg Gly Tyr Gly Leu Ser Ala Gly Ser Lys Val Arg Phe
 995 1000 1005

<210> 191

<211> 977

<212> PRT

<213> Chlamydia

<400> 191

Met Ala Ser Met Thr Gly Gly Gln Gln Met Gly Arg Asp Ser Ser Leu
 1 5 10 15
 Val Pro Ser Ser Asp Pro His His His His His Gly Leu Ala Arg
 20 25 30
 Glu Val Pro Ser Arg Ile Phe Leu Met Pro Asn Ser Val Pro Asp Pro
 35 40 45
 Thr Lys Glu Ser Leu Ser Asn Lys Ile Ser Leu Thr Gly Asp Thr His
 50 55 60
 Asn Leu Thr Asn Cys Tyr Leu Asp Asn Leu Arg Tyr Ile Leu Ala Ile
 65 70 75 80
 Leu Gln Lys Thr Pro Asn Glu Gly Ala Ala Val Thr Ile Thr Asp Tyr
 85 90 95
 Leu Ser Phe Phe Asp Thr Gln Lys Glu Gly Ile Tyr Phe Ala Lys Asn
 100 105 110
 Leu Thr Pro Glu Ser Gly Gly Ala Ile Gly Tyr Ala Ser Pro Asn Ser
 115 120 125
 Pro Thr Val Glu Ile Arg Asp Thr Ile Gly Pro Val Ile Phe Glu Asn
 130 135 140
 Asn Thr Cys Cys Arg Leu Phe Thr Trp Arg Asn Pro Tyr Ala Ala Asp
 145 150 155 160
 Lys Ile Arg Glu Gly Gly Ala Ile His Ala Gln Asn Leu Tyr Ile Asn
 165 170 175
 His Asn His Asp Val Val Gly Phe Met Lys Asn Phe Ser Tyr Val Gln
 180 185 190
 Gly Gly Ala Ile Ser Thr Ala Asn Thr Phe Val Val Ser Glu Asn Gln
 195 200 205
 Ser Cys Phe Leu Phe Met Asp Asn Ile Cys Ile Gln Thr Asn Thr Ala
 210 215 220
 Gly Lys Gly Gly Ala Ile Tyr Ala Gly Thr Ser Asn Ser Phe Glu Ser
 225 230 235 240
 Asn Asn Cys Asp Leu Phe Phe Ile Asn Asn Ala Cys Cys Ala Gly Gly
 245 250 255

Ala Ile Phe Ser Pro Ile Cys Ser Leu Thr Gly Asn Arg Gly Asn Ile
 260 265 270
 Val Phe Tyr Asn Asn Arg Cys Phe Lys Asn Val Glu Thr Ala Ser Ser
 275 280 285
 Glu Ala Ser Asp Gly Gly Ala Ile Lys Val Thr Thr Arg Leu Asp Val
 290 295 300
 Thr Gly Asn Arg Gly Arg Ile Phe Phe Ser Asp Asn Ile Thr Lys Asn
 305 310 315 320
 Tyr Gly Gly Ala Ile Tyr Ala Pro Val Val Thr Leu Val Asp Asn Gly
 325 330 335
 Pro Thr Tyr Phe Ile Asn Asn Ile Ala Asn Asn Lys Gly Gly Ala Ile
 340 345 350
 Tyr Ile Asp Gly Thr Ser Asn Ser Lys Ile Ser Ala Asp Arg His Ala
 355 360 365
 Ile Ile Phe Asn Glu Asn Ile Val Thr Asn Val Thr Asn Ala Asn Gly
 370 375 380
 Thr Ser Thr Ser Ala Asn Pro Pro Arg Arg Asn Ala Ile Thr Val Ala
 385 390 395 400
 Ser Ser Ser Gly Glu Ile Leu Leu Gly Ala Gly Ser Ser Gln Asn Leu
 405 410 415
 Ile Phe Tyr Asp Pro Ile Glu Val Ser Asn Ala Gly Val Ser Val Ser
 420 425 430
 Phe Asn Lys Glu Ala Asp Gln Thr Gly Ser Val Val Phe Ser Gly Ala
 435 440 445
 Thr Val Asn Ser Ala Asp Phe His Gln Arg Asn Leu Gln Thr Lys Thr
 450 455 460
 Pro Ala Pro Leu Thr Leu Ser Asn Gly Phe Leu Cys Ile Glu Asp His
 465 470 475 480
 Ala Gln Leu Thr Val Asn Arg Phe Thr Gln Thr Gly Gly Val Val Ser
 485 490 495
 Leu Gly Asn Gly Ala Val Leu Ser Cys Tyr Lys Asn Gly Thr Gly Asp
 500 505 510
 Ser Ala Ser Asn Ala Ser Ile Thr Leu Lys His Ile Gly Leu Asn Leu
 515 520 525
 Ser Ser Ile Leu Lys Ser Gly Ala Glu Ile Pro Leu Leu Trp Val Glu
 530 535 540
 Pro Thr Asn Asn Ser Asn Asn Tyr Thr Ala Asp Thr Ala Ala Thr Phe
 545 550 555 560
 Ser Leu Ser Asp Val Lys Leu Ser Leu Ile Asp Asp Tyr Gly Asn Ser
 565 570 575
 Pro Tyr Glu Ser Thr Asp Leu Thr His Ala Leu Ser Ser Gln Pro Met
 580 585 590
 Leu Ser Ile Ser Glu Ala Ser Asp Asn Gln Leu Gln Ser Glu Asn Ile
 595 600 605
 Asp Phe Ser Gly Leu Asn Val Pro His Tyr Gly Trp Gln Gly Leu Trp
 610 615 620
 Thr Trp Gly Trp Ala Lys Thr Gln Asp Pro Glu Pro Ala Ser Ser Ala
 625 630 635 640
 Thr Ile Thr Asp Pro Gln Lys Ala Asn Arg Phe His Arg Thr Leu Leu
 645 650 655
 Leu Thr Trp Leu Pro Ala Gly Tyr Val Pro Ser Pro Lys His Arg Ser
 660 665 670
 Pro Leu Ile Ala Asn Thr Leu Trp Gly Asn Met Leu Leu Ala Thr Glu
 675 680 685
 Ser Leu Lys Asn Ser Ala Glu Leu Thr Pro Ser Gly His Pro Phe Trp

690 695 700
 Gly Ile Thr Gly Gly Gly Leu Gly Met Met Val Tyr Gln Asp Pro Arg
 705 710 715 720
 Glu Asn His Pro Gly Phe His Met Arg Ser Ser Gly Tyr Ser Ala Gly
 725 730 735
 Met Ile Ala Gly Gln Thr His Thr Phe Ser Leu Lys Phe Ser Gln Thr
 740 745 750
 Tyr Thr Lys Leu Asn Glu Arg Tyr Ala Lys Asn Asn Val Ser Ser Lys
 755 760 765
 Asn Tyr Ser Cys Gln Gly Glu Met Leu Phe Ser Leu Gln Glu Gly Phe
 770 775 780
 Leu Ser Thr Lys Leu Val Gly Leu Tyr Ser Tyr Gly Asp His Asn Cys
 785 790 795 800
 His His Phe Tyr Thr Gln Gly Glu Asn Leu Thr Ser Gln Gly Thr Phe
 805 810 815
 Arg Ser Gln Thr Met Gly Gly Ala Val Phe Phe Asp Leu Pro Met Lys
 820 825 830
 Pro Phe Gly Ser Thr His Ile Leu Thr Ala Pro Phe Leu Gly Ala Leu
 835 840 845
 Gly Ile Tyr Ser Ser Leu Ser His Phe Thr Glu Val Gly Ala Tyr Pro
 850 855 860
 Arg Ser Phe Ser Thr Lys Thr Pro Leu Ile Asn Val Leu Val Pro Ile
 865 870 875 880
 Gly Val Lys Gly Ser Phe Met Asn Ala Thr His Arg Pro Gln Ala Trp
 885 890 895
 Thr Val Glu Leu Ala Tyr Gln Pro Val Leu Tyr Arg Gln Glu Pro Gly
 900 905 910
 Ile Ala Thr Gln Leu Leu Ala Ser Lys Gly Ile Trp Phe Gly Ser Gly
 915 920 925
 Ser Pro Ser Ser Arg His Ala Met Ser Tyr Lys Ile Ser Gln Gln Thr
 930 935 940
 Gln Pro Leu Ser Trp Leu Thr Leu His Phe Gln Tyr His Gly Phe Tyr
 945 950 955 960
 Ser Ser Ser Thr Phe Cys Asn Tyr Leu Asn Gly Glu Ile Ala Leu Arg
 965 970 975
 Phe

<210> 192

<211> 848

<212> PRT

<213> Chlamydia

<400> 192

Met Ala Ser His His His His His Gly Ala Ile Ser Cys Leu Arg
 1 5 10 15
 Gly Asp Val Val Ile Ser Gly Asn Lys Gly Arg Val Glu Phe Lys Asp
 20 25 30
 Asn Ile Ala Thr Arg Leu Tyr Val Glu Glu Thr Val Glu Lys Val Glu
 35 40 45
 Glu Val Glu Pro Ala Pro Glu Gln Lys Asp Asn Asn Glu Leu Ser Phe
 50 55 60
 Leu Gly Ser Val Glu Gln Ser Phe Ile Thr Ala Ala Asn Gln Ala Leu
 65 70 75 80
 Phe Ala Ser Glu Asp Gly Asp Leu Ser Pro Glu Ser Ser Ile Ser Ser

[illegible]

Gly Ala Leu Val Phe Asn Ala Leu Trp Glu Glu Gly Ala Val Leu Ser
 530 535 540
 Ala Leu Lys Asn Ala Arg Phe Ala His Asn Leu Thr Ala Gln Arg Met
 545 550 555 560
 Glu Phe Asp Tyr Ser Thr Asn Val Trp Gly Phe Ala Phe Gly Gly Phe
 565 570 575
 Arg Thr Leu Ser Ala Glu Asn Leu Val Ala Ile Asp Gly Tyr Lys Gly
 580 585 590
 Ala Tyr Gly Gly Ala Ser Ala Gly Val Asp Ile Gln Leu Met Glu Asp
 595 600 605
 Phe Val Leu Gly Val Ser Gly Ala Ala Phe Leu Gly Lys Met Asp Ser
 610 615 620
 Gln Lys Phe Asp Ala Glu Val Ser Arg Lys Gly Val Val Gly Ser Val
 625 630 635 640
 Tyr Thr Gly Phe Leu Ala Gly Ser Trp Phe Phe Lys Gly Gln Tyr Ser
 645 650 655
 Leu Gly Glu Thr Gln Asn Asp Met Lys Thr Arg Tyr Gly Val Leu Gly
 660 665 670
 Glu Ser Ser Ala Ser Trp Thr Ser Arg Gly Val Leu Ala Asp Ala Leu
 675 680 685
 Val Glu Tyr Arg Ser Leu Val Gly Pro Val Arg Pro Thr Phe Tyr Ala
 690 695 700
 Leu His Phe Asn Pro Tyr Val Glu Val Ser Tyr Ala Ser Met Lys Phe
 705 710 715 720
 Pro Gly Phe Thr Glu Gln Gly Arg Glu Ala Arg Ser Phe Glu Asp Ala
 725 730 735
 Ser Leu Thr Asn Ile Thr Ile Pro Leu Gly Met Lys Phe Glu Leu Ala
 740 745 750
 Phe Ile Lys Gly Gln Phe Ser Glu Val Asn Ser Leu Gly Ile Ser Tyr
 755 760 765
 Ala Trp Glu Ala Tyr Arg Lys Val Glu Gly Gly Ala Val Gln Leu Leu
 770 775 780
 Glu Ala Gly Phe Asp Trp Glu Gly Ala Pro Met Asp Leu Pro Arg Gln
 785 790 795 800
 Glu Leu Arg Val Ala Leu Glu Asn Asn Thr Glu Trp Ser Ser Tyr Phe
 805 810 815
 Ser Thr Val Leu Gly Leu Thr Ala Phe Cys Gly Gly Phe Thr Ser Thr
 820 825 830
 Asp Ser Lys Leu Gly Tyr Glu Ala Asn Thr Gly Leu Arg Leu Ile Phe
 835 840 845

<210> 193

<211> 778

<212> PRT

<213> Chlamydia

<400> 193

Met His His His His His His Gly Leu Ala Ser Cys Val Asp Leu His
 1 5 10 15
 Ala Gly Gly Gln Ser Val Asn Glu Leu Val Tyr Val Gly Pro Gln Ala
 20 25 30
 Val Leu Leu Leu Asp Gln Ile Arg Asp Leu Phe Val Gly Ser Lys Asp
 35 40 45
 Ser Gln Ala Glu Gly Gln Tyr Arg Leu Ile Val Gly Asp Pro Ser Ser
 50 55 60

Phe Gln Glu Lys Asp Ala Asp Thr Leu Pro Gly Lys Val Glu Gln Ser
 65 70 75 80
 Thr Leu Phe Ser Val Thr Asn Pro Val Val Phe Gln Gly Val Asp Gln
 85 90 95
 Gln Asp Gln Val Ser Ser Gln Gly Leu Ile Cys Ser Phe Thr Ser Ser
 100 105 110
 Asn Leu Asp Ser Pro Arg Asp Gly Glu Ser Phe Leu Gly Ile Ala Phe
 115 120 125
 Val Gly Asp Ser Ser Lys Ala Gly Ile Thr Leu Thr Asp Val Lys Ala
 130 135 140
 Ser Leu Ser Gly Ala Ala Leu Tyr Ser Thr Glu Asp Leu Ile Phe Glu
 145 150 155 160
 Lys Ile Lys Gly Gly Leu Glu Phe Ala Ser Cys Ser Ser Leu Glu Gln
 165 170 175
 Gly Gly Ala Cys Ala Ala Gln Ser Ile Leu Ile His Asp Cys Gln Gly
 180 185 190
 Leu Gln Val Lys His Cys Thr Thr Ala Val Asn Ala Glu Gly Ser Ser
 195 200 205
 Ala Asn Asp His Leu Gly Phe Gly Gly Gly Ala Phe Val Thr Gly
 210 215 220
 Ser Leu Ser Gly Glu Lys Ser Leu Tyr Met Pro Ala Gly Asp Met Val
 225 230 235 240
 Val Ala Asn Cys Asp Gly Ala Ile Ser Phe Glu Gly Asn Ser Ala Asn
 245 250 255
 Phe Ala Asn Gly Gly Ala Ile Ala Ala Ser Gly Lys Val Leu Phe Val
 260 265 270
 Ala Asn Asp Lys Lys Thr Ser Phe Ile Glu Asn Arg Ala Leu Ser Gly
 275 280 285
 Gly Ala Ile Ala Ala Ser Ser Asp Ile Ala Phe Gln Asn Cys Ala Glu
 290 295 300
 Leu Val Phe Lys Gly Asn Cys Ala Ile Gly Thr Glu Asp Lys Gly Ser
 305 310 315 320
 Leu Gly Gly Gly Ala Ile Ser Ser Leu Gly Thr Val Leu Leu Gln Gly
 325 330 335
 Asn His Gly Ile Thr Cys Asp Lys Asn Glu Ser Ala Ser Gln Gly Gly
 340 345 350
 Ala Ile Phe Gly Lys Asn Cys Gln Ile Ser Asp Asn Glu Gly Pro Val
 355 360 365
 Val Phe Arg Asp Ser Thr Ala Cys Leu Gly Gly Gly Ala Ile Ala Ala
 370 375 380
 Gln Glu Ile Val Ser Ile Gln Asn Asn Gln Ala Gly Ile Ser Phe Glu
 385 390 395 400
 Gly Gly Lys Ala Ser Phe Gly Gly Gly Ile Ala Cys Gly Ser Phe Ser
 405 410 415
 Ser Ala Gly Gly Ala Ser Val Leu Gly Thr Ile Asp Ile Ser Lys Asn
 420 425 430
 Leu Gly Ala Ile Ser Phe Ser Arg Thr Leu Cys Thr Thr Ser Asp Leu
 435 440 445
 Gly Gln Met Glu Tyr Gln Gly Gly Gly Ala Leu Phe Gly Glu Asn Ile
 450 455 460
 Ser Leu Ser Glu Asn Ala Gly Val Leu Thr Phe Lys Asp Asn Ile Val
 465 470 475 480
 Lys Thr Phe Ala Ser Asn Gly Lys Ile Leu Gly Gly Gly Ala Ile Leu
 485 490 495
 Ala Thr Gly Lys Val Glu Ile Thr Asn Asn Ser Gly Gly Ile Ser Phe

```

      500                      505                      510
Thr Gly Asn Ala Arg Ala Pro Gln Ala Leu Pro Thr Gln Glu Glu Phe
      515                      520                      525
Pro Leu Phe Ser Lys Lys Glu Gly Arg Pro Leu Ser Ser Gly Tyr Ser
      530                      535                      540
Gly Gly Gly Ala Ile Leu Gly Arg Glu Val Ala Ile Leu His Asn Ala
      545                      550                      555
Ala Val Val Phe Glu Gln Asn Arg Leu Gln Cys Ser Glu Glu Glu Ala
      560                      565                      570
Thr Leu Leu Gly Cys Cys Gly Gly Gly Ala Val His Gly Met Asp Ser
      575                      580                      585
Thr Ser Ile Val Gly Asn Ser Ser Val Arg Phe Gly Asn Asn Tyr Ala
      590                      595                      600
Met Gly Gln Gly Val Ser Gly Gly Ala Leu Leu Ser Lys Thr Val Gln
      605                      610                      615
Leu Ala Gly Asn Gly Ser Val Asp Phe Ser Arg Asn Ile Ala Ser Leu
      620                      625                      630
Gly Gly Gly Ala Leu Gln Ala Ser Glu Gly Asn Cys Glu Leu Val Asp
      635                      640                      645
Asn Gly Tyr Val Leu Phe Arg Asp Asn Arg Gly Arg Val Tyr Gly Gly
      645                      650                      655
Ala Ile Ser Cys Leu Arg Gly Asp Val Val Ile Ser Gly Asn Lys Gly
      660                      665                      670
Arg Val Glu Phe Lys Asp Asn Ile Ala Thr Arg Leu Tyr Val Glu Glu
      675                      680                      685
Thr Val Glu Lys Val Glu Glu Val Glu Pro Ala Pro Glu Gln Lys Asp
      690                      695                      700
Asn Asn Glu Leu Ser Phe Leu Gly Ser Val Glu Gln Ser Phe Ile Thr
      705                      710                      715
Ala Ala Asn Gln Ala Leu Phe Ala Ser Glu Asp Gly Asp Leu Ser Pro
      720                      725                      730
Glu Ser Ser Ile Ser Ser Glu Glu Leu Ala Lys Arg Arg Glu Cys Ala
      735                      740                      745
Gly Gly Ala Asp Ser Ser Arg Ser Gly Cys
      750                      755                      760
      765                      770                      775

```

<210> 194

<211> 948

<212> PRT

<213> Chlamydia

<400> 194

```

Met Ala Ser Met His His His His His Val Lys Ile Glu Asn Phe
  1                      5                      10                      15
Ser Gly Gln Gly Ile Phe Ser Gly Asn Lys Ala Ile Asp Asn Thr Thr
  20                      25                      30
Glu Gly Ser Ser Ser Lys Ser Asn Val Leu Gly Gly Ala Val Tyr Ala
  35                      40                      45
Lys Thr Leu Phe Asn Leu Asp Ser Gly Ser Ser Arg Arg Thr Val Thr
  50                      55                      60
Phe Ser Gly Asn Thr Val Ser Ser Gln Ser Thr Thr Gly Gln Val Ala
  65                      70                      75                      80
Gly Gly Ala Ile Tyr Ser Pro Thr Val Thr Ile Ala Thr Pro Val Val
  85                      90                      95
Phe Ser Lys Asn Ser Ala Thr Asn Asn Ala Asn Asn Ala Thr Asp Thr

```

	100		105		110	
Gln Arg Lys	Asp Thr Phe Gly	Gly Ala Ile	Gly Ala Thr	Ser Ala Val		
	115	120	125			
Ser Leu Ser	Gly Gly Ala His Phe	Leu Glu Asn	Val Ala Asp	Leu Gly		
	130	135	140			
Ser Ala Ile	Gly Leu Val Pro Asp	Thr Gln Asn	Thr Glu Thr	Val Lys		
145	150	155		160		
Leu Glu Ser	Gly Ser Tyr Tyr Phe	Glu Lys Asn	Lys Ala Leu	Lys Arg		
	165	170	175			
Ala Thr Ile	Tyr Ala Pro Val Val	Ser Ile Lys	Ala Tyr Thr	Ala Thr		
	180	185	190			
Phe Asn Gln	Asn Arg Ser Leu Glu	Gly Ser Ala Ile	Tyr Phe Thr			
	195	200	205			
Lys Glu Ala	Ser Ile Glu Ser Leu	Gly Ser Val Leu	Phe Thr Gly	Asn		
	210	215	220			
Leu Val Thr	Pro Thr Leu Ser Thr	Thr Thr Glu	Gly Thr Pro	Ala Thr		
225	230	235	240			
Thr Ser Gly	Asp Val Thr Lys Tyr	Gly Ala Ala Ile	Phe Gly Gln	Ile		
	245	250	255			
Ala Ser Ser	Asn Gly Ser Gln Thr	Asp Asn Leu Pro	Leu Lys Leu	Ile		
	260	265	270			
Ala Ser Gly	Gly Asn Ile Cys Phe	Arg Asn Asn Glu	Tyr Arg Pro	Thr		
	275	280	285			
Ser Ser Asp	Thr Gly Thr Ser Thr	Phe Cys Ser Ile	Ala Gly Asp	Val		
	290	295	300			
Lys Leu Thr	Met Gln Ala Ala Lys	Gly Lys Thr Ile	Ser Phe Phe	Asp		
305	310	315	320			
Ala Ile Arg	Thr Ser Thr Lys Lys	Thr Gly Thr Gln	Ala Thr Ala	Tyr		
	325	330	335			
Asp Thr Leu	Asp Ile Asn Lys Ser	Glu Asp Ser Glu	Thr Val Asn	Ser		
	340	345	350			
Ala Phe Thr	Gly Thr Ile Leu Phe	Ser Ser Glu Leu	His Glu Asn	Lys		
	355	360	365			
Ser Tyr Ile	Pro Gln Asn Val Val	Leu His Ser Gly	Ser Leu Val	Leu		
	370	375	380			
Lys Pro Asn	Thr Glu Leu His Val Ile	Ser Phe Glu Gln	Lys Glu Gly			
385	390	395	400			
Ser Ser Leu	Val Met Thr Pro Gly	Ser Val Leu Ser	Asn Gln Thr	Val		
	405	410	415			
Ala Asp Gly	Ala Leu Val Ile Asn	Asn Met Thr Ile	Asp Leu Ser	Ser		
	420	425	430			
Val Glu Lys	Asn Gly Ile Ala Glu	Gly Asn Ile Phe	Thr Pro Pro	Glu		
	435	440	445			
Leu Arg Ile	Ile Asp Thr Thr Thr	Ser Gly Ser Gly	Gly Thr Pro	Ser		
	450	455	460			
Thr Asp Ser	Glu Ser Asn Gln Asn	Ser Asp Asp Thr	Lys Glu Gln	Asn		
465	470	475	480			
Asn Asn Asp	Ala Ser Asn Gln Gly	Glu Ser Ala Asn	Gly Ser Ser	Ser		
	485	490	495			
Pro Ala Val	Ala Ala Ala His Thr	Ser Arg Thr Arg	Asn Phe Ala	Ala		
	500	505	510			
Ala Ala Thr	Ala Thr Pro Thr Thr	Thr Pro Thr Ala	Thr Thr Thr	Thr		
	515	520	525			
Ser Asn Gln	Val Ile Leu Gly Gly	Glu Ile Lys Leu	Ile Asp Pro	Asn		
	530	535	540			

Gly Thr Phe Phe Gln Asn Pro Ala Leu Arg Ser Asp Gln Gln Ile Ser
 545 550 555 560
 Leu Leu Val Leu Pro Thr Asp Ser Ser Lys Met Gln Ala Gln Lys Ile
 565 570 575
 Val Leu Thr Gly Asp Ile Ala Pro Gln Lys Gly Tyr Thr Gly Thr Leu
 580 585 590
 Thr Leu Asp Pro Asp Gln Leu Gln Asn Gly Thr Ile Ser Ala Leu Trp
 595 600 605
 Lys Phe Asp Ser Tyr Arg Gln Trp Ala Tyr Val Pro Arg Asp Asn His
 610 615 620
 Phe Tyr Ala Asn Ser Ile Leu Gly Ser Gln Met Ser Met Val Thr Val
 625 630 635 640
 Lys Gln Gly Leu Leu Asn Asp Lys Met Asn Leu Ala Arg Phe Asp Glu
 645 650 655
 Val Ser Tyr Asn Asn Leu Trp Ile Ser Gly Leu Gly Thr Met Leu Ser
 660 665 670
 Gln Val Gly Thr Pro Thr Ser Glu Glu Phe Thr Tyr Tyr Ser Arg Gly
 675 680 685
 Ala Ser Val Ala Leu Asp Ala Lys Pro Ala His Asp Val Ile Val Gly
 690 695 700
 Ala Ala Phe Ser Lys Met Ile Gly Lys Thr Lys Ser Leu Lys Arg Glu
 705 710 715 720
 Asn Asn Tyr Thr His Lys Gly Ser Glu Tyr Ser Tyr Gln Ala Ser Val
 725 730 735
 Tyr Gly Gly Lys Pro Phe His Phe Val Ile Asn Lys Lys Thr Glu Lys
 740 745 750
 Ser Leu Pro Leu Leu Leu Gln Gly Val Ile Ser Tyr Gly Tyr Ile Lys
 755 760 765
 His Asp Thr Val Thr His Tyr Pro Thr Ile Arg Glu Arg Asn Gln Gly
 770 775 780
 Glu Trp Glu Asp Leu Gly Trp Leu Thr Ala Leu Arg Val Ser Ser Val
 785 790 795 800
 Leu Arg Thr Pro Ala Gln Gly Asp Thr Lys Arg Ile Thr Val Tyr Gly
 805 810 815
 Glu Leu Glu Tyr Ser Ser Ile Arg Gln Lys Gln Phe Thr Glu Thr Glu
 820 825 830
 Tyr Asp Pro Arg Tyr Phe Asp Asn Cys Thr Tyr Arg Asn Leu Ala Ile
 835 840 845
 Pro Met Gly Leu Ala Phe Glu Gly Glu Leu Ser Gly Asn Asp Ile Leu
 850 855 860
 Met Tyr Asn Arg Phe Ser Val Ala Tyr Met Pro Ser Ile Tyr Arg Asn
 865 870 875 880
 Ser Pro Thr Cys Lys Tyr Gln Val Leu Ser Ser Gly Glu Gly Gly Glu
 885 890 895
 Ile Ile Cys Gly Val Pro Thr Arg Asn Ser Ala Arg Gly Glu Tyr Ser
 900 905 910
 Thr Gln Leu Tyr Pro Gly Pro Leu Trp Thr Leu Tyr Gly Ser Tyr Thr
 915 920 925
 Ile Glu Ala Asp Ala His Thr Leu Ala His Met Met Asn Cys Gly Ala
 930 935 940
 Arg Met Thr Phe
 945

<210> 195

<211> 821

<212> PRT

<213> Chlamydia

<400> 195

```

Met His His His His His Glu Ala Ser Ser Ile Gln Asp Gln Ile
 1          5          10          15
Lys Asn Thr Asp Cys Asn Val Ser Lys Val Gly Tyr Ser Thr Ser Gln
      20          25          30
Ala Phe Thr Asp Met Met Leu Ala Asp Asn Thr Glu Tyr Arg Ala Ala
      35          40          45
Asp Ser Val Ser Phe Tyr Asp Phe Ser Thr Ser Ser Gly Leu Pro Arg
 50          55          60
Lys His Leu Ser Ser Ser Ser Glu Ala Ser Pro Thr Thr Glu Gly Val
 65          70          75          80
Ser Ser Ser Ser Ser Gly Glu Asn Thr Glu Asn Ser Gln Asp Ser Ala
      85          90          95
Pro Ser Ser Gly Glu Thr Asp Lys Lys Thr Glu Glu Glu Leu Asp Asn
      100          105          110
Gly Gly Ile Ile Tyr Ala Arg Glu Lys Leu Thr Ile Ser Glu Ser Gln
      115          120          125
Asp Ser Leu Ser Asn Pro Ser Ile Glu Leu His Asp Asn Ser Phe Phe
      130          135          140
Phe Gly Glu Gly Glu Val Ile Phe Asp His Arg Val Ala Leu Lys Asn
      145          150          155          160
Gly Gly Ala Ile Tyr Gly Glu Lys Glu Val Val Phe Glu Asn Ile Lys
      165          170          175
Ser Leu Leu Val Glu Val Asn Ile Ser Val Glu Lys Gly Gly Ser Val
      180          185          190
Tyr Ala Lys Glu Arg Val Ser Leu Glu Asn Val Thr Glu Ala Thr Phe
      195          200          205
Ser Ser Asn Gly Gly Glu Gln Gly Gly Gly Ile Tyr Ser Glu Gln
      210          215          220
Asp Met Leu Ile Ser Asp Cys Asn Asn Val His Phe Gln Gly Asn Ala
      225          230          235          240
Ala Gly Ala Thr Ala Val Lys Gln Cys Leu Asp Glu Glu Met Ile Val
      245          250          255
Leu Leu Thr Glu Cys Val Asp Ser Leu Ser Glu Asp Thr Leu Asp Ser
      260          265          270
Thr Pro Glu Thr Glu Gln Thr Lys Ser Asn Gly Asn Gln Asp Gly Ser
      275          280          285
Ser Glu Thr Lys Asp Thr Gln Val Ser Glu Ser Pro Glu Ser Thr Pro
      290          295          300
Ser Pro Asp Asp Val Leu Gly Lys Gly Gly Ile Tyr Thr Glu Lys
      305          310          315          320
Ser Leu Thr Ile Thr Gly Ile Thr Gly Thr Ile Asp Phe Val Ser Asn
      325          330          335
Ile Ala Thr Asp Ser Gly Ala Gly Val Phe Thr Lys Glu Asn Leu Ser
      340          345          350
Cys Thr Asn Thr Asn Ser Leu Gln Phe Leu Lys Asn Ser Ala Gly Gln
      355          360          365
His Gly Gly Gly Ala Tyr Val Thr Gln Thr Met Ser Val Thr Asn Thr
      370          375          380
Thr Ser Glu Ser Ile Thr Thr Pro Pro Leu Val Gly Glu Val Ile Phe
      385          390          395          400
Ser Glu Asn Thr Ala Lys Gly His Gly Gly Gly Ile Cys Thr Asn Lys

```

405 410 415
 Leu Ser Leu Ser Asn Leu Lys Thr Val Thr Leu Thr Lys Asn Ser Ala
 420 425 430
 Lys Glu Ser Gly Gly Ala Ile Phe Thr Asp Leu Ala Ser Ile Pro Thr
 435 440 445
 Thr Asp Thr Pro Glu Ser Ser Thr Pro Ser Ser Ser Ser Pro Ala Ser
 450 455 460
 Thr Pro Glu Val Val Ala Ser Ala Lys Ile Asn Arg Phe Phe Ala Ser
 465 470 475 480
 Thr Ala Glu Pro Ala Ala Pro Ser Leu Thr Glu Ala Glu Ser Asp Gln
 485 490 495
 Thr Asp Gln Thr Thr Ser Asp Thr Asn Ser Asp Ile Asp Val Ser
 500 505 510
 Ile Glu Asn Ile Leu Asn Val Ala Ile Asn Gln Asn Thr Ser Ala Lys
 515 520 525
 Lys Gly Gly Ala Ile Tyr Gly Lys Lys Ala Lys Leu Ser Arg Ile Asn
 530 535 540
 Asn Leu Glu Leu Ser Gly Asn Ser Ser Gln Asp Val Gly Gly Gly Leu
 545 550 555 560
 Cys Leu Thr Glu Ser Val Glu Phe Asp Ala Ile Gly Ser Leu Leu Ser
 565 570 575
 His Tyr Asn Ser Ala Ala Lys Glu Gly Gly Val Ile His Ser Lys Thr
 580 585 590
 Val Thr Leu Ser Asn Leu Lys Ser Thr Phe Thr Phe Ala Asp Asn Thr
 595 600 605
 Val Lys Ala Ile Val Glu Ser Thr Pro Glu Ala Pro Glu Glu Ile Pro
 610 615 620
 Pro Val Glu Gly Glu Glu Ser Thr Ala Thr Glu Asn Pro Asn Ser Asn
 625 630 635 640
 Thr Glu Gly Ser Ser Ala Asn Thr Asn Leu Glu Gly Ser Gln Gly Asp
 645 650 655
 Thr Ala Asp Thr Gly Thr Gly Val Val Asn Asn Glu Ser Gln Asp Thr
 660 665 670
 Ser Asp Thr Gly Asn Ala Glu Ser Gly Glu Gln Leu Gln Asp Ser Thr
 675 680 685
 Gln Ser Asn Glu Glu Asn Thr Leu Pro Asn Ser Ser Ile Asp Gln Ser
 690 695 700
 Asn Glu Asn Thr Asp Glu Ser Ser Asp Ser His Thr Glu Glu Ile Thr
 705 710 715 720
 Asp Glu Ser Val Ser Ser Ser Ser Lys Ser Gly Ser Ser Thr Pro Gln
 725 730 735
 Asp Gly Gly Ala Ala Ser Ser Gly Ala Pro Ser Gly Asp Gln Ser Ile
 740 745 750
 Ser Ala Asn Ala Cys Leu Ala Lys Ser Tyr Ala Ala Ser Thr Asp Ser
 755 760 765
 Ser Pro Val Ser Asn Ser Ser Gly Ser Asp Val Thr Ala Ser Ser Asp
 770 775 780
 Asn Pro Asp Ser Ser Ser Ser Gly Asp Ser Ala Gly Asp Ser Glu Gly
 785 790 795 800
 Pro Thr Glu Pro Glu Ala Gly Ser Thr Thr Glu Thr Pro Thr Leu Ile
 805 810 815
 Gly Gly Gly Ala Ile
 820

<211> 525

<212> PRT

<213> Chlamydia

<400> 196

```

Met His His His His His Thr Ala Ala Ser Asp Asn Phe Gln Leu
 1          5          10          15
Ser Gln Gly Gly Gln Gly Phe Ala Ile Pro Ile Gly Gln Ala Met Ala
          20          25          30
Ile Ala Gly Gln Ile Lys Leu Pro Thr Val His Ile Gly Pro Thr Ala
          35          40          45
Phe Leu Gly Leu Gly Val Val Asp Asn Asn Gly Asn Gly Ala Arg Val
          50          55          60
Gln Arg Val Val Gly Ser Ala Pro Ala Ala Ser Leu Gly Ile Ser Thr
          65          70          75          80
Gly Asp Val Ile Thr Ala Val Asp Gly Ala Pro Ile Asn Ser Ala Thr
          85          90          95
Ala Met Ala Asp Ala Leu Asn Gly His His Pro Gly Asp Val Ile Ser
          100          105          110
Val Thr Trp Gln Thr Lys Ser Gly Gly Thr Arg Thr Gly Asn Val Thr
          115          120          125
Leu Ala Glu Gly Pro Pro Ala Glu Phe Pro Leu Val Pro Arg Gly Ser
          130          135          140
Pro Leu Pro Val Gly Asn Pro Ala Glu Pro Ser Leu Leu Ile Asp Gly
          145          150          155          160
Thr Met Trp Glu Gly Ala Ser Gly Asp Pro Cys Asp Pro Cys Ala Thr
          165          170          175
Trp Cys Asp Ala Ile Ser Ile Arg Ala Gly Tyr Tyr Gly Asp Tyr Val
          180          185          190
Phe Asp Arg Val Leu Lys Val Asp Val Asn Lys Thr Phe Ser Gly Met
          195          200          205
Ala Ala Thr Pro Thr Gln Ala Ile Gly Asn Ala Ser Asn Thr Asn Gln
          210          215          220
Pro Glu Ala Asn Gly Arg Pro Asn Ile Ala Tyr Gly Arg His Met Gln
          225          230          235          240
Asp Ala Glu Trp Phe Ser Asn Ala Ala Phe Leu Ala Leu Asn Ile Trp
          245          250          255
Asp Arg Phe Asp Ile Phe Cys Thr Leu Gly Ala Ser Asn Gly Tyr Phe
          260          265          270
Lys Ala Ser Ser Ala Ala Phe Asn Leu Val Gly Leu Ile Gly Phe Ser
          275          280          285
Ala Ala Ser Ser Ile Ser Thr Asp Leu Pro Met Gln Leu Pro Asn Val
          290          295          300
Gly Ile Thr Gln Gly Val Val Glu Phe Tyr Thr Asp Thr Ser Phe Ser
          305          310          315          320
Trp Ser Val Gly Ala Arg Gly Ala Leu Trp Glu Cys Gly Cys Ala Thr
          325          330          335
Leu Gly Ala Glu Phe Gln Tyr Ala Gln Ser Asn Pro Lys Ile Glu Met
          340          345          350
Leu Asn Val Thr Ser Ser Pro Ala Gln Phe Val Ile His Lys Pro Arg
          355          360          365
Gly Tyr Lys Gly Ala Ser Ser Asn Phe Pro Leu Pro Ile Thr Ala Gly
          370          375          380
Thr Thr Glu Ala Thr Asp Thr Lys Ser Ala Thr Ile Lys Tyr His Glu
          385          390          395          400

```


cagagctagc ttaaaagatc aatcgcaatc cagtattc 38

<210> 202
<211> 5
<212> DNA
<213> Chlamydia

<400> 202
caatc 5

<210> 203
<211> 31
<212> DNA
<213> Chlamydia

<400> 203
tgcaatcatg aaaaaagcgt tttttttttt c 31

<210> 204
<211> 31
<212> DNA
<213> Chlamydia

<400> 204
cagaacgcgt ctagaatcgc agagcaattt c 31

<210> 205
<211> 30
<212> DNA
<213> Chlamydia

<400> 205
gtgcaatcat gattcctcaa ggaatttacg 30

<210> 206
<211> 31
<212> DNA
<213> Chlamydia

<400> 206
cagaacgcgt ttagaaccgg actttacttc c 31

<210> 207
<211> 50
<212> DNA
<213> Chlamydia

<400> 207
cagacatatg catcaccatc accatcacga ggcgagctcg atccaagatc 50

<210> 208
<211> 40
<212> DNA
<213> Chlamydia

<400> 208
cagagggtacc tcagatagca ctctctccta ttaaagtagg 40

<210> 209
<211> 55
<212> DNA
<213> Chlamydia

<400> 209
cagagctagc atgcatcacc atcaccatca cgttaagatt gagaacttct ctggc 55

<210> 210
<211> 35
<212> DNA
<213> Chlamydia

<400> 210
cagagggtacc ttagaatgtc atacgagcac cgcag 35

<210> 211
<211> 36
<212> DNA
<213> Chlamydia

<400> 211
cagacatatg catcaccatc accatcacgg gtttagc 36

<210> 212
<211> 35
<212> DNA
<213> Chlamydia

<400> 212
cagagggtacc tcagctcttc cagcacactc tcttc 35

<210> 213
<211> 51
<212> DNA
<213> Chlamydia

<400> 213
cagagctagc catcaccatc accatcacgg tgctatttct tgcttacgtg g 51

<210> 214
<211> 38
<212> DNA
<213> Chlamydia

<400> 214
cagagggtact taaaagatca atcgcaatcc agtattcg 38

<210> 215
<211> 48
<212> DNA
<213> Chlamydia

<400> 215
 cagaggatcc acatcaccat caccatcacg gactagctag agagggtc 48

 <210> 216
 <211> 31
 <212> DNA
 <213> Chlamydia

 <400> 216
 cagagaattc ctagaatcgc agagcaattt c 31

 <210> 217
 <211> 7
 <212> DNA
 <213> Chlamydia

 <400> 217
 tgcaatc 7

 <210> 218
 <211> 22
 <212> PRT
 <213> Chlamydia

 <400> 219
 Met Ala Ser Met Thr Gly Gly Gln Gln Met Gly Arg Asp Ser Ser Leu
 1 5 10 15
 Val Pro Ser Ser Asp Pro
 20

 <210> 219
 <211> 51
 <212> DNA
 <213> Chlamydia

 <400> 219
 cagagggtacc gcacaccat caccatcaca tgattcctca aggaatttac g 51

 <210> 220
 <211> 33
 <212> DNA
 <213> Chlamydia

 <400> 220
 cagagcggcc gcttagaacc ggactttact tcc 33

 <210> 221
 <211> 24
 <212> PRT
 <213> Chlamydia

 <400> 221
 Met Ala Ser Met Thr Gly Gly Gln Gln Asn Gly Arg Asp Ser Ser Leu
 1 5 10 15

Val Pro His His His His His His
20

<210> 222

<211> 46

<212> DNA

<213> Chlamydia

<400> 222

cagagctagc catcaccatc accatcacct ctttggccag gatccc

46

<210> 223

<211> 30

<212> DNA

<213> Chlamydia

<400> 223

cagaactagt ctagaacctg taagtgggtcc

30

<210> 224

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> Made in a lab

<400> 224

Met Ser Gln Lys Asn Lys Asn Ser Ala Phe Met His Pro Val Asn Ile

1

5

10

15

Ser Thr Asp Leu

20

<210> 225

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> Made in a lab

<400> 225

Lys Asn Ser Ala Phe Met His Pro Val Asn Ile Ser Thr Asp Leu Ala

1

5

10

15

Val Ile Val Gly

20

<210> 226

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> Made in a lab

<400> 226

His	Pro	Val	Asn	Ile	Ser	Thr	Asp	Leu	Ala	Val	Ile	Val	Gly	Lys	Gly
1				5					10					15	
Pro	Met	Pro	Arg												
				20											

<210> 227

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> Made in a lab

<400> 227

Ser	Thr	Asp	Leu	Ala	Val	Ile	Val	Gly	Lys	Gly	Pro	Met	Pro	Arg	Thr
1				5				10						15	
Glu	Ile	Val	Lys												
				20											

<210> 228

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> Made in a lab

<400> 228

Val	Ile	Val	Gly	Lys	Gly	Pro	Met	Pro	Arg	Thr	Glu	Ile	Val	Lys	Lys
1				5				10						15	
Val	Trp	Glu	Tyr												
				20											

<210> 229

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> Made in a lab

<400> 229

Gly	Pro	Met	Pro	Arg	Thr	Glu	Ile	Val	Lys	Lys	Val	Trp	Glu	Tyr	Ile
1				5					10					15	
Lys	Lys	His	Asn												
				20											

<210> 230

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> Made in a lab

<400> 230
Ile Lys Lys His Asn Cys Gln Asp Gln Lys Asn Lys Arg Asn Ile Leu
1 5 10 15
Pro Asp Ala Asn
20

<210> 231
<211> 20
<212> PRT
<213> Artificial Sequence

<220>
<223> Made in a lab

<400> 231
Asn Cys Gln Asp Gln Lys Asn Lys Arg Asn Ile Leu Pro Asp Ala Asn
1 5 10 15
Leu Ala Lys Val
20

<210> 232
<211> 20
<212> PRT
<213> Artificial Sequence

<220>
<223> Made in a lab

<400> 232
Lys Asn Lys Arg Asn Ile Leu Pro Asp Ala Asn Leu Ala Lys Val Phe
1 5 10 15
Gly Ser Ser Asp
20

<210> 233
<211> 20
<212> PRT
<213> Artificial Sequence

<220>
<223> Made in a lab

<400> 233
Ile Leu Pro Asp Ala Asn Leu Ala Lys Val Phe Gly Ser Ser Asp Pro
1 5 10 15
Ile Asp Met Phe
20

<210> 234
<211> 20
<212> PRT
<213> Artificial Sequence

<220>

<223> Made in a lab

<400> 234

Asn Leu Ala Lys Val Phe Gly Ser Ser Asp Pro Ile Asp Met Phe Gln
1 5 10 15
Met Thr Lys Ala
20

<210> 235

<211> 22

<212> PRT

<213> Artificial Sequence

<220>

<223> Made in a lab

<400> 235

Phe Gly Ser Ser Asp Pro Ile Asp Met Phe Gln Met Thr Lys Ala Leu
1 5 10 15
Ser Lys His Ile Val Lys
20

<210> 236

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> Made in a lab

<400> 236

Val Glu Ile Thr Gln Ala Val Pro Lys Tyr Ala Thr Val Gly Ser Pro
1 5 10 15
Tyr Pro Val Glu
20

<210> 237

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> Made in a lab

<400> 237

Ala Val Pro Lys Tyr Ala Thr Val Gly Ser Pro Tyr Pro Val Glu Ile
1 5 10 15
Thr Ala Thr Gly
20

<210> 238

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> Made in a lab

<400> 238

Ala Thr Val Gly Ser Pro Tyr Pro Val Glu Ile Thr Ala Thr Gly Lys
1 5 10 15
Arg Asp Cys Val
20

<210> 239

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> Made in a lab

<400> 239

Pro Tyr Pro Val Glu Ile Thr Ala Thr Gly Lys Arg Asp Cys Val Asp
1 5 10 15
Val Ile Ile Thr
20

<210> 240

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> Made in a lab

<400> 240

Ile Thr Ala Thr Gly Lys Arg Asp Cys Val Asp Val Ile Ile Thr Gln
1 5 10 15
Gln Leu Pro Cys Glu
20

<210> 241

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> Made in a lab

<400> 241

Lys Arg Asp Cys Val Asp Val Ile Ile Thr Gln Gln Leu Pro Cys Glu
1 5 10 15
Ala Glu Phe Val
20

<210> 242

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> Made in a lab

<400> 242

Asp Val Ile Ile Thr Gln Gln Leu Pro Cys Glu Ala Glu Phe Val Arg

1 5 10 15

Ser Asp Pro Ala

20

<210> 243

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> Made in a lab

<400> 243

Thr Gln Gln Leu Pro Cys Glu Ala Glu Phe Val Arg Ser Asp Pro Ala

1 5 10 15

Thr Thr Pro Thr

20

<210> 244

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> Made in a lab

<400> 244

Cys Glu Ala Glu Phe Val Arg Ser Asp Pro Ala Thr Thr Pro Thr Ala

1 5 10 15

Asp Gly Lys Leu

20

<210> 245

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> Made in a lab

<400> 245

Val Arg Ser Asp Pro Ala Thr Thr Pro Thr Ala Asp Gly Lys Leu Val

1 5 10 15

Trp Lys Ile Asp

20

<210> 246

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> Made in a lab

<400> 246

Ala	Thr	Thr	Pro	Thr	Ala	Asp	Gly	Lys	Leu	Val	Trp	Lys	Ile	Asp	Arg
1				5				10					15		
Leu	Gly	Gln	Gly												
				20											

<210> 247

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> Made in a lab

<400> 247

Ala	Asp	Gly	Lys	Leu	Val	Trp	Lys	Ile	Asp	Arg	Leu	Gly	Gln	Gly	Glu
1				5				10					15		
Lys	Ser	Lys	Ile												
				20											

<210> 248

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> Made in a lab

<400> 248

Val	Trp	Lys	Ile	Asp	Arg	Leu	Gly	Gln	Gly	Glu	Lys	Ser	Lys	Ile	Thr
1				5				10					15		
Val	Trp	Val	Lys												
				20											

<210> 249

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> Made in a lab

<400> 249

Arg	Leu	Gly	Gln	Gly	Glu	Lys	Ser	Lys	Ile	Thr	Val	Trp	Val	Lys	Pro
1				5					10					15	
Leu	Lys	Glu	Gly												
				20											

<210> 250

<211> 20

<212> PRT
<213> Artificial Sequence

<220>
<223> Made in a lab

<400> 250
Gly Glu Lys Ser Lys Ile Thr Val Trp Val Lys Pro Leu Lys Glu Gly
1 5 10 15
Cys Cys Phe Thr
20

<210> 251
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Made in a lab

<400> 251
Gly Glu Lys Ser Lys Ile Thr Val Trp Val Lys Pro Leu Lys Glu Gly
1 5 10 15

<210> 252
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> Made in a lab

<400> 252
Lys Ile Thr Val Trp Val Lys Pro Leu Lys Glu Gly
1 5 10

<210> 253
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Made in a lab

<400> 253
Gly Asp Lys Cys Lys Ile Thr Val Trp Val Lys Pro Leu Lys Glu Gly
1 5 10 15

<210> 254
<211> 20
<212> PRT
<213> Artificial Sequence

<220>
<223> Made in a lab

<400> 254
Thr Glu Tyr Pro Leu Leu Ala Asp Pro Ser Phe Lys Ile Ser Glu Ala
1 5 10 15
Phe Gly Val Leu
20

<210> 255
<211> 20
<212> PRT
<213> Artificial Sequence

<220>
<223> Made in a lab

<400> 255
Leu Ala Asp Pro Ser Phe Lys Ile Ser Glu Ala Phe Gly Val Leu Asn
1 5 10 15
Pro Glu Gly Ser
20

<210> 256
<211> 20
<212> PRT
<213> Artificial Sequence

<220>
<223> Made in a lab

<400> 256
Phe Lys Ile Ser Glu Ala Phe Gly Val Leu Asn Pro Glu Gly Ser Leu
1 5 10 15
Ala Leu Arg Ala
20

<210> 257
<211> 20
<212> PRT
<213> Artificial Sequence

<220>
<223> Made in a lab

<400> 257
Ala Phe Gly Val Leu Asn Pro Glu Gly Ser Leu Ala Leu Arg Ala Thr
1 5 10 15
Phe Leu Ile Asp
20

<210> 258
<211> 20
<212> PRT
<213> Artificial Sequence

<220>

<223> Made in a lab

<400> 258

Asn Pro Glu Gly Ser Leu Ala Leu Arg Ala Thr Phe Leu Ile Asp Lys
1 5 10 15
His Gly Val Ile
20

<210> 259

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> Made in a lab

<400> 259

Leu Ala Leu Arg Ala Thr Phe Leu Ile Asp Lys His Gly Val Ile Arg
1 5 10 15
His Ala Val Ile
20

<210> 260

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> Made in a lab

<400> 260

Thr Phe Leu Ile Asp Lys His Gly Val Ile Arg His Ala Val Ile Asn
1 5 10 15
Asp Leu Pro Leu
20

<210> 261

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> Made in a lab

<400> 261

Lys His Gly Val Ile Arg His Ala Val Ile Asn Asp Leu Pro Leu Gly
1 5 10 15
Arg Ser Ile Asp
20

<210> 262

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> Made in a lab

<400> 262

Arg His Ala Val Ile Asn Asp Leu Pro Leu Gly Arg Ser Ile Asp Glu

1	5	10	15
Glu Leu Arg Ile			
20			

<210> 263

<211> 897

<212> DNA

<213> Chlamydia

<220>

<221> misc_feature

<222> (1)...(897)

<223> n = A,T,C or G

<400> 263

atggccttcta	tatgcggacg	tttaggggtct	ggtacagggga	atgcctctaaa	agctttttttt	60
acacagcccca	acaataaaaat	ggcaaggggta	gtaataaaga	cgaaggggagt	ggataaagact	120
atataaggttg	ccaagtctgc	tgccgaattg	accgcaaata	ttttggaaca	agctggagggc	180
gcgggctctt	ccgcacacat	tacagcttcc	caagtgctcca	aaggattagg	ggatgcgaga	240
actgtttgtcg	ctttaggga	tgcccttaac	ggagcgttgc	caggaacagt	tcaaagtcgcg	300
caaaagcttct	tctctcacat	gaaagctgct	agtcagaaaa	cgcaagaagg	ggatgagggg	360
ctcacagcag	atctttgtgt	gtctcataag	cgcagagcgg	ctgcggctgt	ctgtagcattc	420
atcggaggaaa	ttacctacct	cgcgacattc	ggagctatcc	gtccgattct	gtttgtcaac	480
aaaatgcttg	caaaaaccgtt	tctttcttcc	caaaactaaag	caaatatggg	atcttctgtt	540
agctatatta	tggcggctaa	ccatgcacgc	tctgtggtgg	gtgctggact	cgctatcagt	600
gcgnaaaagag	cagattgcga	agcccgctgc	gctcgtattg	cgagagaaga	gtcgttactc	660
gaagtcgccg	gagaggaaaa	tgcttgcgag	aagaaaagtcg	ctggagagaa	agccaagacg	720
ttcacgcgca	tcaagtatgc	actcctcact	atgctcgaga	agtttttgga	atgcgttccc	780
gacgttttca	aattgggtgcc	gctgcctatt	acaatgggta	ttcgtgcgat	tgtggctgct	840
ggatgtacgt	tcacttctgc	aattattgga	ttgtgcactt	tctgcgccag	agcataa	897

<210> 264

<211> 298

<212> PRT

<213> Chlamydia

<220>

<221> VARIANT

<222> (1)...(298)

<223> Xaa = Any Amino Acid

<400> 264

Met	Ala	Ser	Ile	Cys	Gly	Arg	Leu	Gly	Ser	Gly	Thr	Gly	Asn	Ala	Leu
1		5						10					15		
Lys	Ala	Phe	Phe	Thr	Gln	Pro	Asn	Asn	Lys	Met	Ala	Arg	Val	Val	Asn
		20				25							30		
Lys	Thr	Lys	Gly	Val	Asp	Lys	Thr	Ile	Lys	Val	Ala	Lys	Ser	Ala	Ala
		35				40					45				
Glu	Leu	Thr	Ala	Asn	Ile	Leu	Glu	Gln	Ala	Gly	Gly	Ala	Gly	Ser	Ser
	50					55					60				

Ala His Ile Thr Ala Ser Gln Val Ser Lys Gly Leu Gly Asp Ala Arg
 65 70 75 80
 Thr Val Val Ala Leu Gly Asn Ala Phe Asn Gly Ala Leu Pro Gly Thr
 85 90 95
 Val Gln Ser Ala Gln Ser Phe Phe Ser His Met Lys Ala Ala Ser Gln
 100 105 110
 Lys Thr Gln Glu Gly Asp Glu Gly Leu Thr Ala Asp Leu Cys Val Ser
 115 120 125
 His Lys Arg Arg Ala Ala Ala Val Cys Ser Ile Ile Gly Gly Ile
 130 135 140
 Thr Tyr Leu Ala Thr Phe Gly Ala Ile Arg Pro Ile Leu Phe Val Asn
 145 150 155 160
 Lys Met Leu Ala Lys Pro Phe Leu Ser Ser Gln Thr Lys Ala Asn Met
 165 170 175
 Gly Ser Ser Val Ser Tyr Ile Met Ala Ala Asn His Ala Ala Ser Val
 180 185 190
 Val Gly Ala Gly Leu Ala Ile Ser Ala Xaa Arg Ala Asp Cys Glu Ala
 195 200 205
 Arg Cys Ala Arg Ile Ala Arg Glu Glu Ser Leu Leu Glu Val Pro Gly
 210 215 220
 Glu Glu Asn Ala Cys Glu Lys Lys Val Ala Gly Glu Lys Ala Lys Thr
 225 230 235 240
 Phe Thr Arg Ile Lys Tyr Ala Leu Leu Thr Met Leu Glu Lys Phe Leu
 245 250 255
 Glu Cys Val Ala Asp Val Phe Lys Leu Val Pro Leu Pro Ile Thr Met
 260 265 270
 Gly Ile Arg Ala Ile Val Ala Ala Gly Cys Thr Phe Thr Ser Ala Ile
 275 280 285
 Ile Gly Leu Cys Thr Phe Cys Ala Arg Ala
 290 295

<210> 265

<211> 897

<212> DNA

<213> Chlamydia

<220>

<221> misc_feature

<222> (1)...(897)

<223> n = A,T,C or G

<400> 265

atggcttcta	tatgcggacg	tttaggggtct	ggtacagggga	atgctctctaaa	agctttttttt	60
acacagccca	acaataaaat	ggcaagggta	gtaataaaga	cgaaggggaat	ggataagact	120
atgaaggttg	ccaagtctgc	tgccgaattg	accgcaaata	ttttggaaca	agctggaggcg	180
gcgggtctct	ccgcacacat	tacagcttcc	caagtgtcca	aaggattagg	ggatgcgaga	240
actgtgtgcg	ctttagggaa	tgcccttaac	ggagcgttgc	caggaaacagt	tcaaatgtcgg	300
caaagcttct	tcctccacat	gaaagctgct	agtcagaaaa	cgcaagaagg	ggatgagggg	360
ctcacagcag	atcttttgtt	gtctcataag	cgagagcgg	ctgcggctgt	ctgtagcatt	420
atcggaggaa	ttacctacct	cgcgacattc	ggagctatcc	gtccgattct	gtttgtcaac	480
aaaatgctcg	caaaaacgtt	tcctttcttc	caaaactaaag	caaataatggg	atcttctgtt	540
agctatatata	tggcgggttaa	ccatgcagcg	tctgtgtgtg	gtgcgtggact	cgctatcagt	600
gcgnaaagag	cagattgcga	agcccgctgc	gctcgtattg	cgagagaaga	gtcgttactc	660
gaagtgcggg	gagagggaaa	tgcttgcgag	aagaaaagtcg	ctggagagaa	agccaagacg	720
ttcacgcgca	tcaagtatgc	actcctcact	atgctcgaga	agtttttggg	atgcgttgcc	780

gacgttttca aattggtgcc gctgcctatt acaatgggta ttctgtcgcat tgtggctgct 840
 ggatgtacgt tcactttctgc aattattgga ttgtgcactt tctgcgccag agcataa 897

<210> 266

<211> 298

<212> PRT

<213> Chlamydia

<220>

<221> VARIANT

<222> (1)...(298)

<223> Xaa = Any Amino Acid

<400> 266

Met	Ala	Ser	Ile	Cys	Gly	Arg	Leu	Gly	Ser	Gly	Thr	Gly	Asn	Ala	Leu
1				5				10					15		
Lys	Ala	Phe	Phe	Thr	Gln	Pro	Asn	Asn	Lys	Met	Ala	Arg	Val	Val	Asn
		20					25					30			
Lys	Thr	Lys	Gly	Met	Asp	Lys	Thr	Ile	Lys	Val	Ala	Lys	Ser	Ala	Ala
		35				40					45				
Glu	Leu	Thr	Ala	Asn	Ile	Leu	Glu	Gln	Ala	Gly	Gly	Ala	Gly	Ser	Ser
		50			55					60					
Ala	His	Ile	Thr	Ala	Ser	Gln	Val	Ser	Lys	Gly	Leu	Gly	Asp	Ala	Arg
65				70				75					80		
Thr	Val	Val	Ala	Leu	Gly	Asn	Ala	Phe	Asn	Gly	Ala	Leu	Pro	Gly	Thr
		85				90						95			
Val	Gln	Ser	Ala	Gln	Ser	Phe	Phe	Ser	His	Met	Lys	Ala	Ala	Ser	Gln
		100				105					110				
Lys	Thr	Gln	Glu	Gly	Asp	Glu	Gly	Leu	Thr	Ala	Asp	Leu	Cys	Val	Ser
		115				120					125				
His	Lys	Arg	Arg	Ala	Ala	Ala	Ala	Val	Cys	Ser	Ile	Ile	Gly	Gly	Ile
130				135				140							
Thr	Tyr	Leu	Ala	Thr	Phe	Gly	Ala	Ile	Arg	Pro	Ile	Leu	Phe	Val	Asn
145				150				155					160		
Lys	Met	Leu	Ala	Lys	Pro	Phe	Leu	Ser	Ser	Gln	Thr	Lys	Ala	Asn	Met
		165						170					175		
Gly	Ser	Ser	Val	Ser	Tyr	Ile	Met	Ala	Ala	Asn	His	Ala	Ala	Ser	Val
		180					185					190			
Val	Gly	Ala	Gly	Leu	Ala	Ile	Ser	Ala	Xaa	Arg	Ala	Asp	Cys	Glu	Ala
		195				200					205				
Arg	Cys	Ala	Arg	Ile	Ala	Arg	Glu	Glu	Ser	Leu	Leu	Glu	Val	Pro	Gly
210				215							220				
Glu	Glu	Asn	Ala	Cys	Glu	Lys	Lys	Val	Ala	Gly	Glu	Lys	Ala	Lys	Thr
225				230						235				240	
Phe	Thr	Arg	Ile	Lys	Tyr	Ala	Leu	Leu	Thr	Met	Leu	Glu	Lys	Phe	Leu
		245						250					255		
Glu	Cys	Val	Ala	Asp	Val	Phe	Lys	Leu	Val	Pro	Leu	Pro	Ile	Thr	Met
		260					265					270			
Gly	Ile	Arg	Ala	Ile	Val	Ala	Ala	Gly	Cys	Thr	Phe	Thr	Ser	Ala	Ile
		275				280						285			
Ile	Gly	Leu	Cys	Thr	Phe	Cys	Ala	Arg	Ala						
		290				295									

<210> 267

<211> 680

<212> DNA

<213> Chlamydia

<400> 267

tcctatatcca	tattgatagg	aaaaaacgtc	gcagaaagat	tttagctatg	acgtttatccc	60
gagcttttagg	atattcaaca	gatgcagata	ttattgaaga	gttcttttct	gtagaggagc	120
gttcctctacg	ttcagagaag	gattttgtcg	cgttagtgtg	taaagtttta	gctgataacg	180
tagttgatgc	ggattcttca	ttagttttacg	ggaaagctgg	agagaagcta	agtactgcta	240
tgctaaaaag	catcttagat	acgggagtc	aatctttgaa	gattgctggt	ggcgcagatg	300
aaaatcacc	aattattaag	atgctcgcaa	aagatcctac	ggattcttac	gaagctgctc	360
ttaaagattt	ttatcgcaga	ttacgaccag	gagagcctgc	aacttttagct	aatgctcgat	420
cccaattat	cggtttattc	ttcgatgcta	aacggtataa	tttaggccgc	gttggacggt	480
ataaattaaa	taaaaaatta	ggcttcccat	tagacgacga	aacattatct	caagtgaatt	540
tgagaaaaga	agatgttatc	ggcgcgttga	aataattgat	tcgtttcgca	atgggcatg	600
agaagacatc	tatcgatgat	attgaccatt	tggcaaacgc	acgagttcgc	tctgttgag	660
aactaatcca	gaatcactgt					680

<210> 268

<211> 359

<212> DNA

<213> Chlamydia

<400> 268

cttatgttct	ggagaaatgt	gcaacaacat	attaatcgaa	ccagctcctc	ctagtaacat	60
agaaaccaag	cccttttgag	aaaaaacctg	tacttcgcgt	cccttagcca	tttgttgaa	120
agtccttaac	aaagagctaa	ttttttcctc	ttccttggtt	ttctgaggcg	ctgtggactc	180
taaatatagc	aagtgctctt	ggaacacctc	atcaacaatc	gcttgctcta	gattagggtat	240
agagactgtc	tctccatcaa	ttaaatggag	tttcaaagta	atatccctct	cgtccctccc	300
atcacagaag	tctatgaaag	ctatctgatt	ccatcgagca	gaaatgtatg	gggaataac	359

<210> 269

<211> 124

<212> DNA

<213> Chlamydia

<400> 269

gatcgaatca	attgagggag	ctcattaaca	agaatagctg	cagtttcttt	gcgtttcttt	60
ggaatacaaa	gaaataggta	atcggtacca	ttgatagaac	gaacacgaca	aatcgcagaa	120
ggtt						124

<210> 270

<211> 219

<212> DNA

<213> Chlamydia

<400> 270

gatcctgttg	ggcctagtaa	taatacgttg	gatttcccat	aactcacttg	tttatcctgc	60
ataagagcac	ggatacgctt	atagtggtta	tagacggcaa	ccgaaatcgt	tttttccgcy	120
cgctcttg	caatgacata	agagtcgatg	tggcgtttga	tttcttttagg	gggttaacat	180
ctcagacttg	ttggagagct	tgtggaagat	gttcgcatc			219

<210> 271

<211> 511

<212> DNA

<213> Chlamydia

<220>
 <221> misc_feature
 <222> (1)...(511)
 <223> n = A,T,C or G

<400> 271
 ggatccgaat tcggcacgag gagaaaaat aggaggttcc akcatcggaa gatctaatag 60
 acaaaagggt ttggcatag atggctctc cttgtacgtt caacgatgat tgggagggat 120
 tgttatcgat agcttgggtt ccagagaact gacaagtccc gctacatga gagaatgtaa 180
 cctgttctcc atagatagct cctctacta cacctgaata agttggtgtt gctggagatg 240
 atggtgcggc tgctgctggc gcttgtaggg aagcagcagc tgcagcagggt gctgaagctg 300
 ttgttgcgac tcctgtggat gaggagtgtt ctttgttgtt cgagaaagag aagcctgatt 360
 tcgattaga aatatttaca gttttagcat gtaagcctcc acctctcttc ccaacaaggt 420
 tctctgttac agataaggag actagangca tctagtttta aagatttttt acagcagata 480
 cctccaccta tctctgtagc ggagtcttca g 511

<210> 272
 <211> 598
 <212> DNA
 <213> Chlamydia

<400> 272
 ctcttctct cctcaatcta gttctggagc aactacagtc tcgactcag gagactctag 60
 ctctgggtca aactcggata cctcaaaaac agttccagtc acagctaaag gcggtgggct 120
 ttatactgat aagaattctt cgattactaa catcacagga attatcgaaa ttgcaaaataa 180
 caaagcgaca gatgttggag gtggtgctta cgtaaaagga acccttacct gtaaaaaactc 240
 tcaccgtcta caatttttga aaaactcttc cgataaacaa ggtggaggaa tctacggaga 300
 agacaacatc accctatcta atttgacagg gaagactcta ttccaagaga atactgccaa 360
 aaaagagggc ggtggactct tcataaaaagg tacagataaa gctcttcaaa tgacaggact 420
 ggatagtttc tgttttaatta ataacacatc agaaaaacat ggtggtgagg gcctttgtta 480
 ccaaaagaaat ctctcagact tacacctctt gatgtggaaa caattccagg aatcacgcct 540
 gtacatgggt aaacagtcac tactggcaat aaattctacag gaggtaatgg tggagggc 598

<210> 273
 <211> 126
 <212> DNA
 <213> Chlamydia

<400> 273
 ggatccgaat tcggcacgag atgagcctta tagtttaaca aaagctctc acattccttc 60
 gatagctttt tattagccgt ttttagcatc ctaatgagat ctctcgtctc gtaacaaata 120
 cgagag 126

<210> 274
 <211> 264
 <212> DNA
 <213> Chlamydia

<400> 274
 ggatccgaat tcggcacgag ctctttttaa tettaattac aaaagacaa attaatcaa 60
 tttttcaaaa aagaatttaa acattaatgt ttgtaaaaaa acaatattha tttcaaaata 120
 ataaccatag ttacggggga atctctttca tggtttattt tagagctcat caacctagge 180
 atacgcctaa aacatttctt ttgaaagttc accattcgtt ctccgataag catcctcaaa 240
 ttgctaaagc tatgtggatt acgg 264

<210> 275
 <211> 359
 <212> DNA
 <213> Chlamydia

<400> 275
 ggatccgaat tcggcacgag ataaaacctg aaccacaaca aagatctaaa acttcttgat 60
 ttccagctgc aaattctttt agataaatat caaccatttc ttccagttcca tatcttggaa 120
 ttaaaacttg ttctcttaaa ttaattctag tatttaagfa ttcaacatag cccattatta 180
 atgtaattgg ataattttgc cttaataatt cacattcttt ttccagtaatt ttagggtcta 240
 aaccgtaccg ctttttttct aaaattaatg ttctcttcatt atccatttta taagccactt 300
 tcctttattt ttgattttg ttctcttctg agtaatgctt caataatagt taataattt 359

<210> 276
 <211> 357
 <212> DNA
 <213> Chlamydia

<400> 276
 aaaacaattg atataatttt ttttttcata acttccagac tcctttctag aaaagtcttt 60
 atgggtagta gtgaactctaa cgttttttat tattaagacg atccccggag atccttttaa 120
 tgatgaaaac ggaacatctt ttccgccaga aacttttagca ctattaaaga atcgttacgg 180
 gttagataag cctttattca cccagtatct tatctatttg aaatgtctgc taacactaga 240
 ttccggggaa tctcttatct acaagatcg aaatctcagc attattgtctg ccgctcttcc 300
 atcttcgcgt attcttggac ttgaaagctt gtgttactc gtgcogaatt cggatcc 357

<210> 277
 <211> 505
 <212> DNA
 <213> Chlamydia

<400> 277
 ggatccgaat tcggcacgag ctctgtgcga ttgcttgctt cagtcacccc atcggtatag 60
 agcactaaaa gagactcctc ttcaagaacg agagtgtgaag caggggtgag aggaacttca 120
 ggtaaaaaat ctaaggccat accaggatgc gacaggaaaag agatatctcc attaggagct 180
 cggagacacg ctgggtttgt gccacaagaa tagtattcta gttctcgtgt tgcgtaatga 240
 taacaaataa tgcataatgt tacaacatc ccagattcag ctgtctgtgt atagaagaga 300
 gcagctgttt gttgaacgac ttcttgaata gaggagagct cactcaaaaa ggtatgtaac 360
 atgtttttca ggaataagga gtaggcgac gcattgactc ctttcccgga agcatcagca 420
 acgattagaa agagttagc ttggggacct tcgcctataa caaagatattc aaagaaatct 480
 cctctaccg taactgcagg aatat 505

<210> 278
 <211> 407
 <212> DNA
 <213> Chlamydia

<400> 278
 ggatccgaat tcggcacgag aactacttag caaattgggt atccaacttc ctctttacga 60
 aagaaaaaca gaaggcattc tccataccaa gatttgttgc atcgacaata aaactccaat 120
 ctttggctct gctaactgga gcggtgctgg tatgattaaa aactttgaag acctattcat 180
 ctttcgccca attacagaga cacagcttca ggcctttatg gacgtctggt ctcttctaga 240
 aacaaatagc tcctatctgt cccagagag cgtgcttacg gccctactc cttcaagtag 300
 acctactcaa caagatacag attctgatga cgaacaaccg agtaccagcc agcaagctat 360

ccgtatgaga aaataggatt agggaaacaa aacgacagca aaccaca 407

<210> 279

<211> 351

<212> DNA

<213> Chlamydia

<400> 279

ctcgtgccgc	ttacaggagg	cttgatctct	ttaaaataga	gtttttctta	tgaccccatg	60
tggcgatagg	ccgggtctag	cgccgatagt	agaaatatcg	gttggttttt	gtccttgagg	120
ggatcgatata	ctttttcaaa	gtaggtgcc	cgatcgatt	atctggaggc	tcttatgtct	180
ttttttcata	ctagaaaaata	taagctttatc	ctcagaggac	tcttgtgttt	agcaggctgt	240
ttcttaata	acagctgttc	ctctagtcga	ggaaatcaac	ccgctgatga	gagcatctat	300
gtcttgtcta	tgaatcgcat	gatttgtgat	tctcgtgccg	aattcggatc	c	351

<210> 280

<211> 522

<212> DNA

<213> Chlamydia

<400> 280

ggatccgaat	tcggcacgag	cagaggaaaa	aggcgatact	cctcttgaag	atcgtttcac	60
agaagatctt	tccgaagtct	ctggagaaga	ttttcgagga	ttgaaaaatt	cgttcgatga	120
tgattctctt	tctgacgaaa	ttctcgatgc	gctcacaaagt	aaattttctg	atcccaaat	180
aaaggatcta	gctcttgatt	atctaattca	aatagctccc	tctgatggga	aacttaagtc	240
cgctctcatt	caggcaaaag	atcaactgat	gagccagaat	cctcaggcga	ttgttggagg	300
acgcaatgtt	ctgttagctt	cagaaaaact	tgcttccaga	gcaaatatcat	ctcttctatc	360
gcttcgctcc	ttatattttc	aagtaaacctc	atccccctc	aattcgctca	atttacatca	420
aatgcttgtct	tcttactcgc	catcagagaa	aaccgctgtt	atggagtctc	tagtgaatgg	480
catggtagca	gatttaaaat	cggagggcc	ttccattctc	cc		522

<210> 281

<211> 577

<212> DNA

<213> Chlamydia

<400> 281

ggatccgaat	tcggcacgag	atgcttctat	tacaatttgg	ttggatgcgg	aaaaagctta	60
ccagcttatt	ctagaaaagt	tgggagatca	aattcttggg	ggaattgtctg	atactattgt	120
tgatagtaca	gtccaagata	ttttagacaa	aatcacaca	gacctctctc	taggtttgtt	180
gaaagctttt	aacaactttc	caatcactaa	taaaattcaa	tgcaacgggt	tattcaactc	240
caggaaacatt	gaaactttat	taggaggaa	tgaataggga	aaattcacag	tcaaccccaa	300
aagctctcgg	agcatgttct	tagtctcagc	agatatatt	gcatacaaga	tgggaaggcg	360
cgttgttcta	gcttttggtac	gagaagggtga	ttctaagccc	tacgcgatta	gttatggata	420
ctcatcaggc	gttctctaatt	tatgtagtct	aagaaccaga	attattaata	caggattgac	480
tcgcacaacg	tattcattac	gtgtaggcgg	tttagaaaagc	ggtgtgggat	gggttaattgc	540
cttttctaat	ggcaatgata	ttttaggaa	aacaaat			577

<210> 282

<211> 607

<212> DNA

<213> Chlamydia

<400> 282

actmatcttc	cccgggctcg	agtgcggccg	caagcttgtc	gacggagctc	gatacaaaaa	60
------------	------------	------------	------------	------------	------------	----

tgtgtgcgtg	tgaaccgctt	cttcaaaagc	ttgtcttaaa	agatattgtc	tcgcttcggt	120
attagttaca	tgttataaaa	ttgctagaac	aattattatc	ccaaccaagc	tctctgcggt	180
gtcgaaaaaa	cctaaattca	aaagaatgac	tcgcccgtca	tcttcagaaa	gacgatccga	240
cttcataaat	tcgatgtctt	tcccatggg	gatctctgta	gggagccagt	tatttgcgca	300
gccattcaaa	taattgtccc	aagcccat	gtacttaata	ggacaagtt	ggttgacatc	360
gacctggtg	cagttcacta	gacgcttct	atttagatta	acgcttctct	gtttccatc	420
taaaaatct	gcttgcataa	gaaccgttaa	ttttattgtt	attttatatg	attataact	480
gacatgtct	acacccttct	tccaagaac	agacaggtg	tttcttcgct	ttttcaacaa	540
taattctct	cgaagcagac	ttattcttca	tccaacgagg	ctgaattctc	ctcttattaa	600
tattctac						607

<210> 283

<211> 1077

<212> DNA

<213> Chlamydia

<400> 283

ggatccgaat	tcggcacgag	aagttaacga	tgacgatttg	ttcctttggt	agagaaggag	60
caatcgaaac	taaaagtgcg	agagcatgtg	aagactccaa	tgacggaata	atccccctcat	120
ttctagtag	caggaaaaaa	gctcgtaacg	cctcttctac	ggtaggcta	gtataaaaagg	180
ctcgtcctga	ctcatgcat	tcggcatgat	ctggcccaac	tgaaggataa	tctaattccag	240
cggaaatgga	gtgagtttgt	aatacttgtc	catcgtctac	tcgaagaaga	tacgaataaaa	300
atcgtggaa	tactccaggt	cgccctgttg	caaaactgtc	tgcattgttt	cctgaagaaa	360
tgcccagtc	tcceccctcc	actccaatta	attggacttt	tggattcggg	ataaaatgat	420
ggaaaaatcc	aatagcgttg	gagccacctc	cgatacatgc	aatcagaata	tcaggatctc	480
ttctctcaac	tgcattggatt	tgctctttca	cttcagcgct	tataacagac	tgaaaaaatc	540
gaacgatct	gggataagg	aaaggtccca	aggccgatcc	taagcaatag	tgagtaaatg	600
agtgatgttg	tgcccaatct	tgtagagctt	gattaaactgc	atcttttgagt	ccacaagatc	660
cttttcttac	agaaacgact	tcagcaccta	aaaagcgcat	tttctctaca	tttggtttct	720
ctgcttccac	atcttttgc	cccatgtata	ctacacaaac	taactccaga	taagcacagc	780
ctgttctgt	tgctactcca	tggtgtcccg	cacctgttcc	agctacaaca	cgtcttttcc	840
caagatattt	agcaagcaaa	cactgaccaa	gagcattatt	cagtttatgt	gctcctgtat	900
gcataagatc	ttcgcgttta	agaaatactc	tagggccatc	aatagctcga	gcataattct	960
taactctagt	cagaggagtt	tgctctcccg	catagttttt	caaaaacaa	tctagttcag	1020
ataaaaaact	ttgctgagtt	ttgagaatct	cccatctccg	tttttagattc	tgatatag	1077

<210> 284

<211> 407

<212> DNA

<213> Chlamydia

<400> 284

ggatccgaat	tcggcacgag	aactactgag	caaatgggt	atccaacttc	ctctttacga	60
aagaaaaaca	gaaggcatc	tccataccaa	gatttgttgc	atcgacaata	aaactccaat	120
ctttgctctc	gtcaactgga	gcggtgctgg	tatgattaaa	aactttgaag	acctattctat	180
ccttcgccca	attacagaga	cacagcttca	ggcctttatg	gacgtctggg	ctctctcaga	240
aacaaaatag	tctatctgt	cccagagag	cgtgcttacg	gccctactac	cttcaagtag	300
acctactcaa	caagatacat	attctgatga	cgaacaaccg	agtaccagcc	agcaagctat	360
ccgatgaga	aaataggatt	agggaacaa	aacgacagca	aaccaca		407

<210> 285

<211> 802

<212> DNA

<213> Chlamydia

```

<400> 285
ggatccgaat tcggcacgag ttagcttaat gtctttgtca tctctaccta catttgcagc      60
taattctaca ggcacaattg gaatcgtaa tttacgtcgc tgcctagaag agtcgtctct      120
tgggaaaaaa gaatctgctg aattcgaaaa gatgaaaaac caattctcta acagcatggg      180
gaagatggag gaagaactgt cttctatcta ttccaagctc caagacgacg attacatgga      240
aggtctatcc gagaccgcag ctgccgaatt aagaaaaaaa ttccaagatc tatctgcaga      300
atacaacaca gctcaagggc agtattacca aatattaaac caaagtaatc tcaagcgcat      360
gcaaaagatt atggaagaag tgaaaaaagc ttctgaaact gtgcgtattc aagaaggctt      420
gtcagtcctt cttaacgaag atattgtctt atctatcgat agttcggcag ataaaaccga      480
tgctgttatt aaagtctctg atgattcttt tcaaaaataa taacatgcga agctagccga      540
ggagtgcgct atgtctcaat ccacttattc tcttgacaaa tttagctgatt ttttgaaggt      600
cgagtttcaa ggaatatggg ctactcttct ttccggagtt gaagagatcg aggaagcaca      660
aacggccacac atcacattct tagataatga aaaatatgct aaacatttaa aatcatcgga      720
agctggcgct atcatcata ctgcaacaca gtttcaaaaa tatcgagact tgaataaaaa      780
ctttcttate acttctgagt ct
      802

```

<210> 286

<211> 588

<212> DNA

<213> Chlamydia

```

<400> 286
ggatccgaat tcggcacgag gcaatattta ctcccaacat tacggttcca aataagcgat      60
aaggctcttc aataaggaa gtaaatgtaag aggccttttt attgcttttc gtaaggtagt      120
attcgcaaccg cagcgcatg aatgatacgc aagccatttc catcatggaa aagaaccctt      180
ggacaaaaaa acaaaaggag ttcaactcta accagaaaaa gggagagtta gtttccatgg      240
gttttcctta tatacaccg ttccacaaa ttaggagccg cgtctagtat ttggaataca      300
aattgtcccc aagcgaattt tgttcctggt tcagggaatt ctccataatg tccgtgcagc      360
catccgctca ttgtaacgca attagctgta gtaggaaagt caactccaaa caggctcatag      420
aaatcagaaa gctcataggt gctcgacgca ataacaacat tcttgctcga gtgagcgaa      480
tgtttaaaaag atgggcgatt atgagctacc tcatcagaga ctattttaaa tagaccattt      540
tgggtaatca atccttctat agaccatcat tcatcaatga taatctcg
      588

```

<210> 287

<211> 489

<212> DNA

<213> Chlamydia

<220>

<221> misc_feature

<222> (1)...(489)

<223> n = A,T,C or G

```

<400> 287
agtgcctatt gttttgcagg ctttgtctga tgatagcgat accgtacgtg agattgctgt      60
acaagtagct gttatgtatg gttctagttg ctactcgcgc gcgctgggag atttagcgaa      120
aaatgattct tctattcaag tacgcatcac tgcttatcgt gctgcagccg tgttggagat      180
acaagattctt gtgcctcatc tacgagttgt agtccaaaat acacaattag atggaacgga      240
aagaagagaa gcttgagatg ctttatgtgt tcttactcgg cctcatagtg gtgtattaac      300
tggtcatagat caagctttaa tgacctgtga gatgttaaa gaaatccctg aaaagtgtac      360
ggaagaacag attcgtaacat tattggctgc agatcatcca gaagtgcagc tagctacttt      420
acagatcatt ctgagaggag gttagagtatt ccggtcatct tctataatgg aatcggttct      480
cgtgccgnt
      489

```

<210> 288

<211> 191
 <212> DNA
 <213> Chlamydia

<400> 288
 ggatccgaat tcaggatatg ctgttgggtt atcaataaaa aggggttttgc ctttttttaa 60
 gagcactttg tagataacgc taggagctgt agcaataata tcgagatcaa attctctaga 120
 gattctctca aagatgatgt ctaagtgcag cagtcctaaa aatccacagc ggaacccaaa 180
 tccgagagag t 191

<210> 289
 <211> 515
 <212> DNA
 <213> Chlamydia

<400> 289
 ggatccgaat tcggcacgag gagcgacgtg aaatagtga atcttccctt attcttatta 60
 ctctctgctt gccttacgca aatggctcct tgcatttttg acatattacc ggtgcttatt 120
 tgccctcaga tgtttatgcg cgttttcaga gactacaagg caaagaggtt ttgtatatatt 180
 gtgggtctga tgaatacggg atcgcaatta cctttaatgc agagttggca ggcattgggt 240
 atcaagaata tgtcgacatg tatcataagc ttcataaaga tactctcaag aaattgggaa 300
 ttctctgaga ttctcttttc agaactacga acgcttatca tcttgctatt gtgcaagatt 360
 tctatcgaaa ctgcaggaa cgcgcactgg tagagaatca ggtgaccgaa cagctgtatt 420
 ctgaggaaga agggaggttt tttagcggacc gttatgttgt aggtacttgt cccaagtgtg 480
 ggtttgatcg agctcgagga gatgagtgtc agcag 515

<210> 290
 <211> 522
 <212> DNA
 <213> Chlamydia

<400> 290
 ggatccgaat tcggcacgag ggaggaatgg aagggccctc cgattktama tctgctacca 60
 tgccattcac tagaaactcc ataacagcgg ttttctctga tggcgagtga gaagcaagca 120
 tttgatgtaa attagcgcaa tttagaggggg atgaggttac ttgaaataat agggagcgaa 180
 gcgatgaagg agatgtattt gctctggaag caaaggtttc tgaagctaac ggaacattgc 240
 gtctctcaac aatcgctcga ggattctggc tcatcagttg atgctttgcc tgaatgagag 300
 cggacttaag ttcccatca ggggagcta tttgaattag ataatacaga gctagatcct 360
 ttattgtggg atcagaaaaa ttacttgtga gcgcacgag aatttcgtca gaagaagaat 420
 catcatcgaa cgaatttttc aatcctcgaa aatcttctcc agagactctg gaaagatctt 480
 ctgtgaaacg atcttcaaga ggagtatgcg cttttttccy tg 522

<210> 291
 <211> 1002
 <212> DNA
 <213> Chlamydia

<400> 291
 atggcgacta acgcaattag atcggcagga agtcgacgaa gtaagatgct gctgccagtt 60
 gccaaagacg cagcggctgt cagctccttt gctcagaaag ggattttatg tattcaacaa 120
 tttttacaa accctgggaa taagtttagca aagtttgtag gggcaacaaa aagtttagat 180
 aaatgcttta agctaagtaa ggcggtttct gactgtgtcg taggatcgct ggaagagggc 240
 ggatgcacag gggacgcatt gacctccgag aaaaacgccc aggttatgtt aaaaacaact 300
 cgagaagtgt ttgccttagc taatgtgctc aatggagctg ttccatctat cgttaactcg 360
 actcagaggt gttaccaata cacacgtcaa gccttcgagt taggaagcaa gacaaaagaa 420

```

agaaaaacgc ctggggagta tagtaaaatg ctattaactc gaggtgatta cctattggca 480
gcttccaggg aagcttgtac ggcagtcggt gcaacgactt actcagcgac attcgggtgtt 540
ttacgtccgt taatgttaat caataaaactc acagcaaaac cattcttaga caaagcgact 600
gtaggcaatt ttggcacggc tggttgctgga attatgacca ttaatcatat ggcaggaggt 660
gctggtgctg ttggcggaat cgcattagaa caaaagctgt tcaaacgtgc gaaggaatcc 720
ctatacaatg agagatgtgc cttagaaaac caacaatctc agttgagtggt ggacgtgatt 780
ctaagcgcgg aaagggcatt acgtaaagaa cacgttgcta ctctaaaaag aaatgtttta 840
actcttcttg aaaaagcttt agagttgga gtggatggag tcaaacctcat tcctttaccg 900
attacagtgg ctgtctccg tgcaatttct ggagccttga cggcagcatc cgcaggaatt 960
ggcttatata gcatatggca gaaaacaaag tctggcaaat aa 1002

```

<210> 292

<211> 333

<212> FRT

<213> Chlamydia

<400> 292

```

Met Ala Thr Asn Ala Ile Arg Ser Ala Gly Ser Ala Ala Ser Lys Met
1 5 10 15
Leu Leu Pro Val Ala Lys Glu Pro Ala Ala Val Ser Ser Phe Ala Gln
20 25 30
Lys Gly Ile Tyr Cys Ile Gln Gln Phe Phe Thr Asn Pro Gly Asn Lys
35 40 45
Leu Ala Lys Phe Val Gly Ala Thr Lys Ser Leu Asp Lys Cys Phe Lys
50 55 60
Leu Ser Lys Ala Val Ser Asp Cys Val Val Gly Ser Leu Glu Glu Ala
65 70 75 80
Gly Cys Thr Gly Asp Ala Leu Thr Ser Ala Arg Asn Ala Gln Gly Met
85 90 95
Leu Lys Thr Thr Arg Glu Val Val Ala Leu Ala Asn Val Leu Asn Gly
100 105 110
Ala Val Pro Ser Ile Val Asn Ser Thr Gln Arg Cys Tyr Gln Tyr Thr
115 120 125
Arg Gln Ala Phe Glu Leu Gly Ser Lys Thr Lys Glu Arg Lys Thr Pro
130 135 140
Gly Glu Tyr Ser Lys Met Leu Leu Thr Arg Gly Asp Tyr Leu Leu Ala
145 150 155 160
Ala Ser Arg Glu Ala Cys Thr Ala Val Gly Ala Thr Thr Tyr Ser Ala
165 170 175
Thr Phe Gly Val Leu Arg Pro Leu Met Leu Ile Asn Lys Leu Thr Ala
180 185 190
Lys Pro Phe Leu Asp Lys Ala Thr Val Gly Asn Phe Gly Thr Ala Val
195 200 205
Ala Gly Ile Met Thr Ile Asn His Met Ala Gly Val Ala Gly Ala Val
210 215 220
Gly Gly Ile Ala Leu Glu Gln Lys Leu Phe Lys Arg Ala Lys Glu Ser
225 230 235 240
Leu Tyr Asn Glu Arg Cys Ala Leu Glu Asn Gln Gln Ser Gln Leu Ser
245 250 255
Gly Asp Val Ile Leu Ser Ala Glu Arg Ala Leu Arg Lys Glu His Val
260 265 270
Ala Thr Leu Lys Arg Asn Val Leu Thr Leu Leu Glu Lys Ala Leu Glu
275 280 285
Leu Val Val Asp Gly Val Lys Leu Ile Pro Leu Pro Ile Thr Val Ala
290 295 300

```

Cys Ser Ala Ala Ile Ser Gly Ala Leu Thr Ala Ala Ser Ala Gly Ile
 305 310 315 320
 Gly Leu Tyr Ser Ile Trp Gln Lys Thr Lys Ser Gly Lys
 325 330

<210> 293
 <211> 7
 <212> DNA
 <213> Chlamydia

<400> 293
 tgcaatc

7

<210> 294
 <211> 196
 <212> PRT
 <213> Chlamydia

<400> 294
 Thr Met Gly Ser Leu Val Gly Arg Gln Ala Pro Asp Phe Ser Gly Lys
 5 10 15
 Ala Val Val Cys Gly Glu Glu Lys Glu Ile Ser Leu Ala Asp Phe Arg
 20 25 30
 Gly Lys Tyr Val Val Leu Phe Phe Tyr Pro Lys Asp Phe Thr Tyr Val
 35 40 45
 Cys Pro Thr Glu Leu His Ala Phe Gln Asp Arg Leu Val Asp Phe Glu
 50 55 60
 Glu His Gly Ala Val Val Leu Gly Cys Ser Val Asp Asp Ile Glu Thr
 65 70 75 80
 His Ser Arg Trp Leu Thr Val Ala Arg Asp Ala Gly Gly Ile Glu Gly
 85 90 95
 Thr Glu Tyr Pro Leu Leu Ala Asp Pro Ser Phe Lys Ile Ser Glu Ala
 100 105 110
 Phe Gly Val Leu Asn Pro Glu Gly Ser Leu Ala Leu Arg Ala Thr Phe
 115 120 125
 Leu Ile Asp Lys His Gly Val Ile Arg His Ala Val Ile Asn Asp Leu
 130 135 140
 Pro Leu Gly Arg Ser Ile Asp Glu Glu Leu Arg Ile Leu Asp Ser Leu
 145 150 155 160
 Ile Phe Phe Glu Asn His Gly Met Val Cys Pro Ala Asn Trp Arg Ser
 165 170 175
 Gly Glu Arg Gly Met Val Pro Ser Glu Glu Gly Leu Lys Glu Tyr Phe
 180 185 190

Gln Thr Met Asp
195

<210> 295
<211> 181
<212> PRT
<213> Chlamydia

<400> 295
Lys Gly Gly Lys Met Ser Thr Thr Ile Ser Gly Asp Ala Ser Ser Leu
5 10 15
Pro Leu Pro Thr Ala Ser Cys Val Glu Thr Lys Ser Thr Ser Ser Ser
20 25 30
Thr Lys Gly Asn Thr Cys Ser Lys Ile Leu Asp Ile Ala Leu Ala Ile
35 40 45
Val Gly Ala Leu Val Val Val Ala Gly Val Leu Ala Leu Val Leu Cys
50 55 60
Ala Ser Asn Val Ile Phe Thr Val Ile Gly Ile Pro Ala Leu Ile Ile
65 70 75 80
Gly Ser Ala Cys Val Gly Ala Gly Ile Ser Arg Leu Met Tyr Arg Ser
85 90 95
Ser Tyr Ala Ser Leu Glu Ala Lys Asn Val Leu Ala Glu Gln Arg Leu
100 105 110
Arg Asn Leu Ser Glu Glu Lys Asp Ala Leu Ala Ser Val Ser Phe Ile
115 120 125
Asn Lys Met Phe Leu Arg Gly Leu Thr Asp Asp Leu Gln Ala Leu Glu
130 135 140
Ala Lys Val Met Glu Phe Glu Ile Asp Cys Leu Asp Arg Leu Glu Lys
145 150 155 160
Asn Glu Gln Ala Leu Leu Ser Asp Val Arg Leu Val Leu Ser Ser Tyr
165 170 175
Thr Arg Trp Leu Asp
180

<210> 296
<211> 124
<212> PRT
<213> Chlamydia

<400> 296
Ile Tyr Glu Val Met Asn Met Asp Leu Glu Thr Arg Arg Ser Phe Ala
5 10 15

Val Gln Gln Gly His Tyr Gln Asp Pro Arg Ala Ser Asp Tyr Leu
20 25 30

Pro Arg Ala Ser Asp Tyr Asp Leu Pro Arg Ser Pro Tyr Pro Thr Pro
35 40 45

Pro Leu Pro Ser Arg Tyr Gln Leu Gln Asn Met Asp Val Glu Ala Gly
50 55 60

Phe Arg Glu Ala Val Tyr Ala Ser Phe Val Ala Gly Met Tyr Asn Thr
65 70 75 80

Val Val Thr Gln Pro Gln Glu Arg Ile Pro Asn Ser Gln Gln Val Glu
85 90 95

Gly Ile Leu Arg Asp Met Leu Thr Asn Gly Ser Gln Thr Phe Ser Asn
100 105 110

Leu Met Gln Arg Trp Asp Arg Glu Val Asp Arg Glu
115 120

<210> 297
<211> 488
<212> PRT
<213> Chlamydia

<400> 297
Lys Gly Ser Leu Pro Ile Leu Gly Pro Phe Leu Asn Gly Lys Met Gly
5 10 15

Phe Thr Arg Thr Ser Ile Met Lys Met Asn Arg Ile Trp Leu Leu Leu
20 25 30

Leu Thr Phe Ser Ser Ala Ile His Ser Pro Val Arg Gly Glu Ser Leu
35 40 45

Val Cys Lys Asn Ala Leu Gln Asp Leu Ser Phe Leu Glu His Leu Leu
50 55 60

Gln Val Lys Tyr Ala Pro Lys Thr Trp Lys Glu Gln Tyr Leu Gly Trp
65 70 75 80

Asp Leu Val Gln Ser Ser Val Ser Ala Gln Gln Lys Leu Arg Thr Gln
85 90 95

Glu Asn Pro Ser Thr Ser Phe Cys Gln Gln Val Leu Ala Asp Phe Ile
100 105 110

Gly Gly Leu Asn Asp Phe His Ala Gly Val Thr Phe Phe Ala Ile Glu
115 120 125

Ser Ala Tyr Leu Pro Tyr Thr Val Gln Lys Ser Ser Asp Gly Arg Phe
130 135 140

Tyr Phe Val Asp Ile Met Thr Phe Ser Ser Glu Ile Arg Val Gly Asp
 145 150 155 160
 Glu Leu Leu Glu Val Asp Gly Ala Pro Val Gln Asp Val Leu Ala Thr
 165 170 175
 Leu Tyr Gly Ser Asn His Lys Gly Thr Ala Ala Glu Glu Ser Ala Ala
 180 185 190
 Leu Arg Thr Leu Phe Ser Arg Met Ala Ser Leu Gly His Lys Val Pro
 195 200 205
 Ser Gly Arg Thr Thr Leu Lys Ile Arg Arg Pro Phe Gly Thr Thr Arg
 210 215 220
 Glu Val Arg Val Lys Trp Arg Tyr Val Pro Glu Gly Val Gly Asp Leu
 225 230 235 240
 Ala Thr Ile Ala Pro Ser Ile Arg Ala Pro Gln Leu Gln Lys Ser Met
 245 250 255
 Arg Ser Phe Phe Pro Lys Lys Asp Asp Ala Phe His Arg Ser Ser Ser
 260 265 270
 Leu Phe Tyr Ser Pro Met Val Pro His Phe Trp Ala Glu Leu Arg Asn
 275 280 285
 His Tyr Ala Thr Ser Gly Leu Lys Ser Gly Tyr Asn Ile Gly Ser Thr
 290 295 300
 Asp Gly Phe Leu Pro Val Ile Gly Pro Val Ile Trp Glu Ser Glu Gly
 305 310 315 320
 Leu Phe Arg Ala Tyr Ile Ser Ser Val Thr Asp Gly Asp Gly Lys Ser
 325 330 335
 His Lys Val Gly Phe Leu Arg Ile Pro Thr Tyr Ser Trp Gln Asp Met
 340 345 350
 Glu Asp Phe Asp Pro Ser Gly Pro Pro Pro Trp Glu Glu Phe Ala Lys
 355 360 365
 Ile Ile Gln Val Phe Ser Ser Asn Thr Glu Ala Leu Ile Ile Asp Gln
 370 375 380
 Thr Asn Asn Pro Gly Gly Ser Val Leu Tyr Leu Tyr Ala Leu Leu Ser
 385 390 395 400
 Met Leu Thr Asp Arg Pro Leu Glu Leu Pro Lys His Arg Met Ile Leu
 405 410 415
 Thr Gln Asp Glu Val Val Asp Ala Leu Asp Trp Leu Thr Leu Leu Glu
 420 425 430

Asn Val Asp Thr Asn Val Glu Ser Arg Leu Ala Leu Gly Asp Asn Met
435 440 445

Glu Gly Tyr Thr Val Asp Leu Gln Val Ala Glu Tyr Leu Lys Ser Phe
450 455 460

Gly Arg Gln Val Leu Asn Cys Trp Ser Lys Gly Asp Ile Glu Leu Ser
465 470 475 480

Thr Pro Ile Pro Leu Phe Gly Phe
485

<210> 298

<211> 140

<212> PRT

<213> Chlamydia

<400> 298

Arg Ile Asp Ile Ser Ser Val Thr Phe Phe Ile Gly Ile Leu Leu Ala
5 10 15

Val Asn Ala Leu Thr Tyr Ser His Val Leu Arg Asp Leu Ser Val Ser
20 25 30

Met Asp Ala Leu Phe Ser Arg Asn Thr Leu Ala Val Leu Leu Gly Leu
35 40 45

Val Ser Ser Val Leu Asp Asn Val Pro Leu Val Ala Ala Thr Ile Gly
50 55 60

Met Tyr Asp Leu Pro Met Asn Asp Pro Leu Trp Lys Leu Ile Ala Tyr
65 70 75 80

Thr Ala Gly Thr Gly Gly Ser Ile Leu Ile Ile Gly Ser Ala Ala Gly
85 90 95

Val Ala Tyr Met Gly Met Glu Lys Val Ser Phe Gly Trp Tyr Val Lys
100 105 110

His Ala Ser Trp Ile Ala Leu Ala Ser Tyr Phe Gly Gly Leu Ala Val
115 120 125

Tyr Phe Leu Met Glu Asn Cys Val Asn Leu Phe Val
130 135 140

<210> 299

<211> 361

<212> PRT

<213> Chlamydia

<400> 299

His Gln Glu Ile Ala Asp Ser Pro Leu Val Lys Lys Ala Glu Glu Gln
5 10 15

Ile Asn Gln Ala Gln Gln Asp Ile Gln Thr Ile Thr Pro Ser Gly Leu
 20 25 30
 Asp Ile Pro Ile Val Gly Pro Ser Gly Ser Ala Ala Ser Ala Gly Ser
 35 40 45
 Ala Ala Gly Ala Leu Lys Ser Ser Asn Asn Ser Gly Arg Ile Ser Leu
 50 55 60
 Leu Leu Asp Asp Val Asp Asn Glu Met Ala Ala Ile Ala Met Gln Gly
 65 70 75 80
 Phe Arg Ser Met Ile Glu Gln Phe Asn Val Asn Asn Pro Ala Thr Ala
 85 90 95
 Lys Glu Leu Gln Ala Met Glu Ala Gln Leu Thr Ala Met Ser Asp Gln
 100 105 110
 Leu Val Gly Ala Asp Gly Glu Leu Pro Ala Glu Ile Gln Ala Ile Lys
 115 120 125
 Asp Ala Leu Ala Gln Ala Leu Lys Gln Pro Ser Ala Asp Gly Leu Ala
 130 135 140
 Thr Ala Met Gly Gln Val Ala Phe Ala Ala Lys Val Gly Gly Gly
 145 150 155 160
 Ser Ala Gly Thr Ala Gly Thr Val Gln Met Asn Val Lys Gln Leu Tyr
 165 170 175
 Lys Thr Ala Phe Ser Ser Thr Ser Ser Ser Ser Tyr Ala Ala Ala Leu
 180 185 190
 Ser Asp Gly Tyr Ser Ala Tyr Lys Thr Leu Asn Ser Leu Tyr Ser Glu
 195 200 205
 Ser Arg Ser Gly Val Gln Ser Ala Ile Ser Gln Thr Ala Asn Pro Ala
 210 215 220
 Leu Ser Arg Ser Val Ser Arg Ser Gly Ile Glu Ser Gln Gly Arg Ser
 225 230 235 240
 Ala Asp Ala Ser Gln Arg Ala Ala Glu Thr Ile Val Arg Asp Ser Gln
 245 250 255
 Thr Leu Gly Asp Val Tyr Ser Arg Leu Gln Val Leu Asp Ser Leu Met
 260 265 270
 Ser Thr Ile Val Ser Asn Pro Gln Ala Asn Gln Glu Glu Ile Met Gln
 275 280 285
 Lys Leu Thr Ala Ser Ile Ser Lys Ala Pro Gln Phe Gly Tyr Pro Ala
 290 295 300

Val Gln Asn Ser Val Asp Ser Leu Gln Lys Phe Ala Ala Gln Leu Glu
 305 310 315 320

Arg Glu Phe Val Asp Gly Glu Arg Ser Leu Ala Glu Ser Gln Glu Asn
 325 330 335

Ala Phe Arg Lys Gln Pro Ala Phe Ile Gln Gln Val Leu Val Asn Ile
 340 345 350

Ala Ser Leu Phe Ser Gly Tyr Leu Ser
 355 360

<210> 300

<211> 207

<212> PRT

<213> Chlamydia

<400> 300

Ser Ser Lys Ile Val Ser Leu Cys Glu Gly Ala Val Ala Asp Ala Arg
 5 10 15

Met Cys Lys Ala Glu Leu Ile Lys Lys Glu Ala Asp Ala Tyr Leu Phe
 20 25 30

Cys Glu Lys Ser Gly Ile Tyr Leu Thr Lys Lys Glu Gly Ile Leu Ile
 35 40 45

Pro Ser Ala Gly Ile Asp Glu Ser Asn Thr Asp Gln Pro Phe Val Leu
 50 55 60

Tyr Pro Lys Asp Ile Leu Gly Ser Cys Asn Arg Ile Gly Glu Trp Leu
 65 70 75 80

Arg Asn Tyr Phe Arg Val Lys Glu Leu Gly Val Ile Ile Thr Asp Ser
 85 90 95

His Thr Thr Pro Met Arg Arg Gly Val Leu Gly Ile Gly Leu Cys Trp
 100 105 110

Tyr Gly Phe Ser Pro Leu His Asn Tyr Ile Gly Ser Leu Asp Cys Phe
 115 120 125

Gly Arg Pro Leu Gln Met Thr Gln Ser Asn Leu Val Asp Ala Leu Ala
 130 135 140

Val Ala Ala Val Val Cys Met Gly Glu Gly Asn Glu Gln Thr Pro Leu
 145 150 155 160

Ala Val Ile Glu Gln Ala Pro Asn Met Val Tyr His Ser Tyr Pro Thr
 165 170 175

Ser Arg Glu Glu Tyr Cys Ser Leu Arg Ile Asp Glu Thr Glu Asp Leu
 180 185 190

Tyr Gly Pro Phe Leu Gln Ala Val Thr Trp Ser Gln Glu Lys Lys
 195 200 205

<210> 301
 <211> 183
 <212> PRT
 <213> Chlamydia

<400> 301
 Ile Pro Pro Ala Pro Arg Gly His Pro Gln Ile Glu Val Thr Phe Asp
 5 10 15
 Ile Asp Ala Asn Gly Ile Leu His Val Ser Ala Lys Asp Ala Ala Ser
 20 25 30
 Gly Arg Glu Gln Lys Ile Arg Ile Glu Ala Ser Ser Gly Leu Lys Glu
 35 40 45
 Asp Glu Ile Gln Gln Met Ile Arg Asp Ala Glu Leu His Lys Glu Glu
 50 55 60
 Asp Lys Gln Arg Lys Glu Ala Ser Asp Val Lys Asn Glu Ala Asp Gly
 65 70 75 80
 Met Ile Phe Arg Ala Glu Lys Ala Val Lys Asp Tyr His Asp Lys Ile
 85 90 95
 Pro Ala Glu Leu Val Lys Glu Ile Glu Glu His Ile Glu Lys Val Arg
 100 105 110
 Gln Ala Ile Lys Glu Asp Ala Ser Thr Thr Ala Ile Lys Ala Ala Ser
 115 120 125
 Asp Glu Leu Ser Thr Arg Met Gln Lys Ile Gly Glu Ala Met Gln Ala
 130 135 140
 Gln Ser Ala Ser Ala Ala Ser Ser Ala Ala Asn Ala Gln Gly Gly
 145 150 155 160
 Pro Asn Ile Asn Ser Glu Asp Leu Lys Lys His Ser Phe Ser Thr Arg
 165 170 175
 Pro Pro Ala Gly Gly Ser Ala
 180

<210> 302
 <211> 232
 <212> PRT
 <213> Chlamydia

<400> 302
 Met Thr Lys His Gly Lys Arg Ile Arg Gly Ile Gln Glu Thr Tyr Asp
 5 10 15

Leu Ala Lys Ser Tyr Ser Leu Gly Glu Ala Ile Asp Ile Leu Lys Gln
 20 25 30
 Cys Pro Thr Val Arg Phe Asp Gln Thr Val Asp Val Ser Val Lys Leu
 35 40 45
 Gly Ile Asp Pro Arg Lys Ser Asp Gln Gln Ile Arg Gly Ser Val Ser
 50 55 60
 Leu Pro His Gly Thr Gly Lys Val Leu Arg Ile Leu Val Phe Ala Ala
 65 70 75 80
 Gly Asp Lys Ala Ala Glu Ala Ile Glu Gly Ala Asp Phe Val Gly
 85 90 95
 Ser Asp Asp Leu Val Glu Lys Ile Lys Gly Gly Trp Val Asp Phe Asp
 100 105 110
 Val Ala Val Ala Thr Pro Asp Met Met Arg Glu Val Gly Lys Leu Gly
 115 120 125
 Lys Val Leu Gly Pro Arg Asn Leu Met Pro Thr Pro Lys Ala Gly Thr
 130 135 140
 Val Thr Thr Asp Val Val Lys Thr Ile Ala Glu Leu Arg Lys Gly Lys
 145 150 155 160
 Ile Glu Phe Lys Ala Asp Arg Ala Gly Val Cys Asn Val Gly Val Ala
 165 170 175
 Lys Leu Ser Phe Asp Ser Ala Gln Ile Lys Glu Asn Val Glu Ala Leu
 180 185 190
 Cys Ala Ala Leu Val Lys Ala Lys Pro Ala Thr Ala Lys Gly Gln Tyr
 195 200 205
 Leu Val Asn Phe Thr Ile Ser Ser Thr Met Gly Pro Gly Val Thr Val
 210 215 220
 Asp Thr Arg Glu Leu Ile Ala Leu
 225 230

<210> 303
 <211> 238
 <212> PRT
 <213> chlamydia

<400> 303
 Ile Asn Ser Lys Leu Glu Thr Lys Asn Leu Ile Tyr Leu Lys Leu Lys
 5 10 15
 Ile Lys Lys Ser Phe Lys Met Gly Asn Ser Gly Phe Tyr Leu Tyr Asn
 20 25 30

```

Thr  Gln  Asn  Cys  Val  Phe  Ala  Asp  Asn  Ile  Lys  Val  Gly  Gln  Met  Thr
      35                      40                      45

Glu  Pro  Leu  Lys  Asp  Gln  Gln  Ile  Ile  Leu  Gly  Thr  Thr  Ser  Thr  Pro
      50                      55                      60

Val  Ala  Ala  Lys  Met  Thr  Ala  Ser  Asp  Gly  Ile  Ser  Leu  Thr  Val  Ser
      65                      70                      75                      80

Asn  Asn  Pro  Ser  Thr  Asn  Ala  Ser  Ile  Thr  Ile  Gly  Leu  Asp  Ala  Glu
      85                      90                      95

Lys  Ala  Tyr  Gln  Leu  Ile  Leu  Glu  Lys  Leu  Gly  Asp  Gln  Ile  Leu  Gly
      100                     105                     110

Gly  Ile  Ala  Asp  Thr  Ile  Val  Asp  Ser  Thr  Val  Gln  Asp  Ile  Leu  Asp
      115                     120                     125

Lys  Ile  Thr  Thr  Asp  Pro  Ser  Leu  Gly  Leu  Leu  Lys  Ala  Phe  Asn  Asn
      130                     135                     140

Phe  Pro  Ile  Thr  Asn  Lys  Ile  Gln  Cys  Asn  Gly  Leu  Phe  Thr  Pro  Arg
      145                     150                     155                     160

Asn  Ile  Glu  Thr  Leu  Leu  Gly  Gly  Thr  Glu  Ile  Gly  Lys  Phe  Thr  Val
      165                     170                     175

Thr  Pro  Lys  Ser  Ser  Gly  Ser  Met  Phe  Leu  Val  Ser  Ala  Asp  Ile  Ile
      180                     185                     190

Ala  Ser  Arg  Met  Glu  Gly  Gly  Val  Val  Leu  Ala  Leu  Val  Arg  Glu  Gly
      195                     200                     205

Asp  Ser  Lys  Pro  Tyr  Ala  Ile  Ser  Tyr  Gly  Tyr  Ser  Ser  Gly  Val  Pro
      210                     215                     220

Asn  Leu  Cys  Ser  Leu  Arg  Thr  Arg  Ile  Ile  Asn  Thr  Gly  Leu
      225                     230                     235

```